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PREFACE
The main reason for writing this book is that I have spent many rewarding years working as 
a physician and neurologist in Africa and would like to pass on some of that experience and 
knowledge to students there. Neurological disorders are common in Africa and the burden 
there has increased significantly because of the HIV epidemic and the emerging epidemic of 
non-communicable diseases. Students often find neurology a difficult subject to approach and 
there is a need for an easily accessible guide to neurology teaching and education in Africa. 
The aim of this book is for students to gain an understanding of neurology, learn the necessary 
clinical skills and obtain sufficient knowledge to care for patients presenting with neurological 
disorders. Diagnosis in neurology is based on accurate history and physical examination and 
this book emphasizes these principles. It is written mostly from the perspective of a general 
physician practising neurology rather than that of a neurologist. 
The book has two sections, the first on clinical skills, with medical students in wards and 
clinics as its main target group and the second on neurological disorders in adults with students 
and doctors as its main target group. The order of chapters is based on their importance in 
Africa, with the most common disorders there; epilepsy, stroke, infections, coma, paraplegia 
and neuropathies covered in the earlier chapters. The book includes chapters on head and 
spinal injury and care in neurology, because of their increasing significance within Africa. The 
choice of content included in each chapter is guided by the experience of the author. It is 
therefore subjective, selective and restricted by the size of the book. I have earnestly tried to 
avoid repetition; however in the attempt to make each chapter self-contained some repetition 
was unavoidable. I have included key points summarizing each section, which I hope will assist 
students with review. There is also a summary list of useful medical and neurological websites 
at the end of the book.
The term Africa is used throughout as a handy designation to mean sub-Saharan Africa. The 
lists of references at the end of each chapter are intended as a general guide to reading about 
neurology in Africa. For further information I refer the reader to a major neurology textbook.
In writing Neurology in Africa I have borrowed ideas and concepts from a wide range of 
excellent textbooks of neurology and tropical medicine and I am deeply indebted to their 
authors. I apologize in advance for any weaknesses and omissions and welcome comments 
and criticisms. I am reminded daily by students that the Internet is the new medium for 
education. With that in mind the book is available free online at www.uib.no/cih/en/resources/
neurology-in-africa. 
The gap between need and resources is well documented in Africa and it is my experience that 
neurology is no different. It is my sincere hope that students and doctors in Africa will find this 
book a useful step towards filling that gap in neurology. 
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CHAPTER 1
HISTORY AND EXAMINATION
Introduction
Neurology relies on the fundamental skills of history taking and physical examination. The 
aim of this section is to help the medical student to learn the basic clinical skills necessary to 
carry out a neurological history and examination and interpret the findings. Most students 
find neurology difficult to remember and in particular what to do, how to do it and what it all 
means. The history is the most important part of neurological evaluation because it is a guide to 
the underlying disease and also determines which part of the examination needs to be focused 
on. Indeed many neurological diseases like migraine have symptoms but no abnormal signs. 
The neurological examination determines abnormal neurological findings and helps to localize 
the site of the disease (Chapters 2 & 12). The history, examination and localization all together 
help to determine which disease has occurred at that site. The necessary competence required 
to carry out these tasks is formed by a combination of knowledge, skills and experience. 
Neurological knowledge is mostly self learned while clinical skills are taught at the bedside and 
experience gained over time. The nervous system by its nature is complex but its assessment can 
be learned with patience, plenty of practice and time. 
HISTORY TAKING
Introduction
The history is the most important part of the neurological assessment. The student should 
aim to be a good listener showing interest and sympathy as the patient’s story unfolds. It is 
important to get the patient’s trust and confidence. First introduce yourself to the patient, 
explain who you are and ask permission to take a history and to carry out an examination. 
Find out the patient’s name, age, address, occupation. Determine handedness by asking which 
hand do you write with or use more often. Some clinical findings are apparent to the examiner 
during history taking; these include general state of health and obvious neurological deficits 
and disabilities. If there is alteration in the level of consciousness or the patient is unable 
to give a history then it may be necessary to obtain a history and witnessed account from a 
relative or friend before proceeding directly to neurological examination. The patient’s history 
reveals his personality, intelligence, memory and speech and his body language his attitude and 
mood. The questions should aim to learn the character, severity, time course and the particular 
circumstances of each main symptom. The order of history taking is summarized below under 
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key points. While the history is being taken the level of alertness, mental well being and higher 
cerebral function becomes apparent to the examiner.
Key points in a neurological history
 · age, sex, occupation, handedness
 · presenting complaints 
 · history of presenting complaints
 · neurology system review questions
 · past history
 · family history and social history
 · drug history
 · gynaecological and obstetrical history
Presenting complaint
Start the formal history by asking the patient to state what the problems are and the reason for 
hospital admission or referral. This could begin with open questions such as “what is the main 
problem or “tell me about it from the start”. Try to let the patient tell the story of the illness as 
it has happened without any interruption. Make certain that you understand clearly what the 
patient is describing by their complaints. Determine the order of the presenting complaints, 
these should ideally not number more than three or four and be in order of importance. 
For each complaint determine the main site, character, onset, time course, exacerbating and 
relieving factors, associated symptoms and previous investigations and treatments.
Key points
 · what are the problems
 · what is the main problem
 · when did it start
 · site, character, time course, exacerbating & 
relieving factors, associated symptoms  
 · previous investigations and treatments
Time course
The time course of symptoms is essential to understanding the underlying cause. Ask the patient 
to describe the onset, progress, duration, recovery and frequency of each main complaint. In 
particular ask if the onset was sudden over seconds or minutes as occurs in stroke or more 
slowly over weeks or months as occurs in mass lesion e.g. tumour. Describe progress whether it 
was stationary as in a stroke or worsening as in an infection or intermittent as in epilepsy. If the 
symptoms are intermittent enquire about their frequency and the interval between them. Ask 
about precipitating or relieving factors, associated neurological symptoms and any particular 
circumstances in which the symptoms occur.
Key points
 · onset
 · progress
 · duration 
 · frequency
 · recovery
Systems review
A systematic enquiry may reveal symptoms related to the patient’s illness. This may include 
a general medical review in addition to neurological systems review. Carry out a neurological 
systems review by asking the patient specific screening questions concerning symptoms 
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affecting the various levels of higher cerebral and nervous system functioning. Finally ask if 
there is anything else that the patient would like to tell you.
Neurology systems review key questions
 · change in mood, memory, concentration or 
sleep
 · pain, headache, face or limbs
 · loss of consciousness or dizzy spells
 · loss of vision or double vision 
 · loss of hearing or balance
 · difficulty speaking or swallowing
 · weakness or heaviness in limbs
 · difficulty walking
 · pins and needles or numbness in arms, legs or 
body
 · difficulty with passing urine, bowels and 
sexual function
Interpretation
As the history unfolds the examiner begins to hypothesize about the meaning of the history 
and the cause of the disorder. To reinforce this information it may be necessary to rephrase the 
questions in different ways or ask some direct questions. The main potential sites of disease 
are the brain, spinal cord, cranial and peripheral nerves, neuromuscular junction and muscles. 
It is helpful to attempt to anatomically localize the main site of the disease. Defining an 
anatomical limit to main symptoms is also helpful e.g. the upper limit of a sensory level in 
paraplegia, or the motor loss on one side in hemiplegia, or the glove and stocking sensory loss 
in a polyneuropathy. If the amount of time is limited then it is better to spend time on the 
history and be selective about the examination concentrating it on the main areas of interest. 
Past medical history (PMH)
Enquire about past medical illnesses and accidents including hospitalizations and operations, 
and record their details in the notes. Where relevant ask specifically about a history of infections, 
seizures, head injuries, birth and childhood development, diabetes, hypertension and stroke. 
Enquire if there is a past history of neurological episodes similar to the presenting complaint and 
outline any investigations, their results and treatments received, and any persisting disabilities. 
Family history
Document the patient’s first degree relatives i.e. parents, siblings and children including their 
ages, sex and health. Enquire if there is anyone else in the family with the same illness, if 
so record the full family tree with their names and ages and indicating any affected family 
members and any deaths and their causes if known.
Personal & social history
Ask concerning occupation, employment, travel, alcohol intake in number of units per week 
and smoking in pack years (packs per day times years smoked); if relevant ask concerning the 
use of recreational drugs. Enquire how the current illness has affected work and social life 
including time lost from work over the last 6 months. Have a neurological patient describe the 
home environment, caregivers, community and financial circumstances if relevant. 
Drugs, allergies
List the medications the patient is taking including names, duration and dosages. Describe any 
problems with medications and known allergies.
history taking
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Menses
Record whether menses are normal and if the patient is pregnant or on the pill. 
Key points
 · allow the patient time to tell the story of their 
illness
 · listen to the patient
 · if patient is unable to give a history obtain it 
from family or friends
 · ask if there “is anything else you wish to tell me”
 · history determines the site of interest for 
neurological examination
General examination
The neurological examination must be performed in the context of a general physical examination. 
This includes recording the vital signs and examination of the cardiovascular system including 
listening for carotid bruits, and the respiratory, abdominal, and musculoskeletal systems. 
NEUROLOGICAL EXAMINATION
Neurological examination is often considered by the student to be the most difficult part of 
neurological evaluation. This arises mainly because of technique and uncertainty over what is 
normal or abnormal. The best way to overcome this is to spend time early on learning the basic 
neurologic skills and then to practise on colleagues and patients until confident. The main 
aim is to become familiar with the routine of neurological examination and range of normal 
findings. The student will then gradually be introduced to abnormal findings in patients with 
neurological disorders and to what are termed neurological signs. In general, neurological signs 
are objective, reproducible and cannot be altered by the patient whereas less reliable findings 
tend to be variable, subjective and less reproducible. The neurological examination may involve 
an assessment of the level of consciousness, cognitive and mental function, cranial nerves, limbs 
and gait. Details concerning the clinical examination of level of consciousness and cognitive 
function are at the end of this chapter. In summary it is wise to listen attentively to the patient’s 
complaints, stick to the routine of a basic neurological examination and to concentrate the 
neurological exam on the problem area highlighted by the history. 
General observations
Observe the patient’s general appearance, for any obvious neurological deficit and level of 
consciousness. The patient’s level of consciousness, alertness, higher cerebral function, mental 
state and ability to give a history become apparent during the history taking. Neurological 
disorders affecting speech, posture, movement and gait may also become apparent at this stage. 
CRANIAL NERVE EXAMINATION
These are tested with the patient in the sitting position. 
Olfactory nerve (cranial nerve 1)
The olfactory nerve is responsible for smell. In a routine neurological examination it is sufficient 
to ask the patient if there is any loss of smell (anosmia). If anosmia is suspected then it should 
be tested at the bedside. This can be done by simply asking the patient to identify up to four 
familiar bedside items: e.g. orange peel, cloves, coffee, and soap. Before the test the nasal airway 
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should be shown to be clear by getting the patient to sniff. 
Explain to the patient to close both eyes and block off one 
nostril by applying pressure with a finger. In the manner 
shown in the diagram the item to be identified is then 
presented to the other open nostril and the patient tries 
to identify the smell and its source. The procedure is then 
repeated for each item and on the other side. Patients may 
only become aware of the loss of smell whilst eating when 
the perception is often a loss of taste. The most common 
cause of loss of smell is local disease in the nose or sinuses 
e.g. head cold, hay fever and smoking. 
Figure 1.1 Testing smell
Optic nerve (cranial nerve 2)
Visual acuity
Ask if the patient has any difficulty seeing. Visual acuity (VA) is tested and measured routinely 
by using a Snellen chart. The patient should stand 6 metres away from the chart and correct 
for any known refractive error by wearing appropriate glasses. Ask the patient to cover each eye 
in turn with his hand and find the smallest line that he can read fully without difficulty. VA is 
expressed as the distance between the chart and the patient over the smallest line completely 
visible to the patient. The numbers on the chart (below the line) correspond to the distance 
at which a person with normal vision should be able to see and identify the appropriate line. 
Below the age of 40 years most should see 6/6 or better. If 6/6 is normal and 36 represents 
the line that the patient can comfortably read at 6 metres with both eyes then visual acuity for 
that patient should be recorded as 6/36 in the right (VAR) and left eye (VAL). If VA is 6/60 
or less then you can assess the patient’s ability to see at 1 meter distance by counting fingers 
(CF), VA = CF, or seeing hand movements (HM), VA = HM or perceiving light (PL) VA = 
PL, if unable to perceive light then the patient is blind (NPL). At the bedside setting crude 
levels of visual acuity can be established by using a small hand held chart e.g. Jaeger chart or by 
using ordinary newspaper print. Colour vision is not tested routinely, however it can be tested 
by a using a book of Ishihara plates where at least 15/17 coloured plates identified correctly is 
considered normal. The most common causes of decreased visual acuity are optical problems, 
mainly refractive errors in lens, followed by cataracts and lastly diseases involving the retina, 
macula and optic nerve.
Figure 1.2 Testing visual acuity
Testing smell
Olfactory nerve
Distance
6 metres
Testing visual acuity
  The Snellen chart
Cranial nerve examination
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Key points
 · VA is measured standing 6 metres from a 
Snellen chart 
 · VA is distance between patient and chart over 
the smallest line identified correctly 
 · VA can be tested at bedside using a small hand 
held chart or newspaper
 · most common causes of decreased VA are 
refractive errors and cataracts 
Visual fields
The organization of the visual pathways means that the pattern of visual field loss varies at 
different sites along its way. This means that testing for the pattern of visual field loss is useful 
for localization of lesions along the visual pathway. Visual fields are always described and 
recorded from the perspective of the patient looking outwards with the fields divided into 
nasal and temporal halves. At the bedside visual fields are examined by confrontation. The 
main patterns of loss are homonymous & bitemporal hemianopia, & monocular blindness.
Confrontation
This involves sitting about 1 meter in front of the patient with your eyes at the same horizontal 
level. Ask the patient to look with both eyes at your eyes (the bridge of your nose). Hold your 
hands upright halfway between you and the patient held approximately half a meter apart and 
at about 30 cm above the horizontal. While looking at the patient’s eyes first move the index 
finger tip of one hand (or a 5-7 mm red pin head) and ask the patient to correctly identify 
which finger moved. The patient should immediately point or indicate the hand on which the 
finger moved. Do the same with the other hand. Repeat the manoeuvre with the hands held 
about 30 cm below the horizontal. To examine the visual fields in each eye separately, ask the 
patient to cover one eye e.g. patient’s right eye and the examiner covers the eye opposite, in this 
case his own left eye. Ask the patient to focus on your uncovered eye. Move your index finger 
in each of the four quadrants starting in the temporal field followed by the nasal field in same 
manner as you did on confrontation for both eyes. Repeat for the other eye. Remember that 
the nose and prominent eyebrows may partially block vision and mistakenly give a field deficit.
Figure 1.3 Examining visual fields Testing for visual defects by confrontation 
Field perimetry
Field perimetry can be tested in the same manner using a moving finger tip or a white pin head 
5-7 mm target. Start behind the patient’s visual field coming forward diagonally in a convex 
plane from all four quadrants at a 45 degree angle, northeast to southwest and northwest 
1 metre
Testing visual elds by confrontation
Testing for visual eld defects by confrontation
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to southeast and the same in reverse asking the patient to indicate as soon as he sees the 
movement. This establishes the posterior limit of the patient’s visual field. The blind spot (optic 
nerve head) and any central field defects can be easily identified using red pin head moving in 
the horizontal plane from outside. 
Key points
 · patients are often unaware of loss of visual 
fields 
 · major visual field loss is identified by 
confrontation 
 · peripheral visual fields are tested by perimetry 
examination 
 · main patterns of loss are homonymous 
& bitemporal hemianopia & monocular 
blindness
Ocular fundi
Ocular fundi are tested by fundoscopy. The aim of fundoscopy is to inspect the optic nerve 
head, arterioles, veins and retina. This is an important part of the neurological examination 
and is used mainly to exclude papilloedema or swelling of the optic nerve. The main cause of 
papilloedema in Africa is raised intracranial pressure secondary to CNS infections and mass 
lesions. Swelling of the optic disc may also be caused by inflammation of the optic nerve and 
this is called papillitis. The main cause of papillitis is optic neuritis.
How to use an ophthalmoscope
Students and young doctors at first find fundoscopy difficult but the skill comes with training 
and practice. The most important thing to understand is the position of the optic nerve head 
within the field of vision you are testing. The optic nerve head lays 15-20 degrees lateral to the 
point of fixation of the patient’s eyes and slightly below the horizontal and corresponds to the 
blind spot. 
The following instructions should be helpful. The patient should fix his gaze straight ahead. 
Check the focus on the ophthalmoscope is set at zero and the light is bright, then sit opposite the 
patient and examine the right eye. With the ophthalmoscope in the right hand approach from 
the patient’s right side, look at the patient’s right eye from 30 cm away with the ophthalmoscope 
level or slightly below the patient’s eye about 15-20 degrees 
outside or lateral to the patient’s line of fixation or direction 
of gaze. Aim at the centre of the back of head and keep out 
of the line of sight of the other eye. You should be able to 
see the pupil as pink in colour; this is the normal retinal 
or red reflex. Gradually move in towards the eye, encourage 
patient to continue to look or fixate at a point behind you 
straight ahead and bring ophthalmoscope to within 1-2 cm 
of the patient’s right eye. It’s important to keep patient’s 
eye, point of fixation and ophthalmoscope all on the same 
plane. Adjust the lens for focus so that you can see the blood 
vessels clearly and follow blood vessels as they get larger and 
converge on the disc. Look at the optic disc, blood vessels, 
retinal background and repeat for the other eye. 
Figure 1.4 Fundoscopy
Examining the eye with an ophthalmoscope
Cranial nerve examination
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What you find
The normal disc is circular and pale pink in colour, the edge of the disc is clear although 
not as well demarcated on the nasal side as the temporal side (Chapter 12). The temporal 
half of the disc is normally paler than the nasal half. The physiological optic cup from which 
the blood vessels emerge is a well defined depression in the centre of the nerve head. It is 
pale and occupies about 40-50% of size of the optic disc. The rest of the fundus has an even 
red background because of blood in the choroid layer. The retina may be darkly pigmented 
depending on racial background. The macula with a central darker area called fovea lies about 
one and a half disc spaces from the disc on its temporal side and is free of blood vessels. It 
can easily be found by asking the patient to look directly at the light of the ophthalmoscope. 
The arterioles are normally two thirds the sizes of veins and appear a brighter shade of red 
than veins. The veins on the disc appear to pulsate in 70-80% of normal people in the sitting 
position, and the absence of pulsation may be an early sign of papilloedema. In papilloedema 
the whole disc is usually pink red and the veins become distended and lose their pulsation. 
The optic cup is lost and the edge of the disc and the vessels emerging may appear elevated. 
Later the whole disc itself becomes indistinct and blurred especially on the nasal side which is 
normally less distinct and haemorrhages and exudates may be seen on or near its margins and 
vessels disappearing without an obvious optic disc (Chapter 12). In chronic papilloedema the 
disc becomes pale as occurs in optic atrophy. 
Key points
 · approach patient’s right eye at same eye level 
from 30 cm out & 15-20 degrees laterally 
 · identify red reflex and follow beam of light 
into eye looking for a normal pale pink disc 
 · main sign of papilloedema is swelling of the 
optic disc with blurring of the disc margins 
 · main sign of optic atrophy is a pale white optic 
disc 
 · practise on colleagues and patients with 
normal eyes
Pupillary reactions
These are examined after the optic nerve and before eye movements. The normal pupillary 
reactions include the light reflex, the accommodation reflex and the consensual reflex. 
Assessing the pupils
Inspect the pupils at rest for size and shape and 
whether they are equal, central and circular 
and react to light. It’s not always easy to assess 
pupillary size in a darkened room or in patients 
with a darkened iris. A difference in pupil size is 
called anisocoria. It helps to inspect the pupils 
at rest by shining a torch on the bridge of the 
patient’s nose allowing light to scatter but not 
affecting the pupils.
Figure 1.5 Testing the light reflex
Testing the light reex
Optic nerve
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The light reflex
To test the pupillary light reflex, ask the patient to look in the distance and not into direct light. 
It may help to block off the other eye in the manner shown in the diagram.
Then bring a bright light in from behind or from the side into the patient’s field of vision and 
observe the eye for direct or ipsilateral pupillary constriction. This is called the direct light 
reflex. Then repeat this again in the same eye now looking for the same response in the other 
eye. This is called the consensual reflex. Check for the same reflexes in the other eye.
The accommodation reflex
The accommodation reflex has two components and is much less clinically important than the 
light reflex. To test this reflex ask the patient to look in the distance and then at the examiner’s 
finger held 10 cm in front of the patient’s nose. As the gaze is shifted from a distant to near 
object the eyes adduct and pupils constrict. The first component is convergence which requires 
adduction of both eyes at the same time. The other component involves bilateral simultaneous 
constriction of the pupils; this combined with adduction is the normal accommodation reflex. 
Pupillary disorders
Large and small pupils which react to light and accommodation can occur normally in young 
and old persons respectively. Pupillary disorders are generally categorized as those resulting in 
large dilated non or slowly reacting pupils and those resulting in small constricted reacting or 
non reacting pupils. The main causes of these are to be found in disorders affecting the optic 
nerve and the iris and its autonomic parasympathetic and sympathetic nerve supply. 
Key points
 · inspect pupils for size, shape and whether they 
are equal or not
 · light reflex: shine a bright light into the eye 
and watch for pupillary constriction  
 · consensual reflex: inspect the other eye at 
the same time for pupillary constriction 
 · accommodation reflex: watch eyes adduct 
& pupils constrict as gaze is shifted to a near 
object
Oculomotor, Trochlear and Abducens (cranial nerves 3, 4 & 6)
Eye movements
The 3rd 4th and 6th cranial nerves are tested together by examining eye movements. Eye 
movements are generated in two main ways each of which should be tested separately. Firstly 
voluntary movements are generated from the frontal lobe; they are also called saccadic because 
of the rapid jumping movement from one point of fixation to another. These are tested by 
asking the patient to look rapidly from one side to the other or right and left and are impaired 
in cortical brain disease. Secondly and more important clinically are pursuit eye or tracking 
movements which are generated from the occipital lobe when the eyes stay on and follow the 
point of fixation. These are tested by asking the patient to follow the examiner’s moving finger 
and are impaired in brain stem and cranial nerve disorders. Lastly the cerebellum also plays a 
main role in controlling eye movements in response to body movements in order to keep the 
point of fixation. All eye movements are integrated in the brain stem so that the eyes can move 
together conjugately in all directions. Eye movement abnormalities are usually noted because 
the patient complains of double vision or diplopia and because the eyes appear to the observer 
be looking in different directions. When this happens it is called a squint or strabismus. The 
Cranial nerve examination
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main causes of diplopia are disorders affecting the function of the 3rd 4th and 6th cranial 
nerves. The main sites for these disorders are eye muscles, the neuromuscular junction, or the 
individual nerves and their central connections in the brain stem. The most common causes 
are vascular and inflammatory disorders affecting the individual nerves and neuromuscular 
junction respectively. 
Testing for pursuit eye movements
Pursuit eye movements are routinely examined during the neurological examination. The 
examiner tests for horizontal and vertical eye movements by instructing the patient “to follow 
my finger with your eyes” whilst keeping the patient’s head steady. The examiner holds a finger 
about half a meter away from the patient’s face and makes horizontal and vertical movements 
in the shape of a cross sign being careful not to move the hand too rapidly. The movement 
is carried out with the index finger 
held vertically moving horizontally 
30-45 degrees right and left from 
mid point and then repeated in the 
same way moving vertically with 
the finger held horizontally. The 
trochlear nerve is tested by repeating 
the same movements but this time in 
the shape of H sign. This should be 
carried out in each eye field separately 
to confirm any weakness. Any loss or 
impairment of normal eye movement 
or jerkiness (nystagmus) should be 
noted.
Figure 1.6 Testing eye movements
Nystagmus
Nystagmus is an involuntary rhythmic oscillatory movement of the eyes. Nystagmus is usually 
asymptomatic. To test for nystagmus ask the patient to follow the examiner’s fingers using the 
same method as when testing for normal eye movements. Nystagmus should be examined in 
three main positions, at rest, looking right and left horizontally and looking up and down 
vertically. Be careful not to move the eyes too quickly or too far laterally (not beyond 30 
degrees from midline) and note the presence of any nystagmus. Nystagmus is only considered 
pathological when it is sustained. The characteristics of nystagmus help to localize the site 
of neurological disease. The main causes of nystagmus are disorders affecting the vestibular 
system and its central connections, the brain stem, cerebellum and the eye including early 
onset blindness. It can also rarely be congenital. 
up
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Key Points
 · eye movements  are tested by following examiner’s finger as it traces a cross (+) or (H) sign in the air
 · H sign tests the trochlear nerves in addition to the oculomotor and the abducens
 · nystagmus is an involuntary oscillatory movement of the eyes
 · diplopia is mostly caused by weakness of the ocular muscles
Trigeminal nerve (cranial nerve 5)
The trigeminal nerve has three divisions ophthalmic (V1), maxillary (V2), and mandibular 
(V3). It is responsible for facial sensation and mastication. 
Sensation
To test sensation, first ask if the patient feels any numbness or altered sensation on the face. 
Then test for light touch (and gentle pinprick and temperature only if necessary) in each of 
the three divisions of the trigeminal nerve comparing one side with the other. If a sensory loss 
is found then determine its limits by moving from an abnormal area to normal. Remember 
that the ophthalmic division extends posteriorly to the vertex and also supplies the cornea 
and the tip of the nose. The angle of the jaw is supplied by the C2 nerve root rather than the 
trigeminal nerve. Sensory loss on the face is caused mainly by lesions in the brain stem and 
the trigeminal nerve.
Figure 1.7 Testing facial sensation
Motor
The motor division of the trigeminal nerve can be tested by inspecting for wasting above the 
zygomatic arch and asking the patient to clench the teeth and to palpate the masseters and 
pterygoids for force of contraction. Power can be assessed by jaw opening and jaw closure and 
side to side movements against resistance. Ask the patient to open and close his mouth against 
the resistance of your hand. In unilateral paralysis the jaw deviates to the weak or affected 
side. Motor involvement affecting the trigeminal nerve is very uncommon. Causes include 
myasthenia gravis, motor neurone disease and muscular dystrophy.
Jaw jerk
The jaw jerk is a brain stem stretch reflex which may be absent or present in normal people. To 
elicit the reflex the patient should let his jaw sag open. Place your finger lightly on the chin. 
Then tap your finger gently and feel and observe for a brief contraction or movement upwards 
V2
V1
V3
V2
V1
V3
Facial sensation: left side ophthalmic (    ), maxillary (    ) and mandibular (    )
divisions of the trigeminal nerve
V2V1 V3
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of the lower jaw. The jaw jerk may be increased in an upper motor neurone lesion and indicates 
a lesion in the midbrain or above. 
Corneal reflex
The trigeminal nerve provides the afferent arc of the corneal 
reflex. The facial nerve provides the efferent arc. It is a 
consensual reflex and may be tested by lightly touching the 
cornea (the coloured part of the eye) with a wisp of cotton wool 
and observe for reflex blinking in both eyes. The lower lid may 
be held down while the patient looks up making access to the 
cornea from below easy. The normal response to touching the 
cornea is that blinking of both eyes should occur. A unilateral 
trigeminal nerve lesion therefore results in loss of blinking on 
both sides whereas a unilateral seventh nerve lesion results in 
loss of the reflex on the affected side. 
Figure 1.8 Testing the corneal reflex (V and VII)
Key points
 · trigeminal nerve supplies sensation to the face and power to the muscles of mastication
 · sensation is tested  touching in each division of trigeminal nerve & comparing  sides 
 · power is tested by resisting jaw opening, closure & side to side movements 
 · corneal reflex is tested by touching the cornea lightly from below with a wisp of cotton 
 · loss of the corneal reflex may be caused by either a 5th or 7th cranial nerve lesion
Facial nerve (cranial nerve 7)
The facial nerve is primarily a motor nerve that is responsible for facial expression, which 
includes wrinkling of the forehead, eye closure, closure of the lips and smiling. The sensory 
portion is responsible for special sensation to the anterior two thirds of tongue via the chorda 
tympani branch. There are also a few sensory fibres to the outer ear canal. In clinical practice 
there are two types of facial nerve paralysis, a lower motor neurone type which includes Bell’s 
palsy and an upper motor neurone type which is most frequently seen in stroke. It is important 
to be able to distinguish clinically these two types from each other. 
In a lower motor neurone facial palsy there is a complete ipsilateral facial weakness with loss of 
forehead wrinkling, eye closure, nasolabial fold and drooping of the lips on the affected side. 
This is in contrast to an upper motor neurone lesion where the facial paralysis affects mainly 
the lower half of the face with preservation of wrinkling and partial eye closure although they 
may be reduced. 
Examining the facial nerve
To objectively test motor function in the facial nerve start in the upper half of the face by asking 
the patient to look upwards towards the ceiling by elevating his eyebrows or wrinkling the 
forehead. Then test eye closure by asking the patient to shut the eyes tightly and assess strength 
by trying to open patient’s eyes with your fingers. If there is a lower motor neurone pattern 
of weakness there is loss of wrinkling and reduced or no resistance to forced eye opening on 
the affected side. Movements in the lower half of the face are tested by asking the patient to 
   Corneal reex (V and VII)
Touch cornea from below with wisp of cotton wool
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smile, whistle and finally to blow out of the cheeks and to keep the 
lips closed against the examiner’s attempt to open them. Any weakness 
or asymmetry implies a lesion in the seventh nerve. The reason that 
both the forehead and eye closure are partially spared in a unilateral 
upper motor neurone lesion is that they are bilaterally innervated. A 
bilateral lower motor neurone weakness can be easily missed clinically 
unless the facial nerves are specifically tested. To assess taste apply a 
solution of salt, sweet, sour or bitter to the anterior tongue comparing 
the response on both sides. 
Figure 1.9 Testing facial movements Facial nerve palsy, right (lower motor 
neurone lesion) Loss of wrinkling of forehead Loss of nasolabial fold Drooping 
of mouth
Key points
 · inspect for drooping of the mouth, loss of nasolabial fold,  eye closure and wrinkling 
 · ask the patient to smile, close their eyes and look up
 · a complete  facial weakness on one side indicates a lower motor neurone lesion 
 · facial weakness on one side confined to the lower half indicates an upper motor neurone lesion
Acoustic nerve (cranial nerve 8)
The acoustic nerve has two divisions: the cochlear (hearing) and the vestibular (balance). 
Hearing
Hearing is first assessed by asking if the patient has a hearing problem. Hearing can be tested 
clinically by rubbing the thumb and finger close to the patient’s ear and asking if hearing is 
different between the two sides. Hearing loss is then crudely confirmed by whispering numbers 
and asking the patient to repeat them whilst standing behind the patient about 60 cm away 
from the test ear. At the same time hearing in the non affected ear is masked by rubbing fingers 
close to the tragus or by occluding it with a finger. If the patient cannot hear whispering, then 
a normal or louder voice is used. The test is then repeated on the other side if necessary. Bedside 
testing is relatively insensitive and may miss lower levels of hearing loss for which audiometry is 
required. There are two main types of hearing loss, conductive deafness where there is a failure 
of transmission of sound (air conduction AC) from the outer to the inner ear or cochlea, and 
sensorineural deafness or (bone conduction 
BC) which is due to disease in the cochlea or 
its neural connections. The Rinne and Weber 
tuning fork tests can help distinguish whether 
the hearing loss is conductive or sensorineural 
in type. The main causes of conductive hearing 
loss are wax in the outer ear and infection in the 
middle ear. The main causes of sensorineural 
hearing loss deafness are ototoxicity, infections, 
Ménière’s disease and presbycusis.
Figure 1.10 Testing hearing
       Facial nerve palsy, right
(lower motor neurone lesion)
       Loss of wrinkling of forehead
       Loss of nasolabial fold
       Drooping of the mouth
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Rinne’s test
Use a 256 Hz tuning fork, tap on knee or forearm, then hold the base of beating tuning fork on 
the mastoid process behind the ear. When the patient stops hearing it then place it beside the 
external auditory meatus in line with the ear canal. In normal hearing air conduction is greater 
than bone conduction (AC>BC) so the patient will still hear the tuning fork. In conductive 
deafness there is impairment of conduction and bone conduction is better (BC>AC). In 
sensorineural deafness the normal pattern is retained AC>BC but both components are reduced 
compared to the normal ear. 
Weber’s test
The base of a vibrating tuning fork is placed on the middle of the forehead or on the top of the 
head (vertex) and the patient asked in which ear the sound is loudest in, normally the sound is 
heard equally in both ears or in the middle. If the sound is heard best in the affected ear then 
there is unilateral conductive hearing loss on that side as only the vibration transmitted directly 
through bone to the middle ear ossicles can be heard. In contrast if it is heard best in the good 
ear then there is sensorineural hearing loss in the affected ear. 
Figure1.11 Distinguishing the type of deafness The Rinne test A + B The Weber test C
Balance
The vestibular portion of the eight nerves transmits sensory information from the vestibular 
apparatus to the brain stem and cerebellum. Balance depends on normal input from this 
system in combination with proprioception and eyes. Symptoms and signs suggestive of 
vestibular dysfunction include positional vertigo, ataxia, nausea, vomiting and nystagmus on 
looking away from the side of the lesion. Vestibular balance is not routinely tested in a bedside 
examination but can be tested clinically in disease by the caloric and Hallpike’s manoeuvre. 
The main vestibular causes of loss of balance are benign positional vertigo, vestibular neuronitis 
and Ménière’s disease.
Key points
 · hearing is crudely tested by whispering numbers in one ear while blocking the other ear
 · conductive hearing loss is failure of transmission through air, BC > AC 
 · sensorineural hearing loss is failure of transmission through cochlea/neural connections, AC > BC 
 · Rinne test can discriminate between unilateral conductive and sensorineural hearing loss
 · Weber test lateralizes to the affected ear in conductive loss & to normal ear in sensorineural loss
Glossopharyngeal and Vagus nerves (cranial nerves 9 and 10)
Together these supply power to the palate, throat and larynx and are responsible for normal 
speech and swallowing. The glossopharyngeal nerve supplies ordinary sensation to the posterior 
pharyngeal wall and sensation to the posterior one third of tongue. The vagus supplies the 
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muscles of the palate, pharynx and larynx. The vagus also has a large autonomic innervation 
including heart lungs and abdomen. 
Testing the gag reflex
Routine testing can be performed by watching the soft palate and uvula move upwards in 
the midline in response to the patient saying “aah”. This is called the voluntary gag reflex. 
The gag reflex can also be elicited by gently touching each side of the soft palate with an 
orange stick or tongue depressor and asking the patient if the sensation was the same on both 
sides and watching the palate rise involuntarily. This is called the involuntary gag reflex. The 
involuntary gag tests both the afferent glossopharyngeal and the efferent vagus nerve whereas 
the voluntary gag tests the efferent vagus nerve 
only. A unilateral paralysis of the palate deviates 
away from the side of the lesion. It indicates a 
lower motor neurone lesion of the vagus nerve 
e.g. a bulbar palsy. An upper motor neurone 
lesion has to be bilateral to result in any palatal 
paralysis and then the paralysis of the palate is 
total e.g. pseudo bulbar palsy. The main causes 
are brain stem stroke and motor neurone disease. 
Figure 1.12 Testing the gag reflex Glossopharyngeal 
and vagus nerves
Accessory nerve (cranial nerve 11)
The accessory nerve supplies the sternomastoid and trapezius muscles as shown in the diagrams 
respectively. Wasting of both muscles should be checked for on inspection. Power is assessed by 
resisting the movements of both muscles. Note that the right sternomastoid turns the head to 
the left and vica versa. The strength is gauged by asking the patient to twist the head and the 
examiner placing a hand on the opposite side of the lower face and resisting the movement. 
Similarly the strength of the trapezius muscle can be gauged by asking the patient to first 
elevate or shrug the shoulders and then against resistance. Weakness of these muscles is unusual 
in clinical practice but does occur mostly in muscle disease and myasthenia gravis.
Figure 1.13 Examining the accessory nerve Testing the sternomastoid and the trapezius
Key point
 · test the sternomastoid and trapezius by resisting head turning and shoulder elevation
palate
uvula
tongue
Testing the gag reex
glossopharyngeal and vagus nerves
Testing the trapezius
    Accessory nerve
Testing the sternomastoid
       Accessory nerve
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Hypoglossal nerve (cranial nerve 12)
The hypoglossal nerve is a purely motor nerve which supplies the muscles of the tongue. Testing 
the 12th cranial nerve is done by inspecting the tongue at rest and on protrusion. It is first 
inspected in the floor of the mouth checking carefully for evidence of wasting or fasciculation 
or spasticity. The mobility and strength of the tongue can be assessed by asking the patient to 
protrude it in and out quickly as well as from side to side. The strength of the two sides can be 
assessed by pushing the tongue into either cheek whilst opposing it with your thumb from the 
outside and comparing the sides. A unilateral lower 
motor neurone weakness will result in atrophy and 
fasciculations on the affected side and also deviation 
towards the same side as the lesion. A unilateral upper 
motor neurone lesion will result in tongue deviation 
away from affected side.
Figure 1.14 Examining the tongue Hypoglossal nerve
Key points
 · voluntary gag reflex is tested by getting the patient to say “aah” 
 · involuntary gag reflex is tested by touching the soft palate on both sides
 · normal gag reflex causes a symmetrical elevation of the soft palate and uvula
 · tongue should be inspected at rest in the mouth,  protruded & during movement
EXAMINATION OF THE LIMBS
The arms and legs are examined in the following order, inspection, tone, power, coordination, 
reflexes and sensation. The upper limbs are examined in the sitting position and the lower in 
the lying position.
Inspection
The examination starts with bedside observation for obvious deformities, disabilities, postures, 
contractures or involuntary limb movements or any other abnormality. The way the patient 
moves to undress for the examination also provides useful information concerning power and 
coordination. Start the inspection with the patient in the sitting position and the limbs exposed 
by looking at the skin for scars and trophic changes and the muscles for size, wasting and 
fasciculation. Compare the right side with the left. Muscle wasting should be looked for in the 
hands, arms, shoulders, trunk, thighs and legs. In the hands the front and back of the hands, 
including thenar and hypothenar eminences and the small hand muscles should be checked. 
Fasciculations are spontaneous rippling movements of muscle motor units and their presence 
implies a lower motor neurone lesion. They may take a few minutes of continuous observation 
to see. However they are often benign especially in the calves and after exercise. 
Tone
Tone is tested by moving the limbs passively as the examiner feels the degree of resistance. 
Muscle tone is maintained by the stretch reflex which occurs on passive moving and stretching 
of muscles around joints. The patient should be relaxed and the joint put through its full 
range of movement while comparing sides. Tone is categorized as normal, decreased or 
increased. Decreased tone is uncommon and occurs in lower motor neurone lesions, muscle 
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and cerebellar disease. Increased tone is classified as either pyramidal (upper motor neurone) 
or as extrapyramidal (Parkinson’s disease). In an upper motor neurone lesion increased tone 
is best appreciated in the arm as a spastic catch on rapid flexing and extending the elbow and 
on pronation and supination of the forearm. In the leg tone is best appreciated in the lying 
position with the legs straight by rolling the knee from side to side and on rapid flexing and 
extending the leg at the knee and ankle joints. The initial resistance and the sudden give away 
or release is called clasp knife rigidity. This is best appreciated just at the start of flexion at the 
knee and extension at the elbow. It may be necessary to get the patient to relax by distracting 
him by asking to count backwards from 100 and to try different speeds of passive movement. A 
rapid rhythmic persistent contraction and relaxation of the muscles is called clonus. This can be 
best elicited by dorsiflexing the ankle briskly and maintaining the pressure on the forefoot with 
the knee flexed to about 90 degrees. Persistent clonus or more than 5 beats is always abnormal 
and indicates an upper motor neurone lesion. Clonus occurs less commonly around other 
joints but may be present at the knee and wrist. In extrapyramidal disease the tone is increased 
and is classified as either lead pipe or cogwheel in type. The rigidity is equally stiff throughout 
both flexion and extension and is best appreciated by slowly fully flexing and extending the 
elbow and knee and by pronating and supinating the wrist. It may be increased by distracting 
the patient by asking him to move the contralateral limb e.g. tapping the thigh at the same 
time. Cog wheeling represents intrusion of rest tremor into lead pipe rigidity. 
Figure 1.15 Testing tone Roll the wrist Roll the knee
Key points
 · patient should be relaxed and the joint put through full range of movement passively 
 · increased tone is either pyramidal (clasp knife) or extrapyramidal (lead pipe or cogwheel) 
 · pyramidal rigidity is best appreciated at the start of rapid flexion at the elbow and knee 
 · extrapyramidal rigidity is best elicited by slow flexion/extension of elbow/knee or rolling wrist 
 · clonus is elicited by dorsiflexing the ankle briskly & maintaining pressure on the forefoot
Power
Power is tested in a proximal to distal direction comparing sides with the patient in the 
seated position for the upper limbs and the lying position for the lower limbs. The patient 
first demonstrates muscle strength by active movements and then the examiner opposes those 
movements. This is done by the examiner stabilizing the limb proximal to the joint where the 
movement is being tested and then passively resisting the movement. Recognizing normal 
power is a matter of experience and allowances have to be made for the sick, old, young and for 
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effort. Power loss is graded as mild moderate or severe or as according to the Medical Research 
Council (MRC) classification (Table 1.1).
Table 1.1 Measuring strength
MRC Grade Degree of strength MRC Grade Degree of strength
5 normal power 2 moves but not against gravity 
4 weakness 1 flicker of movement
3 moves against gravity 0 no movement
In a routine neurological examination it is sufficient to test one proximal and one distal muscle 
group in the limbs. A screening test for mild loss of power in the upper limbs is the pronator test; 
this involves holding the arms outstretched with the hands held in supination and eyes closed. 
If an arm drifts downwards and pronates it suggests mild pyramidal weakness on that side. If 
the arm rises or deviates outwards it suggests parietal or cerebellar disease. In the ambulant 
patient walking on the heels is also a good guide to foot drop and walking on toes to weakness 
of the calf muscles. Rising out of a chair or from the squat position and climbing stairs are the 
best tests for weakness of the quadriceps and ileopsoas. The trunk muscles should be tested by 
asking the patient to sit up from the lying position. If the umbilicus moves excessively upwards 
in paraplegia it is called Beevor’s sign. 
To test power in the individual muscle groups do the following: 
 · for shoulder abduction (C5, deltoids), ask the patient to abduct the arms 90 degrees and push upwards 
against the examiners hands resisting the movement
 · for elbow flexion (C6, biceps), ask the patient to extend the elbow 90 degrees and bend or pull the 
forearm towards his face against resistance
 · for elbow extension (C7 triceps), the patient extends (straightens) his forearm 90 degrees against 
resistance
 · for wrist extension (C7, wrist extensors), extension of the patient’s wrist with the fist closed is resisted
 · for finger extension (C7, 8), the examiner uses two fingers to try to resist the patient extending the 
fingers
 · for finger flexion (C8), the patient’s curled fingers of the hand cannot be prised open
 · for abduction and adduction of fingers (T1), forceful spread and coming together of the patient’s 
“fingers” is opposed
 · for abduction of the thumb (T1), the patient’s thumb is brought to a right angle with the palm and 
the movement opposed
examining for power in the lower limbs starts with hip flexion (L1, L2 ileopsoas)
 · for hip flexion the patient flexes the hip and knee to 90 degrees and continues flexing the hip as hard as 
he can, the examiner places a hand on the lower thigh just above the knee to assess strength
 · for hip extension (L5 gluteus maximus), the patient lies flat and pushes down into the bed against the 
examiner’s hand which is placed under his heel
 · for knee extension (L3, L4 quadriceps) ask the patient to bend the knee to 90 degrees and to straighten 
the leg against resistance
 · for knee flexion (S1 biceps femoris), ask the patient to flex or bring his knee in 90 degrees towards his 
bottom while the examiner tries to straighten the leg against resistance
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 · for foot dorsiflexion (L4, L5 tibialis anterior), ask the patient to extend the foot to 90 degrees while the 
examiner opposes the movement
 · for plantar flexion (S1 gastrocnemius), the patient pushes his foot down towards the ground against 
resistance
Figure 1.16 Testing power
Key points
 · power should be attempted actively by the patient before being examined passively by doctor 
 · power should be tested proximally before distally 
 · weakness is graded as mild moderate and severe or 0-5 according to MRC classification 
 · pattern of muscle weakness is a clue to the underlying disorder
Hip exion
Iliopsoas
Lumbar plexus and femoral nerve
L1 L2
Knee extension
Quadriceps femoris
Femoral nerve
L3 L4
Knee exion
Hamstrings
Sciatic nerve
L5 S1
Hip extension
Gluteus maximus
Sciatic nerve
L5 S1
Hip exion
Quadriceps femoris
Femoral nerve
L3 L4
Ankle dorsiexion
Tibialis anterior
Common peroneal nerve
L4 L5
Plantar exion
Gastrocnemius and soleus
Sciatic nerve
S1 S2
Finger extension
Extensor digitorum
Radial nerve
C7
Elbow extension
Triceps
Radial nerve
C7
Elbow exion (forearm midpronated)
Brachioradialis
Radial nerve
C6
Finger exion
Flexor digitorum
Median and ulnar nerve
C8
Shoulder abduction
Deltoid
Axillary nerve
C5
Extensors
Radial nerve
C7
Wrist extension
Finger abduction
Dorsal interossel
Ulnar nerve
T1
Thumb abduction
Abductor pollicis brevis
Median nerve
T1
examination of the limbs
William Howlett Neurology in Africa 31
Coordination
The cerebellum and its connections are responsible for the coordination of voluntary movement. 
These movements depend on normal power and joint position sense. Any significant weakness 
or impairment of joint position sense invalidates the tests for coordination. Abnormalities of 
the cerebellar hemispheres produce ipsilateral signs. Cerebellar dysfunction is characterized by 
incoordination of speech, limbs and gait. The speech in cerebellar disease is dysarthric or slow 
and slurred with a typical scanning quality of getting stuck on the consonants. Nystagmus is 
a sign of cerebellar disease and is worse on looking to the side of the lesion. The main tests of 
incoordination are the finger nose test, the heel shin test and gait. These are carried out with 
the eyes open. Other clinical features are dysarthria, nystagmus and hypotonia of muscles. 
The finger nose test
This test is carried out with the arms fully extended horizontally by asking the patient to touch 
the tip of his nose with the tip of the index finger of his right hand followed by the same with 
his left hand. An alternative method involves asking the patient to touch the tip of his nose 
followed by touching the tip of the examiner’s index 
finger. This is called the finger nose finger test and has 
the advantage of two targets. The examiner’s index 
finger should be held at arm’s length away in front of 
the patient ensuring that the patient has to fully stretch 
to touch the finger. The examiner should observe the 
patient for any obvious limb ataxia and intention 
tremor with increased oscillation on nearing the target.
Figure 1.17 Testing co-ordination The finger-nose test
The heel shin test
This is a two step test. The first step is asking the patient to first hold 
the foot up in the air, then step two to place the heel on the other knee 
and slowly run it down the shin. Any wobble on reaching the target or 
side to side or falling off movement on sliding down the shin points to 
cerebellar disease on the same side. 
Figure 1.18 Testing co-ordination The heel-shin test
Other tests of cerebellar incoordination are rapid alternating hand movements and dysmetria. 
The former is known as dysdiadochokinesia and is demonstrated by rapid tapping the palm 
of one hand alternately with the palm and back of the other hand and then repeating on the 
opposite hand. In the normal person the alternate movements are smooth and regular whereas 
in cerebellar disease they are irregular in amplitude and timing and are jerky. Difficulty judging 
distance or dysmetria is shown by repeatedly tapping the back of one hand with the palm of 
the other. This can normally be done rhythmically and quickly but in cerebellar disease the 
movement is uneven and jerky which can be both seen and heard. The rebound phenomenon 
occurs in cerebellar disease where the tapped outstretched hand oscillates before coming back 
to rest. The gait in cerebellar disease is wide based and ataxic and worse on walking a straight 
line with a tendency to fall to the side of the lesion. 
  Testing co-ordination
  The nger-nose test
Testing co-ordination
   The heel-shin test
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Key points
 · finger nose test is performed with the patient sitting & observed for intention tremor 
 · rapid alternating hand movements (dysdiadochokinesia) is a test of cerebellar disease
 · heel shin test is performed with the patient lying flat being observed  for ataxia 
 · the gait in cerebellar disease is wide based and ataxic 
 · the main signs of cerebellar disease are dysarthria, nystagmus & incoordination
Reflexes
A tendon reflex results from stretching a muscle stretch receptor which in turn discharges via 
an afferent sensory pathway to an anterior horn cell in the spinal cord. The resulting motor 
discharge leads to a muscle contraction. These tendon reflexes are easily demonstrable by a 
blow from a tendon hammer. To elicit a reflex the patient first has to be comfortable and 
relaxed. The muscle to be tested must be under a degree of stretch and it is normal to test the 
main reflexes with the arms, knees and ankles flexed at a 90 degree angle. If reflexes are still 
absent despite relaxation then this should be confirmed with reinforcement, pulling the flexed 
fingers of two hands tightly together for the lower limbs and clenching the teeth for the upper 
limbs. Use the whole length of the patella hammer and swing the rubber end on to a tendon or 
your finger overlying the tendon. The action of the reflex i.e. the contraction of the muscle and 
the movement that it elicits may be both seen and felt by the examiner (Table 1.2). 
Table 1.2 Grading reflexes
Reflexes Grade What it means
absent 0 lower motor neurone lesion, neuropathy
absent but present 
with reinforcement 
+/– normal, but may indicate neuropathy
present + normal
brisk ++ may be normal, but may indicate upper motor neurone lesion
very brisk +++ upper motor neurone lesion
Persistent absent reflexes indicate a lower motor neurone lesion or neuropathy or rarely a 
myopathy or in the case of a single absent reflex a root lesion. The most common cause of 
absent reflexes is poor technique with a clumsy or inadequate blow off target. The ankle reflexes 
may also be absent in the elderly. Increased reflexes may be due to nervousness (or rarely 
thyrotoxicosis) when in time they will revert to normal and the plantar reflexes are down going. 
Very brisk reflexes indicate an upper motor neurone lesion in particular when coupled with 
other signs such as hypertonia, clonus and extensor plantar responses. In order to elicit the 
main reflexes do as follows:
 · elicit the biceps with the arm adducted across the chest wall, put your finger on the biceps tendon and 
tap it watching the biceps muscle for contraction
 · for the supinator reflex, place your finger over the lower third of the radius and hit the finger with a 
hammer watching the brachioradialis contract
 · for the triceps reflex, with the arm in the same position strike the tendon at a 90 degree angle watching 
for the triceps to contract
 · in the legs for the knee reflex, place the free arm under and supporting the knees keeping them flexed 
to a 90 degree angle. Strike the patella tendon near its origin and watch the quadriceps for contraction
examination of the limbs
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 · for the ankle reflex, the knee should be flexed to 90 degrees with the leg in external rotation lying to 
the side and the medial malleolus pointing upwards. Hold the foot at 90 degree angle exerting gentle 
pressure on the toes and strike the Achilles tendon and look at the calf muscles for contraction.
 · in order to elicit the plantar reflex, explain to the patient what you are going to do. Gently draw a blunt 
key up the lateral border of the sole of the foot crossing the foot pads or metatarsal heads. Look for the 
first movement of the big toe at the metatarsophalangeal joint. If the first movement is up going or 
extensor then this a Babinski sign and indicates an upper motor neurone lesion. In the calloused foot 
it may be useful to run the stimulus on the outside or lateral aspect of the foot
Figure 1.19 Testing reflexes
Key points
 · reflexes are elicited in the upper limbs with the 
patient sitting and in the lower limbs lying 
 · examiner needs to be skilled in placing finger 
over appropriate tendons and tapping them
 · reflexes are either absent, reduced, normal or 
increased 
 · plantar response can be either up going 
(abnormal), or down going or mute (normal)
Sensation
The sensory examination is often difficult, time consuming and requires the concentration of 
the examiner and the cooperation of the patient. The technique should be speedy and efficient. 
The aim of the examination is to detect any loss of sensation and the pattern of loss. There are 
five main modalities of sensation to test for, these are light touch, pin prick and temperature 
(superficial) and vibration and joint position (deep). The patient should be instructed about 
The biceps reflex
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the test being performed and first demonstrate the test you are using on familiar non affected 
places e.g. the face by asking the patient to say yes every time he feels the stimulus. Then start 
the examination with the patient’s eyes closed by testing from a distal to proximal direction 
touching main dermatomes and comparing right and left sides. The patient indicates that he 
has felt the stimulus by saying “yes” or by communicating some other way. 
Testing superficial sensation
It is usually sufficient to touch each site once varying the timing and moving from an area of 
abnormal sensation to normal sensation. The same method is applied for testing pain. If the 
neurological examination is a screening examination to exclude any unsuspected sensory findings 
then it’s enough to use one example of superficial sensation (light touch) and one example of 
deep sensation (joint position sense) and to test on all four limbs distally. If the patient has 
noticed an altered sensation in any part of the body then a more detailed sensory examination 
is required, testing the main sensory modalities. Sensory 
testing begins with testing for light touch by using a 
wisp of cotton wool or a finger tip being careful each 
time to touch or dab the skin lightly rather than to drag 
it across the skin. To test for pain use a blunt pin or 
sharp tooth pick taking care not to draw blood. Do not 
reuse the pin on another patient. Temperature is not 
usually tested in the routine examination. For formal 
testing it is necessary to fill two test tubes, one with hot 
and other with cold iced water and ask the patient to tell 
you which tube is hot or cold on random touching of 
the limbs, face and trunk.
Figure 1.20 Testing superficial sensation
Joint position
Joint position is first tested on the finger tips and toes. The tip of the digit being tested is held at 
the sides between the examiner’s thumb and the index finger. The patient is shown an upward 
and downward movement first with his eyes open and told that he will be asked to identify 
the direction of movement once his eyes are closed. If the patient cannot identify the direction 
correctly then the next proximal larger joints should be tested until a joint with intact joint 
position sense is found. 
Figure 1.21 Testing deep sensation Testing joint position in the finger (left)  
A) Joint position sense B) Vibration sense
Testing supercial sensation light touch
Testing joint position in the nger
A
B
Testing deep sensation
A   Joint position sense
B   Vibration sense
A
B
Testing deep sensation
A   Joint position sense
B   Vibration sense
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Vibration
Vibration sense is tested using a 128 Hz or 256 Hz tuning fork. The beating fork should be first 
placed on the back of terminal phalanx of the index finger and big toe and the patient asked if 
he can feel the vibration. If not felt distally it must then be placed on the metacarpal phalangeal 
joints, wrist, elbow and shoulder in the upper limbs and the medial malleolus, tibial tuberosity 
in the lower limbs moving onto the anterior iliac crest, rib margin, sternum or clavicle in search 
of an intact vibration level. Vibration is often lost early on in neuropathies. 
Localization
The pattern of sensory loss may indicate the underlying disease. A distal glove and stocking 
loss of sensation points to a peripheral neuropathy, loss of sensation below a level on the 
trunk points to a spinal cord lesion, hemisensory loss on the body points to a central brain 
lesion, loss of temperature discrimination on the face and trunk should suggest a spinothalamic 
lesion, and a dermatomal loss points to a nerve or nerve root lesion. Details concerning cortical 
sensory loss including sensory extinction, two point discrimination, graphanaesthesia, and 
astereognosis can be found in chapter 2.
Key points
 · patient should be trained to indicate each stimulus & the direction of movement of the joint
 · patient indicates stimulus by saying “yes” and type eg “sharp or blunt”, “hot or cold”
 · testing should be speedy, efficient, starting distally before moving proximally
 · routine sensory testing should be restricted to peripheral light touch & joint position 
 · pattern and type of sensory loss helps to determine the underlying disorder
EXAMINATION OF THE GAIT
The gait provides useful clues to the underlying 
neurological disorder and it is important to examine 
it. Ask the patient to walk normally with the arms 
hanging loose by the sides and observe the gait for 
the following; movement, balance, posture, arm 
swing, turning and symmetry. If the gait is abnormal 
note the main characteristic and whether the patient 
walks unaided or uses a stick or crutch. Note whether 
the patient is unsteady and if he is able to walk a 
straight line by putting one foot in front of the 
other. Gaits can then be categorized as symmetrical 
or asymmetrical. Examples are the small symmetrical 
steps of Parkinson’s disease and asymmetrical steps 
of hemiplegic gait. The main abnormal types of gaits 
are: hemiplegic, paraplegic, cerebellar, Parkinsonian, 
sensory ataxic, neuropathic and myopathic. These 
are described in chapter 2.
Figure 1.22 Testing gait
Testing gait
The Romberg test
    (eyes closed)
Testing joint position sense
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Romberg’s test
To carry out a Romberg’s test ask the patient to stand unsupported with his heels together, toes 
apart and eyes closed. Reassure the patient that you will catch him if he falls. If he falls or sways 
repeatedly with eyes closed but not with eyes open this is a positive test indicating impairment 
of joint position sense in the feet or posterior columns in the spinal cord (proprioception).
Key points in testing gait
 · ask the patient to stand with heels together, feet apart and eyes closed
 · observe for swaying or falling 
 · ask the patient to walk normally with arms hanging loosely by the sides 
 · observe for balance, posture, arm swing and unsteadiness
 · if ataxia is still suspected, ask the patient to walk a straight line & place one foot in front of the other
CONSCIOUSNESS
Consciousness is a state of awareness of self and environment and any alteration or impairment 
requires objective measurement. In neurology patients the level of consciousness may range from 
being awake and fully conscious which is normal through confusion to altered consciousness 
and coma (Table 1.3). The level of alertness or confusion can be measured by checking for 
orientation in time, person and place. Coma can be measured using the Glasgow Coma Scale 
(GCS) (Table 1.5). Their value is that they produce objective measurement of the patient’s level 
of alertness (orientation) and consciousness (coma) which are important for the assessment and 
ongoing care of the patient. 
Table 1.3 States of consciousness
Level Clinical features Measurement scale
Normal awake and fully conscious 
Confused inability to think and speak clearly with lack of 
attention and memory and disorientation 
orientation in time, person and place (10/10)
Coma altered level of consciousness Glasgow Coma Scale (15/15)
Table 1.4 Testing for orientation 10/10*
Time Person Place
time
day
month
year
name
age
year of birth
hospital
town/district
country
* score one for each correct answer
ConsCiousness
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Table 1.5 Glasgow Coma Scale
Activity Best response Score
Eye opening - spontaneously
- to speech
- to pain
- nil
4
3
2
1
Motor response - obeys commands
- localizes stimulus
- flexes withdrawal
- flexes weak
- extension
- nil
6
5
4
3
2
1
Best verbal - oriented fully
- confused
- inappropriate
-  incomprehensible 
(sounds only)
- nil
5
4
3
2
1
Maximum score 15
when assessing record, eye opening (E4), motor (M6), & best verbal response (V5) patients are considered 
comatose if GCS ≤8/15
Mental state
The general physical state, appearance and behaviour of the patient is also helpful e.g. a recent 
onset of confusion points to an organic cause whereas a chronic unkempt unconcerned patient 
with a thought disorder is more likely to be non organic or psychiatric. Patients with psychiatric 
disorders should be referred for psychiatric evaluation. However an organic cause may need to 
be excluded first.
Cognitive function
The level of patient cooperation and insight into the illness are also important factors. Patients 
presenting with confusional states or delirium may need further cognitive evaluation. This 
initially involves simple bedside clinical tests for attention and concentration. These include 
testing for orientation in time and place, checking the ability to repeat a set of up to 6 numbers 
or to count back from 20 or recite the months of the year backwards or other learned abilities. 
In chronic organic brain disease states e.g. dementia or localized brain disease a more detailed 
evaluation of cognitive function may be helpful. This involves additional cognitive testing 
including tests for registration, memory, calculation and language. These can be formally 
measured by the Mini mental state examination (MMSE) (Chapter 17).
Key points
 · patient’s general appearance & performance 
are indicators of neurological & mental health
 · a detailed assessment of mental state & higher 
cerebral function is done when the history 
indicates 
 · level of alertness and orientation are used to 
monitor the confused patient 
 · Glasgow Coma Scale is used to monitor level 
of consciousness in the semi or unconscious 
patient
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Other neurological signs
 · Signs of meningism
 · Frontal lobe release signs
 · Superficial reflexes
 · Straight leg raising test
Signs of meningism
These signs are found in patients with meningitis, subarachnoid haemorrhage and other causes 
of meningism. However be aware that the neck may be stiff or rigid in other conditions such as 
cervical spondylosis, Parkinsonism and tetanus giving rise to a false positive sign of meningism.
 · neck stiffness
 · Kernig’s sign
 · Brudzinski’s sign
Neck stiffness
The patient should be lying flat. The head should be supported 
by placing your hands under the patient’s occiput until the 
weight of the head is carried in the hands indicating the patient 
has relaxed. Neck flexion should be induced slowly by gently 
lifting the head off the bed whilst at the same time feeling 
for tone or resistance to the movement. In the normal person 
the neck flexes easily without resistance with the chin usually 
reaching the chest. Neck stiffness is present when the neck is 
rigid or resists any attempt to passively flex the neck. This will 
result in failure to bring the chin onto the chest. Neck stiffness is 
the most sensitive of the signs of meningism. 
Figure 1.23 Examining for neck stiffness Use your fingers to flex the 
neck whilst assessing the degree of resistance
Kernig’s sign
The patient should be lying flat. This is elicited by passively 
attempting to straighten the leg after flexing both the thigh and 
knee to an angle of greater than 90 degrees. In meningitis this 
is met by pain and resistance in the lumbar area as a result of 
stretching of inflamed nerve roots. In patients with meningeal 
irritation the sign is positive on both sides. 
Figure 1.24 Testing for meningism Kernig’s sign
Brudzinski’s sign
Whilst examining the patient for neck stiffness observe whether forward flexing of the neck 
induces any involuntary hip and knee flexion. Involuntary lower limb flexion indicates 
meningeal irritation. This is a sensitive test for meningitis in young children but not in adults.
Use your ngers to ex the neck whilst assesing the degree of resistance
           Testing for neck stiness.
pain
Kernig´s sign
ConsCiousness
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Frontal lobe release signs (FLRSs)
These signs may be present infrequently in normal persons. However they occur more 
frequently and are usually exaggerated in frontal lobe disorders and other diffuse mainly 
cortical neurological disorders. 
Snout reflex
This is elicited by pressing or tapping on the closed lips in the midline with a patella hammer 
or closed knuckle. In positive cases this elicits a puckering of the lips (orbicularis oris) and 
occasionally a contraction of the chin (mentalis muscle).
Palmomental reflex
Scratch the palm of the hand at the base of the thumb in a distal direction with a key. In positive 
cases there is a contraction of the chin (mentalis muscle) on the same side as the stimulus.
Grasp reflex
Place your fingers in the palm of the patient’s hand and stroke it gently whilst pulling your 
hand away. In positive cases the patient’s hand will involuntarily curl and grasp the examiner’s 
hand. A unilateral grasp reflex indicates contralateral frontal lobe pathology.
Superficial reflexes
These are present in healthy persons but are absent in an UMNL. The abdominal reflexes may 
also be absent in obese persons and after pregnancy and after abdominal surgery. 
Abdominal reflex
Test by stroking lightly with the sharp end of the patella hammer in each of the four quadrants 
of the abdomen from the outside in a diagonal or horizontal approach. The abdominal wall 
contracts in each quadrant in the normal patient. 
Cremasteric reflex
This is performed in men. The inner aspect of the upper thigh is stroked lightly from below 
upwards. In the normal male this results in an elevation of the testes on the same side. Its 
absence may indicate an UMNL above the level of L1. 
Straight leg raising test
This is a test for entrapment of the lumbar and sacral nerve roots. With the patient lying flat 
after placing a hand under the patient’s heel lift the fully extended or straightened leg. An angle 
of 90 degrees is normal but may be less in older patients. Limitation of movement with pain 
suggests nerve root entrapment on the affected side. Note the angle achieved and the difference 
if any between the two sides. The most common cause is herniation of an intervertebral disc.
Figure 1.25 Testing for sciatica Lift leg to 90 degrees with leg fully extended
pain
  Lift leg to 90 degrees with leg fully extended
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KEY TO BASIC NEUROLOGICAL EXAMINATION
GENERAL ASSESSMENT assess for alertness, orientation, level of consciousness
CRANIAL NERVES
Visual acuity can you see normally, if vision is decreased then check VA
first cover one eye & read letters on this chart, repeat for other eye
Visual fields tell me when you see my finger tip moving, test on each side 
Fundoscopy look at the optic disc and fundus
Pupils shine bright light in each eye, look for pupillary constriction
Eye movements follow my finger moving right left and up down
check for diplopia and any loss of eye movements
Facial sensation with your eyes shut, say “yes” when you feel me touching your face 
Facial movements inspect the face
look up at the ceiling
close your eyes tightly & don’t let me open them 
smile or show me your teeth
Hearing can you hear normally, if not examine each ear 
“repeat numbers I am whispering or speaking”
use tuning fork tests only if deafness is confirmed
Palatal movement & tongue open your mouth and say “aah”, inspect gag reflex 
inspect tongue at rest, protruded and on movement
Neck/shoulders turn your head against my hand
shrug your shoulders against my hands
LIMBS
Inspection look for wasting and fasciculation in arms, legs & trunk
Tone bend and straighten the patient’s elbow & knee
Power: Arms
Power: Legs 
hold elbows out from your sides & push upwards 
bend & straighten your elbow 
bend your wrist & fingers upwards 
separate your fingers sideways 
bend your thumb upwards 
push your thigh upwards 
bend & straighten your knee 
push your foot down & upwards towards your face 
Co-ordination touch tip of your nose with tip of your index finger
hold foot in the air, touch knee with heel & run it down the shin
Reflexes tap briskly the biceps, triceps, supinator, knee and ankle tendons
elicit the plantar response
Sensation (eyes closed) say “yes” or ”indicate” when you feel me touching you 
“I am moving your finger/big toe Tell me is it up or down”
GAIT
observe standing, heels together & toes separated (eyes closed) 
observe walking normally, straight line, heel to toe
key to basiC neurologiCal examination
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CHAPTER 2
LOCALIZATION
The site of the lesion 
The nervous system can be divided into the 
central (CNS) and peripheral (PNS) nervous 
system. In the CNS the main sites of disease 
are the cerebral hemisphere, basal ganglia, 
cerebellum, brain stem and spinal cord (Fig. 
2.1). In the PNS the main sites of disease are 
the cranial and peripheral nerves. Diseases of 
the neuromuscular junction and muscle are 
included by convention.  The main aim of this 
chapter is to localize abnormal neurological 
findings to their main site of origin within 
the nervous system. After reading the chapter 
the student should aim to distinguish 
between an upper and lower motor neurone 
lesion and to be able to localise neurological 
disorders to their main site of origin. Details 
concerning localization and the cranial nerves 
are outlined in Chapter 12. 
Figure 2.1 Main sites of neurological disorders
MOTOR SYSTEM
CNS
The motor system in the CNS consists of the brain and spinal cord, beginning in the motor 
cortex and extending down the brain stem and spinal cord to end at the lower border of L1. 
The motor tract begins in the frontal lobe, descends via the corona radiata on the same side 
to become the internal capsule. It then descends into the brain stem as the pyramidal tract 
and mostly (85%) crosses at the lower end of the medulla to the opposite side. From there 
it descends into the spinal cord as the lateral corticospinal tract and finally synapses with 
the anterior horn cells at the front (anterior) of the spinal cord on the same side (Fig. 2.2). 
A lesion anywhere along this pathway in the brain or spinal cord results in an upper motor 
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neurone lesion (UMNL). The neurological signs of an UMNL are loss of power, increased tone 
(hypertonia), clonus, increased reflexes (hyper-reflexia) and extensor plantar response (up going toes 
or Babinski sign). The presence of these signs localise the site of the lesion to the CNS. The main 
UMN disorders presenting with these signs are hemiplegia arising from lesions in the brain 
and quadriplegia arising from lesions in the brain stem. The other main UMN disorders are 
quadriplegia and paraplegia arising from the spinal cord depending on the level of the lesion.
Figure 2.2 The corticospinal tract (left) Spinal cord section Main motor and sensory tracts (right)
PNS
The motor system in the PNS consists of cranial and peripheral nerves, extending from their 
nerve nuclei in the brain stem and anterior horn cells in the spinal cord to the neuromuscular 
junction in muscle (Fig. 2.3). A lesion anywhere along this pathway is called a lower motor 
neurone lesion (LMNL). The neurological signs of a LMNL are loss of power, muscle wasting, 
fasciculation, decreased tone (hypotonia) and decreased or absent reflexes (hyporeflexia or areflexia). 
The presence of LMN signs 
localise the site of the lesion 
to the peripheral nervous 
system. The main clinical 
disorders causing these signs 
are peripheral neuropathies, 
mononeuropathies and 
cranial nerve palsies. 
Figure 2.3 The peripheral 
reflex pathway
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The diagram “the peripheral reflex arc” outlines the pathway of a peripheral reflex. It is essential 
to be able to distinguish clinically between an UMNL and a LMNL, in order to be able to 
correctly localise a neurological disorder to its main site of origin. It is important to note that 
loss of power is common to both and therefore does not help to distinguish between them, 
and that these signs may not all be present in any one individual patient. The main differences 
between them are summarized in the table 2.1 below. 
Table 2.1 Key differences between UMNL & LMNL
Neurological findings UMNL* LMNL*
wasting  yes
fasciculations yes
tone
increased
decreased
clonus
yes
yes
yes
reflexes
increased
decreased/absent
yes
yes
Babinski sign yes
* a blank space means no
SENSORY SYSTEM
The sensory system comprises of nerves and tracts which carry stimuli arising from the 
periphery including skin, joints, muscle and viscera via the peripheral nervous system (PNS) 
to the brain. In the CNS there are two main sensory pathways, the dorsal columns and the 
spinothalamic tracts (Fig. 2.4). The dorsal columns transmit joint position sense, vibration sense 
and light touch. The peripheral nerves transmitting these 
sensations enter via enter the posterior roots of the spinal 
cord and ascend in the dorsal columns to the lower end 
of the medulla, where they synapse. They then cross the 
midline and ascend to reach the thalamus, from where a 
further relay goes to the sensory cortex in the parietal lobe 
of the brain on the same side. Sensory symptoms arising 
from the posterior columns are numbness, tingling and loss 
of co-ordination. The spinothalamic tract transmits pain, 
temperature and crude touch. These enter the posterior 
spinal cord ascend a few segments, and then cross the 
midline to ascend in the anterolateral spinothalamic tract 
via second order neurones to the ipsilateral thalamus, 
and finally to the parietal lobe on the same side. The 
main sensory symptoms arising from disorders of the 
spinothalamic tract are pain and dysaesthesia. Sensory 
symptoms arise from disease at different levels in the 
nervous system. The main sensory sites of clinical interest 
are at the level of peripheral nerves, spinal cord and brain.
Figure 2.4 The spinothalamic tract (left) 
sensory system
William Howlett Neurology in Africa 49
The anatomical pattern of sensory loss helps to localise the site 
of the underlying disorder. The main patterns of sensory loss 
are outlined in the following figures 2.5–7.
Figure 2. 5 Sensory loss in peripheral neuropathy glove and stocking 
distribution (left)
In peripheral nerve disorders the most common pattern of 
loss is that seen in peripheral neuropathies where the loss 
is mainly distal and affects the feet and hands in a glove and 
stocking distribution. The main causes of this are HIV and 
diabetes mellitus. 
Figure 2.6 Sensory loss in paraplegia (right)
In spinal cord disorders the loss involves the limbs (usually the 
legs) and the trunk below the level of the lesion. The extent 
and pattern of loss depends on the underlying lesion, e.g. 
complete or partial cord involvement resulting in paraplegia. 
The main causes are trauma and infection. 
Figure 2.7 Sensory loss in brain stem lesion (left) Sensory loss in 
hemiplegia (right)
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In brain disorders sensation is lost or more commonly altered on the side of the body opposite the 
site of lesion. The main causes are vascular and space occupying lesions.
CEREBRAL HEMISPHERES
The brain has two hemispheres, each containing a frontal, parietal, temporal and occipital 
lobe, each lobe with their own distinctive functions. The main neurological signs indicating a 
lesion on one side of the brain are a loss of power or less frequently sensation on one side of the 
body, a loss of speech if the dominant hemisphere is involved and a loss of vision to one side if 
the optic pathway is involved. The presence of these focal neurological signs help to localize 
the site of the lesion to a cerebral hemisphere on one side and also to an individual lobe within 
that hemisphere (Fig. 2.8). 
Figure 2.8 Cerebral hemispheres
Frontal lobe
The frontal lobe contains the motor cortex, which is responsible for motor function and 
movements of the opposite half of the body. Disorders affecting either frontal lobe result in 
weakness or a loss of power involving the opposite side of the body and also a loss or impairment 
(dysphasia) of speech (aphasia, expressive), if the speech area (Broca’s area) in the dominant 
hemisphere is affected. Personality changes with features of social disinhibition and urinary 
incontinence may also occur. Frontal lobe release signs, including the grasp reflex may also be 
present. 
Parietal lobe
The parietal lobe contains the sensory cortex whose main function is discriminatory sensation 
involving the opposite half of the body. Patients with lesions in the parietal lobe have subtle 
sensory impairments, which require higher sensory testing to demonstrate. They have an 
inability to recognise familiar shapes, textures and numbers and an impairment of fine touch when 
tested on the opposite hand on either side. Lesions involving the dominant hemisphere result 
in difficulty with calculation, writing and apraxia (difficulty performing task related movements) 
and a receptive dysphasia if the dominant hemisphere is affected (Wernicke’s area). Lesions 
involving the non dominant hemisphere result in a lack of visuo-spatial awareness with hemi-
neglect of the opposite side of the body. This can result in an inability to dress or wash on the 
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receptive dysphasia (dominant)
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affected side. A lesion in either parietal lobe may result in an inferior quadrantic visual field 
defect or a loss of the lower half of the visual field coming from the opposite side. 
Temporal lobe
The temporal lobe contains Wernicke’s receptive speech area in the dominant hemisphere. 
Damage to it results in loss of understanding of speech and writing (aphasia, receptive) and loss of 
memory. Seizures originating in the temporal lobe may begin with a characteristic hallucinatory 
prodrome of smell, taste, vision, hearing or emotion. A lesion in either lobe may result in a 
superior quadrantic visual field defect or loss of the upper half of the visual field coming from 
the opposite side. 
Occipital lobe
The occipital lobe is responsible for vision. Lesions of the occipital lobe may result in a 
contralateral homonymous hemianopia or loss of the visual field coming from the opposite side. 
SPEECH DISORDERS
There are three main types of speech disorder: dysphonia, dysarthria and dysphasia. 
Dysphonia
This is a disorder of voice production of sound as air goes through the vocal cords. It results 
in inability to produce a normal volume of speech or sound. It is usually recognized during 
the history taking, because the sound the voice generates is low, hollow or hoarse. It arises 
from failure of adduction of the vocal cords due either to paralysis or to local disease in the 
larynx. It can be suspected by asking the patient to cough, when instead of the normal sharp 
explosive cough there is a characteristic husky or bovine like cough. The diagnosis is confirmed 
by inspection of the larynx and vocal cords. The main causes are a local lesion e.g. a tumour, 
recurrent laryngeal nerve paralysis, and myasthenia gravis.  
Dysarthria
This is an inability to coordinate the movements of tongue, lips and pharynx to articulate or 
produce understandable sounds. This makes words sound slow and slurred and leads to difficulty 
in their understanding. Any neurological disorder which affects the muscles or movements 
involved in speech production can produce a dysarthria. The main causes are stroke, cerebellar 
disease, and cerebral palsy. 
Dysphasia
This is a disorder of language production resulting in either a loss of understanding or expression 
of words or both. It arises because of damage to the speech areas in the brain in the dominant 
hemisphere. The main speech centres are situated on the left side of the brain in >90% of right 
handed people and also in about two thirds of left handed people. Dysphasia and aphasia are 
clinically classified as either receptive, expressive or global.
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Key points
 · listening determines the type of speech disorder
 · it can be dysphonia, dysarthria or dysphasia
 · pts with dysphonia can’t make the sounds
 · pts with dysarthria can make the sounds but the words don’t sound normal
 · pts with dysphasia cannot either understand or say words normally or both 
Figure 2.9 Main speech areas of the brain
Key points
 · establish whether the patient is right or left handed and his/her language
 · listen to speech for fluency, content & meaning
 · assess reception by simple commands/questions eg ”close your eyes”
 · assess expression by asking the patient to name 3 familiar objects; eg pen, watch & glasses
Receptive
A patient with receptive aphasia loses understanding for both the spoken and written word, and 
is unable to follow even simple bedside questions and commands. The speech content is fluent 
but meaningless and many words are either incorrect or newly created. It is caused by a lesion 
in Wernicke’s area (Fig. 2.9).
Expressive
A patient with expressive aphasia understands normally but has difficulty in finding the words. 
In this type of aphasia there are often great gaps between the words, with non fluent telegraphic 
or monosyllabic speech and lack of rhythm. Writing may be poor. The patient is usually aware, 
though frustrated and may use gestures to try to help to express. It is caused by a lesion in 
Broca’s area in the dominant frontal lobe (Fig. 2.9).
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Global
This occurs when the patient is neither able to understand the spoken or written word or able to 
express himself. It is caused by an extensive lesion of the dominant hemisphere, affecting both 
temporal and frontal speech areas. The main cause of aphasia is stroke. 
Key points
 · pts with receptive aphasia do not understand
 · pts with expressive aphasia cannot express the right words
 · pts with global aphasia can neither understand nor express the right words
BASAL GANGLIA
The basal ganglia and their connections control movement. Diseases affecting them cause 
movement disorders, which are characterised by either too little or too much movement. 
Parkinson’s disease (PD) causes too little movement. The main clinical features of which are 
bradykinesia, rest tremor, rigidity and gait disorder. Disorders that result in too much movement 
include dystonia and chorea. The main causes are medications and stroke. 
CEREBELLUM
The cerebellum and its connections coordinate voluntary movement. Disorders affecting 
the cerebellum cause incoordination. The main symptoms and signs of cerebellar disease are 
dysarthria, nystagmus and incoordination of the limbs and gait. Hypotonia and pendular reflexes 
are additional signs but may not always be present. Cerebellar signs are localizing and the 
presence of unilateral cerebellar signs help to localise a lesion to the cerebellum to the same 
side. The main causes are stroke, drugs including alcohol, hereditary disorders, tumours and 
forms of neurodegenerative disease. 
BRAIN STEM
The brain stem (Fig. 2.10) comprises the 
midbrain, pons and medulla. It is responsible for 
the lower ten cranial nerves, the ascending motor 
and descending sensory tracts, integrating co-
ordination and balance and the central regulation 
of heat, respiration, circulation and consciousness. 
The clinical features of a brain stem disorder will 
depend on the site and the extent of the lesion. 
In general a brain stem lesion is suggested when 
cranial nerve palsies and ataxia occur on one side 
of the head and a loss of power and sensation occurs 
on the opposite half of the body. An alteration or 
loss of consciousness and quadriplegia occurs with 
extensive brain stem lesions. The main causes are 
stroke, trauma and mass lesions.
Figure 2.10 Brain stem Main cranial nerve nuclei in the brain stem
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SPINAL CORD
The spinal cord (CNS) extends from the top of C1 vertebra down to the end of L1. It is then 
continuous with the cauda equina (PNS) which extends from L1 down to S5 (Fig. 2.11). 
The spinal cord is surrounded by three layers, a thick dura, an arachnoid and a pia which is 
adherent to the cord. The subarachnoid space contains cerebrospinal fluid and extends down 
to S5. The cord is made up of a large H shaped grey area in the centre containing many nerve 
cells and a peripheral white area which contains the ascending and descending axons or tracts 
(Fig. 2.12). 
Figure 2.11 Spinal cord  
Spinal nerve and vertebra coloumn
The main ascending tracts are the spinothalamic and dorsal columns (Fig 2.4) and the main 
descending tracts are the corticospinal tracts of which the lateral (LCST) is the main one (Fig 
2.2). These main tracts all cross the spinal cord to supply the opposite side. The spinothalamic 
tract crosses shortly after entry and the posterior columns and the corticospinal tract cross at 
the lower end of the medulla. Any lesion affecting the spinal cord may result in loss of motor, 
sensory and autonomic function below the level of the lesion. Disorders affecting the spinal cord 
result in either a quadriplegia or paraplegia, depending on the site and level of injury or disease. 
The main causes are trauma, TB, infections, myeloneuropathies and peripheral neuropathies.
Paraplegia
Paraplegia means paralysis of the legs. This results from a lesion affecting either the spinal cord or 
the cauda equina. It can very rarely arise from a lesion within the brain. When the lesion affects 
the spinal cord above the level T12, L1 the clinical findings are those of spastic paraplegia. These 
UMNL signs are almost always combined with loss of sensation at and below the level of the 
lesion. The sensory level below which sensation is lost or reduced is very important as its upper 
limit usually indicates the site of the lesion. When the lesion affects the spinal cord below 
the level L1 it involves the cauda equina and the neurological findings are those of a flaccid 
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Figure 2.12 Vertebra showing spinal cord, nerve 
roots and spinal nerves
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paraplegia. In this case the findings are all LMNL signs which when combined with upper limit 
of sensory loss in the legs and perineum will help to determine the site of the lesion. 
Quadriplegia
Quadriplegia indicates paralysis of all four limbs. The clinical findings are the same as for 
paraplegia except in this case all four limbs are involved. When the site of the lesion is in the 
lower half of cervical cord there may be radiculopathy or lower motor neurone signs involving 
the arms (C5-T1) at the level of the lesion and upper motor neurone signs and sensory loss 
below the level of the lesion. Both spastic and flaccid forms of quadriplegia and paraplegia are 
associated with loss of bladder and bowel control.
Bladder
The bladder is innervated by the autonomic and somatic or voluntary nervous system. The 
autonomic supply comprises of the parasympathetic fibres from S2-4 which are involved in 
emptying the bladder and the sympathetic fibres from T11-L2 which are involved with urine 
retention. The voluntary nerve fibres (S2-4, 
pudendal nerve) supply the external bladder 
neck sphincter. Loss of control of bladder 
function or neurogenic bladder arises 
primarily because of lesions in the spinal 
cord or cauda equina. Patients with spinal 
cord lesions present with a spastic paraparesis 
and spastic bladder with frequency, urgency 
and incontinence. They may develop 
satisfactory reflex bladder emptying or 
require intermittent self-catheterization 
and anticholinergic drugs. Patients with 
cauda equina lesions present with flaccid 
paraparesis and flaccid bladder with urine 
retention and usually require a permanent 
urinary catheter. Constipation is a feature of 
both types of paraplegia. 
Figure 2.13 Sensory loss associated with spinal 
cord lesions A: Hemisection of cord  
B: Complete transverse section of cord
Localization
A lesion affecting one half of the spinal cord results in a hemi section or a Brown-Sequard 
syndrome (Fig. 2.13). This has three main and diagnostic neurological features all occurring 
below the level of the lesion. These are a loss of power (UMNL) and a loss of joint position sense 
and vibration occurring on the same side as the lesion and a loss of pain and temperature on the 
opposite side the lesion. A lesion causing a complete transverse section of the cord results in a 
total loss of power and feeling below the level of the lesion and loss of bowel and bladder control 
(Fig. 2.13).
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PERIPHERAL NERVOUS SYSTEM
Peripheral nerves
The peripheral nervous system is made up of mixed motor and sensory fibres comprising the 
cranial and peripheral nerves. Details concerning cranial nerve disorders and localization are 
presented later in chapter 12. In general disorders affecting the peripheral nerves are divided 
into two main groups called neuropathies: mononeuropathies which involve single nerves and 
polyneuropathies which involve all nerves. The main causes of these are HIV, diabetes and 
leprosy. 
The diagrams below are to help to remind the student of the following, a typical peripheral 
reflex arc using the knee jerk as an example (Fig. 2.14), the main segmental motor movements 
and their nerve roots (Fig. 2.15), the main peripheral reflexes and their nerve root of origin (Fig 
2.16), and the main sensory dermatomes (Fig. 2.17). 
Figure 2.14 The knee reflex
The diagram entitled “the segmental limb movements” shows the main movements tested 
during motor neurological examination and their nerve roots innervations. 
Figure 2.15 The segmental limb movements
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The diagram marked “reflexes” shows a simplified method of remembering the nerve root origins of 
the main peripheral reflexes. This is done by “counting from 1 to 8 from below up”.
Figure 2.16 Reflexes Count from the ankle
The diagram marked skin territories shows the main sensory dermatomes and their nerve root 
origin.
Figure 2.17 Skin territories of landmark nerve roots
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The main sites of neurological disorders and the resulting patterns of motor and sensory loss 
are summarized in Tables 2.2 & 3.
Table 2.2 Main sites and patterns of motor loss
Site Pattern of motor loss (weakness)
CNS (UMNL)
hemisphere
brain stem
spinal cord (C1-T12)
hemiparesis
cranial nerve palsies one side & hemiparesis on other side  
quadriparesis & LOC*
quadriparesis 
paraparesis 
PNS (LMNL)
spinal cord (L1-S5)
anterior horn cell
nerve root 
nerve plexus
mononeuropathy 
(cranial or peripheral)
polyneuropathy
paraparesis
localised/generalized 
root distribution
>one nerve root
single peripheral nerve 
feet and legs > hands and arms
* these may occur in an extensive brain stem lesion
Table 2.3 Main sites and patterns of sensory loss 
Site Sensory loss
PNS 
single nerves 
all peripheral nerves 
spinal nerve roots
cauda equina
nerve distribution 
glove and stocking
dermatomal 
both legs & perineum
CNS
Spinal cord
complete transection
hemisection  
(Brown Sequard Syndrome) 
all below level of the lesion
joint position/vibration/light touch on same side & pain/temperature on 
opposite side 
Brain
brain stem
parietal lobes*
face on same side as lesion & limbs on side opposite lesion
on side opposite the lesion
a numbness
b agnosia
c loss of two point discrimination
d astereognosis 
e graphanaesthesia
f sensory inattention
* cortical sensory testing
peripheral nervous system
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Cortical sensory testing: Definitions
agnosia: abnormality of perception despite normal sensory pathways
two point discrimination: ability to determine whether one or two points are being applied at 
the same time (normal discrimination on finger tips: 2-3 mm)
astereognosis: inability to recognise familiar shapes and textures when felt in either hand with 
both eyes shut
graphanaesthesia: inability to identify numbers drawn on the palms with both eyes shut
sensory inattention: inability to correctly recognise and report a stimulus (visual or tactile) 
coming from the side opposite the lesion when the two stimuli are presented together to both 
sides at the same time
NEUROMUSCULAR JUNCTION
Neuromuscular disease results in a pattern of weakness which is characteristically fatigable 
on repeated testing. The neurology examination is usually normal apart from the muscle 
weakness. The degree of weakness ranges from drooping of the eye lids and diplopia in mild 
cases to difficulty to talk, swallow, breathe, move eyes and limbs in severe cases. The main cause 
of neuromuscular junction weakness is myasthenia gravis. 
MUSCLE
Muscle disease results in weakness and sometimes muscle wasting. Neurology examination 
is normal apart from the muscle weakness and reflexes are usually preserved until late in the 
disease when they may be lost. The clinical characteristic of myopathic weakness is that the 
proximal muscles are more involved than the distal ones. This is most obvious whilst asking the 
patient to repeatedly elevate the arms over the head or whilst attempting to stand up from a 
seated position on the ground or in a chair. The main causes of muscle weakness are myopathy, 
polymyositis and muscular dystrophy.
GAIT DISORDERS
A normal functioning gait requires the coordinated action of an intact sensory and motor 
system, which in turn relies on normal balance and muscles. Neurological causes of gait 
disorder may arise from any one or all of these. Gait disorders are classified on the basis of their 
main clinical presentation. The main types of abnormal gait are outlined below in Table 2.4. The 
site of abnormality is suggested by the characteristic gait and confirmatory neurological signs. 
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Table 2.4 Common gait disorders seen in clinical practice
Gait disorder Clinical features
Hemiparetic gait arm adducted, leg extended, stiff & circumducting
Spastic paraparesis slow, stiff, jerky with scissoring/adduction at knees & dragging of toes
Cerebellar wide based & unsteady, can’t walk a straight line
Parkinson’s slow & stiff with small & shuffling steps, neck & trunk & limbs 
semi flexed & decreased or no arm swing
Sensory ataxic high stepping gait with stomping feet
Neuropathic high stepping with foot drop
Myopathic waddling or rolling
Key points
 · neurological history & examination are essential
 · most important question is whether the lesion is in the CNS or PNS 
 · neurological findings help to correctly localize the site of the lesion 
 · localization determines the likely cause, investigations & management
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Part ii – Neurological Disorders
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CHAPTER 3
PUBLIC HEALTH
Global burden of neurological disorders 
Public health is about the prevention of disease and the promotion of healthy living. Public 
health necessarily focuses on the community and groups of people; this is in contrast to 
the doctor who focuses on the patient. However, they both represent two ends of the same 
spectrum, one dealing with disease at population level, and the other dealing with disease at 
individual level. This chapter briefly outlines some of the basic principles of public health and 
their relationship to neurological disorders and health care delivery. The student should aim to 
be able to define incidence, prevalence and mortality rates and to understand disease burden 
and its measurement and prevention with particular regard to neurological disorders. 
MEASUREMENT OF DISEASE
Disease occurrence
The simplest measurement of any disease is how common it is or the frequency of the disease 
in a community. In order to answer that question accurately, public health has first to be able 
to define and diagnose the disease, according to certain criteria and then measure its frequency 
in relation to the size of population in which the disease occurs or cases arise. This information 
is essential for public health planning and implementation. The science and art of gathering 
such information are the instruments of public health, much in the same way as the neurology 
history and examination are the instruments used for clinical neurology. The parameters used 
most frequently to report information on disease are the incidence, prevalence and mortality 
rates. 
Incidence rate
Incidence rate is the most accurate method of measuring the frequency of a disease. The 
incidence rate is the number of new cases occurring in a defined population over a period 
of time. Measuring incidence over a period of time in a defined population gives an accurate 
measurement of disease frequency. Incidence measured over a year can be used to obtain the 
annual incidence of the disease. The annual incidence of the disease will include all new cases, or 
events occurring in the defined population during one year, including those who die soon after 
getting the disease, and those who recover from their disease. Incidence is measured as a rate, 
since it is always necessary to specify the time of observation. Incidence rate is often expressed 
as the number of new cases per 1000 person-years, 10,000 person-years, or 100,000 person-
years, according to how common the disease is. For very common diseases, like diarrhoea 
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or the common cold, or for diseases where epidemics occur over a short period of time, the 
incidence rate can be expressed as number of new episodes per 1000 person-months, or 10,000 
person-months. In contrast some neurological disorders are expressed per 100,000 person-
years because they are uncommon or rare like myasthenia gravis or Guillain Barre Syndrome 
GBS. 
Prevalence rate/ratio
Prevalence measures the number of cases of a particular disorder in a defined population at a 
fixed point in time. This includes all cases, not just new cases. Prevalence is expressed as a ratio 
of the number of cases per 1000, 10,000 or 100,000 of the population. Prevalence is used 
mostly to measure the frequency of chronic diseases and disabilities that accumulate in the 
community over time. A disease with a short duration can have low prevalence despite a high 
incidence, whereas a disease with a long duration may have a high prevalence despite a relatively 
low incidence rate. Many neurological diseases have long durations and despite relatively low 
incidence rates, they can still have relatively high prevalence. These include chronic diseases 
like epilepsy, paraplegia, leprosy and stroke. Some neurological disorders have a particularly 
high prevalence e.g. migraine 5-10,000/100,000 of the population. When a disease is this 
common its frequency can be expressed more simply, as the proportion or percentage of the 
population affected, in the case of migraine 5-10%. Though epilepsy is ten times less common 
its prevalence can still be expressed more simply as 0.5-1% of the population affected.
Mortality rate
Mortality is expressed as the total number of deaths in a defined population over a defined 
period of time, usually during one year. Mortality rates are often expressed as the number of 
deaths per 1000, 10,000 or 100,000 of the population per year, according to how high the 
mortality is. The overall or crude death rate for all causes is often given as the total number of 
deaths per 1,000 of the population occurring during one year. The crude mortality rate for all 
causes in Sub-Saharan Africa is around 18/1,000 per year in contrast to around 9/1,000 per 
year in high income countries. However this does not mean that the risk of dying is just twice 
as high in Africa. In fact the risk is higher because crude death rate is heavily dependent on the 
age structure and life expectancy of a population. As the population in Africa is mainly young 
(50% <12 yrs) and average life expectancy short (<50 yrs) then the figure 18/1000 actually 
represents a much higher overall risk of death in Africa. Crude mortality rates are therefore 
a better guide to a change in overall risk within a population than to the comparison of risk 
across populations in different countries. 
Mortality rate can be calculated for specific age groups, e.g. 0-1 year, 1-4 years, 5-14 years, 10 
years e.g. 20-29 years & 15-49 years. Such age-specific rates can be used to validly compare 
mortality across population groups within countries and across different countries. During 
emergency situations e.g. epidemics of cholera a shorter study time period of a day, week or 
month may be used when calculating mortality rates. 
Case fatality ratio
Case-fatality ratio or proportion can be defined as the number of deaths from a disease divided 
by all cases of that disease that occurred over a period of time. It is usually expressed as a 
percentage. The case fatality for rabies is 100% and for tetanus is over 50%, in contrast the case 
fatality for tension headache is zero.
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Definitions
 · Incidence rate: number of new cases of a disease occurring in a population during a specified time 
period
 · Prevalence rate: total number of cases present in a defined population at a point in time
 · Prevalence ratio: proportion of a population affected by a disease at a given point in time
 · Mortality rate: the total number of deaths in a population during a specific time period
 · Case fatality ratio: the number of deaths divided by the number of cases diagnosed during a 
specific time period
DISEASE BURDEN
Disability-adjusted life years (DALYs)
WHO uses the term disability adjusted life years (DALYs) lost to measure disease burden. 
This approach combines the number of years of healthy life lost (YLL) as a result of premature 
death, and the years lost through disability or (YLDs). The combined sum of YLLs and YLDs 
is called DALYs which is defined as the number of healthy years lost due to disability and 
premature death. This provides a measure of the number of years of healthy life which are lost 
as a result of a particular illness or disease. Burden of disease measurements like DALYs are 
particularly useful for measuring the community burden of neurological disorders, many of 
which are chronic, disabling and eventually shorten life. 
Disability is counted in terms of years, but because it is not the same for every disorder, e.g. 
the degree of disability with paraplegia is much greater than that with headache, it needs to be 
adjusted depending on the type of the disability and also the age of the patient. The disability 
severity varies on a scale between 0 and 1 and this disability weight reflects the average degree 
of disability associated with each disorder. The years lived with a disability are multiplied by 
the disability weight for the condition in question to get the years lost due to the disability. 
The disability weight scale assigned to the different neurological disorders is available through 
WHO. 
The gold standard assumes an expected healthy life of 82.5 years. For example if a man dies 
at the age of 30 years as a complication of a paraplegia which resulted from a RTA which 
happened when he was 20 years old then the number of years of expected life lost (YLLs) due 
to his premature death are 82.5 - 30 = 52.5 years. The number of DALYs lost is even greater as 
it includes the 10 years of life lived with paraplegia that has a disability weight of 0.671. This 
will then correspond to 10 x 0.671 = 6.7 life years lost due to disability, and the sum of DALYs 
lost will be: 52.5 + 6.7 = 59.2 years. 
Definitions
 · YLLs: years of life lost due to premature death
 · YLDs: years lived with a disability
 · DALYs: the sum of life years lost due to premature death and disability
The burden of neurological disorders in Africa
The burden of deaths and disability attributable to neurological disorders in Africa is presented 
below according to WHO estimate 2005. 
disease burden
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Death
Neurological disorders are an important cause of mortality and constitute about 12% of all 
deaths worldwide, with stroke alone accounting for 85% of all neurologic deaths. In Africa the 
proportion of all deaths (YLLs) attributable to neurological disorders is 4.6% (Fig 3.1). This 
is comprised of stroke 3.2%, infections 1.0% 
and epilepsy 0.4%. The main reasons for this 
relatively lower proportion are the younger 
population distribution with high rates of fatal 
non neurological infections and also notably the 
burden of neurological deaths related to human 
immunodeficiency virus (HIV) infection are 
not included in this figure. 
Figure 3.1 Deaths caused by neurological disorders
Disability
Disability can be defined as a physical or mental impairment that substantially limits one 
or more major life activities. Disabilities can be caused by disease, trauma or other health 
conditions and may require ongoing medical care. Many neurological diseases result in 
disability, and lasting disability is the most common outcome after a neurological illness or 
injury. The main neurological disabilities are impairment of motor or cognitive functions. These 
include a wide range, from loss of mobility in stroke and paraplegia to cognitive impairment 
in head injury. Other lasting disabilities include epilepsy and loss of sight or hearing. Disability 
may be a fixed disability as occurs in head injury or progressive as in dementia. Neurological 
disorders contribute >14% of the total burden of YLDs in Africa. (Fig. 3.2). The causes include 
infections 4.2%, nutrition/neuropathies 4%, head injuries 3.6%, epilepsy 0.9%, migraine 
0.6%, stroke 0.4%, and neurodegeneration 0.4%. 
Mental Disease
Neuropsychiatric disorders including 
depression, psychoses, alcohol abuse 
and substance use account for significant 
proportion of global disease burden >14% 
of YLDs. These frequently coexist with 
neurological disorders but are not covered in 
this textbook. Neurological and mental disease 
together account for >28% of total YLDs in 
Africa.
Figure 3.2 Disability caused by neurological disorders
Death and disability (DALYs)
Globally neurological disorders contribute >6% of the total DALYs. In Africa NDs account for 
about 3% of total burden of disease as measured by DALYs. The main neurological disorders 
contributing to DALYs in Africa are stroke 1.1%, infections (mostly tetanus & meningitis) 
0.9%, and epilepsy 0.5%. However this is an underestimate as the burden of HIV related 
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neurological disorders is not included in this category by WHO estimate. HIV/AIDS on its 
own accounts for over 5% of total DALYs worldwide, most of which occurs in SSA. 
HEALTH PROMOTION AND DISEASE PREVENTION
Health promotion can be defined as the process of enabling people to increase control over 
their health and its determinants, and thereby improve their lives. The primary means of health 
promotion occurs through developing a healthy public policy that addresses the prerequisites 
of health such as income, housing, food, water, security, employment, transport and quality 
working conditions.
Disease prevention (preventive medicine or preventive care) refers to measures taken to prevent 
illness or injury, rather than curing them. The major preventable risk factors for global disease 
are outlined below in Table 3.1. Prevention strategies are designed to decrease morbidity and 
mortality and are categorised as primary, secondary and tertiary prevention (Table 3.2). These 
strategies are aimed either at the general population or targeted at selective subgroups of the 
population. Specific examples of prevention strategies in neurology are presented in Table 3.3.
Table 3.1 Major preventable risk factors for disease globally, WHO
Risk factor % global disease burden
Under nutrition 
Over nutrition 
Unsafe sex 
Tobacco
Alcohol 
Unsafe water/sanitation/hygiene
15
13
6
4
4
4
Primary prevention strategies intend to avoid the development of a disease. Primary 
prevention stops a disease from happening or stops individuals from becoming at risk. Most 
population-based health promotion activities are primary preventive measures. General or 
population based prevention is designed to stop or reduce known risks in the whole population. 
Examples are to vaccinate all infants at birth in order to prevent tetanus and to promote healthy 
eating and exercise to prevent non communicable diseases.
Selective or targeted primary prevention normally targets high risk groups and may require 
some form of screening test in order to identify those at increased risk. Examples are preventive 
programmes targeted towards high risk groups, identified after screening for non communicable 
diseases or HIV. 
Secondary prevention activities are aimed at early disease detection and treatment, 
thereby increasing opportunities for interventions to prevent disease progression and the 
emergence of symptoms. Secondary prevention aims at decreasing disease severity through 
the early detection, diagnosis and treatment of the disease. Examples of this include diagnosing 
and treating hypertension to prevent stroke or treating HIV with ARTs to prevent AIDS. 
Tertiary prevention reduces the negative impact of an already established disease by 
restoring function and reducing disease-related complications. Thus tertiary prevention 
involves treating and managing disease complications which have already occurred, in order to 
prevent death and reduce disability. Examples of this in neurology are rehabilitation of stroke 
and paraplegia. Rehabilitation is an active process by which those affected by injury or disease 
health promotion and disease prevention
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achieve a full or optimum recovery, in all aspects of life. It is one of the key components of 
health care, along with prevention and treatment. 
The distribution and determinants of risks in a population have major implications for 
which type of public health intervention is used. Decreasing a small risk in a large number of 
people usually results in more cases being prevented than decreasing a larger risk in a smaller 
number. Thus, general prevention strategies aiming at reaching the whole population are often 
more cost-effective than prevention targeted to high risk groups only. However, combining 
population-based and high risk strategies can be even more effective. 
Table 3.2 Prevention of disease
Primary preventing a disease before it happens
Secondary decreasing disease severity through early detection, diagnosis and treatment
Tertiary treating & managing disease complications to increase quality of life, reduce disability & 
prevent death
Table 3.3 Examples of prevention strategies in neurological disorders in Africa
Prevention strategies Measures Expected outcome
Primary prevention vaccination 
increased exercise
healthy diet
low salt diet
stop smoking
reduce cholesterol
wearing seatbelts/helmets
prevents tetanus 
combined with secondary measures 
decreases stroke by 70%
decreases death/head injury by 40-50%
Secondary prevention 
(screening, early diagnosis and 
treatment)
treating epilepsy 
treating hypertension 
ART and OI prophylaxis
decreases mortality, morbidity 
>70% seizure free
decrease stroke, heart and renal failure
decreases mortality/morbidity in HIV
Tertiary prevention
(rehabilitation & palliative care)
rehabilitation hospital and 
community based 
palliative care
improved quality and independence of life
 
stops/decreases pain and other symptoms
HEALTH DELIVERY
Governments, departments of health and health care planners define health policies and 
implement disease prevention and care strategies. They are supported by non government 
organizations and voluntary organizations. The debate in health care in Africa as elsewhere 
in the world is “where to get the best value for your money”. In general where resources are 
limited it is the public health based population primary prevention interventions that have 
the greatest priority and potential to save lives (Table 3.3). However, within health delivery 
there needs to be a balance between prevention and care as the successful implementation of 
both are linked and interdependent. In neurology successful examples of primary prevention 
include vaccination to prevent tetanus and meningitis and bed nets to prevent cerebral malaria. 
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Examples of secondary prevention include treating epilepsy, ART, prophylaxis of opportunistic 
infections in HIV and treatment of hypertension to prevent stroke. Both approaches are 
complementary to health care policy in Africa. 
Neurological service provision
Adequate health systems are a prerequisite for health care. These are the institutions and 
organizations within a country that provide and deliver the health services. The basic resources 
needed to provide these services are staff, facilities, equipment and medications. Staff includes 
the ministry of health and the health care workers (HCW) including traditional practitioners. 
The services which they provide are delivered at three main levels in Africa (Table 3.4). 
Primary care is the first point of contact of the health service with the patient. Health care 
is delivered at this level by primary health care workers (PHCW), mainly medical assistants 
and nurses working at dispensaries and health care centres. The most common neurological 
disorders encountered in primary care are headache and epilepsy. Limitations to the successful 
delivery of neurological service at this level include the lack of adequate education and training 
in neurology, cultural barriers and practical constraints both financial and geographic. Any 
long term measures designed to improve services at this level must be targeted on education 
and be culturally appropriate, sustainable and adequately resourced.
Secondary care is provided at district, regional and mission hospitals. The main health care 
workers (HCW) involved in secondary care are nurses, medical assistants and doctors. Available 
facilities at this level include general inpatient and outpatient services, paediatric, medical, 
surgical and obstetrical care in addition to laboratory, radiological and some rehabilitation 
services. Public health and some HCW training are sited at regional and also at some mission 
hospitals. The balance and make up of each facility depends on the type of hospital and where 
it is. However diagnostic neurology facilities including a CT scanner or electrophysiology 
facilities (EEG) are usually not available at this level. Patients presenting with major neurological 
disorders often present at this level for the first time. The most common disorders include 
epilepsy, stroke, infections, paralysis and coma and are the subject of individual chapters in 
this book. 
Tertiary care is provided at referral or teaching hospitals. These specialist hospitals act as referral 
and care centres serving large areas of the country with populations involving many millions. The 
HCWs providing the service at this level are nurses, occupational and physiotherapists, doctors 
and specialists. The main aim in neurology is to provide a specialist diagnostic, treatment and 
management service. However because of the lack of trained specialists, mainly neurologists 
and neurosurgeons there is frequently only a limited service available. Diagnostic facilities 
usually available at these centres include neuroimaging, a CT scanner (occasionally MRI), 
electrophysiology facilities including EEG, and rehabilitation services including physiotherapy 
and occupational therapy. These centres also provide national facilities for undergraduate and 
postgraduate teaching and training and also for research into neurological disorders. The aim 
of this book is to support neurological education and training in Africa.
health delivery
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Table 3.4 Health care level and activities in Africa
Level Site/population Staff (HCW) Activities
Primary 
health care
dispensary/health care 
centre (2000-5000)
nurses/medical assistants immunization, maternal and 
child, family planning, treatment 
of common diseases including 
epilepsy
Secondary 
health care 
district/mission hospital
(100,000-200,000)
regional hospital
(05-1 million)
nurses/medical assistants and 
1-2 doctors 
nurses/medical assistants and 
doctors
emergency and curative services 
 
care, preventative and training 
Tertiary 
health care
consultant hospital 
(millions)
nurses/doctors and specialists care, teaching, research
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CHAPTER 4
EPILEPSY
Introduction
Epilepsy is a predisposition to recurrent unprovoked seizures. Seizures are caused by attacks 
of sudden, excessive, abnormal electrical discharges arising mainly from the neurones in the 
cortex of the brain. The site, spread and pattern of electrical discharges determine the clinical 
features of epilepsy. The seizures may range from a brief awareness of sensation lasting only 
seconds to a sudden loss of consciousness associated with involuntary stiffening and jerking 
body movements. The latter is termed generalized tonic-clonic epilepsy and historically was 
called grand mal. Epilepsy is the most common community based major neurological disorder 
and the individual case history and description of the seizure are crucial to the diagnosis of 
epilepsy. This chapter outlines the main epilepsy syndromes, their classification, causes, clinical 
presentation diagnosis and management. The student should aim for an overall understanding 
of epilepsy and in particular its burden, diagnosis, management and treatment.
EPILEPSY SYNDROMES
Epilepsy is classified according to cause and clinical seizure type. Idiopathic epilepsy (60-70%) 
occurs where no known cause is found or suspected and many of these are most likely genetic 
in origin. Symptomatic epilepsy (30-40%) occurs when there is an underlying structural 
abnormality in the cerebral cortex such as a scar or tumour or another condition predisposing 
to seizures. Seizures in epilepsy may be classified according to their clinical presentation 
and their site of electrical origin in the brain (Table 4.1). If seizures arise focally from one 
site within the brain these are termed as the partial onset seizures. These can present with 
motor, sensory, autonomic and psychological symptoms. If the electrical discharge remains 
focal and consciousness is fully retained, these are classified as simple partial seizures. If the 
electric discharge arises focally and consciousness is altered, these are classified as complex 
partial seizures. If the electrical discharge arises focally and spreads to involve the rest of the 
entire cerebral cortex, this results in a generalized tonic-clonic seizure. These are classified 
as secondary generalized tonic-clonic seizures (grand mal) and are the most common type 
of seizure disorder (70%). Seizures may also arise from electrical discharges deep within the 
brain spreading equally rapidly to all parts of the cortex at the same time. These are termed as 
generalized onset seizures (30%). These include “absence” seizures (petit mal) myoclonic 
seizures, tonic-clonic seizures (grand mal) and atonic seizures. Epilepsy may also be 
described as active or inactive, controlled or uncontrolled depending on the degree of remission 
and response to treatment. 
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CLASSIFICATION
Table 4.1 Classification of Seizures
Category Seizure type Consciousness
Partial onset seizures (70%) simple partial 
complex partial 
secondary generalized tonic–clonic 
not impaired 
impaired
loss of consciousness
Generalized onset seizures (30%) absence 
myoclonic 
primary generalized tonic-clonic
impaired
not clinically impaired 
loss of consciousness
EPIDEMIOLOGY
Epilepsy is defined as the tendency to have recurrent seizures. It affects 0.4 to 0.6% of the 
world’s population at any point in time, with a larger proportion of the general population 
(3-5%) having one or two non-recurrent isolated seizures throughout their life which do not 
develop into epilepsy. The global burden of epilepsy is estimated to be >50 millions of whom 
80% live in low or middle income countries. Estimates of the frequency in Africa vary widely 
and studies from there have in the past suggested that active epilepsy is 2-3 times higher than in 
high income countries with a median frequency of 15/1000 (1.5%). However methodological 
difficulties make it difficult to compare most studies. A recent multicentre study from five 
sites in East Africa which reproduces strict methodology suggests a median frequency there of 
<0.5% which is similar to other parts of the world. The criteria used to diagnose active epilepsy 
were 2 or more unprovoked seizures during the previous 12 month period. There are two peak 
age groups when epilepsy occurs, the first one is in childhood and adolescence during which 
both birth related and genetic causes are typically found and the second peak occurs in older 
adults (>65 years) when there is usually an underlying structural cause in the brain. 
AETIOLOGY
The aetiology is unknown or idiopathic in about two thirds of cases of epilepsy in Africa. This 
may in part be a function of under investigation due to lack of resources. Epilepsy has many 
causes and it is likely that genetic and historical causes account for a significant proportion 
of these. The main causes and their estimated frequencies in Africa are presented in Table 
4.2. Genetic predisposition and brain injury are both known risk factors for epilepsy. Genetic 
factors are indicated by a positive family history of epilepsy. The underlying mechanisms 
of epilepsy are not known but a chronic pathological process as a result of tissue injury or 
some other common mechanisms seems likely in many cases. Pre and perinatal brain injuries 
arise largely as a result of hypoxia and hypoglycaemia because of intrauterine infections e.g. 
toxoplasmosis, rubella, HIV etc and because of poor obstetric care. Febrile convulsions (FC) 
as an infant or young child are a significant risk factor for scarring in the temporal lobe and 
epilepsy in later life. 
A history of previous CNS infection is a major risk factor for epilepsy in Africa. This is particularly 
the case for infants, children and younger adults. The main infections are meningitis, cerebral 
malaria, neurocysticercosis, encephalitis and brain abscess. Malaria is the most common cause 
of acute symptomatic seizures in children in malaria endemic parts of Africa. HIV is the most 
common cause in young adults. However it is important to remember that single seizures or 
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those occurring during a febrile illness are not classified as epilepsy. Helminthic infections are 
an important cause of epilepsy in parts of Africa, in particular where free-range pig rearing is 
practised resulting in neurocysticercosis. Traumatic head injury mainly as a result of road traffic 
accidents and falls are increasingly a cause of epilepsy in young adults. Brain tumours and 
cerebrovascular disease account for a proportion of epilepsy mainly affecting adults. 
Table 4.2 Main causes of epilepsy in Africa & their estimated frequency
Cause % of total (range)
genetic 40 (6-60)
pre & perinatal 20 (1-36)
infections & febrile convulsions 20 (10-26)
cerebrovascular disease 10 (1-42)
head injury 5 (5-10)
brain tumour 5 (1-10)
Ref Preux & Druet-Cabanac Lancet Neurol 2005; 4: 21-31
Key points
 · active epilepsy affects at least 05% of the population in Africa
 · peak age groups affected are young children, teenagers & older adults
 · cause is unknown in up to two thirds of cases 
 · genetic factors may account for a sizable proportion 
 · pre & perinatal brain injury & infections are main causes in young persons 
 · stroke, head injury and tumour are main causes in older age groups
COMMON FORMS OF SEIZURES
Generalized tonic-clonic seizure (GTCS)
This is the most common form of epilepsy in adults. Typically it involves consecutive clinical 
phases including tonic-clonic limb movements, loss of consciousness, frothing from the mouth, 
tongue biting, incontinence and post ictal confusion. If the origin of the seizure is focal as in 
secondary or partial onset epilepsy an aura may be present at the onset. In contrast there is no 
aura in primary or generalized onset epilepsy.
Aura phase
The clinical type of aura depends on the site of origin of the seizure. This phase typically 
lasts a few seconds or less and consists of a brief recurring stereotyped episode. The episode is 
characterized by an awareness of a familiar, typically epigastric feeling or the hallucination of a 
smell, taste but rarely hearing, usually coupled with automatisms if the origin is in the temporal 
lobe. If the origin is the parietal lobe, the episode is sensory, if in the frontal lobe it is motor 
and if in the occipital lobe it is visual. The aura phase of a partial onset GTCS may be forgotten 
because of retrograde amnesia. 
Tonic phase
The tonic-clonic phase starts suddenly with loss of consciousness; the patient may make a loud 
noise or a cry and fall to the ground. There is a brief stiffening and extension of the body due 
to sustained tonic muscle contraction lasting about 10 seconds but which can last a minute. 
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During this tonic phase breathing stops and cyanosis may be recognised by observers. Urinary 
incontinence and less frequently faecal incontinence may occur at the end of this stage.
Clonic phase
The tonic phase is followed by the clonic phase characterized by repeated generalized convulsive 
muscle spasms. These are violent, sharp, rhythmical, powerful, jerky movements involving the 
limbs, head, jaw and trunk. The eyes roll back, the tongue may be bitten and frothing from 
the mouth may occur due to excess salivation as the result of excessive autonomic activity. 
This phase typically lasts a minute or two but may be more prolonged. The patient remains 
unconscious.
Coma phase
When the jerking has stopped normal breathing pattern returns but is shallow, the limbs 
are now flaccid and the patient remains unconscious and cannot be roused. The duration of 
unconsciousness ranges typically from about 5-20 minutes and reflects the extent and duration 
of the seizure. Then there is a gradual return of consciousness. 
Post-ictal phase
On recovery of consciousness there may be confusion accompanied by a headache, drowsiness 
and typically sleepiness for a variable period sometimes lasting for up to several hours. Over 
the following days, there is usually some muscle stiffness and soreness and evidence of any 
injury sustained during the attack. Patients have retrograde amnesia for the seizure but may 
sometimes remember the aura phase before loss of consciousness.
Diagnostic features of a GTCS
 · witnessed convulsion
 · loss of consciousness
 · tonic-clonic limb movements
 · incontinence
 · tongue biting
 · postictal confusion
Absence seizures
This is the most common form of primary generalized onset epilepsy. It affects mainly children 
usually <10 yrs, (4-12 yrs) and is more common in girls. An attack occurs without warning. 
Usually parents or teachers note that the child suddenly stops what he or she is doing for a few 
seconds but does not fall down or convulse. The eyes remain open staring blankly ahead with 
occasionally blinking or eyelid fluttering. There is no response to an outside stimulus during 
the attack which ends as suddenly as it starts, usually with the child resuming activities unaware 
of what has happened. The attacks are brief lasting, typically between 5-15 seconds and can 
reoccur several times daily. The EEG shows a characteristic 3 per sec symmetrical slow and spike 
wave discharges. Both attacks and EEG changes can be provoked by hyperventilation. The 
attacks respond well to treatment with low dose sodium valproate or ethosuximide. Children 
usually grow out of these attacks in their late teens but some few may develop into generalized 
onset TCS.
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Diagnostic features of absence seizures
 · mainly a childhood disorder & more common 
in girls
 · stereotyped recurring episodes of loss of 
awareness or absences  
 · child goes blank, switches off for few seconds, 
stares ahead & may blink 
 · unresponsive during attack but does not 
convulse or fall down
Myoclonic seizures
These are another form of primary generalized onset seizures which are characterized by sudden, 
brief involuntary jerky limb movements lasting a few seconds. These seizures typically occur 
in young teenagers in the mornings after waking, with consciousness being preserved. Simple 
myoclonic jerks, which are generally benign, must be distinguished from juvenile myoclonic 
epilepsy (JME). JME consists of the triad of myoclonic jerks on waking occurring in all 
patients, generalized onset TCS in >90% of patients and typical day time absences in about 
one-third of patients. Absences may sometimes be an early feature, they begin in childhood 
and early teens and myoclonic jerks follow usually at around the age of 14-15 years. GTCS 
usually appears a few months after the onset of myoclonic jerks typically occurring shortly 
after waking. Occasionally JME may start or become clinically identified in adult life as ‘adult 
myoclonic epilepsy’. The EEG in JME shows typical polyspikes and slow wave discharges 
and may show photosensitivity. Treatment with low dose sodium valproate is usually very 
successful. 
Diagnostic features of juvenile myoclonic epilepsy
 · simple myoclonic jerks are benign and may not need treatment
 · JME consists of morning myoclonic jerks, daytime absences & GTCS on waking
Partial onset seizures
If the site of electrical discharge is restricted to a focal area of the cortex in one cerebral 
hemisphere, then the patient will have partial onset seizures. The main causes include infections, 
infarcts, head injuries, tumours and hippocampal sclerosis, the latter due to frequent febrile 
convulsions in childhood. The clinical features depend on the site of the cortical focus and thus 
may be sensory or motor and involve alteration in consciousness. If there is no accompanying 
alteration of consciousness, then it is classified as a simple partial motor or sensory seizure. 
If there is alteration or clouding of consciousness, then it is a complex partial seizure. If the 
electrical spread becomes generalized, then it is classified as a secondary GTCS. Any patient 
presenting with new partial onset seizure disorder should be investigated with a brain scan to 
exclude a focal underlying cause.
Temporal Lobe epilepsy (TLE)
Complex partial seizures arise mainly in the temporal or frontal lobes. Temporal lobe epilepsy 
(TLE) is the commonest type of complex partial seizure disorder. The temporal lobe structures, 
particularly the hippocampus, are susceptible to injury during febrile convulsions, which may 
result in mesial temporal sclerosis (Fig. 4.6) and later TLE. The clinical features reflect the 
functions of the temporal lobe which include memory, speech, taste and smell. Seizures present 
as stereotyped episodes characterised by subjective experiences and movements. The subjective 
experiences include blank spells or absences, a sense of fear or déjà vu (an indescribably familiar 
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feeling “that I have had this before”), or an inexplicable sensation rising up in the abdomen or 
chest. They may also include memories rushing back and hallucinations of smell, taste, hearing 
or images. To an observer the patient may appear confused and exhibit repeated stereotyped 
movements or automatisms including chewing and lip smacking. The attack typically lasts 
seconds to minutes depending on the extent and cause of the lesion. Attacks can be still more 
complex and if the electrical activity spreads to the rest of the brain then a GTCS may occur. 
Diagnostic features of TLE
 · stereotyped episodes lasting seconds 
 · déjà vu, depersonalization, rising sensation in 
epigastrium
 · hallucination of mainly taste or smell
 · movements, automatisms: lip smacking, 
chewing
 · confusion and altered emotion
 · may develop into a GTCS
Motor seizures (Jacksonian epilepsy)
This is a partial onset motor seizure disorder which occurs as a result of a focal lesion in the 
frontal lobe in or near the motor cortex. The convulsive movement begins typically in the 
corner of the mouth or in the index finger or big toe and then spreads slowly proximally to 
involve the leg, face, and hand (Jacksonian march) on the side of the body opposite the lesion. 
There may also be clonic movements of the head and eyes to the side opposite the lesion. The 
attack may develop into a secondary GTCS, and may infrequently result in a temporary limb 
paralysis (Todd’s paralysis). 
Diagnostic features of focal motor seizures
 · clonic movements begin focally in the corner 
of mouth or finger or toe 
 · spreads slowly to involve face, hand, arm, foot 
& leg on the same side
 · may develop into a secondary GTCS
 · may result in a temporary limb paralysis
Febrile convulsions
Febrile convulsions are seizures in children which typically occur between the ages of 3 months 
and 5 years as a result of fever from any cause. They are mostly GTCS in type and are a 
known risk factor for epilepsy in later life, and in particular TLE. They can cause damage 
to the temporal lobe that subsequently causes epilepsy. The scarring is mainly in the mesial 
temporal lobe and can be seen on MRI. The worldwide risk of epilepsy after childhood febrile 
convulsions is estimated to be 2-5%. In Africa this risk increases to around 10%, particularly 
after a history of repeated convulsions in malaria. Convulsions complicating malaria are 
one of the most common reasons for children presenting to clinics and hospitals in Africa. 
Convulsions occurring in uncomplicated malaria tend to be brief and non recurrent, whereas 
those occurring with complicated and cerebral malaria are more prolonged, multiple and 
recurrent, and carry a higher subsequent risk of epilepsy. 
Clinical diagnosis
The diagnosis of epilepsy is mainly clinical. Epilepsy is difficult to diagnose and there is both 
under and over diagnosis of the condition. The first principle of diagnosis is to obtain a 
clear history from the patient and an eye-witnessed account of the episode. This involves the 
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context in which the attack occurs, the details of the minutes or seconds leading up to and 
what happened during and after the attack. An attack of a GTCS is diagnostic if it includes a 
description of the convulsion, incontinence, tongue biting (Fig. 4.1) and post ictal confusion. 
All of these may not be present in any one patient. The description may alternatively be that 
of the typical vacant episodes of absence seizures or the aura of a partial onset seizure or of any 
another type of seizure disorder. If a patient cannot describe what happened, very often it is 
necessary to interview and record an eye-witnessed account or review a video of the attack if 
available. 
The history from the patient or family should include current illnesses and specific questions 
concerning known risk factors for seizures including perinatal injury, febrile convulsions, 
infection, head injury, alcohol consumption and drugs. A detailed family history is helpful 
particularly in suspected cases of primary generalized seizures. There should be a thorough 
general and neurological examination. Look for evidence of seizures including tongue biting, 
scars and evidence of injuries. Patients who have had a single 
non recurrent seizure are not considered to have epilepsy, 
they should however be investigated to exclude an underlying 
cause e.g. toxoplasmosis in HIV, a vascular cause or tumour. 
The differential diagnosis of epilepsy includes any cause of 
syncope or loss of consciousness including, pseudoseizures, 
hypoglycaemia, hyperventilation and transient ischaemic 
attacks (Chapters 5 & 9). The main differences between 
epileptic and or non epileptic attacks (pseudoseizures) are 
summarised below in Table 4.3.
Figure 4.1 Tongue biting
Key points
 · obtain a clear history from the patient 
 · get an eye witnessed account of the episodes
 · check past & family for any risk factors for 
epilepsy 
 · do a general & neurological examination
 · look for stigmata of seizure/epilepsy
Pseudoseizures (non epileptic dissociative attacks)
Some patients have unexplained GTCS like episodes of loss of consciousness either consciously 
or subconsciously. The diagnosis should be suspected if there are atypical episodes of loss 
of consciousness occurring in a teenager or young adult, often female, lasting longer than 
5 minutes. These episodes resemble seizures and are considered to be psychogenic or non 
epileptic in origin and are a major cause of misdiagnosis of epilepsy. There are no absolute 
criteria to distinguish between pseudoseizures and epileptic attacks clinically (Table 4.3). The 
attacks can mimic a GTCS and can occur in association with known epilepsy. In high income 
countries as many as one third of patients with known epilepsy may suffer from a non epileptic 
attack at some time. During a typical attack there is no tonic phase, there may be shouting and 
coordinated limb movements particularly involving hyperextension of the back, pelvic thrusting 
and repeated side to side head turning. There is no post-ictal confusion phase and the patient 
typically reports no awareness during the attack or memory of the episode afterwards. The 
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vital signs and neurological reflexes remain normal during the episode. Definitive assessment 
of a suspected case requires simultaneous co-registration of both the clinical attack and an 
EEG using telemetry. Management includes reassurance and in particular the avoidance of 
unnecessary antiepileptic medications. A psychiatric opinion may be helpful in persistent cases.
Table 4.3 Differences between epileptic and non epileptic attacks
Clinical features Epileptic Non epileptic
Sex any sex females > males
Age group any teenagers/young adults
Duration minutes prolonged
Vital signs
Tonic/post ictal phases
abnormal
present
normal
absent
Body movements repetitive stereotyped
Plantar response may be up going normal
EEG abnormal normal
INVESTIGATIONS
The diagnosis of epilepsy is primarily based on a clinical description of the seizures. The main 
aim of investigations is to confirm or exclude the diagnosis, to establish a cause and to classify 
the type of epilepsy. Routine investigations including full blood count, serum glucose, renal 
and liver function tests are rarely helpful in screening for causes of epilepsy. However other 
screening tests should include HIV and other possible local causes of seizures in sub Saharan 
Africa (SSA) including cysticercosis. Electroencephalography (EEG) and brain imaging are the 
main methods of investigation of epilepsy. 
Electroencephalography
The EEG is extremely useful in the diagnosis and classification of epilepsy. It is particularly 
useful if recorded during an epileptic attack, where the finding of epileptiform activity (spikes 
and sharp waves) confirms the clinical diagnosis. However the majority of EEGs are recorded 
interictally (between the attacks) when the EEG may be normal (Fig. 4.2). Only about 50% 
of persons with proven epilepsy have an abnormal first interictal EEG. This percentage can be 
increased to around 85% with repeated EEG testing, using provocation tests (hyperventilation 
and flashing lights) and by doing sleep recordings. The finding of a normal interictal EEG 
therefore does not exclude the diagnosis of epilepsy. By the same token more than 10% of 
normal persons may have non-specific EEG abnormalities and approximately 1% may 
have epileptiform paroxysmal activity without clinical seizures. The prevalence of these 
abnormalities is higher in children, with about 2-4% having functional spike discharges. The 
EEG is particularly useful in children and young adults where a diagnosis of either primary 
or secondary seizure disorder is suspected. This is especially true for absence seizures when 
the characteristic symmetric 3 per second spike and wave pattern is seen in all leads (Fig. 
4.3). In partial onset seizures the EEG frequently reveals sharp wave abnormalities originating 
focally from one area of the brain (Fig. 4.4). In generalized seizures the EEG shows electrical 
discharges in all leads (Fig. 4.5). 
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Figure 4.2 EEG normal
Figure 4.3 EEG absence seizure Three per second spike & wave
Figure 4.4 EEG focal seizure Unilateral right sided electrical discharge
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Figure 4.5 EEG generalized seizure Bilateral electrical discharge
Brain imaging
Brain imaging with CT or MRI is helpful when a focal cause of epilepsy is suspected, particularly 
in partial onset epilepsies. This is even more so the case in epilepsies of later age onset, 25 yrs 
or greater because of their likely focal onset. Brain imaging is expected to be normal in most 
generalized onset epilepsies which occur in a mainly younger age group e.g. teenagers. MRI 
scanning is more sensitive than CT, and may be necessary to show the underlying lesion e.g. 
mesial temporal sclerosis (Figure 4.6) in some partial onset seizure disorders. 
Figure 4.6 MRI T1 Mesial temporal sclerosis Sclerosis & contracted hippocampus (left)
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Key points
 · aim is to confirm the clinical diagnosis, find the cause & classify epilepsy
 · EEG & imaging are indicated in recent new onset seizure disorders
 · EEG may be normal initially & need repeating with provocation testing & sleep
 · EEG can distinguish between partial & generalized onset seizure disorders 
 · brain imaging is mostly indicated in new onset partial seizure disorders in adults
MANAGEMENT OF EPILEPSY
General advice
Remember that epilepsy has a bad name and has been falsely attributed to witchcraft, spirits, 
and demonic possession and to contagion in Africa. The sudden unpredictable attacks, the need 
to take medications every day for years and their side effects and obvious restrictions on social 
life and occupation make patients feel stigmatized. It is important therefore to listen to patient’s 
and family’s anxieties and to explain the nature of epilepsy and its management. Antiepileptic 
drugs (AED) are usually advised when two or more unprovoked seizures have occurred within 
the previous 12 months. Patients may require medication for years and sometimes for life, and 
all the AEDs have side effects. It is important to explain that about two thirds of patients with 
epilepsy suppress their attacks completely by using a single AED in adequate doses and also 
that young people with primary generalized onset seizure disorders tend to grow out of their 
epilepsy in their late teens or early twenties. 
The patient should be made aware of the potential triggering effect on seizures of fatigue, 
sleep deprivation, alcohol, infections and also flashing lights if photosensitive. Driving may 
be legally restricted nationally and some jobs may be off limits including bus, lorry and train 
drivers, airline pilots, and the armed forces. Some activities are obviously dangerous to the 
patients with epilepsy and precautions are necessary, these include fishing, boating, swimming, 
working at heights, near moving machinery and open fires. Remember that most patients in 
Africa will visit the traditional healer and receive advice and treatment. Patients with epilepsy 
are most probably safer when they are with other people.
Key points
 · epilepsy is a very stigmatizing disease
 · listen to worries of patient & family & explain  the nature of epilepsy
 · AED treatment is advised if two or more unprovoked seizures occur within the last12 months
 · explain the hazards & restrictions & that AED treatment may need to be taken for life
 · 60-75% become seizure free on single AED if taken in adequate doses
First aid for seizures
Most tonic-clonic seizures do not require emergency drug treatment. Firstly, avoid injury by 
removing the patient from any immediate danger e.g. fire, road traffic, water etc. See the scars 
from burns and scalds in Fig 4.7. Do not attempt to force anything between the teeth. Wait 
until the tonic-clonic phase is over, and then make certain that the airway is clear by extending 
the neck. Then place the patient on his side in the recovery position to avoid aspiration if he 
vomits. If the seizure stops and there is a previous history of seizures, then no further medical 
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action is required. If the seizure does not cease spontaneously, emergency medical treatment is 
needed. In children with febrile convulsions, it is important to lower the temperature and treat 
the underlying cause. 
Figures 4. 7 Scars & deformities as a result of burns & scalds 
DRUG TREATMENT
The aim of drug treatment is to make the patient seizure free. The choice of drug is determined 
mainly by the type of epilepsy. Every effort should be made early on to find the single best 
drug (monotherapy) available using the smallest dose with the fewest side effects. The main 
drugs, their indication, dosage and side effects for treatment of epilepsy in Africa are outlined 
in Table 4.4. Treatment is started at low dose and increased slowly as necessary to an effective 
maintenance dose, when seizures are controlled or the patient develops intolerable side effects. 
The single most common reason for failed drug treatment is using insufficiently high doses 
of medication where necessary. One of the main limiting factors in epilepsy treatment is the 
side effects of medication. Other reasons for treatment failure include non-compliance due 
to lack of accessibility and availability of drugs, their cost, and life style including alcohol. 
However, if seizures still persist despite using an adequate dose of an appropriate single AED, 
then another first line drug is added withdrawing the first drug only after establishing seizure 
Upper Limbs
Lower Limbs
Trunk and face
Chapter 4  epilepsy
Part ii – Neurological Disorders 90
control. Treatment is always aimed at making the patient completely seizure-free but this 
may not be possible in up to one third of patients. Reasons include refractory epilepsy and 
underlying cause. In these situations when monotherapy is ineffective a group of epilepsy 
patients will require two and possibly even three drugs in combination (polytherapy). Deaths 
directly attributed to the AEDs are uncommon (<1:50,000) and are usually caused by early 
idiosyncratic reactions.
Key points
 · using one drug start slow & aim low 
 · if seizures are stopped, do not increase the dose any further 
 · if seizures are not controlled, increase dose as long as no or few side-effects
 · if seizures still persist add a second AED
 · all drugs prescribed should be available locally
Drugs
Phenobarbitone (PHB): This is indicated for all types of epilepsies and is widely available and 
used in Africa. WHO recommends it as the first line drug for the treatment of epilepsy in Africa 
in both children and adults. Phenobarbitone is usually used in previously untreated patients 
and is particularly useful in status epilepticus because with an adequate loading dose it has a 
quick effect. It has a long half life and may be used in a single daily dose often taken at night 
just before sleep. The starting dose for teenagers and adults is usually 60 mg, it can be increased 
by 30 mg weekly to a usual maximum maintenance dose of either 180 mg once daily or 90 mg 
twice daily. For children the dose should be calculated by weight at 5 mg/kg. Any reduction 
in dosage needs to be particularly slow (every 2 weeks) and gradual because of the risk of 
withdrawal seizures and status epilepticus. The main side effects are sedation, photosensitivity 
and cognitive/behavioural dysfunction in children. Phenobarbitone is a potent microsomal 
liver enzyme inducer and decreases the half life of other drugs metabolised in the liver. This 
becomes particularly relevant clinically with concomitant use of the oral contraceptive pill, 
where the dose of the pill has to be increased to be effective.
Carbamazepine (CBZ): This is used in all types of epilepsy except in absences and myoclonus. 
It is the drug of first choice for partial onset epilepsies and is very effective. The starting dose is 
low at 100 mg twice daily increasing slowly by 200 mg increments every 2 weeks until seizures 
are controlled. The usual therapeutic dose is between 400-1600 mg daily in divided doses. 
The maximum dose is 2,400 mg daily. Most people respond to a daily dose of 2-400 mg twice 
or three times daily. The main side effects are drowsiness, ataxia and dizziness which are dose 
dependent and decrease with time but may limit the dose. The onset of rash and hypersensitivity 
allergic reaction usually within the first two weeks of starting treatment requires immediate 
stopping of the medication. CBZ is the least teratogenic of the main AEDs and has a liver 
enzyme induction effect similar to phenobarbitone. 
Phenytoin (PHT): This is used to treat all types of epilepsy except absence seizures. Its 
advantages are that it can be given once daily as a single dose usually at night. Loading with 
phenytoin is possible in previously untreated patients and in status epilepticus for a quick 
effect. The usual loading dose is 900 mg and the usual oral starting dose is 200-300 mg daily. 
The main disadvantage is that it has a narrow therapeutic range and dose adjustments may 
produce large changes in plasma concentrations and intoxication. Therefore any increase in 
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dosage should be by small increments of 25-50 mg every 2 weeks up to a usual maximum 
dose of 400-450 mg daily. If available, the measurement of drug levels can guide dosage. The 
main side effects are ataxia, drowsiness and dizziness which are dose dependent. The chronic 
toxicity effects of hirsutism, gum hypertrophy, facial skin thickening and acne limit its long 
term usage over years particularly in young persons. Liver enzyme induction occurs similarly 
to phenobarbitone. 
Sodium valproate (SVP): This is the drug of first choice for idiopathic and generalized onset 
epilepsies and is also used in partial onset secondary generalized seizures. The starting dose is 
200 mg twice daily increasing by 200-400 mg increments if necessary every 2 weeks up to a 
maximum of 1.4 gm twice daily. The main side effects are nausea, vomiting, tremor, weight 
gain, hair loss, polycystic ovary syndrome and teratogenesis all of which are dose dependent. 
Hepatotoxicity is idiosyncratic and may very rarely be fatal. It displaces phenytoin from plasma 
protein binding which may lead to phenytoin toxicity.
Ethosuxamide: This is indicated for generalized absence seizures only. It is given twice daily 
and the starting dose is 250 mg daily increasing weekly to a maintenance dose of 750-1500 
mg in divided doses. The main side effects are nausea, drowsiness, headache and ataxia. Rare 
idiosyncratic reactions include lupus like syndrome and blood dyscrasias.
Newer drugs for epilepsy
These include lamotrigine, levetiracetam and topiramate amongst many others. They are used 
in people who have not responded or tolerated standard AEDs. Levetiracetam is a particularly 
useful second line drug in adults with uncontrolled focal epilepsies. Information on these drugs 
is available in larger textbooks and online.
Table 4.4 Drug treatment of epilepsy in Africa
Drug Main 
indications
Dosage
starting
Dosage
maintenance
Main side effects
Phenobarbitone all epilepsies 60 mg/po/daily 180 mg/daily sedation, ataxia, 
photosensitivity, cognitive/
behavioural dysfunction 
Carbamazepine partial onset 
epilepsies
100 mg/po/bd 2–800 mg/bd ataxia/sedation (dose 
dependent), rash, allergic 
reaction 
Phenytoin partial onset/
secondary 
generalized 
seizures
200–300 mg/
po/nocte 
3–450 mg/daily ataxia, drowsiness, dizziness 
(dose dependent) hirsutism, 
gum hypertrophy, facial skin 
thickening and acne
Sodium Valproate primary 
generalized 
and partial 
onset 
epilepsies 
200 mg/po/bd 400–1400 mg/bd nausea, vomiting, tremor, 
weight gain, hair loss, 
polycystic ovary syndrome, 
hepatotoxicity, teratogenesis 
(dose dependent), 
Ethosuxamide absence 
seizures only
250 mg/po/od 250–750 mg/bd nausea, drowsiness, headache, 
ataxia, blood dyscrasia
Discontinuing of AEDs
AEDs may be effectively withdrawn in some patients who have been seizure free for 2-5 years. 
This will largely depend on the type of epilepsy, the implications for recurrence and the side 
effects of medications. There is an increased risk of recurrence in adults particularly between 
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1 and 2 years after stopping. This risk is greatest in partial onset seizures which are severe. 
Children who have been seizure free for 2 years off medication tend to remain so. The final 
decision to withdraw medication must be made by the patient or family and be carried out 
slowly over months with gradually decreasing doses because of the risk of provoking seizures 
by too rapid a withdrawal. 
AEDs AND WOMEN
There are some special precautions when using AEDs in women. Carbamazepine, phenytoin 
and phenobarbitone are all liver enzyme inducers that decrease blood levels of oestrogen 
and progesterone. In patients taking these AEDs, the dose of oestrogen in the contraceptive 
pill needs to be increased from 25mg to at least 50 mg in order to be effective and even 
then contraceptive efficacy is reduced. Depot preparations are less affected by concomitant 
AED usage. The use of AEDs in women with epilepsy is associated with increased risk of 
teratogenicity. Women should be counselled about the risks of taking AEDs before becoming 
pregnant. The rate of major malformations born to mothers taking valproate, carbamazepine, 
phenytoin or phenobarbitone is 4-8%. This risk increases proportional to number of AEDs 
and the dosage used. Valproate is the most inclined to cause malformations and these defects 
include the neural tube defects, anencephaly and spina bifida, hole in the heart, hare lip and 
cleft palate. In order to decrease this risk the total recommended daily dose of valproate in 
childbearing women is <1000 mg. 
Best practice is to use a single drug in the lowest effective dose and to offer folic acid prophylaxis 
before conception. A dose of folic acid of 5 mg daily has been shown to decrease incidence of 
neural tube defects in women not taking AEDs. Note that this dose is higher than the usual 
prophylactic dose (0.4mg) prescribed with ferrous sulphate in early normal pregnancy. The 
dose of AEDs may have to be increased in pregnancy particularly during the third trimester 
and just before delivery because of an increased risk of seizures which happens in about one 
quarter of patients. Any dose increase can be reversed 6 weeks after delivery. 
Vitamin K is routinely recommended in patients taking enzyme inducing AEDs starting one 
month before delivery and also to the baby at delivery.  Seizures occurring in late pregnancy or 
in the immediate postpartum period should suggest the possibility of eclampsia. In eclampsia, 
magnesium sulphate is the drug of choice in a dose of 3-4 gm iv stat (max 20 gm daily). 
Key points
 · oestrogen dose should be increased to 50 mg in some women on AEDs and the pill
 · AEDs increase risk of teratogenesis, SVP is the most teratogenic & CMZ is the least 
 · folic acid 5mg before conception decreases the risk of neural tube defects
 · dose of AEDs may need to be increased in the 3rd trimester 
 · vitamin K is given to mother & all infants if on enzyme inducing AEDs
STATUS EPILEPTICUS
Status epilepticus is defined as continuous seizures or two or more repeated attacks of GTCS 
without recovery of consciousness between attacks or an attack lasting longer than 30 minutes. 
It is a medical emergency with a mortality rate of 10-20% in Africa.  Permanent brain damage 
can occur as a result of hypoxia and acidosis if repeated or single seizures last longer than 30 
aeds and women
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minutes. The main risk factors in Africa are a history of epilepsy, current infection, suddenly 
stopping AEDs in particular phenobarbitone, mental handicap and an underlying structural 
brain disorder.
Management
The drug treatment of status is outlined in Table 4.5. General measures include ensuring a 
clear airway with adequate oxygenation (> 95% oxygen saturation) and ensuring an adequate 
circulation (pulse & BP) and establishing iv access (Chapter 9). A blood glucose should be 
checked and if low (<2.5 mmols) treated with 50 ml of 50% glucose. Infections are treated. 
If there is a history of alcohol abuse or poor nutrition then thiamine 100-250 mg should be 
given iv slowly. Reasons for failure to respond to emergency treatment include inadequate 
doses of phenytoin or phenobarbital, failure to continue adequate maintenance therapy and 
the presence of acidosis or an underlying medical disorder.
Table 4.5 Drug treatment of status epilepticus
Stage Drug/route/rate Comment
early status (0-30 mins) diazepam 10 mg/iv bolus over 2 
minutes
or
lorazepam 4 mg (01 mg/kg) iv 
bolus over 2 minutes
if seizures continue after 5 mins 
either one can be repeated just 
once but may cause respiratory 
depression
established status (30-60 mins) 
(if seizures continue & patient is not 
on phenytoin or phenobarbitone)
phenytoin iv n saline infusion of 15 
mg/kg (900-1,000 mg total dose) @ 
50 mg/min/iv (in N/S over 20 mins) 
or
phenobarbitone infusion iv 10 
mg/kg/@100 mg/min/ over 7-10 
minutes (adult total dose is 700 mg)
if iv is unavailable,  
give phenytoin via nasogastric 
tube, (absorption is excellent)
if patient is already on phenytoin 
or phenobarbitone then use half 
the usual full loading dose
if seizures stop continue with  
maintenance oral phenytoin or 
phenobarbitone 
refractory status (>60 mins)  
(if seizures still continue)
involve anaesthesia & proceed to 
ventilation,
Rx thiopentone or midazolam or 
propofol
if seizures are stopped for >24 
hours; stop ventilation & continue 
daily maintenance dose of 
phenytoin or phenobarbitone & 
reinstate regular AEDs 
PROGNOSIS
The standardised mortality rate worldwide in patients with epilepsy is 2-3 times higher than 
in the general population and studies suggest that mortality is much higher in Africa, possibly 
5-6 times. Some of this is explained by the underlying cause at diagnosis but most is related to 
the epilepsy itself, its severity and the lack of diagnosis and treatment in Africa. Risk factors for 
increased mortality include age group, seizure type, frequency and drug compliance. The main 
causes of mortality and morbidity due to seizures include accidents, drowning, falls and burns. 
Status epilepticus and sudden unexpected or unexplained death which occurs in epilepsy 
(SUDEP) may each account for 5-10% of all epilepsy related deaths.
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Driving and epilepsy
Patients with epilepsy must not drive unless their seizures are completely controlled by 
medication. Generally driving is not allowed until the newly diagnosed and treated seizure 
patient has been seizure-free for at least three months. When AEDs are discontinued, driving 
again is forbidden until the patient has been seizure-free for at least three months after the last 
dose of medication. Legal restrictions on driving with epilepsy vary between countries and 
should be researched and followed.
TREATMENT GAP
In Africa the vast majority of people with epilepsy (75-80%) do not receive any or adequate 
treatment for their disease. This is called the treatment gap. Among the reasons for this are the 
social stigma, poor medical infrastructure, insufficient supply and cost of and accessibility of 
AEDs, and the scarcity of well informed or trained medical personnel. There are also higher 
levels of cognitive impairment among the patients with epilepsy. Future plans for intervention 
must prioritise and find novel ways to encourage the diagnosis and treatment of epilepsy in the 
community. This is supported by first raising the level of awareness of epilepsy and ensuring 
that adequate supplies of the first line AEDs are available with clear guidelines concerning their 
use. These AEDs should be free or affordable and available at sites which are convenient and 
accessible to the patient. There is also a need to provide and train health care workers and to 
involve traditional health care workers and patient’s supporters and families in the care of the 
patient.
Key points
 · epilepsy is the most common major community based neurological disorder 
 · majority do not receive or get adequate treatment
 · reasons include stigma, lack of education, resources, manpower & infrastructure
 · there is a great need to improve the care of epilepsy in Africa
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CHAPTER 5
STROKE
Introduction
Stroke is a major medical disorder caused by interruption of blood supply to the brain which 
results in a loss of neurological function. It usually occurs suddenly without warning and 
frequently results in death or disability. The two main mechanisms are blocking of the arteries 
causing ischaemia and rupture of the arteries causing haemorrhage. The aim of management 
of stroke is to try to limit the area of damage in the brain, assist recovery and prevent any 
recurrence. The management of stroke in high income countries over the last two decades has 
witnessed marked improvement with the creation of dedicated stroke care units in hospitals 
and a more active approach to the management and prevention of stroke. This chapter presents 
an overview of the main characteristics of stroke. The student should aim for an overall 
understanding of stroke, including its increasing burden, main causes and prevention, and in 
particular to be able to diagnose and manage a patient presenting with stroke.
Definition: Stroke is a sudden neurological deficit lasting more than 24 hours with no 
explanation other than a vascular cause. If the patient recovers fully within 24 hours without 
any neurological deficit, then this is classified as a transient ischaemic attack (TIA). 
Epidemiology
Stroke is the third most common cause of death worldwide after heart disease and cancer. It 
is reported to be the leading neurological cause of death in Africa (Chapter 3). The annual 
incidence of stroke in high income countries is 2-3 per 1000 persons and the prevalence 
reaches 0.5 to >1% of the population in older age groups (>65 yrs). A similar high incidence 
rate has been reported recently in one study in Tanzania. The overall prevalence of stroke is 
reported to be lower in Africa with age adjusted rates being less than half that in high income 
countries. However with increasing urbanization and life style changes the burden of stroke is 
steadily increasing and it is now one of the leading causes of neurological admissions and death 
in urban hospitals throughout Africa. 
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AETIOLOGY
Stroke occurs as a result of ischaemia or haemorrhage 
Ischaemia
Ischaemia accounts for >80% of strokes worldwide and for 60-80% in Africa. Ischaemia is 
caused by thrombosis or embolism resulting in loss of blood supply to part of the brain (Fig. 
5.1). Thromboembolism is the main cause and arises from atheromatous plaques situated in the 
major blood vessels in the neck and brain (Fig. 5.5). This is termed athero-thromboembolism. 
It results in occlusion of the arteries supplying the brain, most commonly the middle cerebral 
artery (Figs. 5.2 & 3). A smaller number of ischaemic strokes arise from occlusion of the 
small end arteries arising from the larger blood vessels deep within the brain. These are called 
lacunar strokes. Ischaemia is also caused by cardioembolism. This arises mainly from mitral 
valve disease, atrial fibrillation, cardiomyopathy and much less frequently, recent myocardial 
infarction. Less common causes of ischaemic strokes are sickle cell disease, HIV infection, 
vasculitis and venous sinus thrombosis.
Haemorrhage
About 10-20% of strokes worldwide are caused by haemorrhage. This percentage is higher in 
Africa (20-40%) probably because of the high burden of untreated or inadequately treated 
hypertension. Haemorrhagic stroke occurs when there is sudden release of blood into the 
brain. The main types are intracerebral haemorrhage (ICH) and subarachnoid haemorrhage 
(SAH) (Figs. 5.4 & 6). Hypertension is the major cause of ICH and is also a risk factor for 
SAH. The sources of bleeding in chronic hypertension are ruptured Charcot-Bouchard micro 
aneurysms which form on small perforating end arteries deep in the brain. Less common 
sources of bleeding are arteriovenous malformations (AVMs), tumours, trauma and amyloid. 
The most common site affected is the internal capsule area which usually results in a complete 
hemiparesis. When the source of bleeding is in the brain stem, or cerebellum there is usually 
quadriparesis with cranial nerve palsies, ataxia and coma. Subarachnoid haemorrhage (SAH) 
is mainly caused by a ruptured underlying intracranial saccular (berry) aneurysm arising from 
the circle of Willis and less frequently AVM. 
Key points
 · stroke is a leading cause of death in adults in 
Africa
 · the main causes are ischaemia & haemorrhage
 · ischaemia is caused by atheroma & embolism
 · haemorrhagic strokes arise from ICH or SAH
 · main causes are hypertension & aneurysms  
Pathogenesis
When the blood supply to the brain is lost acutely either as a result of ischaemia or haemorrhage, 
a core area of the brain will undergo infarction/necrosis. This core area of the brain is irreversibly 
damaged. However in ischaemia, because of collateral blood supply, a surrounding area called 
a penumbra remains potentially viable for a limited time. This time period is usually about 3-6 
hours, during which it will recover if the blood supply is restored. This is the target for the early 
treatment directed at decreasing thrombosis and improving blood supply. The swelling in the 
brain is caused by cytotoxic and vasogenic oedema as a result of infarction or haemorrhage. 
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This is frequently responsible for the clinical deterioration in the days immediately following 
on the acute stroke. 
Vascular Risk Factors
The main risk factors for stroke are hypertension, atrial fibrillation, diabetes mellitus, smoking 
and lack of exercise (Table 5.1). Together, these account for over two thirds of all strokes and 
represent modifiable risk factors. The risk of stroke increases exponentially with age, with a 
much greater risk in the elderly population. Hypertension is the most important modifiable 
risk factor for both ischaemic and haemorrhagic stroke. The risk almost doubles with every 7.5 
mm Hg rise in diastolic pressure even within the normal range of blood pressure. Established 
cardiovascular disease is an important risk factor for stroke, particularly a previous stroke 
or TIA, atrial fibrillation, rheumatic mitral valve disease and heart failure. Diabetes, high 
cholesterol and low density lipoproteins, sickle cell disease, the oral contraceptive pill, migraine 
and infections are all known risk factors for ischaemic stroke. The main modifiable life style 
risk factors include diet, salt intake, obesity, lack of exercise, cigarette smoking and increased 
alcohol consumption. 
Table 5.1 Main risk factors for stroke
Risk factors Relative degree of risk
ageing highest
hypertension
atrial fibrillation
previous stroke or TIA
very high
ischaemic heart disease
diabetes 
high
life style: 
diet 
increased salt intake 
lack of exercise
smoking
alcohol
moderate
obesity low
Key points
 · age is the strongest non modifiable risk factor for stroke
 · hypertension and AF are among the main modifiable risk factors in secondary prevention 
 · life style is the major modifiable risk factor in primary prevention
Main causes of stroke
 · atheroma 
 · hypertension
 · cardioembolism
aetiology
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CLINICAL PRESENTATION
The key features of a stroke are a sudden onset of a focal neurological deficit in a person who 
was previously well. Strokes occur more frequently at night and in the early morning. The 
clinical findings will depend on the type of stroke, the vascular site affected and the underlying 
cause. The most common presentations are a sudden, unilateral loss of power or sensation in 
an arm or leg or both, a loss of speech, vision or balance (Table 5.2). These help to localize the 
site of origin of the stroke. There are no features that can reliably distinguish between ischaemia 
and haemorrhage, although headache, vomiting, complete hemiparesis, reduced level of 
consciousness and severe hypertension are more common in haemorrhage. In subarachnoid 
haemorrhage (SAH), the onset is characterized by a new, sudden and severe headache with neck 
stiffness, usually without any focal neurological deficit, but alteration or loss of consciousness 
may be present. If the patient is unable to give a history, then the details should be obtained 
from a relative. The general examination should be directed at looking for the main underlying 
risk factors for stroke, including hypertension, atrial fibrillation, cardiac murmurs, carotid 
bruits and signs of systemic illness. CT imaging is usually necessary to distinguish between the 
two main types of stroke. 
Table 5.2 Main clinical features of stroke
sudden onset either all at once or over minutes or hours
focal neurological symptoms and signs
loss of neurological function
motor loss: weakness of one side or part of one side of  the body
sensory loss: decreased sensation on one side or part of one side of the body
aphasia: loss or impairment of speech, understanding, reading or writing
visual: loss of vision to one side, hemianopia (patient usually unaware)
other symptoms: altered consiousness, dysphagia, dysarthria, ataxia, diplopia, quadriparesis
Localization
Ischaemic strokes can be divided into anterior and posterior circulation strokes. Anteriorly the 
internal carotid artery (ICA) divides to form the anterior and middle cerebral arteries (ACA 
& MCA). Posteriorly the vertebral arteries join at the lower pons to form the basilar artery 
which in turn divides into two posterior cerebral arteries (PCA). The anterior and posterior 
circulations are joined in front by the anterior communicating artery and at the back by the 
posterior communicating artery to form the circle of Willis (Fig. 5.1). This ensures collateral 
circulation in the brain. The MCA supplies the anterior lateral two thirds of the brain and the 
ACA supplies the remaining medial two thirds. The PCA supplies the posterior one third or 
the occipital lobe. The brain stem and cerebellum are supplied in turn by the vertebral and 
basilar arteries. The most common sites affected are the MCA followed by the ACA, followed 
by lacunar and PCA (Table 5.3).
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Table 5.3 Localization and strokes
Artery Main clinical findings
Internal carotid artery hemiplegia, (arm = face = leg)
hemisensory deficit
hemianopia
Anterior cerebral artery hemiplegia, (leg > arm)
Middle cerebral artery hemiplegia & numbness (face = arm > leg) 
aphasia *(if the dominant hemisphere involved)  
hemianopia 
sensory inattention (if the non dominant hemisphere involved)
Posterior cerebral artery hemianopia 
Lacunar hemiplegia, (face = arm = leg) 
hemisensory, (face = arm = leg) 
Vertebro-basilar arteries 
(brain stem)
dysphagia, dysarthria,
hemiplegia/quadriplegia
cranial nerve palsies
ataxia
*  left hemisphere is dominant in most (>90%) right handed persons and in approx 70% of left handed persons
Figure 5.1 Circle of Willis Angiogram of circle of Willis (COW) Normal (right)
Key points
 · stroke is a sudden neurological deficit due to a vascular cause
 · person is usually aware of a neurological deficit over minutes or less commonly hours 
 · hemiparesis is the most common finding 
 · neurological findings help to localize the site of the lesion
 · most strokes occur in the anterior circulation
TRANSIENT ISCHAEMIC ATTACK (TIA)
A TIA is a sudden ischaemic focal neurological deficit that completely recovers in less than 24 
hours. They typically last for minutes not hours. They are mostly caused by thromboemboli 
arising from the internal carotid arteries in the neck and their branches. Other sources of 
emboli are atrial fibrillation and heart disease. The vascular territory involved determines the 
transient loss of consciousness
anterior cerebral
anterior
communicating
middle cerebral
posterior
communicating
posterior cerebral
internal carotid
basilar
The circle of Willis
transient isChaemiC attaCk (tia)
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neurological findings and the presentations are similar to those already outlined for stroke but 
usually less severe. All TIAs should be investigated in a similar manner and with the same sense 
of urgency as stroke (Table 5.4). After a TIA the overall risk for stroke is about 10% per year, 
the greatest risk being in the days and weeks following the TIA. If the TIA lasts >90 mins in a 
person at risk, then the likelihood of a stroke is greatest (4-8%) within the next 48 hours and 
PCA (left) Parietal (right) Cerebellar (left)
Figure 5.3 Infarction in territories of the main cerebral arteries
MCA (red) ACA (green) PCA (yellow)
Figure 5.2 Territories supplied by main cerebral arteries
CT scans showing infarcts
ICA (left) MCA (right) ACA (left)
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the patient requires urgent hospital admission. The aim of investigations and management is 
to identify and modify preventable risk factors such as smoking, exercise, diet and alcohol and 
aggressively treat underlying diseases such as carotid artery stenosis (Fig. 5.5), hypertension, 
diabetes and atrial fibrillation (Table 5.1). Antiplatelet drugs and anticoagulants are used as in 
the prevention of stroke (Table 5.6).
CT scans showing ICH 
Carotid angiogram
Frontal (right) & intraventricular Frontal (right) Internal capsule (right)
Figure 5.4 Intracerebral haemorrhage (ICH) CT scans showing ICH
Stenosis ICA
Figure 5.5 Internal carotid artery stenosis
transient isChaemiC attaCk (tia)
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Key points
 · most TIAs last for minutes not hours
 · if TIA lasts >1-2 hours, the risk of stroke is greatest over next 48 hours
 · annual risk for stroke after a TIA is around 10%
 · don’t wait for stroke to happen 
 · manage & treat TIA as if it were a stroke
Differential diagnosis
A history of a sudden onset of focal neurological deficit is almost always diagnostic of stroke. 
The differential diagnosis includes other disorders presenting with similar acute or semi acute 
neurological presentations. These include opportunistic processes in HIV disease, subdural 
haematoma, mass lesions, Todd’s paralysis after an unwitnessed seizure, and other causes of 
acute encephalopathy. However in these cases the correct diagnosis should be suggested by 
a different clinical history, sub-acute onset and progressive nature of the neurological deficit. 
Venous sinus thrombosis may present with a stroke but this is uncommon. The clinical context, 
usually a pre-menopausal female with typical fundoscopy changes of venous engorgement with 
haemorrhages should suggest the correct diagnosis. A history of recent head injury or fall 
suggests the possibility of subdural haematoma (SDH), although a history of trauma may be 
absent (Chapter 19). CT scan of the brain may be necessary to make the correct diagnosis. 
There are a number of other medical conditions that can mimic a stroke or TIA at onset; 
these include focal seizures, migraine, hypoglycaemia, syncope, and hysteria. These are usually 
self-limiting often with a history of similar previous episodes and have a normal neurological 
examination.
INVESTIGATIONS AND DIAGNOSIS
Stroke is a clinical diagnosis and investigations are directed at establishing the cause and 
preventing recurrences. The main investigations for stroke are outlined in Table 5.4. 
Computerised tomography (CT) of the head is the investigation of choice in stroke. Ideally this 
should be done within 24-48 hours of onset of the stroke. Its primary role is to rapidly exclude 
haemorrhage, thereby allowing the administration of an antiplatelet drug, usually aspirin. In 
addition, it can determine the nature, size and site of stroke and exclude other disorders. In 
haemorrhagic stroke, CT shows haemorrhage as a white or hyperdense area almost as soon as 
it occurs. In small bleeds, the white area persists for around 48 hours while larger bleeds may 
persist for 1-2 weeks. After two weeks a bleed becomes indistinguishable from an infarct on a 
CT. CT shows ischaemia as an ill defined dark or hypodense area but this can take 24-48 hours 
to appear on the scan. Not all infarcts show up on a CT because of decreased sensitivity, small 
size and also poor imaging of the posterior fossa. If the initial CT is normal and a stroke is still 
suspected then a scan repeated after 3-7 days may show an infarct. If the clinical diagnosis of 
a stroke is certain, then a repeat scan may be unnecessary. In SAH the CT is highly sensitive 
during the first few days, after which it becomes negative and the diagnosis is then confirmed 
by lumbar puncture showing altered blood or zanthochromia. Magnetic resonance imaging 
(MRI) is more sensitive than CT for detecting early and small vessel strokes. 
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Table 5.4 Investigations for stroke
Department Investigation Risk factor
Haematology FBC, ESR, sickle cell test anaemia, polycythaemia, infection, vasculitis, 
sickle cell disease
Biochemistry blood glucose, creatinine, electrolytes, 
liver function tests, lipids 
diabetes, renal disease, hyperlipidaemia
Serology HIV, VDRL infections
Microbiology malaria parasites,
blood culture (if febrile)
infections
Cardiology ECG atrial fibrillation, myocardial infarction
Imaging chest X-ray
CT/MRI of head
cardiomegaly, hypertension 
ischaemia or haemorrhage
Ultrasound echo heart (if cardiac origin suspected)
carotid doppler (if carotid origin 
suspected)
mitral valve disease, thrombus, endocarditis
large vessel atheroma
Key points
 · CT head may be necessary in suspected stroke to make the correct diagnosis
 · CT scan can detect over 90% of all strokes
 · CT scan done during the first 24-48 hours after onset of stroke may miss ischaemia
 · CT scan done during the first 1-2 weeks after onset of stroke usually confirms haemorrhage
SUBARACHNOID HAEMORRHAGE
SAH is the term usually reserved for spontaneous or non traumatic bleeding into the 
subarachnoid space which occurs as a result of a ruptured saccular (berry) aneurysm or an 
arteriovenous malformation (AVM) (Fig. 5.6). The majority (75-80%) occur as a result of 
bleeding from a ruptured saccular aneurysm. These aneurysms arise mainly at the junctions 
of the arteries that form the circle of Willis in the subarachnoid space at the base of the brain. 
In 5-10% of cases the SAH arises from an AVM and in a small percentage of cases no cause 
is found. SAH occurs in 5-10/100,000 persons per year in the UK. The frequency of SAH 
in SSA is not known but it may be more common there. A patient presenting with SAH is 
usually younger than in other types of haemorrhagic stroke (ICH) and first degree relatives are 
at an increased risk of stroke. Other risk factors for SAH include hypertension and a history 
of smoking. 
Clinical presentation
The main clinical feature of SAH is a sudden explosive severe headache described as “like being 
hit on the back of the head with a hammer.” There may be a prior history of sentinel or warning 
headaches for some weeks beforehand. The suddenness of onset helps to differentiate it from 
the pain of meningitis. The headache in SAH is usually accompanied by nausea, vomiting, 
fever, meningism and variable loss of consciousness. The loss of consciousness typically occurs 
at the moment of the bleed. The clinical findings vary from a fully alert patient with severe 
headache and meningism to a deeply comatose patient with decerebrate rigidity. Blood pressure 
is frequently elevated, mostly as a result of the SAH. Focal neurological signs and deficits may 
occur as a result of raised ICP, ICH or compression from the aneurysm. These include 3rd nerve 
subaraChnoid haemorrhage
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palsy, 6th nerve palsy, hemiparesis, bilateral extensor plantar responses and papilloedema with 
or without subhyaloid haemorrhages (10-20%). Focal neurological deficits are more common 
in ruptured AVMs.
Investigations
CT of the head is highly sensitive for SAH with >90% of patients showing evidence of fresh 
blood in the subarachnoid space or ventricles (Fig 5.6). This lasts for 24-48 hours after which it 
becomes negative. CT may not show evidence of an aneurysm unless it is large but will usually 
show evidence of an AVM especially if contrast is given. In a patient with suspected SAH if a 
CT is normal or unavailable then it is necessary to do lumbar puncture (LP) and check for fresh 
uniformly mixed blood which fails to clear in all 3 consecutive CSF samples. The opening CSF 
pressure may be elevated in SAH. Xanthochromia occurs when the CSF is uniformly straw or 
yellow in colour. This is due to the presence of degraded blood in the CSF which is older than 
24 hours and it persists for up to 2 weeks. The CSF may be entirely normal if examined within 
the first few hours or later than 2 weeks after the bleed. 
Key points
 · most common cause of SAH is a ruptured saccular aneurysm 
 · diagnostic feature of SAH is a sudden severe explosive headache
 · meningism is a key feature of SAH
 · level of consciousness in SAH ranges from being fully alert to deep coma
 · diagnosis confirmed by finding evidence of blood either on CT or in CSF
Management
SAH carries a very high mortality during the first few days and if left untreated, there is a 
significant risk of rebleeding (20-30%) over the next 6 weeks. Management of acute SAH is 
therefore directed towards immediate treatment and the prevention of further bleeding. Patients 
should be nursed in bed with the head elevated 10-20 degrees, resting in quiet surroundings 
with adequate analgesia to avoid pain and surges in blood pressure. Aspirin should be avoided 
and constipation prevented. Intravenous hydration should be with approximately 3 litres per 
day of normal saline to avoid hypovolaemia. Antihypertensive medications should be avoided 
to prevent hypotension. In order to reduce arterial vasospasm and cerebral infarction secondary 
to the irritative effect of blood on vascular smooth muscle, the calcium channel blocker 
nimodipine 60 mg 4 hourly is prescribed for 3 weeks. Seizures occur in approximately10% of 
patients and usually respond to the phenytoin 300 mg daily after a loading dose of 900 mg. 
Neurosurgical
Neurosurgical intervention is indicated for SAH patients who are fully conscious or mildly 
confused with minimal or no neurological deficits. Patients with altered level of consciousness, 
coma or focal neurological signs usually do not benefit from neurosurgical intervention. The 
overall aim of neurosurgical intervention aim is to occlude the ruptured aneurysm. This can 
be achieved by either a neurosurgeon placing a clip over the neck of the aneurysm or by the 
neuroradiologist endovascularly embolising the aneurysm by packing it with metal coils. The 
latter is now the preferred method for the occlusion of most aneurysms. The optimum time 
for neurosurgical management is within the first 3 days after the initial bleed although the 
aneurysm can be operated on or coiled later.
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Prognosis
The case fatality rate for patients presenting with SAH due to aneurysms is high with 
>10% mortality within the first few days either as a result of the initial haemorrhage or its 
early complications. Of all those patients that do survive the initial bleed and do not have 
neurosurgical intervention, one third die within 3 months, one third go on to make a good 
recovery and one third are left with permanent neurological disability. Case fatality rates for 
patients presenting with SAH secondary to AVM are lower at around 10%. 
Key points
 · main aim of treatment is to prevent another bleed
 · nimodopine helps to reduce vasospasm which may worsen the neurological deficit definitive 
surgical management is by either coiling or clipping the aneurysm 
 · overall mortality in SAH is high
MANAGEMENT
The overall aim of stroke care is to decrease morbidity and mortality, to optimise recovery of 
function and to prevent further strokes. This can be achieved by good nursing care, specific stroke 
treatment, maintenance of fluid and electrolytes, nutrition, avoiding systemic complications 
and early rehabilitation. The outcome improves when stroke care guidelines are followed and 
care takes place in a defined area in hospital by a dedicated team. In Africa hospital care starts 
usually with admission to a general medical ward. Management includes general (Table 5.5) 
and specific measures (Table 5.6).
Table 5.5 General measures in caring for acute stroke patient
1. Start neurological observations hourly and change to 4 hourly if stable 
•	 level of consciousness using GCS 
•	 vital signs
•	 oxygen saturation 
2.  Monitor blood glucose (if >11 mmol/L start insulin sliding scale) 
intravenous fluids in dehydrated patients, unable to swallow
CT (without contrast) Magnetic resonance angiogram COW
Blood in the subarachnoid space Aneurysm in left posterior cerebral artery
Figure 5.6 Subarachnoid haemorrhage & aneurysm
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4. Evaluate swallowing after 24 hours 
•	 observe the patient attempting to swallow sips of water in upright position
•	 check for coughing or gagging
•	 if swallowing impaired keep nil per oral (NPO)
•	 continue iv fluids for 48 hours then start nasogastric tube feeding if still unable to swallow
5. Urinary catheterization if incontinent or in retention 
6. Prevent constipation by adequate hydration and laxatives
7. Prevent pressure sores by supervising 2 hourly turning*
8.  Decrease the risk of deep vein thrombosis (DVT) by using compression stockings in addition to oral 
aspirin if ICH excluded
* this is done best by a relative or carer permanently at the bedside
Specific measures
Antiplatelet drugs
All ischaemic strokes should have aspirin immediately or as soon as possible after onset followed 
by long term treatment (Table 5.6). Ideally, haemorrhage should be first excluded on CT. If a 
CT scan is unavailable, then aspirin should be used cautiously in the first two weeks and then 
only in cases strongly suspected of having ischaemic stroke. Aspirin when given effectively 
prevents 15 deaths or major disability for about every 1000 patients treated during the first few 
weeks and prevents about a fifth of recurrent strokes when used longer term. There is a slight 
increased risk of gastro-intestinal haemorrhage. The dose is 300 mg po daily for the first 2 
weeks followed by 75-150 mg po daily thereafter. Patients that are intolerant of aspirin should 
be treated with either clopidogrel or dipyridamole. Combination therapy with both aspirin 
and clopidogrel is increasingly used in acute stroke patients.
Blood pressure
Blood pressure (BP) rises after an acute stroke and tends to fall spontaneously after that. The 
modern management is to avoid lowering blood pressure during the first 24-48 hours as an 
acute drop in BP can reduce perfusion to an already ischaemic brain. Consider treatment 
only if BP is persistently elevated (Table 5.6). The upper limit of persistently elevated blood 
pressure in ischaemic stroke is systolic 180 mm Hg and diastolic 105 mm Hg. The aim is a 
daily reduction of 10-20 mm Hg. Lower levels should not be treated in the first 48 hours unless 
complicated by hypertensive encephalopathy, left ventricular failure or myocardial infarction. 
In ICH, the threshold for starting treatment is lower (>160/100, Table 5.6). If BP needs to be 
treated in the acute phase, consider using nifedipine sublingually for acute reduction and then 
orally twice daily. Other options include captopril for a more gradual reduction or atenolol 
and/or hydralazine.
Anticoagulation
Patients with a proven ischaemic stroke and a cardiac embolic source or atrial fibrillation 
should be anticoagulated to prevent further strokes (Table 5.6). Patients should be first treated 
with aspirin and anticoagulation be delayed for 2 weeks after the stroke because of the risk of 
intracerebral haemorrhage. Warfarin is then the drug of choice in a loading dose, usually 10 mg 
daily for 2 days followed by daily dose, depending on the prothrombin time or international 
normalized ratio (INR). The aim is to have and maintain an INR of 2-3 or a prothrombin 
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time of twice the normal range. In patients with mechanical valve prosthesis the target INR is 
2.5-3.5. 
Thrombolysis
This is a recent development in stroke management and dramatically improves the outcome in 
some ischaemic stroke patients. Thrombolytic therapy is with alteplase, an iv tissue recombinant 
plasminogen activator (rtPA), a thrombolytic agent. This is beneficial in some patients with 
ischaemic strokes who have no early CT evidence of completed infarction or bleed. It has to 
be given as soon as possible after the onset of the stroke usually within 3 hours or 6 hours at 
maximum. Any later treatment has increased risk of bleeding and a lack of efficacy. However 
implementation requires a trained medical team on call and emergency CT scanning facilities. 
Currently <5% of all stroke patients with access in high income countries are treated with 
thrombolysis. 
Table 5.6 Drug treatments in stroke
Measure Treatment Dose Side effects
Blood Pressure
(Indication for Rx in 1st 48 hours)
>180/105 in infarction
>160/100 in haemorrhage
nifedipine 10 mg/sublingually stat 
10/20 mg/po/bd
hypotension
headache
captopril 625/125 mg/po/bd cough, allergy
hydralazine 25/50 mg/im/po/tid rash
atenolol 50/100 mg/iv/po/od asthma, depression, 
hypoglycaemia
Antiplatelet drugs
Indication: ischaemia
aspirin 300 mg/po/stat 
75-150 mg/po/od
indigestion, nausea,
GI bleeding
clopidogrel 75 mg/po/od indigestion
diarrhoea
dipyridamole 200 mg/po/bd headache, indigestion
Anticoagulation
Indication: risk of cardiac embolism
warfarin 10 mg/po/od/for 2 days
1-5 mg/po/od  
(according to INR)
bleeding
Key points
 · acute ischaemic strokes should have aspirin immediately
 · avoid aggressively lowering blood pressure during the first 24-48 hours of acute stroke
 · after first 48 hours, all persistently elevated blood pressures should be lowered
 · embolic strokes should be anticoagulated, but not for two weeks after onset of stroke
COMPLICATIONS
Stroke patients are at risk for complications which may lead to death. Neurological worsening 
is common in the first 48 hours of stroke as a result of brain swelling, extension of the original 
stroke and complications. Patients with coma, extensive stroke and large haemorrhage have a 
poor prognosis.
Acute
The main acute complications are aspiration pneumonia, pulmonary embolism (PE), pressure 
sores and urinary tract infections. These occur in over half of hospitalized stroke patients 
and are associated with a poor prognosis. Pneumonia is the main cause of death in stroke in 
CompliCations
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hospitalized patients. This occurs as a result of aspiration and is more frequent in patients with 
extensive strokes and coma. Management includes avoiding oral intake, chest physiotherapy 
and early antibiotics. Patients with stroke are at significant risk for DVT and PE. The use 
of prophylactic low dose aspirin and compression stockings decreases this risk. Heparin is 
contraindicated in the first 2 weeks after stroke as it increases intracerebral bleeding. Pressure 
sores, spasticity and contractures are common after a stroke and are reduced by early patient 
positioning, 2 hourly turning, passive exercises and limb splinting. 
Chronic
Long term complications include spasticity, contractures, pain, depression, dementia and 
late onset seizures. Post stroke depression is common occurring in over half the patients. It is 
important to recognize it and if necessary offer treatment with tricyclics or selective serotonin 
reuptake inhibitors. Dementia as a result of stroke is common and is a major long term cause 
of dependency, particularly in the elderly. Seizures occur in about 2% of acute stroke patients 
but usually resolve in a few weeks and don’t require long term treatment with anticonvulsants. 
Late onset seizures (6–12 months after stroke) occur in around 5% of stroke patients and are 
persistent, but they respond well to phenytoin. 
Rehabilitation
Rehabilitation is one of the most important aspects in the care of stroke patients. Early 
mobilization and rehabilitation have been shown to help and improve outcome. This should take 
place on a daily basis in the general medical ward or in a specialized stroke area. Physiotherapy 
maximises functional recovery, occupational therapy is necessary for functional assessment and 
the provision of practical aids and speech and language therapy helps with aphasia, dysarthria 
and dysphagia. 
Palliative care
Many stroke patients have no hope of recovery, and the best management is to ensure their 
comfort and avoid any unnecessary investigations and further suffering. It can be very distressing 
for family to witness a dying patient with noisy and laboured breathing because of retained 
airway secretions. Care is best achieved by good nursing and adequate palliative analgesia. It is 
important to explain to family and carers what is happening and many will at this stage choose 
to care for the patient at home. 
Key points
 · main acute complications are aspiration pneumonia & pressure sores
 · pneumonia is a leading cause of death in stroke 
 · early mobilization and rehabilitation are critical to recovery 
 · long-term complications are disability, pain, depression, dementia & seizures 
 · palliative care is important where recovery is unlikely
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PREVENTION
Antiplatelet drugs
Low dose daily aspirin 75-150 mg decreases the risk of another stroke by about one fifth in 
ischaemic strokes. About 10% of patients don’t tolerate aspirin because of gastrointestinal side 
effects, mainly indigestion, nausea and rarely bleeding. This can be decreased by the concomitant 
use of a proton pump inhibitor and by using alternative antiplatelet drugs. Clopidogrel 75 mg 
daily is the drug of first choice in patients with aspirin intolerance but is more expensive. The 
combination of clopidogrel and aspirin is considered more effective than aspirin alone but has 
an increased risk of bleeding. Dipyridamole may also be used. Antiplatelet therapy has to be 
continued indefinitely.
Anticoagulants
The annual risk of embolism with either valvular heart disease or atrial fibrillation is around 
10% per year without anticoagulation. Anticoagulation with warfarin decreases this risk very 
significantly by >50% per year. All ischaemic stroke patients presenting with atrial fibrillation 
or mitral valve disease should be anticoagulated indefinitely unless there is a contraindication.
Blood pressure
Treatment of hypertension significantly reduces the risk of strokes. There is strong evidence 
that lowering blood pressure, irrespective of the previous baseline level down to 130/70 reduces 
the risk of stroke. A mean drop of 9 mm Hg systolic and 4 mm Hg diastolic reduces the relative 
risk of stroke by about a quarter. Blood pressure treatment should be started in hypertensive 
stroke patients 48 hours after onset of the stroke and continued and monitored on discharge 
from hospital. 
Carotid Stenosis
Athero-thromboembolism arising from the carotid and vertebral arteries is the main cause 
of ischaemic stroke in high income countries. Symptomatic carotid stenosis of >70% is an 
indication for carotid surgery wherever this is available (Fig. 5.5). Asymptomatic carotid stenosis 
of >70% and symptomatic stenosis of <70% are managed medically. However atheroma arising 
specifically from the carotids appears to be an uncommon source of ischaemic stroke in Africa.
Other factors
Life style measures such as salt reduction, low animal fat diet, decreasing alcohol consumption, 
stopping smoking and increasing exercise are all very important in both primary prevention 
of stroke at community level and secondary prevention when the stroke/TIA has occurred. 
Education is vital to the successful implementation of these measures. The use of cholesterol 
lowering drugs, simvastatin 20-40 mg po daily or another statin has been shown to decrease 
coronary events and recurrent strokes and these should be prescribed if possible after an 
ischaemic event. The expected relative risk reduction is in the order of 20%. However, the 
statins are expensive and have side effects including myalgia, myositis and liver dysfunction, 
which can lead to them being discontinued in about 10% of patients. An elevation of creatine 
kinase (CK) occurs in many individuals on statins and values up to 1000 IU can be tolerated. 
Adequate long term control of diabetes is important. 
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Prognosis
The outcome for stroke patients is poor. The mortality within the first year is over 30%, with 
a further one third disabled and about one third regaining independent living. The majority 
of deaths occur during the first week and month after the stroke and continue throughout the 
first year. The risk of recurrence continues over time. Over half of all stroke survivors are dead 
within 5 years. The long term prognosis for stroke is probably worse in Africa because of the 
lack of secondary and tertiary care. 
Prognosis of stroke after one year
 · one third die
 · one third are disabled and dependent
 · one third are independent
The future
The majority of strokes occur in low and middle income countries where most of the world’s 
population live. With increasing urbanization, this burden is set to continue and increase over 
time. In low income countries especially, the majority of people have limited or no access to 
facilities for the prevention and management of stroke. These limitations extend from a lack 
of awareness to lack of treatment, rehabilitation and prevention. These in turn are related 
to a lack of trained specialists, education, resources and research. Clearly there is a need for 
more research and intervention particularly in the area of primary and secondary prevention 
of strokes in low and middle income countries, not forgetting the very important link between 
patient care and primary prevention of stroke in the community. 
Key points
 · prevention of stroke is now a top priority in Africa 
 · primary prevention must include public education concerning necessary lifestyle changes 
 · includes decreasing total salt intake, stopping smoking, dietary changes & increasing exercise
 · secondary prevention includes targeting known diseases & risk factors for stroke
 · tertiary measures are important to cope with increasing burden of death & disability
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CHAPTER 6
NEUROLOGICAL INFECTIONS
Introduction
Infections of the nervous system are common in Africa and account for a significant percentage 
of all deaths. The causes of these infections are viral, bacterial, fungal and parasitic, protozoa and 
helminths. Their estimated frequency and mortality is presented in Table 6.1. These infections 
result in CNS illnesses characterized mainly by meningitis, focal neurological disorders and 
coma. Since the onset of the human immunodeficiency virus (HIV) epidemic in Africa three 
decades ago there has been a dramatic change in the overall pattern of CNS infections in 
Africa. CNS opportunistic infections related to HIV have now become commonplace and 
are the leading cause of death in adults in many countries. The main causes are cryptococcal 
meningitis (CM), cerebral toxoplasmosis (CT) and tuberculous meningitis (TBM). At the 
same time cerebral malaria, acute bacterial meningitis (ABM), tetanus, trypanosomiasis, 
neurocysticercosis and brain abscess remain as major causes of neurological illnesses. This 
chapter presents an overview of the main bacterial, fungal and viral infections including clinical 
features, diagnosis and management. After reading this chapter the student should aim to be 
able to diagnose, treat and prevent meningitis and know the other main CNS infections.
Table 6.1 Estimated frequency & treated mortality of main neurological infectious disease in Sub Saharan 
Africa
Disease Estimated frequency per 
year for whole population 
Mortality rates (treated patients)
Acute Bacterial Meningitis 250,000 (children)
50/100,000 
5-40% (children)
10-70% (adults)
Opportunistic infections in HIV
cryptococcus
toxoplasmosis
TB
5-700,000
50%
10-20%
>50%
CNS TB (non HIV) 30,000 20-30%
Cerebral malaria >05 million 10-20%
Human African trypanosomiasis 40,000-300,000 20-30% 
Tetanus 100,000 40-60%
Rabies 10-20,000 100%
Leprosy 40,000 low
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Meningitis
Meningitis is defined as inflammation of the pia and arachnoid meninges and the cerebrospinal 
fluid (CSF) that surrounds the brain and spinal cord. The main infectious causes are viral, 
bacterial and fungal. Meningitis is classified clinically as either acute or chronic. Acute 
meningitis occurs within hours or days, whereas chronic meningitis evolves over weeks. Acute 
meningitis is classified as aseptic which is mostly viral in origin or septic or pyogenic which is 
caused by bacteria. 
The term acute bacterial meningitis (ABM) refers to acute infections caused by pyogenic 
bacteria. The main causes of pyogenic meningitis in Africa are Streptococcus pneumoniae 
(pneumococcus), Neisseria meningitidis (meningococcus) and Haemophilus influenzae type b 
(Hib). Chronic meningitis by definition persists for weeks (four or more). The main causes 
in Africa are cryptococcal infection and tuberculosis. The overall pattern of meningitis in adults 
has changed in Africa, whereas ABM used to be the leading cause of meningitis, cryptococcus 
is now the most common cause followed by tuberculous meningitis (TBM) and ABM. Their 
exact order depends on the geographic location, the extent of HIV epidemic and the age group 
affected.
ACUTE BACTERIAL MENINGITIS (ABM)
EPIDEMIOLOGY
ABM causes over a quarter of a million deaths globally each year with a large proportion of these 
occurring in Africa. ABM occurs mostly in young children, particularly in those <2 years but 
affects all age groups including adults. Africa has some of the highest rates of ABM in the world 
affecting as many as 1/250 of children <5 yrs, in mainly urban parts of West Africa. However 
as many as 1-2% of whole populations in the “meningitic belt” may be affected during cyclical 
meningococcal epidemics which occur every 5-10 years. It is estimated that ABM in Africa is 
5-10 times more common (50/100,000/yr) as compared to high income countries. Risk factors 
for ABM in Africa are crowded living conditions, extremes of age, organism virulence and 
antibiotic resistance, and host predisposition. Individual host factors include HIV infection, 
malnutrition, sickle cell disease, splenectomy, a non functioning spleen, recent head injury 
with fracture or, post neurosurgery with CSF leak, middle ear infection and pneumonia. The 
overall frequency of ABM in adults in Africa appears to have remained relatively constant 
despite the current HIV epidemic there.
Aetiology
In children in Africa the main causative organisms of ABM are Hib, pneumococcus and 
meningococcus. In those countries where Hib vaccination has been instituted, Hib has now been 
replaced as the main cause by pneumococcus and meningococcus. Recently a new pneumococcal 
conjugate vaccine is being used in children in some countries, including South Africa, Gambia 
and Kenya. In adults the main causative organisms are pneumococcus and meningococcus. Other 
less common causes include group B streptococcus, nontyphoidal salmonella, (NTS), staphylococci, 
and Escherichia coli in neonates. Listeria monocytogenes may cause ABM in pregnancy and in 
HIV. Gram negative bacilli and salmonella may cause ABM in HIV and in the elderly.
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Streptococcus pneumoniae
Pneumococcus is a gram positive coccus which exists in pairs (Fig 6.1) with many subtypes. It 
affects mostly infants aged <12 months, young children and adults, but all age groups may be 
affected. It may occasionally occur as epidemics. The main source of meningeal infection is 
haematogenous spread arising from the respiratory tract (pneumonia) and from otitis media, 
although individual host factors are also important. Sporadic invasive pneumococcal disease 
has increased significantly since the arrival of the HIV epidemic and is a significant cause of 
bacteraemia, pneumonia and death in HIV disease. It accounts for >90% of cases of ABM in 
adults in the main HIV affected areas in Africa. The main risk factors for ABM have already 
been outlined above. The case fatality rate (CFR) in Africa in treated pneumococcal meningitis 
is high, ranging from 30-40% in children to 50-70% in adults. 
Neisseria meningitidis
Meningococcus is a gram-negative diplococcus and infection results in meningococcal disease 
(fig. 6.2). It is classified into serogroups with A, B, C, Y, W-135 and X predominating. The most 
common serogroup in Africa is A but there have been recent outbreaks there with serogroups 
W-135 and X. Epidemic strains are sometimes introduced by Hajj pilgrims returning from 
Mecca, where similar epidemics have occurred. Protective vaccines exist for serogroups A and C 
and more recently a quadrivalent vaccine for A, C, Y, and W-135 (meningococcal A-conjugate 
vaccine) but not for group B or X. The usual incubation period for meningococcal disease is 
2-7 days. The peak incidence is in children with a second peak in teenagers and young adults. 
The main risk factor for infection is close household contact with an infected person, when 
the risk of contracting the disease is increased a thousand fold. While most cases are sporadic, 
meningococcal disease also occurs as epidemics in Africa. 
Large scale epidemics occur in sub-Saharan Africa during the dry season in approximately 
10 year cycles. These epidemics occur in a large “meningitis belt” which stretches from the 
Gambia and Senegal in the West to Sudan and Ethiopia in the north and as far south as Kenya 
and Tanzania in the east and Nigeria and Ghana in the west. The reason for epidemics is 
unclear but has been attributed to the loss of accumulated herd immunity and the presence of 
suitably dry conditions for transmission, usually from March to May. During meningococcal 
epidemics, outbreaks occur typically in areas of overcrowding such as towns, schools, barracks, 
and prisons. 
The overall case fatality ratio (CFR) in adults is of around 10% but this can vary (5-20%). 
A lower overall CFR (5%) generally reported across parts of Africa is attributed to infection 
with the most common serogroup A and to meningococcal disease presenting with mostly 
meningitis without associated septicaemia. However a higher CFR of around 20% has been 
reported recently in patients infected with serogroups W-135 and X, and also with HIV 
infection in South Africa. 
Haemophilus influenzae type b (Hib)
Hib is a small gram-negative coccobacillus. It primarily affects young children under the age 
of six years and is a major cause of respiratory tract infection and ABM. Hib related ABM 
primarily affects infants 1-24 months and rarely occurs in adults. The CFR in Africa in children 
is 20-30% and is higher in adults 30-40%. 
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Key points
 · ABM is a major cause of mortality & morbidity in Africa 
 · occurs in any age group but mostly in infants & young children 
 · main causes are pneumococcus, meningococcus & Hib
 · host risk factors are HIV, sickle cell disease, asplenia & head injury 
 · meningococcal infection occurs in both sporadic & epidemic forms
 · CFR varies with the organism & the age group affected
Pathogenesis
All the three main bacterial causes of meningitis colonise the nasopharynx in asymptomatic 
carriers. Colonisation rates of around 10-20% are commonplace in schools, universities 
etc with higher seasonal rates in children, young adults and in case contacts. Spread is by 
droplets from close physical contact with asymptomatic carriers or occasionally direct from 
cases. The presence of a lipopolysaccharide capsule helps bacteria survive and they reach the 
meninges via the bloodstream or by direct invasion. Clinical disease is rare and only occurs 
when there is penetration across the blood-brain barrier with infection of the meninges and 
subarachnoid space (Fig. 6.1). This may occur in association with bacteraemia and septicaemia. 
The multiplication of bacteria in the sterile CSF triggers a massive host immune response with 
release of inflammatory cytokines, which result in activated macrophages and invasion with 
neutrophils, immunoglobulins and other markers of inflammation. This leads to a further 
breakdown in the blood brain barrier and can result in vasculitis, thrombosis, infarction, raised 
intracranial pressure, brain damage and death. 
Clinical diagnosis
The main clinical features of ABM are headache, fever and meningism. When this triad is 
accompanied by alteration in consciousness or seizures, the diagnosis is usually not in doubt. 
Other symptoms include photophobia, nausea, vomiting, backache and lethargy. The finding of 
a haemorrhagic rash on the skin is strongly suggestive of meningococcal infection. Progression 
occurs rapidly over 1-3 days but a smaller number may have an acute fulminant course lasting 
Pathology CSF microscopy
Purulent meninges Purulent ventriculitis Pneumococcus (Gm pos cocci)
Figure 6.1 Brain/csf in acute bacterial meningitis 
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hours. However patients with HIV infection may present with only one or two of these main 
features.
Seizures occur in about one third of patients, typically in children and may be the presenting 
complaint. Focal neurological abnormalities, status epilepticus and coma occur mainly as 
complications. There may also be evidence of infection outside the CNS or an underlying 
condition predisposing to meningitis e.g. pneumonia, HIV, middle ear infection and head 
injury. The differential diagnosis for ABM in adults in Africa includes the other main causes of 
meningitis (cryptococcus, TBM and viral), opportunistic infections in HIV, cerebral malaria, 
viral encephalitis, typhoid fever and other CNS infections. 
Signs of meningitis
The cardinal signs of meningitis are neck stiffness and Kernig’s sign (Chapter 1). Neck stiffness 
is the most important sign and is present when the neck resists passive flexion to bring the 
chin on to the chest. It is found in most adults and over three quarters of children with ABM. 
Kernig’s sign is elicited by passively attempting to straighten the leg with the hip and knee 
flexed to >90 degrees. In cases of meningitis this is met with resistance and pain, caused by 
spasm in the hamstrings as a result of stretching inflamed nerve roots. A forward flexing of the 
neck elicits involuntary hip and knee flexion or Brudzinski’s sign. Brudzinski’s sign is found 
mainly in infants and young children but not in adults. 
These signs of meningitis are present in most cases of established meningitis but are less likely 
to be present early on in the disease and in the young and the elderly. In older children and 
adults, in addition to the classic features, there may be back pain and myalgia and seizures 
in around 20%.  In infants, the combination of fever, respiratory distress, irritability, crying, 
vomiting, drowsiness and failure to feed may be the only findings. In babies, the association 
of bulging fontanel, neck retraction and seizures should prompt the correct diagnosis. In the 
elderly, alteration in the level of consciousness and fever may be the only clinical findings. It is 
important to remember that whenever in doubt about the diagnosis of meningitis, to return to 
re-examine the patient for signs of meningitis, in particular for neck stiffness.
Pneumococcal meningitis
Patients with pneumococcal meningitis present with marked meningism. Signs of an underlying 
pneumonia and septicaemia may be present particularly in children. Patients tend to progress 
rapidly in 24-48 hours to drowsiness, confusion, seizures and coma. 
Meningococcal disease
The main clinical features of meningococcal disease are those of either septicaemia with or 
without meningitis or meningitis alone. The proportion of patients presenting with meningitis 
alone appears to be greater in tropical countries. Meningococcal meningitis without septicaemia 
has a favourable recovery rate (95%). The clinical features of meningococcal septicaemia may 
vary from mildly symptomatic patients to acute fulminant infection. The onset is typically 
abrupt over 24-48 hours. However, symptoms can progress rapidly from drowsiness and rash 
to circulatory failure, coma and death within hours of onset. 
The diagnostic feature of meningococcal disease is the typical haemorrhagic rash, which is 
non-blanching and present in the majority of patients (Fig 6.2). However it may be absent, 
particularly in uncomplicated meningitis in children. The rash may begin as a maculopapular 
rash and develops in a matter of hours into a petechial and purpuric rash all over. The 
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conjunctiva, palate, soles of the feet and palms of the hands should be carefully examined as the 
rash may be easily missed on the limbs and trunk in dark skin. The lesions do not blanch under 
pressure and this can be confirmed by pressure with a glass when the rash can be seen to persist. 
This is called the “tumbler test” (Fig 6.2). Petechiae may later progress to larger confluent 
purpuric areas called purpura fulminans. Complications of meningococcal disease include skin 
necrosis, arthritis, gangrene and Waterhouse-Frederickson syndrome of adrenal failure. 
Hib meningitis
This has a characteristic slow onset over several days often starting with fever or respiratory tract 
infection. The onset of drowsiness, vomiting and convulsions in an infant in this setting may 
suggest the diagnosis.  
Key points
 · headache, fever & meningism are the cardinal clinical features of ABM 
 · neck stiffness is the most sensitive clinical sign 
 · signs are less sensitive in the young, old & in HIV infection
 · meningism & bleeding into skin suggests meningococcal disease
 · When in doubt about the diagnosis return & re-examine the patient
Diagnosis
The diagnosis of ABM is based on clinical and laboratory findings (Table 6.2). Laboratory 
tests include a full blood count, blood glucose, malaria slide, blood culture and an HIV test. 
A lumbar puncture (LP) is the key investigation and is an overall simple and very safe test (see 
appendix). It is always indicated in suspected ABM, unless there is a clear contraindication. 
A LP is contraindicated in the presence of suspected raised intracranial pressure (ICP). The 
clinical features suggestive of raised ICP in ABM are altered level of consciousness, coma, 
focal neurological deficit and papilloedema. These are all indications to avoid a LP and also 
for doing a CT scan of the head if it is available. The CT with contrast may show meningeal 
enhancement in ABM. If the CT of the head shows no mass lesion and there is no other 
evidence of raised intracranial pressure e.g. papilloedema then it is reasonable to proceed 
with the lumbar puncture.  However it is important to note that even a normal CT may not 
necessarily rule out raised ICP, particularly if carried out early on in ABM. 
Skin CSF microscopy
Macular rash Petechial purpuric rash The tumbler test Gm neg cocci
Figure 6.2 Meningococcal meningitis
Chapter 6  neurologiCal infeCtions
Part ii – Neurological Disorders 128
CSF in ABM
The opening CSF pressure is typically elevated >20 cm and the colour is cloudy (Table 6.2). 
On analysis there is a characteristic high white cell count (>60% neutrophils), a very low 
glucose and an elevated protein. In HIV patients who are unable to mount a full inflammatory 
response, a much lower cell count is used as a cut off (>10 cells/mm3) for diagnosis of ABM 
and any protein elevation is also less. A similar pattern may be seen with the other causes 
of meningitis in HIV disease. A gram stain should always be performed on the CSF and a 
specimen sent for bacterial culture. Suspected cases of chronic meningitis patients should have 
their CSF screened for cryptococcus by India ink and cryptococcal antigen (CRAg) if available 
and also for tuberculosis by Ziehl-Neelsen (ZN) stain and culture. 
Table 6.2 Summary CSF findings in meningitis*
acute bacterial 
meningitis
tuberculous cryptococcal viral
opening pressure
(n = <20 cm in adults)
increased increased increased normal/increased
appearance
(n = clear)
cloudy, purulent yellow/cloudy clear/cloudy clear (cloudy)
cells/mm3*
n = <5/mm3
 main type
high
>2,000/mm3 
neutrophils
increased
50-500 
lymphocytes
normal/increased
0-100
lymphocytes
normal/increased
0-500
lymphocytes
glucose
(n = >50% plasma)
very low/absent
<1 mmol/L
low normal/low normal
protein
(n=<0.5gm/L)
elevated
1-2
high/very high
1-5
normal/elevated
05-2
normal/elevated
05-10
diagnosis
confirmed
Gm stain & culture ZN stain & culture India ink stain, 
CRAg/culture
PCR/culture
* see appendix for exceptions
Management
The mainstay of management of ABM is prompt diagnosis and early treatment with 
antimicrobials (Table 6.3). It is important that antimicrobials should be given straight away 
(within 20-30 mins of first seeing the patient) and not to delay treatment because of ongoing 
investigations including a LP or CT. The early treatment is based on a presumed diagnosis of 
ABM and the patient is usually covered with antibiotics for the main possible bacterial causes 
(Table 6.3). In adults ceftriaxone or another extended-spectrum cephalosporin, cefotaxime are 
now the drugs of first choice. If unavailable then it is recommended to give soluble penicillin 
in combination with chloramphenicol. A history of anaphylaxis is a contraindication for 
penicillin but a history of a rash is not. 
Patients at the extremes of life or with a particular risk factor may need additional antibiotic 
cover e.g. flucloxacillin for staphylococcal infection in neonates or gentamycin for some gram 
negatives in neonates and in old age. Additions or changes in antimicrobials are guided by 
laboratory based bacteriology stains and cultures. The use of steroids in the treatment of ABM 
in adults is currently not recommended in Africa as evidenced by recent prospective ABM 
studies in Malawi, showing no additional benefit. Supportive measures include oxygen, careful 
rehydration at less than 1-2 litres in the first 24 hours, maintenance of normal blood pressure, 
urinary output, electrolyte balance and control of pain and fever.
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Table 6.3 Antimicrobial treatment of adult ABM
Drug Dose/ route Frequency Duration*
ceftriaxone 
or
cefotaxime 
2 gm/iv 
2 gm/iv
12 hourly
4 hourly
10-14 days
10-14 days
or
penicillin 
&
chloramphenicol 
24 gm or 4 million units/iv
1 gm/iv
4 hourly
6 hourly
10-14 days
10-14 days
*  children with ABM & meningococcal disease may have shorter courses of antibiotics (5-7 days)
Outcome
Death is inevitable in untreated ABM. Mortality in treated ABM varies with the age group 
affected, the organism causing it and in particular how early on the appropriate antimicrobial 
was given. The case fatality ratio (CFR) in ABM is highest in neonates and adults (50-70%). 
In adults in Africa, CFR is highest in pneumococcus (70%) and lowest in meningococcus (10-
20%). The lowest CFR in ABM is in children with uncomplicated meningococcal meningitis 
(5%). The presence of underlying HIV infection significantly increases the CFR in ABM. 
Resistance to penicillin (20%), chloramphenicol (20%) or both (10%) and a decreased 
susceptibility to cephalosporins (5%) is an increasing problem particularly in Africa because of 
their widespread usage. Permanent neurologic deficits persist in over a quarter of all surviving 
ABM patients. This also varies by age group and organism. Over 50% of neonates and 40% of 
those who survive pneumococcal meningitis have permanent neurological deficits, in contrast 
to about 5-7% of those with meningococcus. The main neurological deficits after ABM are 
hearing loss (>25%), motor loss (12%), cognitive impairment (9%) visual disturbance (6%) 
and seizures.  
Key points
 · death is inevitable in untreated ABM
 · early antibiotics is the most important treatment affecting outcome 
 · cephalosporins are the drugs of first choice 
 · over a quarter of all surviving patients have permanent neurological disabilities
 · disabilities includes deafness, motor loss, cognitive impairment, mental retardation, visual 
disturbance & seizures
Prevention
In sporadic meningococcal infection, chemoprophylaxis should be provided for all household 
and close contacts of the patient within the previous 24 hours. The risk of developing meningitis 
in close contacts is estimated to be about 1 in 300. Adults and children over 12 yrs should 
receive rifampicin 600 mg orally twice daily for 2 days or ciprofloxacin or azithromycin 500 
mg orally as a single dose. Rifampicin should not be given in pregnancy. For children up to 
the age of 12 years, use rifampicin10 mg/kg twice daily for two days or ceftriaxone 125 mg 
im as a single dose. Chemoprophylaxis is not indicated for close contacts of pneumococcal or 
Hib meningitis. Early recognition is the key to management when epidemic meningococcal 
meningitis is suspected. If the number of cases exceeds 15/100,000 per week or 5-10 cases 
per week if the population <30,000, then emergency preventative measures include alerting 
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the appropriate authorities, identifying the organism and use of mass chemoprophylaxis and 
vaccination. All three main causes of ABM are now largely preventable by vaccination.
Key points
 · prevention of individual cases meningococcal infection is based on prophylaxis of close contacts
 · epidemic prevention is based on early recognition, mass chemoprophylaxis & vaccination 
 · vaccines are available to prevent Hib & for some strains of meningococcus & pneumococcus 
 · ABM in SSA is largely preventable by vaccination
TUBERCULOUS MENINGITIS (TBM)
Each year there are around 10 million new cases of tuberculosis worldwide, approximately one 
third of which occur in Africa. TBM now accounts for 8-44% of all cases of meningitis in SSA 
depending on the local HIV and TB prevalence. TB of the CNS is estimated to account for 
<1% of all new cases of TB, but this figure is significantly higher, when there is coexisting HIV 
infection. Tuberculous meningitis (TBM) is the most common CNS presentation. Other CNS 
presentations of TB infection include focal neurological disorders in intracranial tuberculoma 
and paraplegia in spinal cord involvement. In Africa, non HIV associated TBM affects mostly 
children, in particular the age group <5 years but can affect all age groups. In contrast TBM 
in HIV disease mostly affects adults. TB is clinically classified as pulmonary type (85%) and 
extra pulmonary type (15%). Only the pulmonary type is infectious to others. TBM can arise 
in two main ways: either as a complication of pulmonary e.g. disseminated or miliary, or less 
commonly as a result of reactivation of extra pulmonary TB. 
Pathogenesis
Mycobacterium tuberculosis is the main cause of TB but other members of the M. tuberculosis 
complex such as M. bovis and M. africanum may also cause human disease. TB of the CNS 
arises indirectly from primary infection in the lungs, from where it spreads via the blood 
stream to other organs including the brain and spinal cord. In the brain or spinal cord, it has 
a predilection for the subpial sites, where it may present either acutely as TBM or lie dormant 
for years and later reactivate. Under different conditions, notably immunosuppression in 
HIV or sometimes pregnancy these tubercles which are known as Rich foci reactivate and 
rupture. If they rupture into the subarachnoid space they result in TBM, into the brain a 
tuberculoma, or into the spinal cord a myeloarachnoiditis. The immune reaction generated 
is mainly inflammatory with exudates particularly around the base of the brain and in the 
ventricles (Fig. 6.3). This may lead to multiple cranial nerve palsies, arteritis with strokes and 
obstruction to CSF flow and absorption resulting in hydrocephalus. 
Clinical features
TBM is a difficult condition to diagnose and confirm clinically. The clinical features are those 
of slowly progressive chronic meningitis frequently with associated encephalopathy. Symptoms 
develop gradually, usually over 1-3 weeks but can be more acute in children. Constitutional TB 
symptoms including fever, night sweats, weight loss and malaise may be present for a week or 
more early on but these may also be absent or are not specific for TB. The main neurological 
symptoms suggestive of TBM are headache, nausea, vomiting, irritability, behaviour change 
and meningism of gradual onset usually for a period of one week or usually longer in adults. 
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However, headaches may be less prominent in children, fever may be absent in 10-20% of 
adults and the signs of meningitis are generally less prominent as compared to ABM. The main 
neurological signs are those of meningism including neck stiffness coupled with combinations 
of cranial nerve palsies (3rd, 4th, 6 th ,7th & 8th). The presence of focal neurological deficits, 
visual loss, papilloedema, altered level of consciousness, seizures and coma all suggest either 
parenchymal brain involvement or hydrocephalus. Fundoscopy may occasionally reveal typical 
TB retinopathy (characteristic white spots e.g. Fig 6.3). Hydrocephalus may be present early 
on or develop later during the course of the illness. 
Other neurological presentations of TB involving the CNS are tuberculoma in the brain 
and spinal cord TB. Tuberculoma may be solitary or multiple presenting mainly as focal 
neurological deficits, seizures and occasionally raised intracranial pressure. Tuberculoma may 
sometimes complicate TBM and the most common site in adults is above the tentorium 
(supratentorium), whereas in children it is below the tentorium (infratentorium). Spinal cord 
TB presents as paraplegia and the site may sometimes be the source of TBM (Chapter 10). A 
WHO staging based on the main neurological features of TBM is outlined below (Table 6.4).
Pathology Histopathology
Retinal TB AFB on ZN stain
Figure 6.3 Brain/csf in tuberculous meningitis
Fundoscopy Microscopy
Basal meningitis Rich focus Endarteritis obliterans
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Table 6.4 WHO Staging of TBM
Disease Stage Neurological features
Stage I no disturbance of consciousness
no *FND
Stage II alteration in consciousness but not in coma or delirium, no FNDs, cranial nerve palsies 
may be present
Stage III coma &/or FNDs
* FND focal neurological disorder
Key points
 · TBM occurs either as an acute complication of pulmonary TB or as a reactivation of extra 
pulmonary TB 
 · TBM affects mostly young children whereas TBM in HIV affects mostly adults 
 · HIV significantly increases the risk of TBM 
 · symptoms of TBM include headache, fever, vomiting, & meningism for >1 week 
 · signs include neck stiffness, seizures & multiple cranial nerve palsies
Differential diagnosis
The differential diagnosis includes cryptococcal meningitis, partially treated ABM, cerebral 
malaria, brain abscess and other infectious causes of meningoencephalopathies.
Diagnosis
The diagnosis of TBM is based on clinical suspicion and characteristic CSF findings (Table 
6.2). Routine laboratory investigations are of limited value in the diagnosis of TBM. The 
tuberculin skin test is of little diagnostic benefit in adult populations with high levels of TB 
infection or previous BCG exposure and may also be negative in disseminated TB and HIV 
disease. The diagnosis of TBM is supported if there is evidence of concomitant TB elsewhere, 
most frequently pulmonary as evidenced by chest radiograph. Lumbar puncture is safe if there 
are no contraindications e.g., alteration in consciousness, lateralising clinical signs or signs of 
raised intracranial pressure (see appendix). 
In TBM the opening pressure is often raised and the CSF clear in colour but may be slightly 
yellow in established disease. If a sample is left standing overnight in a test tube, the development 
of an appearance of a cobweb or lattice is supportive of TBM. The CSF white cell count in 
TBM is usually elevated, 50-500 cell/mm3 mostly lymphocytes, but notably these may be 
absent in HIV disease or are polymorphs in early infection, particularly in young children. The 
CSF protein level is usually quite elevated and the glucose is low (<50% plasma glucose) but 
these can be normal in early disease and also in HIV infection. The organism is identified by 
acid-fast staining and culture. In TBM, the sensitivity of routine unconcentrated CSF staining 
with Ziehl-Neelsen stain is very low (<5%), but this yield can be improved markedly with 
increased quantity of CSF (10-20 ml in adult), by concentrating the CSF by centrifugation and 
by careful examination or the residue (for at least 20 mins) and by repeated CSF examinations. 
Polymerase chain reaction (PCR) has better sensitivity depending on bacillary load and good 
specificity (90-95%) but the test is not widely available in Africa and the result is no better 
than culture. A new automated PCR test on sputum is now available which gives a result in 4 
hours but running cost is approx 20 US dollars per test which makes it relatively prohibitive 
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in most parts of Africa. Also it has yet to be validated on CSF. Culture is the gold standard 
but limitations include the fact that the result takes 4-6 weeks which is too slow to be of value 
clinically and this facility is again not widely available. The CRAg test in TBM is negative.
Imaging with CT/MRI (Fig. 6.4) can be very helpful. In TBM it may show evidence of 
hydrocephalus and after contrast generalised meningeal enhancement with irregular basilar/
cisternal involvement. It may also reveal infarction or tuberculoma. A tuberculoma shows as 
a rounded lesion with ring enhancement with irregular walls, nodular enhancement, oedema 
and mass effect. They are most commonly situated near the cortex, may be multiple and 
accompany TBM. 
Key points
 · diagnosis of TBM requires a high index of clinical suspicion 
 · laboratory confirmation is by finding evidence of TB in CSF by ZN stain or culture 
 · routine CSF screening sensitivity for AFB is very low 
 · typical CSF findings in TBM are increased lymphocytes, elevated protein & low glucose
 · CT findings in TBM include basilar meningeal enhancement & hydrocephalus
Management of TB
Treatment for CNS TB should start as early as possible with 4 drugs as any delay in treatment 
greatly increases mortality. These include isoniazid, rifampicin, pyrazinamide and a fourth 
drug ethambutol (Table 6.5). Streptomycin is also available but is a second line drug used 
when there is drug resistance or toxicity. The four drugs are continued for the first 2 months 
after which isoniazid and rifampicin are continued usually for another 10 months. In practice 
the standard total period of treatment is 12 months for TBM and longer for tuberculoma 
(18 months). A shorter period of treatment for TBM (total 9-10 months) has been proposed 
but is not common practice in Africa. The main side effects are hepatitis with isoniazid and 
rifampicin, neuropathy with isoniazid and deafness with streptomycin, and rarely optic neuritis 
with ethambutol (Table 6.5). Pyridoxine 20-50 mg daily should be prescribed with isoniazid 
MRI with contrast CT head
Tuberculoma & basal cistern  
& meningeal enhancement
Hydrocephalus with shunt in TBM
Figure 6.4 Neuroimaging in TB CNS
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to prevent neuropathy. All HIV uninfected patients with CNS TB in WHO Stages II and III 
of the disease should be given steroids for the first 6 weeks of chemotherapy. The dose can be 
decreased gradually after the first two weeks. Hydrocephalus is a major complication of TBM 
occurring in >50% cases and may require ventricular peritoneal shunting or drainage as early 
as is clinically indicated. 
Table 6.5 Treatment of CNS tuberculosis, TBM
Chemotherapy Dose/route/frequency/duration* Main side effects
Isoniazid (H) 5-10 mg/kg/po/daily/12 months (300-600 mg daily) & 
pyridoxine 20-50 mg daily to prevent neuropathy
hepatitis, neuropathy
Rifampicin (R) 10-12 mg/kg/po/daily/12 months (600 mg daily) hepatitis
Pyrazinamide (Z) 30 mg/kg/po/daily for 2 months
15-20 gm daily
nausea & vomiting & 
arthralgia, hepatitis
Ethambutol (E) 
or
Streptomycin (S)**
15 mg/kg/day/po/daily for 2 months (800 mg daily)
20 mg/kg/im/daily for 2 months (1 gm daily)
optic neuritis (rare)
nerve deafness, 
nephrotoxicity
Dexamethasone
or
Prednisolone
04 mg/kg/iv/po/daily (24 mg od) for 2 weeks and tapering 
over next 4 weeks 
60 mg/po/daily for 2 weeks and tapering over next 4 weeks
hyperglycaemia, peptic 
ulcer, hypertension & 
psychosis
* a longer course of treatment (18/12) is recommended in tuberculoma
** second line drug
TBM in HIV
The clinical, neuroimaging and laboratory features of TBM are very similar in both HIV 
positive and HIV negative persons apart from decreased or no evidence of inflammation in the 
CSF (15-20%) and more extra meningeal TB in HIV infection. Starting ART is recommended 
after the first 2 weeks of TB treatment. In general steroids are not contraindicated and the 
indications for their use are the same as in non HIV TBM with steroid cover for the first 6 
weeks of TBM treatment. However the clinical course may be complicated by drug resistant 
TB, co-infection, bacteraemia, immune reconstitution inflammatory syndrome (IRIS) and 
decreased drug compliance. 
Outcome
The outcome of TBM in Africa even with treatment is poor with published CFRs varying 
from 13-90%. In adults TBM has a mortality rate of >50%. This is mainly related to late 
clinical presentation and advanced stage of disease (WHO stages II & III) or to underlying 
HIV infection. WHO stage I disease is associated with a good outcome. Permanent deficits 
occur in at least 30-40% of survivors. These include deafness, blindness, paralysis, seizures and 
retardation. 
Prevention
Prevention of TB is based on case or patient finding and treatment. Prophylactic treatment 
with isoniazid is used to prevent reactivation of TB in selected patients in particular with HIV 
infection. The use of BCG vaccination of neonates has been shown to decrease the overall risk 
of TBM in children in Africa.  
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Key points
 · delay in diagnosis greatly increases mortality in TBM
 · duration of treatment in TBM is 9-12 months 
 · steroids are indicated in TBM for the first 6 weeks in most patients  
 · CFR rates and morbidity rates are very high 
 · prevention is by BCG & prophylaxis & active case treatment 
CRYPTOCOCCAL MENINGITIS
Introduction
Cryptococcal disease is caused by Cryptococcus neoformans, a yeast fungus found worldwide 
in soil and bird excrement. It is usually acquired asymptomatically by humans via inhalation 
of encapsulated yeast cells, mostly during the first 5 years of life. Cryptococcal disease in 
immunosuppressed persons occurs mostly as a result of reactivation of latent infection. It 
typically presents as a chronic meningitis in patients during the later stages of HIV disease 
occurring with CD4 counts of <100 cells/mm3. Since the onset of the HIV epidemic, it has 
become the leading cause of meningitis in large parts of Africa accounting for 33-63% of all 
cases depending on the individual country. After TB it is the main cause of death in HIV 
disease in Africa, accounting annually for over half a million deaths or around 25% of all HIV 
related deaths. 
Clinical findings
Cryptococcal disease may present clinically as cryptococcal meningitis (CM), pulmonary 
infection, or uncommonly disseminated disease with skin involvement. Pneumonia is the 
main pulmonary presentation. While occasionally severe, pulmonary involvement is relatively 
uncommon and usually self limiting. Pulmonary symptoms include cough, chest pain 
dyspnoea and fever. CM is the main clinical disease, presenting with a sub acute or chronic 
illness evolving usually over 1-2 weeks or occasionally longer, 3-4 weeks. The main symptoms 
are headache (80-100%), fever (70%) and alteration in mental status (25-30%). 
Clinical features suggestive of CM include headaches which are usually severe and associated 
with nausea and vomiting, and the relative absence of meningism (25-50%). Notably 
confusion or behaviour change with or without fever may be the only clinical feature suggestive 
of underlying CM. Neurological findings include isolated cranial nerve palsies (mainly 6th 
nerves), decreased visual acuity and papilloedema. Neck stiffness is uncommon being present 
in only around 25% of patients. The presence of altered level of consciousness and coma are 
explained by raised intracranial pressure (ICP) secondary to decreased absorption of CSF in 
CM by the arachnoid granulations. Raised ICP is present in about 50% of patients at diagnosis 
and if not properly managed is associated with a worse prognosis. Clinically CM may be 
indistinguishable from TBM.
Diagnosis
The diagnosis of CM requires a high index of clinical suspicion. However, the presentation 
of a patient with an unexplained sub acute illness with headache, fever, altered mental status 
and evidence of underlying HIV infection (CD4 <100 mm3) usually suggests the diagnosis. 
The CSF is abnormal in >80% of CM cases but CSF chemistry remains normal in about 
neurological disorders in HIV
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20%, despite the presence of the disease, usually in early CM or in advanced HIV (Table 
6.2). Typical abnormal CSF findings include increased opening pressure and increased WBCs. 
These include mostly lymphocytes (median 10-20/mm3) but can be <5/mm3, a normal or 
increased protein and normal or slightly low glucose levels in around 50% of cases. 
The diagnosis is confirmed by demonstrating the presence of encapsulated yeast cells in the 
CSF by direct staining of a centrifuged sample with Gram’s or India ink staining (Fig. 6.5). It 
is also demonstrated by the presence of cryptococcal antigen (CRAg) in CSF or blood. While 
the India ink staining method is relatively easy to perform i.e., adding a few drops to CSF, 
and is cheap, it is less sensitive (60-80%) than CRAg which is highly sensitive (>95%). In 
particular all adults in Africa presenting with meningitis and India negative CSF should ideally 
have a CRAg test. CRAg is mostly unavailable in hospitals in Africa because of cost. However a 
newer rapid lateral flow assay or dipstix test for the presence of cryptococcal antigen in blood, 
serum or urine, costing approx 1 dollar per test offers the hope of a more affordable, rapid and 
accurate diagnostic test in Africa. Fungal culture is more sensitive than India ink but takes 
2-5 days for results, is also more complex to perform and is available only in some specialized 
laboratories. CT imaging of brain is less helpful in diagnosis, being normal in over half the 
cases. It may show meningeal enhancement or abscess formation with contrast but its main 
role is to exclude other opportunistic processes. The main differential diagnosis in HIV is with 
TBM and toxoplasmosis. 
Key points
 · CM is the leading cause of meningitis in adults in Africa
 · accounts for >25% of all AIDS related deaths in Africa 
 · occurs mostly in patients with CD4 counts <100 cells/mm3
 · symptoms include severe headache, fever and altered mental status for 1-2 weeks 
 · signs of meningism are frequently absent but papilloedema is common  
 · clinically it is often indistinguishable from TBM
Treatment
The treatment of CM in Africa is mostly based on fluconazole alone (Table 6.6). There are 
three phases, the induction phase lasts 2 weeks using fluconazole 1200 mg daily and the 
consolidation phase lasts the next 8 weeks using fluconazole 800 mg daily. The maintenance 
or prophylaxis phase uses fluconazole 200 mg daily until the CD4 count is >200/mm3 for 
>6 months. The higher treatment phase dosage of fluconazole “1200 mg daily” which is 
recommended here has been shown to be superior to “800 mg daily” in the induction phase 
Pathology Csf microscopy India ink stain
Milky meninges & micro abscesses Encapsulated yeast cells
Figure 6.5 Brain/csf in cryptococcal meningitis
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in Africa but is not yet widely adopted. The recommended first line induction treatment for 
CM is amphotericin B (AmB) 0.7-1mg/kg/day in saline used in combination with flucytosine 
100 mg/kg/day, for the first two weeks of infection followed by the consolidation phase of 
fluconazole, 400 mg po daily for 8-10 weeks followed by the 200 mg daily maintenance phase. 
This is the most effective regime and has been shown to have highest early fungicidal activity 
in the CSF. However the use of AmB and flucytosine in Africa is restricted mainly because of 
availability, cost and the need to monitor renal function every couple of days and check for any 
evidence of bone marrow suppression. Combining fluconazole with either AmB or flucytosine 
has also been shown to be superior to fluconazole alone. 
Table 6.6 Fluconazole treatment for cryptococcal meningitis in Africa
Drug Dose/route Duration Side effects
Fluconazole
treatment phase
consolidation phase
prophylaxis phase
1200 mg/po/daily
800 mg/po/daily
200 mg/po/daily 
2 weeks
8 weeks
until CD4 >200/mm3 for 6/12
headache, dizziness
hepatitis
Lumbar puncture in treatment
Patients with symptomatic raised ICP, papilloedema or opening CSF pressures >25 cm (normal 
OP is <20 cm) benefit from frequent, daily or alternate day lumbar punctures with drainage of 
approx 10-15 ml (max 30 ml) at each LP until symptoms clear or the CSF pressure decreases 
consistently to below 20 cm. Serial lumbar punctures (day 1, 3, 7, & 14) have been shown to 
reduce CM mortality in Africa. 
CM and ART
In CM the very early initiation of ART is associated with a higher case fatality rate. A delay in 
initiation of ART until at least 4 weeks after the start of the treatment phase appears to have a 
better outcome in fluconazole treated patients. In amphotericin treated patients starting at 2 
weeks is better than at 6 weeks. Further studies are underway to determine the exact optimum 
time to start ART. Meanwhile best practice is to follow WHO and national guidelines. 
Adequate secondary prophylaxis with fluconazole is essential to long term survival. Although 
studies from South East Asia suggest that primary prophylaxis (treating all HIV patients with 
fluconazole 200 mg daily) decreases CM this may not be either feasible or practical in Africa. 
However there is strong evidence in Africa that in HIV patients with CD4 count <100/mm3 
the presence of cryptococcal antigenaemia accurately predicts the onset of an attack of CM over 
the following 12 months. This highlights the need for a more targeted approach to screening of 
at risk HIV infected persons e.g. those starting ARTs and the treatment and chemoprophylaxis 
of the CRAg positives.
Prognosis
CM is fatal without treatment and has a high mortality even with treatment. In Africa the two 
week post treatment mortality is 20-40% and the six month mortality rate even with ART 
therapy is >50%. The overall high mortality rates seen in CM in Africa are ascribed to late 
clinical presentation, ongoing immunosuppression, concurrent infections e.g. TB, immune 
reconstitution syndrome (IRIS) which usually occurs within 3 months of initiating ART and 
high rates of relapse. The following clinical features at presentation are associated with poor 
prognosis, abnormal mental status, high fungal burden, increased CSF opening pressure and 
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poor inflammatory response (<20 cells /mm3). Relapse is common (approx 30%) and IRIS can 
occur months after initiating ART in patients with successfully treated CM. Management of 
IRIS includes excluding or treating possible CM relapse, decreasing intracranial pressure (by 
repeated LPs), excluding other possible opportunistic infections e.g. TBM and finally steroids 
if necessary. 
Key points
 · diagnosis is confirmed by CSF microscopy (India ink) and/or CRAg serology
 · repeated lumbar punctures is critical in the management of ICP in CM 
 · treatment is with fluconazole 1200 mg/po for 2/52 followed by 800 mg po for 8/52
 · secondary prophylaxis is necessary until the CD4 count >200/mm3 for 6/12
 · initiating ART for CM patients should be delayed for 4 weeks after treatment 
 · long-term mortality in CM is high (>50%) even with ART
VIRAL MENINGITIS
Viruses are the commonest cause of meningitis worldwide. Viral meningitis is usually a benign 
disease that does not require hospitalization. It is commonest in the age groups 0-1yrs and 
4-15 yrs but can affect all age groups. Human enteroviruses account for >90% of cases and 
are classified into polioviruses, coxsackie viruses and echoviruses. Other viruses that cause 
meningitis include the arboviruses and adenoviruses. Young children are the usual source with 
spread mostly via the faecal oral route within families. It occurs throughout the year with 
seasonal peaks in the hotter weather. Outbreaks can occur in hospitals and schools. 
Clinical features
Clinically there may be a history of a viral like illness with fever, vomiting and rash. The onset 
can be acute or sub acute with fever and headache occurring in most patients. Neck stiffness 
is mild and present in half the cases. Neurologic abnormalities are rare but febrile convulsions 
may occur in young children. The illness can last over a week in children and longer in adults. 
Clinically at onset viral meningitis may be indistinguishable from bacterial meningitis and 
often requires emergency antibiotics until the diagnosis is confirmed by exclusion of other 
causes. A lumbar puncture may be normal or show mild abnormalities including polymorphs 
early on and later lymphocytes (Table 6.2). Treatment is mainly symptomatic and the prognosis 
is generally excellent.
VIRAL ENCEPHALITIS
Encephalitis is inflammation of the brain parenchyma caused by a viral infection. It is 
predominantly a disease of children. The causative virus is not known in >50% of cases. The 
most frequent known forms are caused by an unusual manifestation of common, mainly 
childhood viral infections including measles, chickenpox and mumps. Herpes simplex (HSV) 
is the most common cause of fatal sporadic encephalitis in adults worldwide but it appears 
to be uncommon in Africa. Other well known viruses causing encephalitis include HIV, 
cytomegalovirus (CMV), Epstein-Barr virus (EBV) and rabies. There are great geographic 
variations in the causes of viral meningo-encephalitis worldwide and accounts of viruses specific 
to the African subcontinent including Lassa fever, Marburg disease, Ebola virus and Rift Valley 
Fever can be found in a larger textbook or online. 
viral meningitis
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The main arthropod borne infections causing viral encephalitis are Japanese B encephalitis 
virus in the Far East, West Nile virus in mainly West Africa and Rift Valley Fever in East Africa. 
The vectors are mosquitoes and the hosts may be humans, animals or birds depending on the 
location and virus. Viruses enter the CNS by two distinct routes, haematogenous which is the 
most common route as occurs in the arthropod borne group and by local replication at the 
site of infection and retrograde spread to the brain via peripheral nerves as occurs in herpes 
and rabies. Other main ways of acquiring CNS viral infection include enteric e.g. polio and by 
inhalation e.g. Ebola and sexually e.g. HIV.
Clinical features
Viruses cause a variety of CNS disease including aseptic meningitis, encephalomyelitis, 
myelitis and myeloradiculitis. The signs and symptoms of encephalitis include fever, headache, 
confusion, stupor, coma, seizures, upper motor neurone signs and less commonly focal 
neurological deficits. Virus infections may also infrequently result in a form of autoimmune 
encephalitis called acute demyelinating encephalomyelitis (ADEM) occurring mainly in 
older childhood/early teens which is very responsive to high dose parenteral steroids. The clinical 
presentation of ADEM is that of monophasic illness and can be very similar to encephalitis. 
However, it is difficult to diagnose and confirm in Africa without MRI scanning. 
The diagnosis of viral encephalitis is made by immunological tests, neuroimaging and EEG but 
the viral cause is not usually identified. Effective antiviral therapy (such as the acyclic purine 
nucleoside analogue, aciclovir) is available only for the herpes virus group. The mortality 
is variable and depends on the virus. Preventive measures include control of vectors and 
vaccination when available. 
Key points
 · viruses are leading cause of meningitis/encephalitis worldwide & mainly affect children
 · enteroviruses are main causes of viral meningitis in children 
 · transmission is by close physical contact: inhalation, ingestion, insect bites & sexual contact
 · diagnosis is clinical in combination with CSF & serology findings
 · outcome is excellent in viral meningitis but variable in encephalitis depending on the virus
HERPES ENCEPHALITIS
This is the most common form of fatal sporadic encephalitis worldwide and is important 
because it is treatable if diagnosed early. The frequency is not known in Africa but may be less 
there possibly because of early exposure in childhood. There are two main types, HSV-1 and 
HSV-2. Humans are the reservoir for both types; HSV-1 is more common and affects mainly 
older adults, whereas HSV-2 affects neonates. HSV-I is spread by close physical contact and 
causes predominantly encephalitis, whereas HSV-2 is considered a sexually transmitted disease 
and predominantly causes meningitis. The source of encephalitis is mostly reactivation of latent 
ganglionic infection or less commonly a primary infection. It spreads in a retrograde way either 
via the trigeminal or olfactory nerves to the temporal and frontal areas of the brain 
Clinical findings
Clinically, HSV encephalitis begins as an acute or sub acute non-specific febrile illness 
characterised by headache, fever, irritability, and altered mental status. Most patients go on to 
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experience confusion, personality change, dysphasia, focal neurological findings, memory loss 
and seizures affecting the temporal lobe. Herpetic skin lesions are rare. Symptoms typically 
evolve over several days and may take 2 to 3 weeks to reach their maximum severity. The 
differential diagnosis includes HIV related CNS infections, TB meningitis, partially treated 
acute bacterial meningitis, cerebral malaria and brain abscess. 
Diagnosis
Diagnosis of HSV encephalitis is based on clinical findings and a characteristic CSF with 
lymphocytes, red blood cells and elevated protein. Infection in the CSF may be demonstrated 
by PCR, serologically and viral culture. PCR has a specificity of up to 100% and a sensitivity 
of 95% on CSF taken between day 2 and 10 after the onset of the illness, however serological 
tests are of no help in acute diagnosis of HSE, only in retrospect and then after 2 weeks. An 
EEG can be diagnostic. CT/MRI of the head typically shows oedema and haemorrhage in the 
temporal/frontal lobe (Fig. 6.6).
Management
The antiviral drug aciclovir 10-15 mg/kg/iv 8 hourly is given for 14 days as soon as possible 
after the onset of symptoms if HSE is thought to be at all likely and for 21days if HIV positive. 
Aciclovir is well absorbed orally if the parenteral form is unavailable. Seizures are treated as in 
status epilepticus. Rehabilitation includes physiotherapy, speech therapy, occupational therapy 
and later neuropsychological testing and support. Treated cases have a mortality of 10-20% 
and untreated 50-70%. Morbidity is high and includes memory loss, cognitive impairment 
and persistent seizures. The role of steroids is controversial but should be given at present if 
there is evidence of raised or increasing intracranial pressure.
RABIES
Rabies is mainly a disease of dogs, cats, jackals, mongoose and bats that is transmitted to 
humans. Transmission to humans in Africa is almost inevitably by the bite and saliva of a rabid 
dog or other animal. The severity and site of the bite from the rabid animal determines the risk 
of infection and 35-67% go on to develop rabies. Very rarely transmission is human to human 
e.g., by corneal graft. Rare cases have occurred by inhalation of bat urine in caves. There are 
over 50,000 deaths worldwide each year from rabies mainly in Asia but many also occur in 
Pathology MRI T1
Temporal lobe oedema & multiple micro haemorrhages Temporal lobe oedema
Figure 6.6 Brain in herpes encephalitis
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Africa. Post exposure prophylaxis can be 100% effective (Table 6.7) if it is given on the day of 
exposure or bite and the treatment precautions are rigorously adhered to.
Pathogenesis
Rabies starts with viral replication at the bite site. Then there is flow of the virus via the 
peripheral nerves towards the brain with replication in the brain nerve cells which gives rise 
to the characteristic neuronal inclusions called Negri bodies. Then there is flow back from the 
brain to the rest of the nervous system, in particular to the salivary glands and the clinical disease 
starts. Involvement of the limbic system in the brain results in furious rabies and involvement 
of the spinal cord results in paralytic rabies.
Clinical features
Rabies should be suspected if there are unexplained neurological, psychiatric or laryngo-
pharyngeal symptoms in a patient with a history of an exposure. The usual incubation period 
is between 2-8 weeks but can vary from 9 days to 12 months or rarely more. The disease starts 
with a prodromal illness which lasts a few days, until either furious or paralytic rabies appears. 
The first symptom is itching, pain or paraesthesiae at the now healed bite site. Other prodromal 
symptoms include myalgia, fever, chills, irritability, anxiety, photophobia and headache. 
Furious rabies with tearing from the eyes, tongue protrusion & frothing
Paralytic rabies with facial scars (dog bite), hyper salivation & tongue protrusion
Figure 6.7 Rabies
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The clinical features of furious rabies occur in 80% of cases and include hydrophobia, terror, 
pain, convulsions, hallucinations, aggression, cranial nerve palsies, paralysis and autonomic 
disturbance e.g. hyper salivation or frothing from the mouth, sweating and lacrimation 
(Fig 6.7). Periods of manic confusion may alternate with periods of calm and quiet. Rabies 
is characterised by terrifying hydrophobic spasms. These are typically provoked early on by 
sipping water, swallowing saliva or by blowing air onto the skin and later on by merely the 
sight, sound or mention of water. These are characteristically violent jerky spasms during which 
the neck and back are extended and the arms thrown upward. They can be very severe and end 
in seizures and death.
Paralytic or algid rabies occurs in about 20% of patients (Fig. 6.7). During this the patient 
begins with the usual prodromal symptoms followed by paralysis in the bitten limb, which 
eventually ascends to involve the remaining limbs and breathing. Death in rabies usually 
follows the onset of prodromal symptoms within 1-2 weeks and following the onset of spasms, 
coma and paralysis within days. The differential diagnosis includes causes of spasms including 
tetanus, tetany, dystonic drug reactions, poisoning and paralysis including Guillain-Barre 
syndrome, and CNS infections including cerebral malaria and encephalitis. 
Laboratory diagnosis
The diagnosis is a clinical one based on a history of exposure and clinical findings. There are 
no routine laboratory or rapid tests for the diagnosis of rabies and the ante mortem diagnosis 
requires a reference laboratory as several tests are necessary. Antibodies are detectable in the 
unvaccinated patient during the second week of illness and the virus may be isolated from saliva 
and CSF although it may take 1-3 weeks for a result. Saliva can be tested by virus isolation or 
reverse transcription followed by polymerase chain reaction (RT-PCR). Skin biopsies at the 
nape of the neck can be examined for the presence of rabies antigen (IFA) in the cutaneous 
nerves. The brain of the biting animal and the patient can be examined microscopically for the 
presence of Negri bodies and immunofluorescent antibodies (Fig. 6.8). 
Histopathology
Negri bodies (small red inclusions) Immunofluorescence staining
Figure 6.8 Brain in rabies
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Key points
 · rabies is transmitted to humans mostly by the bite and saliva of a rabid dog
 · diagnosis is by a history of exposure & unexplained neurological or psychiatric symptoms 
 · hydrophobia, terror, pain, convulsions & hallucinations occur in the majority of patients
 · there are no routine clinical laboratory diagnostic tests for rabies
Treatment
Rabies patients should be nursed in a single room in isolation because the patient’s saliva is 
potentially infective. Ideally there should be barrier nursing. Treatment is symptomatic as the 
disease is considered to be universally fatal once symptoms appear apart from a few isolated 
reports of survival with prolonged ICU care in high-income settings. Symptomatic treatment 
involves large doses of sedation using phenothiazines and phenobarbitone and adequate 
analgesia using morphine to relieve the fear and pain. 
Prevention
Rabies is preventable by pre and post exposure vaccination (Table 6.7). Post exposure prophylaxis 
of rabies is based on using available rabies vaccines which are all equally safe and effective. These 
include human diploid cell vaccines (HDCV), purified vero cell vaccine (PVRV), purified 
chick embryo vaccine, (PCECV) and purified duck embryo vaccine (PDEV). The indications 
for prophylaxis are licks on skin or mucosa, scratches, abrasions and bites from animals in 
rabies endemic areas. Post exposure treatment consists of 1) vigorous wound debridement 
and cleaning with alcohol or iodine compounds, 2) starting the vaccine immediately and 
3) using rabies immunoglobulin, if a major exposure (bites) has occurred. These measures, if 
carried out optimally, can reduce the risk of developing rabies to almost zero. 
The vaccine should always be started as early as possible and be given regardless of the time lapse 
since exposure. Costs are reduced by using the intradermal route of administration. The WHO 
recommended vaccination schedules are presented below. Vaccination may be discontinued if 
the animal, usually a dog or a cat remains healthy after 15 days of observation or if it is certain that 
the animal brain biopsy is negative for rabies. The management and control of rabies in endemic 
areas depends on the control and immunization of dogs and the notification of the disease.
Table 6.7 WHO recommended immunization schedule for Rabies
Post exposure prophylaxis (all vaccines) 1.0 ml im (deltoid) never the buttock on day 0, 3, 7, 14, 28
Alternative regimes  
(where vaccine in short supply) 
8 site intradermal (HDCV & PCECV)
2 site intradermal (PVRV, PCECV & PDEV)
 
01 ml id @ eight sites* on day 0
01 ml id @ four sites** on day 7
01 ml id @ one site (deltoid) on day 28 & 90
02 ml id @ two sites (deltoid) on day 0, 3 & 7
&
02 ml id @ one site (deltoid) on day 28 & 90
Previously vaccinated (all vaccines) 10 ml im (deltoid) on day 0,3, &7
id = intradermal
* deltoids, suprascapular, abdominal wall (lower quadrant) & lateral thighs
** deltoids & thighs
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Key points
 · there is no effective treatment for rabies
 · rabies is preventable by vaccination
 · post exposure treatment consists of immediate wound cleaning, vaccination & immunoglobulin
 · vaccine prophylaxis is very effective if started early (<1day) post exposure & according to schedule
TETANUS
Tetanus is caused by exposure to spores of Clostridium tetani, a gram positive anaerobic rod 
which is commonly found in soil. Tetanus follows contamination of a wound by tetanus 
spores. Most cases of adult tetanus follow an acute and sometimes relatively trivial injury to 
feet or legs. Most cases of neonatal tetanus occur as a result of contamination of the umbilical 
cord after birth. The disease is still prevalent in Africa despite the widespread introduction 
of immunization programs for neonates and pregnant women. Tetanus is estimated to cause 
almost a quarter of a million deaths worldwide annually, many of whom live in Africa. It is 
predominantly (90%) a disease of children under five years mainly affecting neonates but also 
affects adults, and in particular males.
Pathogenesis
The tetanus spores incubate in the wound under anaerobic conditions and mature into 
vegetative bacteria. They in turn produce potent neurotoxins, tetanolysin and tetanospasmin. 
Tetanospasmin spreads via nerves by retrograde axonal flow to the spinal cord and brain. In the 
spinal cord and brain, tetanospasmin binds the presynaptic terminal and produces presynaptic 
inhibition of gamma amino butyric acid (GABA) release. This denies the anterior horn cells 
and the alpha motor units of inhibition, resulting in uncontrollable spasms by both agonist 
and antagonist muscles. In addition a lack of neural control of the adrenal glands results in 
release of catecholamines, thus producing a hyper sympathetic state and widespread autonomic 
instability. Recovery only occurs when new terminal synapses are sprouted after 3-4 weeks.
Clinical features
The incubation period for tetanus is between 3-21 days with a median of 7 days. The clinical 
disease progresses over the course of the first 1-2 weeks and then continues for a total of 3-4 
weeks in all. The clinical characteristic of tetanus is increased muscle tone at rest and continuing 
muscle spasms. On examination, there is rigidity of the muscles involving the face, neck, back 
and abdomen. The face may show risus sardonicus (lock jaw) and the body may be held arched 
in the opisthotonos like position (Fig 6.9). Reflex muscle spasms arise spontaneously and are 
provoked by noise, touch, and light and last from seconds to a minute. Their frequency and 
duration is variable from every few seconds to hours and they typically continue for most of the 
duration of the 3-4 week illness. Spasms are painful as full consciousness is retained. Prognosis 
is worse in those patients with wounds nearer the head and with a short incubation time. The 
main complications are pneumonia, asphyxia, hypoxia, arrhythmia and rarely fractures. Death 
usually occurs because of prolonged spasms provoking anoxia, pneumonia or autonomic 
involvement. 
tetanus
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Figure 6.9 Tetanus Opisthotonos, extensor spasms with arching of the back
Diagnosis
The diagnosis is made clinically as there are no confirmatory laboratory findings. The differential 
diagnosis includes dystonia, tetany, rabies, meningitis and poisoning (strychnine). 
Management
The patient is nursed in a quiet and darkened area or room to avoid stimuli provoking spasms. 
The acute management involves wound debridement and exploration for foreign bodies, 
passive immunization with human antitetanus serum, human immunoglobulin 150 IU/kg 
(3-6000 iu) im, and penicillin with metronidazole to treat the infection. Diazepam is the 
most commonly used drug to treat muscle spasms. It may be necessary to use 10-20 mg/po or 
iv, initially 6 hourly increasing the frequency of administration to 4 or 2 hourly as necessary 
in cases of severe muscle spasms. Chlorpromazine, 50 to 100 mg/im, initially 12 hourly and 
increasing the frequency of administration to 6 hourly may be used in combination with 
diazepam. Phenobarbitone is also sometimes used in combination with diazepam. The use of 
regular iv magnesium sulphate has been shown to improve prognosis by decreasing the need 
for antispasmodics and antiarrhythmics. The choice of antispasmodic and their order, dose, 
frequency and duration should be according to the severity of the spasms and local treatment 
protocols. It is good practice to start with lower doses and over sedation should be avoided. 
Beta blockers in the form of atenolol or labetolol or verapamil may be necessary to treat and 
prevent cardiac arrhythmias or hypertension. If there is failure to control the spasms or there 
is respiratory depression or pneumonia, then a tracheostomy or/and mechanical ventilation 
may be necessary. As the required period of intubation is usually prolonged (>7-10 days), early 
tracheostomy is common practice. Active immunization by tetanus toxoid is necessary when 
the disease has resolved as tetanus infection does not confer lasting immunity. 
Prognosis
The case fatality rate with treated tetanus varies between 40-60%, more commonly the latter. 
Those who recover rarely have a neurological deficit.
Prevention 
Primary prevention is by vaccination in early childhood as part of the routine, diphtheria, 
tetanus and pertussis (DTP) immunization and by booster at 4-7 years, in adolescence and 
once again in adulthood. For others who are non immune including pregnancy, these should 
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receive primary immunization followed by 10 yearly booster doses for a total of 5 doses. If a 
person has not been vaccinated during the last 5 years and they receive a tetanus prone injury 
then a booster dose should be given. 
Key points
 · tetanus arises from wounds contaminated by soil containing spores of C. tetani
 · management is by passive immunoglobulin, wound debridement & antibiotics
 · spasms are controlled by diazepam, chlorpromazine & magnesium sulphate
 · complications are pneumonia, asphyxia, hypoxia, arrhythmia & rarely fractures
 · tracheostomy and mechanical ventilation may be necessary, 
 · CFR is frequently >50%
SYPHILIS
Syphilis is caused by the spirochete Treponema pallidum. It is a sexually transmitted disease and 
this route of transmission accounts for most adult cases. However syphilis can be transmitted 
vertically in utero resulting in congenital syphilis or also by blood transfusion. The natural 
history of syphilis is divided into three stages, primary, secondary and tertiary. Primary syphilis 
occurs 1-6 weeks after exposure, secondary syphilis 6-8 weeks post primary and tertiary syphilis 
1-45 years afterwards. It is infective during all stages and transmission rates vary from 10–60%. 
Epidemiology
There are over 12 million new cases of primary syphilis worldwide annually approximately one 
third of which occur in Africa. The prevalence rates for syphilis serology indicating previous 
exposure varies from less than one in ten in pregnancy to one in two in some sex workers. 
Over the last decades, there has been a marked decline in neurosyphilis worldwide. This has 
been attributed to the widespread use of antibiotics accidentally treating syphilis. The annual 
incidence of neurosyphilis is low (<0.5/100,000) in high income countries. Data on the 
incidence of neurosyphilis is not available for Africa. There is some clinical evidence that the 
incidence may be higher in HIV infected adults in Africa but there is no clear epidemiological 
data to support that. 
Pathogenesis of Neurosyphilis
The treponeme invades the CNS within 3-24 months of untreated primary infection in about 
25% of cases. The pathology of neurosyphilis is made up of two main stages: a vascular stage 
causing endarteritis and thrombosis and a granulomatous stage causing gumma formation. 
Neurological findings
Neurosyphilis is divided into two main phases, asymptomatic and symptomatic. Symptomatic 
neurosyphilis is divided into four distinct clinical entities. These include acute syphilitic 
meningitis which occurs in about 25% of untreated cases of primary syphilis and 
meningovascular syphilis, tabes dorsalis and generalised paralysis of the insane which 
occurs in <10% of untreated primary cases.
Asymptomatic
The asymptomatic phase occurs in the period 1-10 yrs after primary infection. During this 
phase the infection is active but there are no symptoms and the only finding is an abnormal 
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CSF showing lymphocytosis, elevation in protein, low glucose and positive serological tests for 
syphilis. 
Symptomatic
Meningitis
This occurs within 2 years of primary infection. The clinical presentation ranges from an 
isolated aseptic meningitis with fever and rash, to an acute basal meningitis presenting with 
cranial nerve palsies and hydrocephalus. 
Meningovascular syphilis
This occurs 5-10 years after primary infection as a result of an obliterative endarteritis affecting 
the small or medium sized arteries supplying the internal capsule. It presents mainly as stroke 
in a younger person.
Tabes Dorsalis (TD)
TD is a late manifestation of tertiary syphilis occurring 15-20 years after primary infection. 
It arises as result of degeneration in the posterior columns in the spinal cord and in the brain 
stem. It presents with unexplained lightning and abdominal pains in combination with an 
ataxic gait disorder. There are characteristic neurological findings including an ataxic stamping 
gait, positive Romberg’s sign, Argyll Robertson pupils and Charcot’s joints, late in the disease.
General paralysis insane (GPI)
GPI is a late manifestation occurring 10-25 years after primary infection. This is characterised 
by a progressive dementia with delusions of grandeur and mania, coupled with varying degrees 
of paralysis. 
Diagnosis of neurosyphilis
The diagnosis of neurosyphilis requires a high index of clinical suspicion combined with CSF 
findings and serological evidence of syphilis in blood and CSF. Laboratory CSF examination 
shows increased lymphocytes, increased protein and a normal or reduced glucose level. 
Diagnosis is by specific treponemal tests; flocculation treponemal antibody (FTA) and 
Treponema pallidum haemagglutination assay (TPHA) and non-treponemal tests including 
venereal disease reference laboratory (VDRL) and rapid reagin tests (RPR). Both RPR and 
VDRL are used as a screening test for syphilis in Africa. VDRL is positive in the blood in 
nearly all cases of syphilis but false positives occur with endemic treponematoses and in other 
diseases e.g. tuberculosis and malaria. However VDRL is positive in the CSF in only <80% of 
cases of neurosyphilis, therefore a negative VDRL in CSF does not exclude the diagnosis. False 
negatives may occur in primary and late syphilis and also in HIV infection. A more specific 
antibody test is the TPHA test. A negative TPHA in the CSF excludes neurosyphilis.
HIV and Neurosyphilis
The natural history of neurosyphilis may be altered in HIV disease. There may be an accelerated 
progression to neurosyphilis, atypical clinical presentation, negative antibody tests and response 
to penicillin may be less effective. Treatment may require a longer and repeated course of 
penicillin. 
Chapter 6  neurologiCal infeCtions
Part ii – Neurological Disorders 148
Treatment of neurosyphilis
The treatment of neurosyphilis is with soluble penicillin 20-24 million units (4 million units 
4 hourly) daily iv for 14-21 days (>17 days). Persons who are allergic to penicillin should 
have erythromycin 0.5 gm 6 hourly or doxycycline 200 mg bid for 28 days. Steroids are given 
with the first few doses of penicillin because of the rare occurrence of the Jarish-Herxheimer 
reaction. The prognosis depends on the stage. Treatment of asymptomatic and meningitis stages 
are curative. Treatment of the other tertiary stages results in an improvement in about one third 
and stabilization in the rest. A follow up CSF examination should be done every 6 months for 
2 yrs and every year if HIV positive. If the CSF shows signs of activity (lymphocytes +++) then 
the patient should be retreated with penicillin. The VDRL may remain positive in CSF and 
become negative in serum. The principles of prevention and control include public education, 
screening, partner notification and treatment. 
Key points
 · syphilis is one of the most common STDs globally with 1/3 of new cases in Africa
 · neurosyphilis occurs in <10% of untreated primary syphilis 
 · neurosyphilis is uncommon & is altered in HIV disease
 · confirmation relies on positive serological test in the CSF
 · treatment is with high dose penicillin iv for 14-21 days
BRAIN ABSCESS
A brain abscess is caused by infection, the main causative organism being either bacteria or 
protozoa. An abscess may be clinically classified as pyogenic and non pyogenic depending on 
the organism. Toxoplasmosis and tuberculosis are the main non pyogenic causes. The main 
causative organisms in pyogenic brain abscess are Streptococcus viridans, Staphylococcus 
aureus and Bacteroides fragilus. Intracranial pyogenic abscess is a focal infection within 
the brain, subdural or epidural space. They are uncommon and can affect any age group. 
The majority arise within the brain from a purulent infection elsewhere in the body so it 
is important to try to find the primary source. The source of infection is either local or 
haematogenous. Local spread arises directly from otitis media, mastoiditis, sinusitis, dental 
abscess or recent head injury in particular skull fracture. Haematogenous spread arises from 
the heart (e.g. endocarditis), the lungs (e.g. bronchiectasis), or from any other infected source 
(e.g. skin abscess).
Clinical features
Most patients present with headache, fever and focal neurological disorders (FND). Headache 
is the most frequent initial symptom. FNDs include seizures, focal motor sensory or speech 
disorders or confusion or alteration in consciousness. The fever is usually low grade or absent 
depending on the duration being usually absent in a mature abscess. Seizures occur in about 
a quarter of patients. Any neurological deficit will depend on the origin, site and extent of 
the abscess. The time from onset to complications usually takes a couple of weeks but may 
occasionally occur in days. Signs of the probable source of the brain abscess may be present.
brain absCess
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Differential diagnosis
The differential diagnosis includes any other cause of a space occupying lesion resulting in 
a focal CNS disorder. These include non pyogenic brain abscess e.g. toxoplasmosis or TB, 
parasitic cyst, intracerebral haemorrhage, subdural haematoma and brain neoplasm. 
Diagnosis
The diagnosis if not already suspected clinically is made by a CT scan of the head. A CT with 
contrast typically shows a ring enhancing mass lesion in the brain with a central area of low 
density surrounded by oedema with mass effect or a subdural/epidural collection (Fig 6.10). 
LP is contraindicated in any suspected intracranial mass lesion.
Management
Management is based on antibiotics and surgical drainage. The choice of antibiotics should 
be based on the likelihood of the primary source of infection. This includes a combined daily 
dose of penicillin 20-24 million units iv in divided doses 4-6 hourly,  chloramphenicol 1 
gm iv 6 hourly and metronidazole 500 mg iv 8 hourly. Alternately an extended-spectrum 
cephalosporin e.g. ceftriaxone 2 gm iv twice daily with metronidazole can also be used depending 
on availability and cost. Where Staphylococcus or gm negatives are suspected flucloxacillin or 
gentamycin, respectively, should be added. Ciprofloxacin intravenously is also an alternative. 
Surgical drainage is indicated in large abscesses or collections of pus (>3cm). This is usually 
done by Burr hole aspiration or by craniotomy. 
All antibiotics should be given intravenously and continued for a total of not less than a period 
of 4-6 weeks. A follow up CT of the head is recommended to assess response to treatment. 
Anticonvulsants may be necessary if there are seizures. The case fatality rate in the high-income 
countries varies from 10% in uncomplicated cases to >50% in patients with coma. Morbidity 
is about 30% and includes epilepsy and focal neurological deficits. 
CT scan (with contrast) Pathology
Frontal lobe (right) Frontal lobe (left)
Figure 6.10 Brain abscess
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Key points
 · pyogenic brain abscesses arise from either direct or haematogenous spread
 · local sources are  mastoiditis, sinusitis, dental & skin infections 
 · haematogenous sources are skin, heart & lungs
 · clinical features are headache, seizures & focal neurological deficits 
 · antibiotics are iv for 4-6/52 & surgical drainage is necessary for large abscesses
APPENDIX LUMBAR PUNCTURE
Indications
A lumbar puncture is indicated in the following clinical situations: 
1) diagnosis of suspected CNS infections, haemorrhage and encephalopathies 
2) to reduce CSF pressure e.g. in cryptococcal meningitis and benign intracranial hypertension
3) administration of intrathecal medications e.g. radio-opaque media
Contraindications
LP is a safe procedure but there is a risk of brain herniation when CSF pressure is high. A 
fundoscopy to exclude papilloedema should always be carried out prior to an LP. An LP is 
contraindicated in the following clinical situations.
1) raised intracranial pressure
2) suspected CNS mass lesion
3) bleeding disorder e.g. anticoagulation, low platelets
4) local infection at the LP site
Positioning
An LP should start with an explanation, reassurance and a warning concerning possible 
complications. The procedure is performed on a bed with a firm or hard edge or alternatively 
on a table. Proper positioning is critical to successfully completing an LP. The patient lies 
horizontally facing away from the operator, usually in the left lateral decubitus position with 
the neck firmly flexed and the knees drawn up to the chin. The back should be in line with 
the edge of the bed with the shoulders and hips aligned in the same vertical plane and the 
patient’s spine maximally flexed in order to open up the lower lumbar spaces. The head may be 
supported by a thin pillow (Fig 6.11). If it is necessary to perform an LP with the patient sitting 
upright this can be done with the patient either sitting astride a chair or on the side of a bed 
with the spine semi flexed and head supported by a pillow and table. The site of the LP should 
now be identified. The spinal cord ends at L1 (L2) in adults and a line drawn down from the top 
of the iliac crest bisects the L3-4 interspace 
which is safe and avoids the danger of 
damaging the spinal cord. After palpating 
and identifying the spines, either the L3-4 
or L4-5 interspace should be marked with a 
pen or a scratch. The LP should now be done 
under full sterile technique using gloves. The 
steps in the procedure are outlined below
Figure 6.11 Lumbar puncture
Lumbar puncture
appendix lumbar punCture
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Procedure
1) clean the L3-4 area including the iliac crest starting centrally and working outwards
2) infiltrate the skin overlying the L3-4/4-5 interspace with 2% lignocaine and wait a few minutes for 
it to work
3) insert the spinal 22 gauge needle in the L3-4 interspace horizontally aiming slightly towards the 
patient’s head 
4) the spinal needle is advanced slowly but firmly through the interspinous ligaments with the tip 
aiming for the umbilicus.  
5) if the needle cannot be advanced it is likely that bone is encountered. Withdraw the needle partially 
and start advancing again with the needle parallel with the floor and the tip again pointing toward 
the umbilicus 
6) the needle is advanced a short distance and continually checked until CSF obtained. Care must be 
taken not to advance the needle too far as it may enter the vertebral vein or disc space
7) if correctly positioned the advancing needle encounters resistance at the ligamentum flavum. After 
penetrating this ligament there is a sudden release as the needle enters the subarachnoid space
8) then remove the stylet from the needle to see if CSF drains, it usually does this slowly
9) CSF pressure is then measured by attaching a manometer to the needle. Ensure the patient is relaxed 
by slightly straightening the legs, when the column of CSF stops rising, its height is then measured 
(opening pressure)
10) CSF is drained from the manometer and from the spinal needle into 3 collection tubes. Approximately 
2-3 ml CSF are collected into each tube and sent to the laboratory for cell count, protein, glucose 
concentrations and bacteriology
11) remove the LP needle and press on the LP site for about 1-2 mins and then apply a small dressing 
over the site 
12) instruct the patient to lie flat for about 2-3 hours preferably prone to reduce the risk of post LP 
headache
Complications
herniation of brain or spinal cord: this is the most serious consequence of an LP. If during or 
after an LP the level of consciousness deteriorates or respiration alters or falls, the patient should 
be placed in the head down position and an infusion of 20% mannitol started. Emergency 
resuscitation measures should begin including possible surgical decompression. 
dry or unsuccessful tap: this usually means that the technique was faulty or the disc space too 
narrow. In such cases another attempt should be done at either the disc space above or below. 
If the puncture is still unsuccessful then the LP should be attempted in the sitting position or 
consult a senior person with neurological or neurosurgical experience
bleeding: the spinal needle is likely to be in a vein so withdraw and try again at a different level
post LP headache: treat symptomatically with NSAIDs. Severe headaches may require a blood 
patch
infections: these include ABM and epidural abscess and are generally related to poor antisepsis
Interpretation of LP findings
CSF is evaluated under the following main headings appearance, pressure, microscopy (cells mm3), protein 
(gms/litre) glucose (mmols/litre) and bacteriology (Table 6.2). 
Chapter 6  neurologiCal infeCtions
Part ii – Neurological Disorders 152
Appearance
The normal CSF is clear and colourless. In meningitis the colour ranges from purulent or 
cloudy in ABM to mostly clear in viral meningitis. If in doubt the colour of CSF can be 
compared to water (which is the same as normal CSF) against a background of white sheet 
of paper when even the slightest opaqueness or yellowness (xanthochromia) in CSF is always 
abnormal.
Bloody CSF
It is important to distinguish between a traumatic tap and SAH. The following points are 
helpful. In SAH the CSF remains uniformly blood stained throughout the procedure and the 
opening pressure is usually elevated.  In contrast in traumatic tap the bleeding into the CSF 
lessens as it flows and pressure is normal. This will have been evident as the CSF leaves the 
spinal needle and when comparing the 1st and 3rd collection tubes which show a clearing or 
lessening of blood. Blood in CSF can persist for up to one week but is gradually replaced by 
bilirubin (xanthochromia) which stays for >2 weeks. A bloody spinal tap will falsely elevate the 
CSF WCC and protein. 
Xanthochromia (yellow discolouration)
This is seen from 24 hours to >2 weeks after a bleed, usually a SAH. It may also be seen in a 
subdural haematoma, high CSF protein, jaundice and rifampicin treatment.
Pressure
The normal CSF opening pressure in adults is 8-16 cm. The normal CSF pressure should never 
be over 20 cm water. CSF pressure is elevated in brain swelling in infections (e.g. meningitis), 
mass lesions, hydrocephalus and trauma. Suspected elevation in intracranial pressure is the main 
contraindication to an LP.   
Cell count 
The normal CSF contains up to five WBC/ml, either lymphocytes or monocytes. The count 
may be higher in children. Increased white cells in CSF usually indicate infection until proved 
otherwise. The presence of predominant neutrophils indicates pyogenic infection, in particular 
ABM and presence of lymphocytes indicates TBM or CM in HIV or viral infection. However 
neutrophils can predominate in early TBM and in some viral and fungal infections (CM) and 
lymphocytes can predominate in partially treated ABM, particularly in the very young. The 
presence of a small number of RBCs may be related to the trauma of the LP but if persisting in 
all 3 samples suggest a CNS source.  
Protein
The normal CSF protein is <0.5gm/litre. Elevation in CSF protein is a common abnormality 
in neurological disorders. Moderate elevations 0.5-1gm/litre suggests infection e.g. meningitis, 
cerebral malaria, abscess, infarction and tumours whereas a more marked elevations in protein 
can be a feature of TBM, Guillain Barre Syndrome or spinal block. 
Glucose
The normal CSF glucose is >50% blood glucose. A concurrent blood glucose (ideally fasting) 
should be checked at the time of the LP. CSF glucose can be reduced, very low or even absent in 
CNS infections. Very low or absent glucose is a characteristic of ABM and may also occur in 
TBM. 
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Microbiology
Normal CSF is sterile. Gram’s stain for bacteria, acid fast stain for TB and India ink stain for 
cryptococcus are indicated in all suspected cases of meningitis. If India ink is negative then a 
cryptococcal antigen test (CRAg) should be carried out on all patients in whom the diagnosis 
of cryptococcal infection is possible. Microbiological screening includes appropriate cultures.
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CHAPTER 7
PROTOZOAL AND HELMINTHIC INFECTIONS
This chapter is concerned with the main protozoal and helminthic infections affecting the 
nervous system in Africa. These include cerebral malaria, toxoplasmosis, and human African 
trypanosomiasis (HAT), neurocysticercosis, schistosomiasis and hydatid disease. The student 
should aim to be familiar with these, including life cycles, clinical presentations, diagnosis, 
management and prevention.
CEREBRAL MALARIA
Cerebral malaria is a severe neurological disease of the brain that is caused by Plasmodium 
falciparum and is characterized by fever, altered level of consciousness and laboratory evidence 
of malaria infection. The research definition of cerebral malaria is unrousable coma, (Glasgow 
coma scale ≤8 or Blantyre coma scale for young children ≤2 (Table 7.2) in the presence of a 
peripheral parasitaemia after other causes of coma have been excluded. 
Epidemiology
Each year there are over 300 million new cases of malaria in Africa resulting in over 1 million 
deaths there, occurring mostly but not exclusively in children. Cerebral malaria is one of the 
most important complications. It is invariably fatal without treatment and each year there are 
over half a million new cases of cerebral malaria in Africa. Most cases occur in non immune 
children (<5 yrs) and the incidence declines progressively as children become older. Cerebral 
malaria also occurs in adults but much less frequently. The mortality rate in treated cerebral 
malaria in children is 15-20% and 10-15% in adults. Recent reports and clinical experience in 
Africa suggest that the overall burden of severe malaria is decreasing significantly there. 
Pathophysiology of cerebral malaria
The mechanism of brain injury in cerebral malaria is not fully understood. The main theories 
involve parasite sequestration, endothelial dysfunction and injury with cytokine release and 
blood brain barrier dysfunction. The brain at post mortem in cerebral malaria is typically 
congested and darkened in colour (Fig 7.1). The histopathology shows many parasitized red 
blood cells (RBCs) sequestered in the capillaries and small blood vessels particularly in the grey 
matter and petechial perivascular ring haemorrhages in white matter (Fig 7.1). The sequestration 
is attributed to cytoadherence or the sticking of parasitized RBCs to vascular endothelium and 
to rosetting; the sticking of unparasitized RBCs around a parasitized RBC, which in turn 
may lead to congestion of the capillaries. These findings have led to the mechanical theory 
of decreased microcirculation or blocked capillaries being a main mechanism. An alternative 
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theory is that sequestration and rupture of trapped parasitized RBCs release many mature 
malaria parasites, trophozoites and schizonts leading to increased local glucose consumption 
and massive local release of endotoxins and cytokines. These in turn result in breakdown in the 
blood brain barrier, increased cerebral blood flow, cerebral oedema and coma. 
Clinical features
The first symptoms of cerebral malaria in adults include fever, headache, myalgia, malaise 
followed by progressive drowsiness, confusion, delirium, stupor and coma. These symptoms 
usually develop over 1-3 days but may occur in <24 hours. The onset can be relatively sudden 
with the patient presenting with a febrile illness over hours followed by a generalised seizure and 
or coma. This is a more common presentation in children and in non immune hosts. Seizures 
occur in >50% of children and about 20% of adults, either at onset or throughout the course of 
the illness. In adults the main neurological findings are those of an acute encephalopathy with 
symmetrical upper motor neurone signs. These include altered level of consciousness, divergent 
gaze, bruxism (teeth grinding), hypertonia and extensor plantar reflexes. The duration of coma 
after starting treatment is on average 1-3 days but may persist for longer in adults. Systemic 
complications include anaemia, acidosis, renal failure, respiratory distress syndrome and 
secondary bacterial sepsis. 
A characteristic malaria retinopathy has recently been described in Malawi occurring in children 
and also in adults with cerebral malaria (Fig. 7.2). This retinopathy is characterized by areas of 
Pathology
Darkened brain with congestion & haemorrhages
Histopathology Microscopy
Parasitized red blood cells blocking capillaries P Falciparum
Figure 7.1 Brain in Cerebral Malaria (CM)
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retinal whitening best seen immediately around the macula/fovea but sparing it, coupled with 
white or orange discolouration of some retinal vessels and capillaries. These features are now 
considered to be specific for cerebral malaria. They are best seen with the direct ophthalmoscope 
provided that the pupils have been dilated and the examiner is already familiar with them. The 
more classical fundoscopy findings in cerebral malaria include retinal haemorrhages (<10% of 
adults) and papilloedema (<1% of adults). Characteristic white centered retinal haemorrhages 
are found in most children and papilloedema in 10%. These however are not specific for 
cerebral malaria. 
Differential diagnosis
The high prevalence of asymptomatic parasitaemia may make the diagnosis less certain and 
therefore other causes of encephalopathy need to be excluded. Infectious causes include acute 
bacterial meningitis (ABM), partially treated ABM, viral meningoencephalitis including rabies, 
semi acute presentations of the main HIV related CNS infections including cryptococcal 
and tuberculous meningitis and toxoplasmosis. Non-infectious causes include metabolic 
abnormalities, intoxication, epilepsy, stroke and other causes.
Diagnosis of malaria
The diagnosis of cerebral malaria is supported by laboratory evidence of infection. This is 
usually done by the demonstration of malaria parasites on a peripheral blood slide. A blood 
slide, usually a thick film is taken first on admission, after the first 24 hours and again at 48 
hours. A negative blood slide on admission needs to be repeated if cerebral malaria is still 
suspected. 
Newer methods of diagnosis include rapid diagnostic tests (RDT) which detect parasitic 
enzymes or antigen in whole blood. Most are sensitive and specific for P. falciparum and are 
very helpful particularly where skilled microscopy is unavailable. RDTs based on antibody 
detection are of less value clinically as they don’t distinguish between old or recent infection 
and are non specific for falciparum. 
A full blood count is frequently normal but may show anaemia especially in children. The 
presence of leucocytosis and thrombocytopenia usually indicates severe systemic malaria or 
coexistent sepsis. Hypoglycaemia is common in severe malaria particularly in children and 
blood glucose should always be regularly checked in cerebral malaria. Other investigations 
Haemorrhages & whitening around fovea White discolouration of blood vessel wall
Figure 7.2 Retina in CM Photographs courtesy of Susan Lewallen Ophthalmology Dept, KCMC
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include renal, liver function, coagulation screen, arterial and blood gases. Urine in malaria may 
rarely be dark or black in colour and an analysis shows red blood cell casts. CSF examination is 
clear in colour with no increase in cells but may show a slightly elevated opening pressure with 
a mild elevation in protein. Neuroimaging is typically normal. 
Key points
 · cerebral malaria is a major cause of death in children <5 yrs 
 · clinical features include headache, fever, myalgia, altered consciousness & seizures 
 · symptoms typically progress over 1-3 days
 · diagnosis is supported by evidence of malaria parasites in blood 
 · other causes of encephalopathies need to be excluded
Treatment of cerebral malaria
The treatment of a patient with cerebral malaria is based on specific drug treatment and the 
early recognition and management of complications. Management of complications includes 
urgent measures to treat hypoxia, hypoglycaemia, seizures, hypovolaemia, anaemia and 
acidosis. Because most deaths in cerebral malaria occur within 24 hours of onset, patients 
should if possible be admitted to a high dependency care area or an intensive care unit and 
have emergency management. Blood sugar should be checked every 4-6 hours particularly 
in children because of recurrent hypoglycaemia. Fluids need to be restricted in the first 48 
hours, if raised intracranial pressure is suspected. Complicated cases may need intubation, 
ventilation, exchange transfusion and dialysis if available. A summary of the steps in emergency 
management of complications is outlined below. 
Management of complications of cerebral malaria
 · maintain airway with oxygen if hypoxaemic or in respiratory distress
 · if high fever present reduce temperature with paracetamol 
 · correct hypovolaemia in children with NS, infusion @ 2-3 ml/kg/hr  
 · treat hypoglycaemia with iv bolus one ml/kg of 50% dextrose
 · give 5-10% dextrose infusion to all cerebral malaria patients to prevent hypoglycaemia
 · control seizures using either diazepam or lorazepam or phenytoin/phenobarbitone
 · offer blood transfusion if the haematocrit is <15% in children or <20% in adults
 · give fresh whole blood, frozen plasma and vitamin K for spontaneous bleeding
 · give first-line antibiotics for possible pyogenic meningitis and sepsis until excluded
 · ventilate adults with respiratory distress syndrome and refer for dialysis if in renal failure
Specific drug treatment
The specific drug treatment of cerebral malaria includes the artemisinin compounds and quinine 
(Table 7.1). Recent studies in severe malaria show that parenteral artemisinin compounds are 
superior to quinine; they are easier to administer, better tolerated with no major side effects 
and have a better outcome. Intravenous artesunate was shown to be more potent than quinine 
(35% greater reduction in mortality rate) in treating cerebral malaria in adults in Vietnam. It is 
also more potent than artemether, possibly because of a more rapid effect. Parenteral artesunate 
is now the drug of first choice in the treatment of cerebral malaria in Africa. 
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Meanwhile quinine is still being used for the treatment of cerebral malaria in many countries 
in Africa and its use should never be delayed if artemisinins are unavailable. The main side 
effects of quinine are cinchonism (tinnitus, deafness, dizziness, nausea and vomiting), cardiac 
depression, hypotension, hypoglycaemia, blindness and very rarely blackwater fever. Quinine 
should also be used cautiously in patients with heart disease and in the elderly. In adults a 
loading dose of 20 mg/kg is given iv over 2-4 hours and then continued by iv infusion at 10 
mg/kg/8 hourly for 5 days or until able to take orally. After 3 days of iv treatment the dose can 
be reduced from 8 to 12 hourly. Intramuscular quinine administered according to instructions 
can be used if iv route is not possible. 
Table 7.1 Drug treatment of cerebral malaria
Drug route Dose loading Dose maintenance Duration
artesunate iv 24 mg/kg 24 mg/kg/ @ 12 and 
24 hours & then daily 
7 days 
or
artemether im 32 mg/kg 16 mg/kg/daily 5 days
or
quinine 
dihydrochloride
iv 20 mg/kg (max 1400 mg) over 4 hours in 
5% dextrose or dextrose/saline
10 mg/kg/8 hourly* 5 days 
* infused over four hours in adults & changed to oral as soon as the patient can swallow 
Prognosis in Cerebral Malaria (CM)
The mortality rate in quinine and artemisinin treated children with cerebral malaria in Africa 
is 15-20%. Mortality rates are lower <10%, in both artemisinin and quinine treated adult 
patients. However mortality rates in pregnancy are up to 50%. Risk factors for death in cerebral 
malaria in adults include anaemia, seizures, respiratory distress syndrome and renal failure. 
Prolonged and deep coma, elevated intracranial pressure and hypoglycaemia are risk factors 
in children. While the majority of patients make a full recovery from treated cerebral malaria, 
permanent neurological deficits still occur in >20% of children and <5% adults. Deficits 
including psychoses, ataxias are usually transient and clear within weeks or months. Gross 
neurological deficits occur in about 10% of children, these include, hemiparesis, quadriparesis, 
cerebellar ataxia, and severe brain damage. Neurocognitive and behavioural dysfunction are 
also more common occurring in >20% and epilepsy occurs in about 10%. Hemiparesis is the 
main deficit in adults. 
Key points
 · parenteral artemisinin is superior to quinine in treatment of cerebral malaria 
 · mortality in treated children is 15-20% and <10% in adults
 · morbidity occurs in >20% of children and <5% adults
 · morbidity (children), neurological & cognitive deficits, behavioural abnormalities & epilepsy 
 · hemiparesis is most frequent complication in adults
Cerebral malaria
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Table 7.2 Blantyre coma scale*
To obtain coma score add the scores from each section**
Best motor response
Localizes painful stimulus
Withdraws limb from painful stimulus
No or inappropriate response
2
1
0
Best verbal response
Cries or speaks appropriately with painful or verbal stimuli
Moans or abnormal cry to painful stimulus
No vocal response to painful stimulus
2
1
0
Eye Movements
Watches or follows eg mother’s face
Fails to watch or follow
1
0
* for use in children
** Score ≤2 & a positive blood slide suggests cerebral malaria
TOXOPLASMOSIS
Introduction
Toxoplasmosis is caused by infection with Toxoplasma gondii. T. gondii is an intracellular 
protozoan parasite whose definitive host is the cat. Humans and other animals may become 
infected accidentally from infected cats via ingestion of food or water contaminated with cat 
faeces. Transmission in Africa is most probably from ingestion of undercooked meat of infected 
animals. Human infection occurs mostly during childhood and antibody seroprevalence rates 
are a measure of latent infection. Worldwide seroprevalence rates vary from 20% to 75% and 
a similar pattern occurs in Africa varying from 27% in Uganda to 75% in Nigeria. Nearly all 
toxoplasmosis illnesses in Africa are caused by reactivation of latent infection in HIV related 
immunosuppression. Cerebral toxoplasmosis or toxoplasma encephalitis (TE) is the main 
form of the disease resulting from reactivation. The frequency of cerebral toxoplasmosis in 
HIV varies within Africa, depending on the local pattern of latent infection. In one major 
HIV autopsy study in West Africa, evidence of cerebral toxoplasmosis was present in15% and 
was considered the main cause of death in 10%. Toxoplasmosis is considered to be the most 
common cause of a focal brain lesion in AIDS patients in most parts of Africa. 
Clinical presentation
Clinically patients present sub acutely over days or more commonly 1 or 2 weeks with headache 
and fever often in combination with focal neurological signs. Focal neurological signs occur 
in around three quarters of patients and include hemiparesis, cranial nerve palsies, ataxia, 
confusion, altered consciousness and seizures. The pattern of neurologic signs will depend on 
the site of the focal lesion within the brain and its duration. There may be associated toxoplasma 
chorioretinitis in 5-10% of affected patients. Cerebral toxoplasmosis occurs mainly in patients 
with a CD4 count of <100 cells/mm3 and is frequently the first presenting complaint of HIV 
infection.
Diagnosis
Laboratory investigations are of limited value in the diagnosis. A positive serological screening 
test for toxoplasmosis usually indicates previous exposure rather than active disease. However 
a negative result does not exclude the disease. The CSF is also non diagnostic showing 
brain abscess
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predominantly lymphocytes with an elevated protein and a modest decrease in glucose. CT 
scan of the head with contrast is very helpful for the diagnosis. In cerebral toxoplasmosis, it 
shows a single or more commonly multiple ring-enhancing lesions with surrounding oedema 
situated usually in the basal ganglia or/and at the junction of the grey white matter in the 
cortex (Fig 7.3).
Differential diagnosis
The differential diagnosis of cerebral toxoplasmosis includes other causes of focal neurological 
disorders in HIV disease, including tuberculoma, primary CNS lymphoma, and rarely 
progressive multifocal leucoencephalopathy (PML). Other HIV related infections including 
cryptococcal and TB meningitis may also need to be considered. The clinical presentation of 
tuberculoma can be very similar to that of cerebral toxoplasmosis, although the clinical course 
in tuberculoma is usually slower and there may be evidence of concomitant TB elsewhere e.g. 
chest X-ray. CT features of tuberculoma in adults are those of a single or multiple ring enhancing 
lesions, with irregular walls of varying thickness and surrounding oedema situated mainly in 
the cortex. Primary CNS lymphoma is relatively uncommon in HIV in Africa occurring in 
<1% of HIV patients. The CT in lymphoma may be similar to toxoplasmosis and shows ring 
enhancing lesions in the deep white matter near the corpus callosum or subependymal areas. 
In the absence of a CT scan empirical treatment for toxoplasmosis should be started in all HIV 
patients presenting with focal neurological signs and CD4 count <200 cells/mm³.
Key points
 · toxoplasmosis is the most common cause of focal brain lesion in AIDS
 · occurs mostly in patients with CD4<100 mm³
 · clinical features include headache, fever & focal neurological signs over days or weeks
 · diagnosis supported by ring enhancing lesions on CT brain scan 
 · differential diagnosis includes tuberculoma & lymphoma
Treatment
Treatment is based on drugs that interfere with the ability of T. gondii to synthesise folate and 
replicate. High dose trimethoprim/sulphamethoxazole (TMP-SMX) is the recommended first 
line treatment for cerebral toxoplasmosis in Africa (Table 7.3). The dose is one TMP-SMX 
tablet (80/400 mg) for each 8 kg body weight, taken in two or three divided doses per day. For 
the average adult this is usually 4 tablets, (1920 mg) twice daily for four weeks, followed by 
CT (with contrast) Pathology Histopathology
Multiple ring enhancing lesions Toxoplasma abscess Bradycyst
Figure 7.3 Brain in toxoplasmosis
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two tablets twice daily for another 8 weeks. Long term secondary prophylaxis with two tablets 
daily is indicated if the CD4 count is <200/cm3 and should be considered for all patients with 
CD4 counts < 350 cells/cm3. A clinical response to treatment is usually seen within 3-4 days 
of starting treatment and definite improvement after 2-3 weeks in over 80% of patients. If 
there is inadequate or no response to treatment, then other diagnoses other than toxoplasmosis 
should be considered including tuberculoma. Relapses should be retreated with full course 
(TMP-SMX). Patients who are intolerant of TMP-SMX because of drug rash or neutropenia 
can be treated with pyrimethamine 50-75 mg daily in combination with clindamycin 600 mg 
8 hourly or azithromycin 1 gram daily. These are continued for a total of 6 weeks. Limiting 
side effects include drug rashes and bone marrow depression. Folinic acid 15 mg daily should 
be prescribed with pyrimethamine. 
Prognosis
The mortality in Africa in treated cases of cerebral toxoplasmosis is 10-15% mainly because of 
late disease and co-morbidity in HIV disease. Relapse rates are considered to be in the order of 
20%, occurring up to 6 months after successful treatment. Antiretroviral therapy (ART) should 
be started within two weeks of starting treatment for suspected or proven toxoplasmosis. 
Key points
 · treatment is with high dose TMP-SMX for 4/52 & maintenance dose for 8/52
 · long term chemoprophylaxis should continue until CD4 is >350 cm3
 · ART should start within two weeks of starting treatment
 · case fatality rate in treated cases is 10-15%
Table 7.3 Drug treatment for toxoplasmosis
Drug Dose/route Duration Side effects
trimethoprim/sulphamethoxazole 
(TMP-SMX)
treatment phase
maintenance phase
chemoprophylaxis phase
4 tab (1920 mg) /po/
twice daily
2 tab/po/twice daily
2 tab/po/ daily
4 weeks
8 weeks
until CD4 >350/cm3
rash, neutropenia
HUMAN AFRICAN TRYPANOSOMIASIS (HAT)
This is a protozoan parasitic infection caused by parasites of the Trypanosoma brucei, which 
are transmitted to humans by the bite of the tsetse fly (Glossina spp) (Fig 7.4). Human African 
trypanosomiasis (HAT), better known as sleeping sickness, is restricted to the distribution 
of tsetse flies in a vast area throughout sub-Saharan Africa (Fig 7.4). It stretches from 14° 
north to 20° south latitude, putting a total of over 60 million people in 36 countries at risk. 
HAT occurs in both epidemic and endemic forms. There are two main types of HAT with 
differences in epidemiology, biology and clinical features: Trypanosoma brucei rhodesiense 
(T.b.r.) affects eastern and parts of southern Africa with savannah bush with game animals 
and cattle as its main reservoir. It accounts for fewer than 5% of reported cases and causes an 
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acute illness. Trypanosoma brucei gambiense (T.b.g.) affects Central and West African river 
and water hole areas with humans as its main reservoir; it accounts for over 95% of all cases 
and causes a chronic illness. In Uganda both types of HAT occur, indicating local geographical 
overlap between Tbr and Tbg infections. The people most at risk live in rural areas and depend 
on agriculture, fishing, animal husbandry and hunting in African rivers and waterhole areas. 
HAT has re-emerged during the last decades as a threat to public health in those affected 
areas. Precise details of disease prevalence are difficult to ascertain. It is estimated that around 
300,000 people in Africa are infected with most of those occurring in Southern Sudan and 
the Democratic Republic of Congo (DRC). Of those approximately 40,000 cases are reported 
annually to WHO. 
Key points
 · thousands cases of HAT or sleeping sickness occur annually in Africa
 · HAT is transmitted  by tsetse fly bites & people most at risk live in rural areas
 · two main types, T b r in E & S Africa and T b g in C & W Africa 
 · wild animals and cattle are the main  reservoirs of  infection in E & S Africa
 · infected humans are the main reservoir in C & W Africa
Clinical features
Tsetse flies acquire the infection by feeding on infected humans (Tbg), wild animals or domestic 
cattle (Tbr). The disease can also be transmitted vertically from mother-to-child and occasional 
accidental infections have occurred in the laboratory, mostly from needle stick injuries. The 
tsetse fly becomes infective approximately 3-5 weeks after biting an infected animal or human 
and later may transmit the trypanosomes to humans by biting. HAT may begin in humans at 
the site of the bite, as a painful indurated erythematous boil-like lesion or primary chancre. 
The primary chancre starts 3-15 days after the bite increasing to a couple of centimetres in size 
over the following 2-3 weeks. It usually does not suppurate and then slowly clears leaving a 
mark on the skin. Primary chancre formation occurs in less than half of cases of T.b.r. cases and 
is uncommon in T.b.g. The trypanosomes multiply at the chancre site, then invade the blood 
	  
Main sleeping sickness areas in Africa Tsetse fly
Figure 7.4 Map of trypanosomiasis distribution in Africa
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stream and lymph nodes and may eventually cross the blood–brain barrier and infect the brain. 
This invasion gives rise to two characteristic clinical stages, the early or haemolymphatic stage 
and the late, or encephalitic stage. T.b.g infection is characterised by distinct stages, a long 
asymptomatic phase followed by a sub acute illness and a chronic, late encephalitic stage, with 
the whole illness lasting up to 3 years or more before death in untreated cases. T.b.r infection 
presents with a more acute illness and less distinct stages with 80% of deaths occurring within 
6 months of onset in untreated cases. The life cycle is outlined below in Figure 7.5. 
Figure 7.5 Life cycle for trypanosomiasis
Haemolymphatic stage
The onset is variable but usually occurs 1-3 weeks after the bite. Irregular episodes of fever 
lasting 1-7 days occur together with generalised lymphadenopathy. Palpable lymph nodes in 
the cervical triangle of the neck are called Winterbottom’s sign (Fig. 7.6). Early associated 
symptoms include headache, joint pains, weakness and weight loss. Systemic involvement 
may then occur with multiple organs affected. In T.b.r this is characterised by fevers, pleural 
and pericardial effusions, myocarditis, hepatosplenomegaly, jaundice, anaemia and endocrine 
disorders. This stage in T.b.r can be fatal within weeks or more commonly progresses to the 
late encephalitic stage. In T.b.g, this early stage is usually less pronounced and more chronic 
and is characterised by hepatosplenomegaly and skin involvement. It may last many months to 
a couple of years before progressing on to the late or encephalitis stage.
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Encephalitic stage
After the haemolymphatic stage, HAT may remain quiet until invasion of the CNS takes place. 
There is not always a clear recognisable transition from early to late stage disease. In T.b.r. 
disease this occurs within weeks or months of onset, whereas in T.b.g disease the late stage 
takes months or years to develop. The onset of encephalitis is often subtle and unnoticed and 
neurological presentations are variable. These can be generally grouped into behavioural and 
psychiatric symptoms, motor, sensory disorders and sleep disorders all of which may overlap. 
Behavioural and psychiatric presentations vary from irritability, headache, personality and habit 
change, to agitation, psychosis and mania with confusion and sleep. Accompanying motor 
signs include limb tremors, incoordination, dysarthria, involuntary movements, pyramidal 
and extra pyramidal findings. Sensory complaints include pruritus, painful hyperaesthesia and 
polyneuritis. The sleep disturbances include undue tiredness and an uncontrollable urge to 
sleep during the day time accompanied sometimes by insomnia at night. Untreated the disease 
eventually progresses to immobility, seizures, continuous sleep, coma and eventually death 
(Fig. 7.6). Late stage neurological features may not be seen in T.b.r as coma and death may 
intervene.
Diagnosis
HAT is diagnosed in Africa on the basis of characteristic clinical findings in a patient 
coming from an endemic area and confirmed by laboratory investigations. Other causes of 
febrile diseases especially malaria, HIV and TB need to be considered. Routine laboratory 
investigations may show a mild anaemia and elevated erythrocyte sedimentation rate (ESR). 
The laboratory diagnosis of HAT is dependent on showing evidence of infection either by 
direct visualization of trypanosomes by microscope or by serological detection of antibody 
to trypanosomes in blood and csf (Fig. 7.7). Direct visualization of trypanosomes in blood is 
usually successful in the haemolymphatic stage of T.b.r because of the continuous parasitaemia, 
whereas it is difficult in T.b.g because of low or intermittent parasitaemia. Chancre aspiration 
and lymph node aspirate may be helpful when these are negative. Concentration methods 
including centrifugation are used to detect low levels of parasitaemia. The methods of direct 
Winterbottom’s sign (enlarged lymph glands) Encephalitic stage (late)
Figure 7.6 Clinical findings in trypanosomiasis
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visualization involve examining the peripheral blood, the buffy coat, csf or rarely bone marrow 
for evidence of motile trypanosomes on a wet preparation or on Giemsa stain. In general the 
longer the duration of the illness the more difficult it is to find the organisms and the tests may 
have to be repeated in suspected cases more than once. The test of choice in suspected T.b.g 
infection is the antibody-detecting card agglutination trypanosomiasis test (CATT) which is 
easy to perform and widely available in endemic areas. Limitations include decreased sensitivity 
(87-98%) and specificity (93-95%).  
CSF examination
It is critical to determine whether or not there is encephalitic involvement because to miss it and 
not to treat it results in the death of the patient. An LP is therefore indicated when encephalitis 
is clinically suspected and also in all cases of CATT positive tests as there are no reliable criteria 
for detecting exclusive early stage disease. It is performed only after one or two doses of suramin 
or pentamidine have been given in order to reduce the risk of parasites inadvertently entering 
the CSF from blood during the procedure. Direct evidence of encephalitis includes finding 
trypanosomes in centrifuged CSF either by direct visualization or by serology in the case of 
T.b.g. (Fig 7.7). Indirect evidence according to WHO includes lymphocytes >5 per ml and a 
raised protein in the CSF, although a cut off at a higher level of lymphocytes >20 per ml has 
been proposed to increase its diagnostic specificity. CT of brain is non diagnostic but may show 
non specific white matter changes and ventricular enlargement in long standing disease. 
Key points
 · HAT occurs in two stages, haemolymphatic & encephalitic 
 · diagnosis: finding typical clinical & lab findings in pts from endemic area 
 · HAT confirmed by microscopy in Tbr & by serology & microscopy in Tbg 
 · LP indicated if encephalitis is suspected & in all CATT positive persons
 · LP is done only after 1-2 doses of suramin or pentamidine
Trypanosomes and lymphocytes
Figure 7.7 CSF in trypanosomiasis
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Treatment
The treatment of HAT is complex and toxic and must be closely monitored (Table 7.4). It is 
determined by the stage of the disease and whether it is T.b.r or T.b.g. The early haemolymphatic 
stage of T.b.r. is treated with iv suramin and of T.b.g. with im pentamidine. Allergy with 
suramin is uncommon (<1%) but can be fatal and a test dose is always administered before 
using it for treatment. Associated nephrotoxicity is usually reversible. This treatment is usually 
successful if the disease is confined to this stage. The late encephalitic stage of T.b.r and T.b.g. 
is treated with iv melarsoprol. This is usually preceded by 1-2 doses of suramin to clear 
peripheral trypanosomes. In T.b.r melarsoprol is usually administered as a series of 3-4 cycles 
of 3 consecutive daily injections (Table 7.4) with a 7 day rest period between each cycle. The 
main danger is an acute reactive encephalopathy which occurs in 5-10% of treated patients, a 
half of whom die because of the drug, therefore just giving melarsoprol therapy has an overall 
fatality rate of 2.5-5%. A new shorter 10 day course of iv melarsaprol at 2.2 mg/kg/daily may be 
effective for T.b.g. Resistance to melarsoprol has recently been reported from the DRC. The 
concomitant use of steroids is controversial but there is evidence that their use may decrease 
the chance of developing the post-treatment encephalopathy particularly in T.b.g. One steroid 
regime is dexamethasone 30 mg iv stat, and 15 mg q 6 hourly or prednisolone 1mg/kg po daily 
starting before the first dose and continuing through the last dose. Eflornithine (DFMO,) is 
a safer therapy than melarsoprol for late stage HAT but is only effective for disease caused by 
T.b.g., being ineffective in the East African disease, T.b.r. However eflornithine is expensive and 
requires 2 weeks of continuous iv drug treatment in hospital. A combination of eflornithine 
infusion, for 7 days and the drug nifurtimox orally, for 10 days has been recently introduced 
(2009) and now appears to be effective primary therapy for T.b.g. It is not effective against T.b.r. 
Table 7.4 Drug treatment of human African trypanosomiasis
Drug Type Stage Route Dose/duration Side effects
Suramin T b rhodesiense Stage 1 iv (5mg/kg test dose slowly 
iv on day 1)  
20 mg/kg/iv (max 1 gm) 
on days 1,3, 5, 12, 19 & 26
allergy, anaphylaxis, 
renal failure, neurologic 
effects
Pentamidine T b gambiense Stage 1 im 4 mg/kg im/od/  
for 7–10 days
nephrotoxicity, 
hypoglycaemia low 
BP, site pain nausea, 
leucopoenia
Melarsoprol 
(Mel B)
T b rhodesiense
&
T b gambiense
Stage 2 iv 36* mg/kg/od for 3 
day cycles (series of 3-4 
cycles) 
acute reactive 
encephalopathy, 
neuropathy, diarrhoea 
and rash
Eflornithine T b gambiense Stage 2 iv 100 mg/kg iv q 6hourly 
for 14 days in diluted 
normal saline/infused 
over 2 hours
leucopoenia, anaemia, 
diarrhoea and 
convulsions
Nifurtimox T b gambiense Stage 1 po 15mg/kg /po/daily (5mg, 
8 hourly) for 10 days
nausea, vomiting, 
abdominal pain, seizures, 
agitation tremor 
(neuropathy)
*  different treatment schedules with doses ranging from 1.2 to 3.6 mg/kg/daily (in 3 divided doses) for consecutive 
3 day cycles administered by slow iv injection, using a glass syringe and avoid leakage as it causes tissue 
necrosis. Total series of 3 to 4 cycles with a 7 day rest period between each cycle (see WHO recommendations), 
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Key points
 · Rx of early stage in T.b.r is with suramin & in T.b.g is with pentamidine
 · Rx of encephalitic stage in T.b.r & T.b.g is  melarsoprol or T.b.g eflornithine
 · Rx of early & late stage T.b.g is with eflornithine & nifurtimox
 · encephalopathy occurs in 5-10% of patients treated with melarsaprol
 · 50% of patients with melarsaprol encephalopathy die
Prognosis
HAT is invariably fatal if untreated. It has been estimated that 20-30% of affected persons 
in endemic areas in Africa may die even with treatment either because of late diagnosis or 
inadequate treatment. The rate of relapse after treatment for the encephalitic stage is up to 
20%. LPs are necessary every 6 months to confirm cure which cannot be assumed until after 
a 2 year follow up.
Prevention
HAT in Central and West Africa is prevented by active case finding through systematic 
community screening and passive clinical case finding and the treatment of all infected persons. 
In East Africa HAT is controlled by avoiding being bitten and by vector control through fly 
trapping and the clearing of riverine tsetse habitat.
Key points
 · overall mortality in trypanosomiasis is high
 · follow up is necessary after treated encephalitic stage and relapse is common
 · prevention in T.b.g is by active case screening & passive case  treatment 
 · prevention in T.b.r is by avoiding tsetse bites & by vector control
Table 7.5 Summary
Gambiense (T.b.g) Rhodesiense (T.b.r)
location Central & West Africa East Africa
reservoir humans cattle & wild animals
clinical presentation sub-acute/chronic acute
diagnosis CATT/lymph node/CSF blood film/CSF
management pentaminine/eflornithine & nifurtimox suramin/melarsoprol
control/prevention case finding & treatment avoid tsetse bites/vector habitat control
NEUROCYSTICERCOSIS
Neurocysticercosis arises from the larvae of the pork tapeworm Taenia solium. This tape worm 
is endemic in large parts of the world including large parts of Africa (Fig 7.8). It is estimated 
that over 50 million people worldwide are infected with cysticerci and it accounts for over 
50,000 deaths annually. As many as 20 million persons in Africa may be infected. Around 
10-40% of infected persons develop seizures and it is responsible for up to 30% of late onset 
epilepsy in endemic areas. It is the most common parasitic infection causing disease of the 
nervous system. 
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Figure 7.8 Map of cysticercosis distribution in Africa
Life cycle
Humans are the definitive hosts of 
the 2-4 meters long tapeworm that 
excretes viable ova in the stool. The 
pig is the intermediate host. Following 
ingestion of human faeces by the pig, 
ova migrate mainly to the pig’s muscles 
and become larvae or cysticerci. Humans 
eat undercooked and measly pork 
containing the viable larvae. The life cycle 
is then complete when the larvae develop 
into an adult tapeworm in the small 
intestine of humans (Fig 7.9). However 
when humans accidentally become the 
intermediate host by ingestion of the 
ova through faecal-oral contamination 
from someone else’s faeces or their own, 
the larval form may migrate and develop 
into cysts either in human brain or other 
organs, mainly muscles skin and eye. The 
most frequent source of ova is a symptom 
free tapeworm carrier in the household. 
Vegetarians and non pork eaters may 
thus acquire cysticercosis. About 15-25% 
of patients with neurocysticercosis will 
either have a past history of tapeworm or 
harbour a live one. 
Figure 7.9 Life cycle cysticercosis
neuroCystiCerCosis
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Pathology
Once in the brain, the mature larvae live dormant for 2-6 yrs and occasionally for 10 years or 
longer. These are known as cysticerci. They expand to 1-2 cms in size and eventually die causing 
the wall of the cyst to break down resulting in an intense local inflammatory reaction and later 
calcification. This cycle of pathology is responsible for the main clinical presentations including 
seizures. The clinical findings will depend on the site, number and stage of cysticerci. They 
occur in many tissues in particular, skin, muscle and brain. Typical skeletal muscles involved 
are those of the limbs and back. The main sites within the brain are the cortex, ventricles and 
subarachnoid space and infrequently the spinal cord. 
Clinical Features
The most common clinical feature of neurocysticercosis is single or repeated seizures. These occur 
in >90% of cases. In endemic countries, including large parts of rural Africa neurocysticercosis 
is the most common cause of acquired epilepsy in adults. The cysts may infrequently cause 
focal neurological disorders; these include hemiparesis, hydrocephalus due to intraventricular 
cysts and rarely paraplegia (5%) due to spinal cord disease. The finding of hydrocephalus and 
raised intracranial pressure are an indication for shunting. There may also be evidence of cysts 
outside the CNS mainly in skin, muscle and eye (1-3%).
Diagnosis
The diagnosis is made mainly by a high index of clinical suspicion in a patient suffering 
from epilepsy coming from an endemic area. The diagnosis is supported by the finding of 
radiological evidence of cysts in muscle or brain. A radiograph of shoulder or thigh muscles 
may reveal typical calcifications following the planes of muscle fibres (Fig 7.10). A CT of head 
shows evidence of neurocysticerci (Fig 7.10), in particular their number, location and activity. 
However MRI is necessary to show intraventricular cysts or the racemose variety. The racemose 
variety of neurocysticercosis is seen on MRI as multiple thin walled cysts with the same signal as 
CSF and no central scolex (Fig 7.10). On CT cysts appear as small isolated or multiple lesions 
at the grey white matter junction or widespread throughout the brain. During this dormant 
phase after contrast, they appear as hypo dense cysts with little enhancement and a visible dot 
like central scolex (Fig 7.10). This is diagnostic of neurocysticercosis. In the later mature or 
dying cyst phase, they appear as ring enhancing cysts surrounded by an area of oedema. Older 
cysts may calcify and there may be hydrocephalus (Fig 7.10). Serological testing should be 
used together with results from neuroimaging to help establish the diagnosis. These include 
ELISA and enzyme immunosorbent/blot/assay tests on both serum and CSF. The tests may 
be negative in isolated cysts, but are usually positive where there are multiple cysts. However 
newer antigen and antibody based serological tests appear more sensitive to detect both active 
and inactive disease. The CSF is abnormal in about half the cases with elevation in white cells 
and protein. There may be an associated eosinophilia early on and also evidence of tape worm 
infection with eggs in the patient’s stool in <20% of patients. 
Treatment
The main indication for treatment is active parenchymal CNS disease. The suggested treatment 
for cysts is albendazole 15 mg/kg po daily for 10-28 days, although a higher dose of 30 mg/
kg po daily has been used in patients with subarachnoid cysts. An alternative but less effective 
treatment is praziquantel 25mg/kg/po three times daily for 14-21 days (Table 7.6). There is 
controversy over the benefits and duration of treatment which ranges from 7 days to 3 months 
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or longer. In general the greater the cyst burden the longer the course of treatment. Cimetidine 
400 mg tds given concurrently increases available blood levels of both anti parasitic drugs. Side 
effects of anti parasitic drug treatment include seizures, headaches and muscle enlargement. By 
starting treatment more cysts may die or die more quickly thereby causing more inflammation, 
oedema and consequently more headaches, seizures and sometimes encephalopathy. 
This risk can be decreased by prescribing steroids. This is in the form of dexamethasone 0.4 
mg/kg/po/daily (24 mg) or prednisolone 60 mg daily during active treatment. This is started 
X-ray thigh CT head CT head (with contrast)
Cysts in muscle Old calcified cysts Dying cyst & surrounding oedema
CT head (with contrast) MRI T1(with contrast
Pathology Histopathology
Multiple cysts with central scolex & hydrocephalus Racemose cysts
Multiple cysts in brain Inflammation around cysts
Figure 7.10 Muscle and brain in cysticercosis
neuroCystiCerCosis
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either a few days before or at the start of antiparasitic drug treatment and continued for at 
least 7 days throughout the treatment course or as long as symptoms e.g. headache persists. 
The presence of subarachnoid, intraventricular and too many intracerebral cysts are a relative 
contraindication to antiparasitic drugs because of danger of fatal encephalopathy. Neurosurgery 
in particular a shunt may be indicated for obstructive hydrocephalus which is mostly due to 
intraventricular forms of cysts blocking the ventricles. Seizures can be controlled with standard 
antiepileptic medications. The outlook in a single symptomatic cyst is excellent. However, the 
more malignant forms presenting with neurological deficits and coma have a grave prognosis 
with CFR rate of >50%. 
Table 7.6 Drug treatment of Neurocysticercosis
Drug route Dose
albendazole 
or
praziquantel
po
po
15 mg/kg/daily for 10-28 days
25 mg/kg/tds for 14-21days
&
dexamethasone 
or
prednisolone
po
po
8 mg/tds for >7 days
60 mg/daily for >7 days
Prevention
Neurocysticercosis is a largely preventable infectious disease. The main strategies for prevention 
include hygiene measures to interrupt direct person to person transmission. This involves 
potentially mass human chemotherapy to eliminate the tapeworm stage, improved human 
sanitation i.e. safe faeces disposal, pig husbandry and meat inspection. 
Key points
 · man is the definitive host of Taenia solium & excretes ova in faeces
 · neurocysticercosis develops when humans ingest ova from human faeces 
 · epilepsy is the most common clinical manifestation
 · diagnosis supported by serology & X-rays showing cysts in muscle & brain
 · treatment is with albendazole 2-4/52 & steroids 1-4/52
 · prevention: personal hygiene & mass Rx & safe, faeces disposal, pig husbandry & meat inspection
HUMAN SCHISTOSOMIASIS
Epidemiology
Schistosomiasis is caused by trematode flatworms (flukes) transmitted by snails. The disease 
is endemic in the tropics with an estimated 200 million people worldwide infected, 80% of 
whom are in Africa. The main species in Africa are Schistosoma mansoni and S. haematobium. 
S. japonicum is the main species in southeast Asia and China. Infection of the CNS is unusual 
in Africa but occurs in 2-4% of patients with S. japonicum infection. 
Life cycle
Humans are infected by contact with fresh water, usually when working, playing or  swimming. 
Cercariae, the larval form released from infected snails, penetrate the skin. The larval forms 
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then migrate and unite as pairs of mature worms with mansoni and japonicum living in the 
lower mesenteric veins (the intestinal form) and haematobium in vesical veins (the urinary 
form). They may live in the veins for up to 30 years but their usual life span is probably 3-5 
years. Humans are the definitive host of the adult worms and excrete their eggs in either stool 
or urine depending on the type of infection. The snail is the intermediate host and miracidiae 
released from eggs coming from humans into water enter the snails and are later released as 
cercariae which in turn penetrate the skin and the life cycle is complete (Fig 7.11).
Figure 7.11 Life cycle schistosomiasis
Pathogenesis
The adult worms evade host immunity and some of their released eggs travel with the blood 
flow and get trapped in viscera and release antigens. This provokes a vigorous cell mediated 
inflammatory response particularly in early infection which forms intense granulomas around 
eggs, which gives rise to local pathology in the organ involved. The main sites for trapped S. 
mansoni and S. japonicum eggs are liver mainly causing portal hypertension and also the large 
intestine. S. haematobium eggs get deposited in the genitourinary tract causing bladder wall 
calcification, polyps, bladder stones and an increased risk of squamous cell cancer. The severity 
of systemic disease is proportional to the duration of worm infection and the egg load. When 
the eggs are deposited in the spinal cord or brain, this can lead to neurological disease. This can 
happen in two main ways, migration of egg laying worms to ectopic sites or embolization of 
eggs. Ectopic sites for worms include the inferior venacaval system with a right to left cardiac 
shunt or the paravertebral veins in the cord/cauda equina, or the cerebral cortical veins in 
the brain (Fig 7.12). Retrograde spread to the spinal cord from the inferior mesenteric veins 
through valveless pelvic veins is also a proposed mechanism for paraplegia. CNS involvement 
human sChistosomiasis
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is unusual in both S. mansoni and S. haematobium. Spinal cord disease accounts for >95% of 
all CNS disease in Africa. It occurs particularly in early infection with mansoni in the non 
immune host and when there is a heavy worm and egg load. 
Clinical Features
The neurological findings occur as a result of eggs deposited in the spinal cord (lower end) 
or rarely in the brain. In the spinal cord, they cause a myeloradiculopathy which may result 
in paraparesis, mostly flaccid in type. Clinical features include low back pain, lower limb 
weakness, paraesthesia, bladder and bowel dysfunction and impotence. This is the most 
common neurological presentation of mansoni. Eggs in the brain present as space occupying 
lesions with focal neurological deficits, seizures and encephalopathy.
MRI brain T1 (enhanced) Pathology Histopathology
Eggs & granuloma in brain Eggs & surrounding granuloma
Figure 7.12 Brain in schistosomiasis
MRI brain T1 (enhanced) Histopathology
Eggs & surrounding oedema Granuloma & eggs
Chapter 7  protozoal and helminthiC infeCtions
Part ii – Neurological Disorders 180
Diagnosis
The diagnosis is suggested by a previous or recent history of water exposure in an endemic area 
and confirmed by ELISA antibody tests or the demonstration of eggs in the stool by faecal 
smear or urine by sedimentation or filtration. Although an ELISA antibody test is less useful 
in endemic areas, a positive CSF test result (sensitivity <60%, specificity >95%) supports the 
diagnosis. CSF may show a mild elevation of cells and protein and slight decrease in glucose. 
Eosinophilia may be present especially early on in the disease. Neuroimaging requires MRI as 
CT is not sensitive for spinal cord disease. MRI shows enlargement of the lower end of spinal 
cord below T6 level usually involving T11-L1 with thickening of the nerve roots and cauda 
equina 
Treatment
Patients with neurological disorders should be treated with praziquantel and steroids (Table 
7.7). There is no consensus on the dose or duration of treatment and doses of praziquantel 
range between 40-60 mg/kg/po/daily for 1-14 days, although in suspected and confirmed cases 
a longer course is frequently used. Steroids should be used in the first instance for 2-6 weeks 
and sometimes continued for 3-6 months. 
Table 7.7 Drug treatment of neuroschistosomiasis
Drug route Dose/duration
praziquantel po 40-60 mg/kg/po/od 1-14 days
and
methyprednisolone
or
prednisolone 
iv
po
15-20 mg*/kg/iv/od (max 1gm) 5-7 days
15 mg/kg/po/od for 3-6/52 and a tapering dose
* followed by oral prednisolone 1.5 mg/kg daily for 2-6 weeks
Prognosis
The prognosis in treated spinal cord disease is good with 70% making a complete recovery. 
Recovery usually begins early within 1-2 days of starting treatment. The remaining patients are 
left with permanent deficits. 
Prevention
The main methods of prevention involve regular intermittent mass drug treatment of exposed 
at risk populations usually school children with praziquantel, reduced contamination of water 
and a reduction or elimination of snails.
Key points
 · neuroschistosomiasis is an uncommon complication of Schistosoma infection
 · paraplegia is the most common neurological disorder & mostly occurs in the non immune host
 · diagnosis is by serology & microscopic evidence of eggs & neuroimaging
 · Rx is with praziquantel for 1-14/7 and steroids for 2-6 weeks
 · secondary prevention: intermittent mass treatment of at risk populations with praziquantel 
 · primary prevention: reduced contamination of water & reduction or elimination of snails
human sChistosomiasis
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HYDATID DISEASE
Echinococcosis in humans is mostly caused by the dog tapeworm Echinococcus granulosus. The 
dog is the definitive host and the adult tapeworm inhabits its intestine. Hydatid disease occurs, 
when humans come into contact with dog’s faeces and the ingested ova develop into the cystic 
stage. The disease is estimated to affect 2-3 million people globally. It is endemic in large 
parts of Africa, mainly affecting the traditional cattle and sheep grazing communities. The 
prevalence in endemic areas ranges from 0.25 to 25%. Neurological involvement occurs in 
about 1-2% of cases. 
Life cycle
The dog excretes the tapeworm eggs in its stool and these are accidentally ingested by grazing 
herbivores which then become intermediate hosts. These are mainly sheep, cattle and goats. The 
larval form penetrates the intestinal mucosa of the animal to lodge in the intestinal mesentery, 
liver and lungs, and develop into cysts. When the animal is killed the dog in turn ingests 
these organs which contain larval hydatid cysts. These larval cysts contain tapeworm heads or 
scolexes, which attach themselves to the intestinal wall of the dog and mature into the adult 
tapeworm and the life cycle is complete. Humans become accidentally infected by ingesting 
food or drink which has been contaminated by faeces containing ova from infected dogs. They 
then accidentally become the intermediate hosts (Fig 7.13).
Figure 7.13 Life cycle Hydatid disease
Clinical features
Hydatid disease is characterized by slow growing cysts. It is a chronic disorder mainly of children 
and young persons but adults are also affected. The main sites are liver, lung but other organs 
may be involved. Neurological features depend on the site, age and maturity of the cysts. 
Cysts in the brain occur mostly in children and younger adults. They may be asymptomatic or 
present acutely with hydrocephalus, focal neurological deficits and seizures. Cysts in the spinal 
cord occur more in adults than children and present with paraparesis. 
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Diagnosis
The diagnosis is made by neuroimaging. CT reveals a striking large well defined rounded 
smooth thin walled unilocular, usually single cyst with mass effect. Calcification occurs in 
20-40% of cases (Fig 7.14). Cysts may occasionally be multiple. The finding of a peripheral 
eosinophilia may be worrying as it may indicate that the hydatid cyst is leaking. Serology 
screening is not sensitive for extra hepatic involvement. The main differential diagnosis is 
between cystic brain tumours, an arachnoid cyst and abscesses.  
Treatment
Management is both medical and surgical. Medical treatment is with albendazole alone or in 
combination with praziquantel. The recommended dosage of albendazole is 400 mg twice daily 
over a three or six month period. The optimum period of treatment remains uncertain. There 
is limited data on praziquantel but 40 mg/kg/week in combination with albendazole has been 
suggested and is the currently recommended treatment of choice. The advantage of two drugs 
is that while albendazole acts on the germinal membrane, praziquantel kills the proto-scolices 
or daughter cysts. The indications for medical treatment include multiple inoperable sites and 
to prevent secondary spread, and as an adjunct to surgery. Outcome with medical treatment is 
variable but clinical improvement and radiological resolution of cysts has been shown. Surgery 
is the management of choice for a lesion when there is symptomatic CNS involvement.
CT head (without contrast) MRI T1cervical cord
pathology histopathology
Hydatid cyst in child Calcified cyst and hydrocephalus Cyst pressing on cervical cord
Multiple cysts in brain & ventricles Hydatid daughter cysts
Figure 7.14 Brain and spinal cord in hydatid disease
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Prevention
Preventative measures in endemic areas include prophylactic dosing of dogs for tapeworm, 
avoiding feeding uncooked offal and raw meat to dogs and the regular inspection of meat for 
the presence of cysts. 
Key points
 · echinococcosis is caused by cystic stage of dog tapeworm
 · humans infected when they accidentally ingest faeces from infected dogs
 · CNS disease occurs in 1-2% & includes hemiplegia, seizures & paraplegia 
 · diagnosis is by imaging showing cysts/Ca++ in the brain and spinal cord
 · Rx: albendazole & praziquantel for >3/12 & surgery if symptomatic
 · prevention: prophylaxis of dogs for tapeworm & inspection of meat for cysts 
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CHAPTER 8
NEUROLOGICAL ILLNESS IN HIV DISEASE
Neurological disorders are a frequent manifestation of HIV infection in Africa. At least a fifth 
of infected persons will present with a major neurological illness either as the first clinical 
manifestation of HIV or occurring during the course of symptomatic HIV disease. The 
proportion of patients with clinical evidence of neurological dysfunction and have abnormal 
neurological findings is however much higher at 40-70%. At post mortem examination, over 
90% of AIDS cases have pathological changes in their nervous system. Neurological disorders 
affect all parts of the nervous system including the brain, spinal cord, peripheral nerves, muscle 
and eye. This chapter outlines the main neurological illnesses arising from HIV infection. 
After reading the chapter the student should aim to understand the main mechanisms, clinical 
presentations, diagnosis and management of these illnesses. 
INTRODUCTION
Neurological disorders in HIV infection are caused by three main processes: loss of cell-
mediated immunity, direct HIV infection, and inflammation/autoimmunity. Adverse 
effects of drugs used to treat HIV and its co infections are also a cause. 
Disorders related to loss in immunity are caused by opportunistic processes (OP), mostly 
infections and occasionally neoplasms. These occur mostly but not exclusively when the 
CD4 count is <200 cells/cm3. The main opportunistic infections (OI) are cryptococcosis, 
toxoplasmosis and tuberculosis (Chapters 6 & 7) and main opportunistic neoplasm is cerebral 
lymphoma. The main neurological presentations occurring as a result of those processes are 
meningitis, focal neurological disorder (FND) and altered level of consciousness or coma 
depending on the cause and CNS site involved. 
Neurological disorders also arise from direct HIV infection of the nervous system and muscle. 
These include HIV-associated dementia (HAD), distal sensory neuropathy (DSN), vacuolar 
myelopathy, retinopathy and myopathy. These also occur mostly during the later stages of 
HIV infection when CD4 count is <100 cells/cm3. 
Other neurological disorders that may occur throughout the course of HIV infection include 
herpes zoster, Bell’s palsy, Guillain-Barre Syndrome (GBS) and polymyositis. These by 
contrast occur mostly during the asymptomatic stage when immunity is still relatively intact 
with CD4 counts typically >200 cells/cm3. GBS and polymyositis are caused by inflammation 
and autoimmunity. The general characteristics of the main HIV related neurological illnesses 
are summarized below in Table 8.1.
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Table 8.1 Characteristics of main neurological illnesses in HIV disease
Cause Clinical presentation CD4 cells/cm3 
( ) = range
Estimated 
frequency in HIV 
Opportunistic processes (0-200) 20-30%
Infections
Cryptococcus neoformans
Mycobacterium tuberculosis
Toxoplasma gondii
Cytomegalovirus
JC virus (progressive multifocal 
leucoencephalopathy)
Tumours
Primary CNS lymphoma  (PCNSL)
meningitis
meningitis, *FND, paraplegia 
*FND
retinitis, radiculopathy, 
encephalitis 
quadriplegia, encephalopathy
*FND
<100
(0-500)
<100
<50
<100
 
<100
10-20%
1-10%
5-15%
1-15%
 
uncommon
 
<1%
Direct HIV infection (0-200) 40-70%
HIV associated dementia (HAD)
vacuolar myelopathy 
distal sensory neuropathy (DSN)
retinopathy
frontal lobe release signs 
<50 
<100
<200
<200
<200
20-30%
5-20%
20-30%
5-10%
50-70%
Inflammatory/autoimmune (200-500)
Bell’s palsy
GBS 
polymyositis
common
rare
rare
Others (0-500)
Varicella zoster
seizures 
stroke
paraplegia
(2-500) 5-10%
5-10%
<1%
1-2%
* FND: hemiparesis, seizures, ataxia, cranial nerve palsies, coma
The main clinical presentations are meningitis, focal neurological deficits, seizures and 
altered level of consciousness; these are mostly caused by opportunistic infections and 
frequently occur, when more than one HIV related illness is present. Disseminated TB occurs 
in >50% of patients with advanced HIV disease in Africa. 
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CLINICAL PRESENTATIONS
MENINGITIS
Meningitis is one of the common neurological presentations of HIV infection in Africa. The 
main causes are C. neoformans and M. tuberculosis (Chapter 6). Both cause chronic meningitis 
and occur predominantly in patients with CD4 counts <100/cm3 although TB meningitis 
(TBM) may also occur at higher CD4 levels. Acute forms of meningitis also occur but 
these are much less common; the main acute forms are acute bacterial (ABM) secondary to 
pneumococcus and viral meningitis. Cryptococcal meningitis (CM) is now the most common 
type of meningitis in many parts of Africa and after TB it is the leading cause of death in AIDS 
in parts of Africa, accounting for up to a quarter of all HIV related deaths there (Fig. 8.1). 
TBM is also common and has been shown at post-mortem in West Africa to be present in 
>10% of AIDS patients (Fig. 8.2). 
Clinically, CM and TBM may be indistinguishable from each other, although the onset of 
headache coupled with fever, nausea and vomiting evolving during the preceding week or two 
is more suggestive of CM. Definite signs of meningism are typically absent in CM in up to 
75% of patients. Raised intracranial pressure with papilloedema is more common in CM but 
occurs in both types of meningitis.
Laboratory investigations can help to distinguish the different types of meningitis. In both 
types of meningitis the CSF shows an elevation in cells (mainly mononuclear) and protein 
but CSF can also be normal in 10-20% of patients. Distinguishing features in the CSF in CM 
are the presence of encapsulated yeast cells on India ink (60-80 %) and cryptococcal antigen 
(95%) and in TBM, AFB (<5% routine ZN staining). The percentage of positive AFB in 
CSF in TBM can be significantly improved (60%) by increasing the volume of CSF to 20 
mls, centrifuging the sample and by microscopy for 20 minutes. The presence of cryptococcal 
antigenaemia may be detected in the blood during the 2-3 weeks preceding the onset of CM 
in some patients allowing for the possibility of earlier treatment. CT of the brain is usually 
not helpful but may show more basal meningeal enhancement in TBM and occasionally the 
presence of a tuberculoma. Supporting evidence for TBM includes the presence of concurrent 
systemic TB, (chest radiograph 40%) or failure to improve after 1-2 weeks of treatment for CM. 
Treatment of either or both CM or TBM is started immediately for suspected or confirmed 
infection as outlined in Table 8.2. 
Pathology Histopathology Microscopy
Meningitis & micro abscess Encapsulated cryptococcal yeast cells
Figure 8.1 Brain & CSF in cryptococcal meningitis
CliniCal presentations
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FOCAL NEUROLOGICAL DISORDERS (FND)
Focal neurological disorders are among the most common neurological disorders in HIV disease. 
The main causes are Toxoplasma encephalitis (TE), tuberculoma and lymphoma. FNDs occur 
typically in patients with CD4 counts <100 cells/cm3 but can occur at higher CD4 counts. The 
main clinical presentations are hemiparesis, cranial nerve palsies and ataxia (50-60%), seizures, 
lethargy, confusion (40%) and coma. TE causing brain abscess is usually the most common 
cause of FND (Chapter 7), occurring in 5-15% of AIDS patients, although its frequency 
within Africa, will vary depending on the local prevalence of toxoplasmosis. Tuberculoma was 
reported to be the most common cause of focal brain lesions in HIV in one study area in 
South Africa. In TE there is usually a history of headache (60%) and fever (40-70%) over 
the preceding days or 1-2 weeks. Other indicators of TE include positive Toxoplasma serology 
and multiple ring-enhancing mass lesions on CT. A negative Toxoplasma serology makes the 
diagnosis of TE unlikely. 
The main differential diagnosis in TE includes tuberculoma and lymphoma. However 
tuberculoma and primary cerebral lymphoma (PCL) are much less common and both have 
a slower clinical course than TE. On CT, while both tuberculoma and lymphoma can appear 
to be similar to TE, (Figs. 8.3-5) they may differ in their site and distribution in the brain 
(Chapter 7). Other less common causes of FND in HIV to be considered include stroke, 
occasionally syphilis and progressive multifocal encephalopathy (PML). 
The choice of treatment in the management FNDs is based mostly on clinical suspicion and 
likely cause and the results of available investigations including a CT scan of the head (Table 
8.2). Treatment is started immediately with high dose trimethoprim-sulfamethoxazole in those 
patients with suspected TE (Table 8.2). Clinical improvement is expected by day 3 in around 
50% and by day 14 in 90% and if resources allow a follow up CT confirming improvement is 
helpful. TB treatment is indicated from the outset in all those suspected TB cases particularly if 
there is evidence of concurrent disseminated TB (e.g. AFB in sputum/typical chest radiograph 
findings for tuberculosis). The diagnosis of CNS TB should also be considered, if there is a 
failure or a poor response to treatment for TE after 7-14 days. If there is any indication from 
the start of either CM or ABM, then appropriate antimicrobials should be added from the start 
of treatment. 
MRI T1 (enhanced) Histopathology Microscopy
Tuberculoma & local  
meningeal enhancement
Rich focus & granuloma ZN stain AFB+++
Figure 8.2 Brain in CNS tuberculosis
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CONFUSION AND COMA
States of confusion, altered level of consciousness and coma are common clinical presentations 
particularly in the advanced stages of HIV disease in Africa. These states are mostly caused 
by the same opportunistic processes, usually infections that result in meningitis and FNDs 
but representing more advanced disease. Other causes of confusion and coma in HIV should 
also be considered, including metabolic disorders, organ failure particularly renal and cardiac, 
and side effects of ART medication, in particular efavirenz. If the cause is not known, then 
presumptive treatment should be started for the main OIs, CM, TE and ABM together until 
the precise diagnosis becomes clear (Chapters 6-7). If there is clinical evidence of TB, then TB 
treatment should also be added (Table 8.2).
STROKE
Stroke typically occurs during the otherwise asymptomatic phase of HIV infection when CD4 
counts are 200-500 cells/cm3. An association between stroke and the persistent generalized 
lymphadenopathy (PGL) stage of HIV has been shown in South Africa. The accumulated 
lifetime prevalence of stroke in HIV disease is <1%. Stroke can be difficult to diagnose 
clinically, mainly because the presentation is very similar to the non vascular causes of focal 
brain lesions in HIV infection. The clinical diagnosis of stroke is suggested by its acute onset, 
non progressive course and better clinical outcome. A CT scan of the brain may be necessary to 
MRI T1 (enhanced) Histopathology Microscopy
Ring enhancing abscess Inflammation (non granulomatous) ZN stain AFB+++
Figure 8.3 Brain in tuberculoma
Abscess Periventricular TE Haemorrhage necrosis (TE) Tachyzoites
Figure 8.4 Brain in toxoplasmosis
CT MRI T1 Pathology Histopathology
Confusion and Coma
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confirm the correct diagnosis. The majority of strokes are ischaemic and occur in the anterior 
circulation. Mechanisms include vasculitis, coagulopathies, meningitis and emboli secondary 
to cardiac disease. Investigations and management are the same as for any stroke patient and 
should include a serology test for syphilis.
SEIZURES
New onset seizures occur in up to 5-9% of HIV infected persons at some stage throughout their 
long illness. Seizures occur most commonly during the later stages of HIV infection mostly 
as a complication of focal brain lesions secondary to opportunistic processes, in particular 
toxoplasmosis and tuberculoma. However, they may also occur at higher CD4 levels during the 
asymptomatic stage of HIV infection without any obvious underlying focal cause when their 
aetiology is related mostly to vasculitis. The seizures, although focal in origin are secondary 
generalized tonic-clonic in type. Management is directed at investigating and treating the 
suspected cause and suppressing the seizures (Table 8.2). 
Table 8.2 Treatment based on presenting neurological disorder & likely cause
Neurological Disorder Opportunistic infection Treatment Regime When to start
FND toxoplasmosis (TE) TMP-SMX# immediate
Meningitis cryptococcus (CM) fluconazole/
amphotericin B
immediate
Coma toxoplasmosis  
cryptococcus
TMP-SMX & fluconazole/ 
amphotericin B
immediate
Meningitis or  
FND or Coma
tuberculosis* isoniazid 
pyrazinamide
rifampicin
ethambutol & steroids 
immediate/or
added@ 2/52** 
# trimethoprim/sulphamethoxazole
* TB treatment is started or added if chest radiograph or other findings indicate TB 
** if there is treatment failure after 2/52 for either TE or CM 
PCL Infarction & haemorrhage Atypical lymphocytes
Figure 8.5 Brain in lymphoma
MRI T1 (enhanced) Pathology Histopathology
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PROGRESSIVE MULTIFOCAL LEUCOENCEPHALOPATHY (PML)
PML is caused by the reactivation of a latent virus (JC virus) which is carried by most healthy 
people. It appears to be uncommon in AIDS in Africa (<1%). PML occurs in advancing 
states of immunosuppression when the CD4 count is <50/cm3 but can occur in patients 
with higher CD4 counts <200 cm3. The clinical presentation is one of a devastatingly severe 
progressive neurological disorder occurring over weeks and months. It is characterized by motor 
dysfunction (hemiparesis, quadriparesis), ataxia, seizures and cognitive changes (60-70%) 
and aphasia, visual problems and cranial nerve palsies (30-40%). CSF examination is usually 
normal. Neuroimaging may show hypodense disease in the white matter brain and cerebellum 
(15%). The diagnosis is confirmed by brain biopsy showing the typical JC inclusions in the 
oligodendrocytes (Fig 8.6). There is no effective treatment for PML but all suspected patients 
should start ART with some showing stabilization or improvement.  
Key points
 · major neurological disorders occur in >20% of HIV infected patients 
 · neurological infections are the leading cause of death in AIDS after systemic TB
 · main presentations are meningitis, focal neurological disorder and coma
 · main causes are cryptococcal meningitis, toxoplasmosis & tuberculosis  
 · management is frequently presumptive based on likely cause
VARICELLA-ZOSTER
The reactivation of latent varicella-zoster virus infection results in herpes zoster (HZ) or shingles. 
Primary infection causes chicken pox. The frequency of HZ is increased in HIV infection and 
characteristic residual scarring from previous zoster infection is present in 5-10% of AIDS 
patients in Africa. HZ occurs mostly during the otherwise asymptomatic stage of HIV infection 
(CD4 200-500 cells/cm3). Acute HZ in HIV is recognizable clinically, by its local aggressiveness, 
involvement of multiple adjacent dermatomes and its tendency to occur at atypical sites including 
chest, face, back, neck, arms and leg (Fig. 8.7).
It also has a higher rate of complications including varicella dissemination (Fig. 8.7), myelitis, 
encephalitis and cranial nerve palsies. Post herpetic neuralgia is also more common. 
PML in cerebellum PML Infected dendrocytes & astrocytes
Figure 8.6 Brain in PML
MRI CT Pathology Histopathology
progressive multifoCal leuCoenCephalopathy (pml)
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Treatment for HZ involves both systemic and local measures. Aciclovir 800 mg/iv/po/tds for 
5-7 days is recommended in the acute phase. The local application of a 1% gentian violet 
solution at the vesicular stage helps to prevent secondary infection and the application of a 1% 
phenol solution with calamine helps with local pain and itching. Analgesics may be required in 
addition to carbamazepine 200-400 mg/po/bid for post herpetic neuralgia. Survival in Africa 
in the pre ART era from onset was on average 3-4 years. 
CYTOMEGALOVIRUS (CMV)
CMV is a common virus affecting most persons in Africa. Primary infection is mostly acquired 
during early childhood, when it is either asymptomatic or associated with a mild febrile illness 
with a rash. Reactivation of CMV in HIV disease typically occurs during the later stages 
of infection when CD4 counts are <50 cells/cm3. CMV retinitis affects around 1-1.5% of 
AIDS patients in Africa and although this figure may vary slightly with location, it is lower 
than that reported from high income countries. CMV retinopathy presents clinically with a 
characteristic painless haemorrhagic chorioretinitis, with loss of visual acuity first affecting 
one eye and later the other eye. Painless loss of vision is the main presenting complaint and 
blindness is inevitable unless treated. Fundoscopy appearance has been described as like that 
of a bush fire or pizza like and once seen is not subsequently easily missed (Fig.8.8). The main 
differential diagnosis is direct HIV retinopathy which is characterized by cotton wool spots and 
occasional haemorrhages which is seen in about 10% of patients with advanced disease (Fig. 
8.9). However direct HIV retinopathy characteristically does not result in loss of vision. Other 
late but uncommon neurological presentations of CMV disease are encephalitis (Fig. 8.10) and 
infrequently a flaccid paraplegia secondary to lumbar radiculopathy. 
Disseminated varicella CNS varicella, thrombosis & infiltrates
Figure 8.7 Varicella-Zoster
Acute HZ Scarring post HZ Keloid post HZ
Skin Histopathology
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The diagnosis of CMV in HIV is mainly clinical and treatment is with ganciclovir 5mg/kg/bd 
for 14 days and/or forscarnet. Thrombocytopenia is a side effect of treatment and blood counts 
should be checked regularly. 
Key points
 · HZ affects 5-10% of patients mostly during the asymptomatic stage of HIV infection
 · HZ typically affects multiple adjacent dermatomes at atypical sites 
 · treatment is with local measures and aciclovir
 · CMV infection results in characteristic retinopathy and blindness in about 1% of AIDS patients 
 · HIV retinopathy occurs in about10% of AIDS patients 
 · CMV may infrequently (<1%) cause a lumbar sacral radiculopathy resulting in paraplegia 
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS)
The immune reconstitution inflammatory syndrome is a complication of ART where the 
immune system directs an increased inflammatory response at an opportunistic infection. This 
results in paradoxical worsening in the patient’s condition despite adequate treatment of the 
OI, hence the term paradoxical IRIS. It may also unmask other hidden OIs. IRIS may occur 
with several of the main neurological CNS OIs. These include CM, TB, TE, CMV and PML. 
It can occur in 20-30% of treated CNS OIs, usually occurring within the first weeks of starting 
TB treatment or sometimes months, in the case of CM treatment. Concurrent CNS TB IRIS 
may arise as a complication in treated pulmonary TB. Management of patients suspected of 
Figure 8.8 Retinopathy CMV Figure 8.9 Retinopathy HIV
Haemorrhages & exudates Cotton wool exudates
CMV ventriculitis CMV retinitis Owl eye inclusion bodies
Figure 8.10 Brain & retina in CMV
Pathology Histopathology Microscopy
immune reConstitution inflammatory syndrome (iris)
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having IRIS frequently involves hospitalization and excluding other possible causes. Treatment 
with steroids for up to 2-3 months is frequently recommended, particularly in the case of TBM 
once other OIs have been excluded. The mortality rate in patients with IRIS is high, >30% in 
the case of treated CM and >10% in case of treated TB. 
DIRECT HIV INFECTION
The HIV virus enters the CNS within days of primary infection and neurological disorders 
related to direct HIV infection have been observed occurring during all stages of the disease 
including early infection. Primary HIV infection of the nervous system is usually asymptomatic, 
but a viral meningoencephalitic illness can occur at this early stage. Also isolated self limiting 
aseptic meningitis can occur during the long period of asymptomatic HIV infection. The 
main clinically recognizable neurological disorders arising from direct HIV infection are HIV-
associated neurocognitive dysfunction (HAND), HIV-associated dementia (HAD), peripheral 
neuropathies, vacuolar myelopathy and HIV retinopathy. These are found mostly during the 
later symptomatic stages of HIV disease when the CD4 counts are low.
HIV-ASSOCIATED DEMENTIA (HAD)
Chronic HIV infection of the brain leads to cognitive dysfunction in over 50% of patients 
(Fig 8.11). This is termed HIV associated neurocognitive dysfunction (HAND) and can range 
from mild impairment in functional performance to its severest form a frank dementia called 
HIV-associated dementia (HAD). HAD is reported to occur in up to a third of patients in high 
income countries but has virtually disappeared there because of the widespread use of ART. 
Varying frequencies of HAD have been reported from Africa with generally lower reported rates 
there (10-20%) being attributed to under diagnosis and poor survival outcomes. However, a 
recent study from South Africa, using appropriate investigations reported HAD in over one 
third of HIV patients. HAD occurs increasingly with advancing levels of immunosuppression 
and is most commonly seen in association with CD4 counts <100/cm3. Factors associated 
with increased frequency of HAD include increasing age, treated CNS OIs and a history of 
substance abuse. 
The defining early clinical characteristic of HAND/HAD is psychomotor retardation or a 
slowing down of both mental and motor activities. Established HAD presents typically with 
abnormalities in multiple domains including cognition, memory and motor function. The 
dementia ranges from early features such as mild apathy, disinterest and loss of attention with a 
general slowing of both mental and motor functions. In the later stages, there is a frank global 
loss of cognitive function with immobility and incontinence in end stage disease. Frequently 
associated neurological findings are frontal lobe release signs (FLRSs) (Fig. 8.12), signs of 
vacuolar myelopathy and distal sensory neuropathy (DSN). However, many patients in Africa 
die of opportunistic processes, mostly infections before reaching these later stages. 
The clinical diagnosis of HAD may require a confirmatory CT of the brain to demonstrate the 
characteristic changes including cerebral atrophy and to exclude alternative causes, in particular 
opportunistic processes. In HIV encephalitis MRI of the brain shows increased signal in white 
matter (Fig. 8.11). Histopathology includes characteristic multi-nucleated giant cells and the 
presence of P-24 antigen on special staining. Management of HAD involves early diagnosis, 
treating any reversible cause and using ART treatment. The rate of HAD in Africa has been 
shown to significantly decrease after 6 months of ART treatment.
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Frontal lobe release signs (FLRSs)
The frequency of some primitive reflexes or FLRSs is increased in HIV disease and increases 
with advancing stages of HIV. The snout reflex (70%) and the palmomental reflex (50%) are 
found in the majority of patients with advanced HIV disease and in particular in association 
with HAD (90%) (Fig. 8.12). Their presence in a mainly younger age group helps to provide 
useful additional clinical evidence to help establish a diagnosis of HIV infection. It is however 
important to note that a snout or palmomental reflex may be present in association with other 
neurological disorders and are found occasionally in otherwise healthy persons. However, in 
healthy persons they are usually less pronounced and tire easily on repeated testing, this is 
in contrast to their presence in HIV disease when they are more pronounced and persist on 
repeated testing.
The Snout reflex is elicited by pressing or tapping lightly on the patient’s closed lips. In positive 
cases this causes a puckering or protrusion of the lips and occasionally the chin giving the 
appearance of a snout. (A slight or brief contraction of the lips may not be significant).
Increased signal in white matter Multi-nucleated giant cells p24 antigen
Figure 8.11 Brain in direct HIV infection
MRI T2 Histopathology brain Special stain for HIV
Snout reflex
Figure 8.12 Frontal lobe release signs
Control A positive snout reflex
hiv-assoCiated dementia (had)
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The Palmomental reflex is elicited by stroking in a distal direction the palm of the hand at the 
base of the thenar eminence. In positive cases it causes a brief contraction of the ipsilateral chin 
muscles and occasionally the corner of the mouth. 
Key points
 · HAND/HAD results from direct infection of the brain with HIV virus 
 · early HAND/HAD is characterised by slowing down of both mental & motor function
 · late HAD is characterised by impairment/loss of cognitive function & memory
 · affects >1/3 of patients in advanced HIV disease in Africa
 · FLRSs are found in the majority of patients with AIDS & HAND/HAD 
 · HAD improves significantly 6 months after the start of ART
SPINAL CORD
The spinal cord is frequently involved in HIV disease. The causes vary with the stage of HIV 
infection and similar to the brain, are mostly related to either opportunistic processes (OPs) or 
to direct infection of cord with the HIV virus itself. Spinal cord disease presents clinically as 
paraparesis occurring typically in an otherwise asymptomatic person. The main opportunistic 
infections causing paraparesis are tuberculosis, herpes zoster, herpes simplex, CMV, syphilis and 
occasionally co-infection with HTLV-1 in endemic areas (Chapter 10). The main opportunistic 
neoplasm is lymphoma. 
Direct infection of the spinal cord with HIV may result in vacuolar myelopathy (VM) of the 
cord which gives rise to clinical signs in about a fifth of HIV patients, particularly in those 
with advanced HIV disease. The main signs of VM are isolated brisk reflexes in the legs with 
extensor plantar responses, typically without any associated loss of power. Frequently, these 
upper motor neurone signs overlap with distal sensory neuropathy and then the ankle reflexes 
are absent. In <1% of patients, mainly in those with advanced HIV disease VM results in a 
spastic paraparesis with immobility and incontinence. Investigations of spinal cord disease are 
directed at diagnosing and treating the underlying cause. 
The palmomental reflex
Figure 8.12 Frontal lobe release signs
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Key points
 · main spinal cord disorder in HIV is paraparesis
 · paraparesis is caused mainly by opportunistic processes and infrequently by direct HIV infection
 · main causes are TB, herpes zoster & simplex, syphilis, HTLV1 & lymphoma  
 · direct HIV infection of cord results in vacuolar myelopathy in >20% of patients
 · signs of VM are isolated brisk knee reflexes, up going toes & rarely paraparesis
PERIPHERAL NEUROPATHIES
HIV frequently affects peripheral nerves. The main mechanisms are direct HIV infection, 
ART associated neuropathy and inflammation/autoimmunity (Chapter 11). The use of drug 
treatment in co-infections in HIV is also a cause of neuropathy e.g. isoniazid in TB treatment. 
The most common neuropathy in HIV disease is distal sensory neuropathy (DSN).
Distal sensory neuropathy (DSN)
DSN is the main HIV related neuropathy. It arises as a result of direct HIV infection of the 
dorsal root ganglion, thereby affecting peripheral nerves mostly on the sensory side. DSN 
affects about one quarter to one third of HIV patients, occurring mainly but not exclusively 
in those with advanced disease (Fig. 8.13). It can occur in association with CD4 >200/cm3. 
The symptoms of DSN include painful, hot, burning, numbness or paraesthesia in feet and 
stocking distribution, developing slowly bilaterally over weeks or more commonly months. 
Power is usually maintained but may be decreased infrequently around the ankle joint. The 
ankle and very occasionally the knee reflexes are absent or decreased and areflexia may be the 
only finding to indicate the presence of DSN. Sensation involving light touch is mostly intact 
but is perceived as painful or dysaesthetic or hyperaesthetic particularly on the soles of the 
feet and palms. Vibration and pinprick are usually normal but may be impaired distally in the 
feet in advanced DSN. The upper limbs are mostly unaffected but the palms may be painful 
to touch. 
Perineural inflammation
Figure 8.13 Peripheral nerves in HIV
Histopathology
peripheral neuropathies
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The mainstay of management is to start ART as early as possible. Symptomatic relief from pain 
may be obtained using simple analgesics and/or amitriptyline. The use of carbamazepine or 
gabapentin either alone or in combination with low dose tricyclics is helpful in some patients. 
However, opiates may be necessary in severe cases. 
ART associated neuropathy
DSN may arise as an adverse effect of antiretroviral therapy. In particular this occurs with 
the use of the nucleoside reverse transcriptase inhibitors, stavudine (d4T). Other ART drugs 
associated with peripheral neuropathy include didanosine (ddl), lamivudine (3TC) and 
zalcitibine (ddC). The incidence of DSN in HIV has been shown to increase with the use of 
d4T and in particular the higher dosage (40 mg) and the duration of its use. ART neuropathy 
may affect up to 20% of patients who have been on dT4 for 6 months or more and increases 
the overall rate of DSN in HIV to >40%. The symptoms and signs are very similar to HIV 
related DSN, although sensory signs may be more marked in ART associated neuropathy. 
However, the two cannot easily be distinguished from each other clinically and hence they may 
both be termed DSN. 
In Sub-Saharan Africa, DSN remains one of the main limiting side effects of first line ARTs. 
Management involves either reducing the standard dose of d4T from 40 to 30 mg (as 
recommended by WHO) or stopping and replacing d4T or the likely causal ART drug. Two 
thirds of patients may improve if switched to a non d4T regime. Many countries in Africa are 
now moving away from the use of stavudine based ART in order to reduce the problem of 
ART associated DSN. Other risk factors increasing the risk of DSN include a history of prior 
or active antituberculous therapy, older age, alcohol use and malnutrition. Care should be 
taken to ensure that pyridoxine 20 mg/po/daily has been prescribed in those patients taking 
isoniazid, and thiamine 100 mg/po/daily should be given in suspected cases of B-1 vitamin 
deficiency. Symptomatic management is otherwise the same as in HIV disease.
Key points
 · HIV affects peripheral nerves by direct infection, ARTs and autoimmunity
 · DSN secondary to direct HIV occurs in about 1/4 of patients & responds well to ART
 · ART usage for >6 months with d4T, is associated with development of DSN
 · majority of ART related neuropathies respond to stopping the offending drug
 · analgesics may be necessary in both types of neuropathies
INFLAMMATION/AUTOIMMUNE
Bell’s palsy, Guillain-Barre syndrome (GBS) and polymyositis occur mostly during previously 
asymptomatic HIV disease. With the exception of Bell’s palsy these are uncommon illnesses 
but frequently prove to be the first indication of underlying HIV infection. 
BELL’S PALSY
Bell’s palsy is the most frequent presentation of mononeuritis in HIV in Africa. On screening 
for HIV in some high endemic areas in Africa, over 50% of patients presenting with idiopathic 
Bell’s palsy early on in the epidemic tested positive for HIV. Therefore, an isolated Bell’s 
palsy is now an indication for HIV screening. Bell’s palsy typically occurs during otherwise 
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asymptomatic HIV infection. A unilateral facial weakness develops over 24 hours and the 
clinical course is similar to that in non HIV associated Bell’s palsy. However facial weakness 
may be bilateral in HIV infection (Fig. 8.14). The treatment and management is the same as 
for non HIV related Bells palsy (Chapter 12).  Other cranial and mononeuropathies in HIV 
infection occur either individually or in combination (mononeuritis multiplex); but these are 
generally much less common than Bell’s palsy. 
GUILLAIN-BARRE SYNDROME (GBS)
GBS or acute inflammatory demyelinating polyneuropathy (AIDP) is an uncommon form of 
autoimmune acute polyneuropathy and when it occurs in HIV, its onset is associated with a 
relatively intact immunity or an elevated CD4 count. Clinically, it is indistinguishable from 
classical or the non HIV associated GBS, apart from the increased number of lymphocytes 
found in the CSF in HIV infection. The clinical course and outcome are also similar (Chapter 
11). Rarely, a more chronic form of polyneuritis occurs, this is called chronic inflammatory 
demyelinating polyneuropathy (CIDP). 
MYOPATHY
There are two main types of muscle disease in HIV disease; myopathy and polymyositis (Fig 
8.15). The most common type is myopathy which is characterised by painless, severe, generalised 
muscle wasting and weakness which occurs in association with systemic illness in advanced HIV 
infection. The severe wasting, myopathy (and diarrhoea) seen first in AIDS in East Africa gave 
rise to the name “Slim Disease”. The second type of muscle disease, polymyositis is uncommon 
and occurs at an earlier stage, typically asymptomatic HIV infection. It is characterized by a 
painful marked proximal muscle weakness affecting the limbs and trunk. It is considered to be 
an autoimmune inflammatory disorder and responds well to steroids, although TB needs to be 
excluded before starting steroid treatment. Myopathies may also occur as a side effect of some 
ART medications. 
Figure 8.14 Bell’s palsy in HIV (bilateral)
Failure to smile Failure to close eyes fully
guillain-barre syndrome (gbs)
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Key points
 · Bell’s palsy, Guillain-Barre syndrome & polymyositis occur during asymptomatic HIV
 · Bell’s palsy is the most frequent mononeuropathy in HIV disease
 · GBS is the same as in non HIV apart from increased lymphocytes in CSF
 · myopathy is common in the later stages of HIV infection
 · polymyositis is uncommon but responds well to steroids
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CHAPTER 9
COMA AND TRANSIENT LOSS OF CONSCIOUSNESS
Loss or alteration in consciousness is a very common clinical disorder. This can be transient 
lasting seconds or minutes as occurs in syncope and seizures or more prolonged as occurs in 
coma. Coma is by definition a state of impaired consciousness during which the patient is unrousable 
by external stimuli. In states of coma the patient remains in a sleep like state with no purposeful 
movements or response to any external stimuli. These can be measured by the Glasgow Coma 
Scale which defines coma as a GCS ≤ 8/15. Coma can be caused by disorders that affect either 
a part of the brain focally or the whole brain diffusely (Figs. 9.1-4). The causes of coma are 
generally classified as intracranial or extracranial and are outlined in Table 9.1. Episodes of 
transient loss of consciousness are by definition intermittent and usually sudden events from 
which the patient recovers fully. These arise either from the disorders of the cardiovascular 
system with an acute reduction of blood flow to the brain (syncope) or a disruption in brain 
electrical activity (seizure). The chapter outlines the main mechanisms, causes, investigations 
and management of coma and syncope. The student should aim to be familiar with these and 
be able to investigate and manage a patient presenting with loss of consciousness. 
Pathophysiology
Consciousness is a person’s awareness of themselves and their surroundings. Normal 
consciousness is maintained by an intact reticular activating system in the brain stem and its 
central connections to the thalamus and cerebral hemispheres. The reticular activating system 
keeps us awake and alert during the waking hours. Disorders that physically affect these areas 
can lead to disordered arousal, awareness and to altered states of consciousness. A focal brain 
lesion occurring below the tentorium (Figs.9.1 & 2) interfering with the reticular activating 
system can result in coma whereas a focal lesion occurring above the tentorium in one cerebral 
hemisphere results in coma only if the contralateral side of the brain is simultaneously involved 
or compressed (Fig.9.3) Diffuse lesions which affect the function of the brain as a whole 
including the reticular activating system can result in coma (Fig.9.4). 
ASSESSMENT
Acute
Coma is an acute life threatening condition and evaluation needs to be quick, comprehensive and 
may involve starting emergency management even before the cause is established. Emergency 
management starts with an immediate assessment of airway, breathing and circulation (ABC) 
and involves the following steps. Firstly check that the airway is clear without secretions and 
that no cyanosis is present. This is achieved by rapid visual inspection and checking the vital 
signs. Secondly ensure that breathing rate is satisfactory (rate >10-12/min), that there are 
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adequate breath sounds bilaterally on auscultation and that the oxygen saturation is >95%. 
If ventilation is inadequate or GCS is ≤8 then consider intubation and assisted ventilation. 
Thirdly check that the circulation is adequate by measuring pulse and BP. If the systolic blood 
pressure is <90 mm Hg then start immediate fluid resuscitation, and with inotropic support 
if BP remains persistently low despite adequate volume replacement. Fourthly insert an IV 
cannula and withdraw blood for laboratory studies. All comatose patients should have their 
blood glucose checked on arrival and treated immediately if hypoglycaemic (blood sugar <2.5 
mmols/l) or hyperglycaemic. Finally treat any other immediately reversible cause without 
delay e.g. iv thiamine 100 mg in patients with history of alcoholism and naloxone 0.4-2 mg in 
patients with drug habituation (Table 9.4). If the patient is stable, then the clinical assessment 
can start.
Key points
 · airway: make sure it is clear
 · breathing: count RR & listen to the lungs, if respiration inadequate give O2 & ventilate 
 · circulation: check pulse/BP and treat if systolic <90 mm Hg
 · glucose: check urgently and treat any reversible cause immediately
tentorium
supratentorial
mass lesion
brain stem
cerebral
hemisphere
Sites that produce loss of consciousness Encephalopathy diuse
Figure 9.3 Sites that produce loss of consciousness Figure 9.4 Encephalopathy diffuse
The reticular activating system
infratentorial
mass lesion
Sites that produce loss of consciousness
Figure 9.1 The reticular activating system Figure 9.2 Sites that produce loss of consciousness
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Clinical assessment
This involves history, general examination, level of consciousness and neurological examination.
The history
The history is the most important part of the assessment as it frequently points to the underlying 
cause of coma. The diagnosis may already be obvious from the circumstances surrounding the 
coma e.g. head injury in a road traffic accident (RTA), stroke in hypertension or hyperglycaemia 
or hypoglycaemia in diabetes or a seizure in epilepsy. If the cause is not obvious then it is 
necessary to obtain a history from the patient’s family members, friends or colleagues. The 
history should include information and details concerning the immediate circumstances and 
the possible cause of the coma. It should also include the patient’s previous medical history, 
medications, allergies, possible toxins and details of social and family history including recent 
travel or anything relevant. In particular, ask if there was a recent preceding illness e.g. fever, 
headache, if the onset was sudden or gradual and check specifically for a history of trauma 
or fall, a history of epilepsy, alcohol or drugs. The main causes of coma are outlined below 
(Table 9.1).
Key points
 · loss of consciousness is a medical emergency
 · assessment needs to be brief and focused
 · history is the most important part of the initial 
assessment 
 · cause may be obvious & reversible causes 
need to be considered 
 · main causes are head injuries, 
encephalopathies, infections & strokes
Table 9.1 Main disorders causing coma
Site/aetiology  Disorder
Intracranial
Focal
stroke
infections
trauma
tumours
Diffuse
infections
seizures
trauma
infarct, ICH, SAH
brain abscess 
haematoma (ICH, EDH, SDH)
primary or secondary
HIV, meningitis, malaria, encephalitis
post ictal/status epilepticus
traumatic brain injury
Extracranial
hypoxia
metabolic/toxic
hypertension
cardiac, respiratory, renal, shock, anaemia
hyper-hypoglycaemia, organ failure, 
hyponatraemia overdose, opiates, alcohol
encephalopathy, eclampsia
Easy way to remember the 
causes of coma
A = anoxia/apoplexy
E =  epilepsy
I = injury/infection
O = opiates
U = uraemia
assessment
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The general examination
This involves confirming the vital signs and checking for evidence of obvious injury or major 
underlying illness. Signs of head injury/basal skull fracture include lacerations or bruising to the 
head, around the eyes, behind the ear (Battle’s sign) or CSF leak from the nose or ears (Chapter 
19). Palpation of the head/neck may show signs of a fracture and swelling. Signs pointing to 
an underlying illness include paresis, hypertension, tongue biting, ketoacidosis, jaundice and 
evidence of infection including fever, meningitis, and pneumonia or discharging ear.
The level of consciousness (LOC)
This is the most important part of the assessment of the unconscious patient. Altered states of 
consciousness range from confusion and delirium to stupor and coma (appendix 1). Confusion is 
characterized by the patient being fully conscious but with impaired attention, concentration 
and orientation. Confusion can be tested at the bedside by checking if the patient is fully 
orientated in time, person and place with a score of 10/10 being fully orientated (Table 9.2). 
Table 9.2 Testing for orientation 10/10*
Time Person Place
time
day
month
year
name
age
year of birth
hospital
town/district
country
*score one for each correct answer
In a state of delirium, the patient although fully conscious is confused and restless with 
hallucinations. In a state of stupor, the patient is in coma but is rousable after intense stimulation; 
this is in contrast to coma where the patient is unrousable. In general the use of these terms has 
been replaced by the Glasgow Coma Scale (GCS) (Table 9.3). 
Glasgow coma scale
The depth of coma can be measured by the GCS. This measures eye opening, best motor and 
verbal response, and is a reliable method for measuring and monitoring level of consciousness. 
It should be carried out and if necessary repeated on every comatose patient. When using 
the GCS, look carefully at the patient’s face while assessing eye opening, and then check on 
the patient’s ability to follow simple motor commands and listen to the patient’s speech for 
content and orientation. If the patient is not responding to voice then test eye opening and 
limb movement response to deep pain by applying pressure to sternum or supra orbital ridge 
or nail beds. Record best eye opening, motor and verbal response as E4, M6 and V5. Patients 
are considered comatose if the GCS ≤ 8/15. 
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Table 9.3 Glasgow Coma Scale
Best response Score
Eye opening (E) spontaneously
to speech
to pain
nil
4
3
2
1
Motor response (M) obeys commands
localizes stimulus
flexes withdrawal
flexes weak
extension
nil
6
5
4
3
2
1
Best verbal (V) oriented fully
confused
inappropriate
incomprehensible (sounds only)
nil
5
4
3
2
1
Maximum score 15
The AVPU Method
A more simplified bedside assessment of the level of consciousness is the AVPU method (yes/
no response). Its advantages are that it assesses the main levels of consciousness quickly and is 
easy and quick to use and communicate. 
AVPU method
A: is the patient alert
V: is the patient responsive to voice
P: is the patient responsive to pain
U: is the patient unresponsive
Key points
 · check the vital signs
 · examine for signs of head injury or a systemic disorder
 · assess the level of consciousness 
 · level of consciousness is the most important part of the assessment
THE NEUROLOGICAL ASSESSMENT
This frequently gives the clues towards establishing the aetiology of the coma. The neurological 
assessment in coma is necessarily shortened concentrating on the possible neurological causes 
of coma e.g. stroke, meningitis and the presence of any localizing signs. Note the level of 
consciousness and any obvious neurological abnormalities such as seizures, the pattern of 
breathing and the position of the eyes and posture of the trunk and limbs. In particular, record 
pupil size, equality, response to light and eye position or movements. Normal pupils are 3-4 
mm in diameter and respond briskly to light. Abnormalities include fixed dilated pupil (s), >7 
mm in size and non reactive to light. In states of coma the most common cause of a unilateral 
fixed pupil is herniation (Table 9.4.) and of bilateral fixed pupils is brain death. The presence 
or absence of the corneal reflexes should be noted and fundi checked for papilloedema. If there 
the neurologiCal assessment
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is no contra indication to moving the neck such as spinal or head injury neck stiffness should 
be tested although its absence is unreliable in coma. 
In the comatose patient eye position and movements are observed and examined at rest and 
during head and neck movement. Eye movements may be checked by stimulating the vestibular 
system. The details concerning the methods of stimulation (Doll’s eyes and caloric tests), are 
outlined in appendix 1. Note the presence of any cranial nerve palsies, the position of the 
limbs and any signs of limb paralysis. Motor response to pain can be checked by noting limb 
movement in response to a painful stimulus e.g. deep Achilles tendon pressure or knuckling 
the sternum. A flexor response in the arms and concurrent extension of the legs indicates a 
cortical site of origin (decorticate) whereas an extensor response at the elbow coupled with 
internal arm rotation and extension of the legs (decerebrate) indicates an upper brain stem 
injury. Unilateral or asymmetrical posturing indicates a contralateral focal brain lesion/injury. 
Tone and reflexes in the limbs are then examined in the routine manner. Main localizing 
neurological features in coma are summarized below in Table 9.4.
Table 9.4 Main localizing neurological features & causes in coma
Neurology finding Localization Main causes 
Respiration pattern
Cheyne Stokes
(breathing progressively deeper 
and then shallower in cycles)
brain stem herniation/
encephalopathy 
ICP, stroke
Eye position 
eyes looking to one side  
(conjugate deviation)
unilateral lesion stroke, head injury & any focal lesion
Pupils
fixed & dilated pupils 
 
a fixed & dilated pupil 
 
 
pin point pupils
brain
herniation of medial temporal 
lobe through tentorium 
compressing 3rd CN
pontine lesion 
anoxia, trauma, brain death
unilateral mass lesion above tentorium 
due to any cause
 
stroke, organophosphorous poisoning,  
opiate overdose
Meningism meningeal inflammation infections & haemorrhage 
Limb position
hemiparetic/asymmetrical
arms flexed, legs extended
all 4 limbs hyper extended  
& extensor posturing to pain
unilateral lesion
decorticate posturing
decerebrate posturing
stroke & any focal lesion 
cortical damage
brain, brain stem damage 
Limb examination
hypertonia & hyperreflexia & 
extensor plantars
bilateral extensor plantars 
brain/cord
non localizing
any diffuse or focal lesion
coma any cause
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Key points
 · assessment of coma needs to be fast & focused 
 · history usually reveals the cause of coma 
 · general examination reveals the level of coma 
 · neurological examination may reveal the site
 · don’t forget fundoscopy
DIFFERENTIAL DIAGNOSIS
The differential diagnosis for persistent coma involves all causes of unresponsiveness including 
psychiatric and neurological disorders. These include unresponsiveness of psychogenic origin 
locked-in syndrome, persistent vegetative state and brain death (appendix 1). 
Psychogenic
This can be a manifestation of severe schizophrenia (catatonia), hysteria (conversion disorder) 
and malingering. These are all diagnoses of exclusion and should only be considered when 
other causes have been excluded and there is strong evidence in their favour. Neurological 
exam in these patients is invariably normal and most will exhibit resistance to eye opening and 
tensing or withdrawal to a painful stimulus. Investigations including caloric tests and EEGs if 
performed are normal. A return to full consciousness is usually the rule.
Locked-in syndrome
The term locked-in is a rare syndrome which describes patients who though fully conscious 
are quadriplegic and unable to speak. The main causes are stroke and trauma affecting the 
brain stem at the level of the pons/midbrain. The patients are usually able to see and hear 
but are unable to move or communicate apart from moving their eyes/eye lids. Only some 
of voluntary eye movements may be preserved e.g. looking upwards. This still allows for non 
verbal communication. The diagnosis can be confirmed by saying/indicating with your own 
eye movements to the patient to “open your eyes”, “look up”, “down” and “towards the tip of 
your nose”. Using this method a way can then be established to communicate with the patient. 
If in doubt ask a senior colleague to examine and check the patient. EEG is normal. Survival 
for months and years is the rule. 
Persistent vegetative state
Patient with this disorder are awake but not aware. Their eyes open and close normally and they 
have a sleep-wake cycle because of an intact brain stem but they show no purposeful response 
to any external stimuli. The cause is usually cerebral hypoxia or ischaemia or occasionally a 
structural lesion. Recovery is uncommon.
Brain death
Brain death is the irreversible loss of all brain stem function. This is loss of consciousness, 
respiration, response to pain and loss of all brain stem reflexes (appendix 2). The patient should 
be unresponsive to any sensory input including pain and speech. The cause should be known, 
irreversible and sufficient to explain the death. Reversible causes of coma should be considered 
including CNS depressant drugs, metabolic disorders and hypothermia. If the patient is on 
assisted ventilation, the criteria for determining brain death are outlined in appendix 2. 
differential diagnosis
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INVESTIGATIONS
The main emergency investigations in patients presenting in coma are outlined below in Table 
9.5. A blood glucose should be checked immediately and glucose given intravenously if <2.5 
mmol/L. Screening for the presence of malaria parasites and checking of HIV status is routine 
practice in patients presenting in coma in Africa. When indicated bloods for other metabolic 
causes of coma should also be checked. A lumbar puncture is relatively contraindicated in states 
of coma. It is specifically contraindicated in states of undiagnosed deep coma (GCS≤8) until 
raised intracranial pressure and focal intracranial lesions have been excluded by fundoscopy 
and CT. Emergency X-rays are important in coma in particular in head injury. A skull X-ray 
may show a fracture and a CT a treatable cause of coma e.g. subdural haematoma. 
Table 9.5 Emergency investigations
Bloods blood sugar 
malaria parasite film
FBC
HIV
biochemistry (renal & LFTs)
Urine sugar & ketones
X-rays
  Skull/neck 
  Chest 
  CT head
may show fracture
may show pneumonia, PCP, TB
may show blood & fracture & structural lesion
MANAGEMENT
The emergency treatments of the main causes of coma are presented in Table 9.6. Medical and 
nursing care involves monitoring and regularly checking the vital signs, level of consciousness 
and pupils, usually every 15 minutes to four hourly depending on the clinical situation. It 
is important at this stage to avoid sedation and strong analgesics. General nursing care of 
eyes, mouth, bladder and bowels should be started early with special attention to avoiding 
pressure sores and prevention of deep vein thrombosis. The ongoing care of the comatose 
patient should ideally take place in an appropriate intensive care unit (ICU) setting, depending 
on the cause. The subsequent medical or surgical management will depend on the underlying 
cause. Consider intubation if GCS ≤ 8.
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Table 9.6 Emergency treatment of coma
Disorder Acute management
Stroke (ischaemic) aspirin 300 mg/po/stat
Infections
cerebral malaria
acute bacterial meningitis
cryptococcal meningitis
toxoplasmosis
sepsis
artemether* 24 mg/kg iv/im stat or
quinine 600 mg/iv over 4 hours
ceftriaxone 2 gm/iv infusion stat 
fluconazole 1200 mg/po/ng tube
co-trimoxazole 80/400mg/4 tablets stat/po/ng tube
ceftriaxone 2 gm/iv infusion stat
gentamycin 80 mg/im/stat
Hypoglycaemia 25-50 ml of 50% dextrose/iv/stat
or 
glucagon 1mg/im stat
Ketoacidosis soluble insulin 5 iu/iv & 5 iu/im stat & start hydration
Raised intracranial pressure mannitol 20%: 100-200 ml iv stat  
dexamethasone 16 mg/iv stat
Poisoning e.g. organophosphates atropine 10 mg/iv/stat & repeat every 15-30 mins
Respiratory depression
(secondary to suspected opiate overdose)
naloxone 04-2 mg iv every 2-3 mins to max of 10 mg
Wernicke’s encephalopathy thiamine 100 mg iv
Anaphylaxis adrenaline 05-1 ml of 1:1000/im/stat
or
adrenaline 05-1 ml of 1:10,000/iv/stat
* artemisinin drugs are the first line drugs recommended for use in cerebral malaria although quinine is mostly available
Prognosis
The underlying cause of the coma is the most important factor in determining outcome. Acute 
reversible causes have the best prognosis; these include acute infections, seizure disorders, drug 
overdose and treatable head injury. Patients with reversible causes may remain unconscious for 
long periods. However significant recovery is very unlikely in those comatose patients without a 
reversible cause who remain unconscious for more than 24 hours after admission. The outcome 
is poorest in those patients with anoxic, ischaemic and structural lesions. In these patients the 
persistent absence of corneal and oculovestibular reflexes and absence of movement to pain are 
bad prognostic signs with the chances of meaningful recovery set at <3%.
Key points
 · emergency treatment of the cause of coma should be started without delay 
 · patients with reversible causes can remain unconscious for long periods
 · patients comatose for >24 hours without a reversible cause have a poor prognosis
management
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TRANSIENT LOSS OF CONSCIOUSNESS
Transient loss of consciousness is a very common clinical disorder. The main causes are outlined 
below in Table 9.7. The most common type is vasovagal or simple faints which occur in all age 
groups. The main differential diagnosis for vasovagal syncope is an epileptic seizure (Table 9.8). 
Table 9.7 Common causes of transient loss of consciousness
vasovagal syncope pseudoseizure
cardiac syncope hypoglycaemia
postural syncope transient ischaemic attack (TIA)
epileptic seizure
Vasovagal Syncope (Faint)
Syncope is a sudden episodic loss of consciousness and postural tone resulting from an acute reduction 
of blood flow to the brain. Syncope of vasovagal origin is the most common form of transient 
loss of consciousness and can affect all age groups especially teenagers, young adults and also 
older persons. It is of cardiovascular origin. There are many contributory causes and syncope 
is often triggered by prolonged standing in crowded warm, indoor surroundings e.g. schools, 
churches, hospitals. Psychogenic factors, emotion, tiredness, fear, pain and sometimes even 
seeing blood, needles or medical procedures may precipitate the syncope or fainting. Rarely, it 
is provoked by micturition or coughing. 
During a typical faint, the person first describes feeling dizzy, hot and cold, sweaty; their vision 
becomes blurred and darkened and nearby voices become distant. This comes on relatively 
quickly over 10-15 seconds or at most a few minutes. The attack may be prevented at this stage, 
by lying flat or alternatively made worse by staying upright in either the standing or sitting 
position. If the attack is not prevented, there is a sudden loss of consciousness with a falling to 
the ground (syncope). The person then remains unconscious lying motionless, pale and sweaty 
for a short period, usually for less than 30 seconds but not more than a minute. There may 
be transient, brief ictal-like limb jerking and very rarely a seizure if there is prolonged anoxia. 
Bradycardia and dilated pupils are usually present. Persons then regain full consciousness 
remembering the events leading up to and immediately after the blackout. They may continue 
to feel sweaty and nauseated but are usually back to normal within 10-15 minutes or less. The 
attack of syncope may recur on attempting to stand up too soon. The differential diagnosis 
includes the other causes of transient loss of consciousness and in particular a seizure disorder. 
Management is one of reassurance and advice to avoid the precipitating factors.
Cardiac syncope
A cardiac cause is suspected when syncope occurs either in relation to exercise or alternatively 
occurs in the sitting or lying position or in a patient with known cardiac disease. The syncope 
is characterized by its sudden onset usually without any warning and then by an equally 
rapid recovery of consciousness on falling to the ground, the entire episode usually lasting 
a matter of seconds. The main causes are arrhythmias e.g. complete heart block and supra 
ventricular tachycardia and cardiac outflow obstruction e.g. aortic stenosis and hypertrophic 
cardiomyopathy. Investigations include ECG, monitoring for arrhythmias and cardiac Echo. 
Management is the treatment of the underlying cardiac disorder.  
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Cerebrovascular syncope
This is an uncommon cause of syncope. The main causes are basilar artery insufficiency, 
large vessel occlusive disease and carotid sinus compression or hypersensitivity. Basilar artery 
insufficiency is characterized by sudden brief attacks of dizziness and vertigo, and sometimes 
transient symptoms of lower cranial nerve dysfunction. These attacks last seconds to minutes 
and may be coupled with a loss of consciousness which can occasionally be more prolonged. 
Management is similar to that outlined in cerebrovascular disease (Chapter 5). Carotid syncope 
is caused by a tight collar or mass in the neck pressing on the carotid sinus or by an abnormally 
sensitive carotid sinus. It is more common in older males and in those taking antihypertensive 
medications, in particular beta blockers.
Postural syncope
The main causes are hypovolaemia, antihypertensive medications and polyneuropathies e.g. in 
DM. These result in either reduced blood volume or autonomic dysfunction. This may occur 
in any age group but is more common in the elderly on medications for hypertension. Syncope 
secondary to posture should be suspected if the patient with a known risk factor complains of light-
headedness or loss of consciousness when standing up rapidly which is relieved when either sitting or 
lying down. The diagnosis is confirmed by a symptomatic drop in systolic blood pressure of >30 
mm Hg on standing as compared to lying. Management includes changing or discontinuing 
any likely causal medications and giving clear instructions to the patient, concerning standing 
up gradually and the wearing of support stockings. 
Hyperventilation syncope
Hyperventilation is a common cause of dizziness and faintness but rarely causes syncope. It 
occurs most commonly but not exclusively in teenage or young women, usually in response to 
stress and anxiety. It is a benign disorder which is caused by over breathing in response to anxiety. 
This results in a respiratory alkalosis and cerebral vasoconstriction which can cause light-
headedness, dyspnoea, and a feeling of unreality, and may proceed to blackouts which mimic 
seizures. The diagnosis should be suspected if the patient is anxious and describes an episode 
of difficulty of getting their breath before and just as the attack develops. There is typically 
associated tingling on the lips, the tip of the nose and finger tips and rarely muscle twitches 
of the fingers, followed by a short episode of loss of consciousness usually lasting seconds. The 
symptoms can be reproduced by getting the patient to hyperventilate voluntarily and then 
stopped promptly by rebreathing from a paper bag. 
Syncope and seizures
The main differential diagnosis of syncope is with epileptic seizures. Distinguishing these can be 
difficult but there are some differences. A clear description of the episode from both the patient 
and an observer is essential. Syncope of vasovagal origin is largely non recurring and tends 
to happen in stereotyped situations e.g. triggered by standing, heat, pain, blood, straining. 
Syncope arising from cardiac, posture and stress disorders is recurring but the underlying 
cause is usually apparent. Seizures are by their nature recurring and happen anywhere. The 
immediate preceding warning symptoms are different in both types of LOC. Patients with 
syncope have a characteristic set of vasovagal warning symptoms including light-headedness, 
nausea, blurred vision sweating and pallor lasting seconds or minutes. This is in contrast to the 
aura in seizures which if present is usually more stereotyped and of shorter duration lasting a 
second or less. The duration of LOC is also shorter in syncope lasting seconds to 1-2 minutes 
transient loss of ConsCiousness
William Howlett Neurology in Africa 223
whereas in epilepsy it usually lasts 4-5 minutes or longer. During a syncopal attack the patient 
lies motionless with only occasional muscle twitching of the limbs and infrequently urinary 
incontinence and only very rarely if brain hypoxia occurs are there associated tonic clonic like 
limb movements and tongue biting. In contrast these are the characteristics of a seizure. In 
syncope recovery of full consciousness occurs within seconds of awakening whereas in seizures 
there is typically a period of postictal confusion which lasts for as long as 10-15 mins. These 
differences are summarized in Table 9.8. 
Table 9. 8 Clinical differences between a fit and a faint
Clinical features Vasovagal attack Epileptic seizure
posture upright any posture
onset gradual sudden
incontinence/tongue biting rare common
period/unconsciousness seconds minutes
recovery rapid within seconds slow
precipitating factor stereotyped non stereotyped
recurring pattern no yes
Pseudoseizures
Some patients have unexplained seizure-like episodes of loss of consciousness. These episodes 
resemble seizures and are considered to be psychogenic or non epileptic in origin. The 
diagnosis should be suspected if there are atypical episodes of loss of consciousness occurring mostly 
in teenagers and young adults, often females, usually lasting longer than 5 minutes. The attacks 
can mimic an epileptic seizure and may occur in association with known epilepsy. The main 
differences are already outlined in chapter 4. 
HYPOGLYCAEMIA
The diagnosis should be suspected if there are feelings of hunger, sweating, nervousness and 
palpitations coupled with episodes of confusion, abnormal speech or unusual behaviour in a 
patient not at risk for seizures or syncope. A blood glucose <2.5 mmols/L is considered to be 
hypoglycaemia. These attacks occur most frequently in diabetics taking oral hypoglycaemic 
agents or insulin. Other less common causes include during or after a period of prolonged 
exercise, fasting, liver disease and malignancies including hepatoma and insulinoma. The loss 
of consciousness in hypoglycaemia can be prolonged (>30 mins) and seizures may occur. If 
untreated this may proceed to coma and brain damage. The diagnosis is confirmed by measuring 
blood glucose during the episode and by its response to treatment. While a blood sugar level 
should always be checked in the unconscious patient in whom hypoglycaemia is suspected, 
intravenous glucose should be given without waiting for the results of a confirmatory blood 
sugar. 
TRANSIENT ISCHAEMIC ATTACK (TIA)
A TIA is a sudden ischaemic focal neurological deficit that completely resolves in <24 hours (Chapter 
5). The neurological findings in TIA typically last for minutes and occasionally, hours and the 
presentations are the same as for stroke and include a loss of consciousness. They are mostly 
caused by thromboemboli arising from the internal carotid arteries or from the heart in atrial 
fibrillation or mitral valve disease. All TIAs should be treated with the same sense of urgency 
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as stroke. The aim is to identify risk factors and prevent a stroke occurring as the risk over the 
following days and weeks is high (>10%). Antiplatelet drugs and anticoagulants are used as in 
stroke.
Key points
 · transient loss of consciousness is a common outpatient problem
 · main differential diagnosis is an epileptic seizure
 · causes tend to be stereotyped
 · history is the key to the correct diagnosis
APPENDIX 1 DESCRIPTIONS OF STATES OF ALTERED 
CONSCIOUSNESS
Confusion disturbed consciousness and impairment of higher cerebral function
Delirium confusion with motor restlessness, and transient hallucinations and delusions
Stupor conscious but rousable only with intense stimulation
Coma unrousable unresponsiveness (GCS ≤ 8/15)
Vegetative state loss of consciousness with preservation of brain stem function
Death loss of consciousness and capacity to breathe spontaneously: irreversible
APPENDIX 2 EXAMINING THE COMATOSE PATIENT FOR SIGNS OF 
BRAIN DEATH
Brain death is the irreversible loss of all brain stem function. This is loss of consciousness, 
respiration, response to pain and loss of all brain stem reflexes. In brain death the following 
brain stem reflexes must be absent:
 · light reflex
 · corneal reflex
 · gag reflex
 · cough to deep tracheal suction 
 · eye movements to testing (Doll’s eyes)
 · oculovestibular reflex (caloric test)
Doll’s eyes or oculocephalic reflex
Check for the normal oculocephalic reflexes by rotating the head 180 degrees to the left or 
right (or up down) holding it there for 3-4 secs and observing the eyes. In the normal intact 
brain stem the eyes deviate to the side opposite to that of the head movement. In brain stem 
disease or deep coma the eyes remain fixed and move in the same direction as the head which 
is abnormal. The oculocephalic reflex is suppressed in the fully conscious patient so it can only 
be tested in the unconscious patient.
appendix 1 desCriptions of states of altered ConsCiousness
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Caloric testing or oculovestibular reflex
First check that the external canal is clear and the tympanic membranes are intact. Then irrigate 
the tympanic membrane in each ear with 50-100 mls of iced cold water. The normal response is 
that the eyes deviate slowly towards the stimulated ear. In brain death and overdose there may 
be no response or if the brain stem is damaged the eyes may diverge.
Certifying brain death in a patient on a ventilator
In order to declare a patient brain dead whilst on a ventilator ideally two doctors must be certain 
that all brain stem reflexes are absent and that there is no reversible cause. The ventilation 
should have continued with the patient in this state for 24 hours. If a patient is on a ventilator 
there should be no spontaneous ventilation 10 minutes after disconnecting from the ventilator 
having preoxygenated the patient with 100% O2 for at least 10 mins.
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CHAPTER 10
PARAPLEGIA NON TRAUMATIC
Introduction
Paraplegia (PP) means paralysis of the legs. It is caused mainly by disorders of the spinal cord 
and the cauda equina. They are classified as traumatic and non traumatic. Traumatic paraplegia 
occurs mostly as a result of road traffic accidents (RTA) and falls (Chapter 19). Non traumatic 
paraplegia (NTP) has multiple causes (Table 10.1) and is the most common cause of adult 
neurological hospital admissions in Africa after stroke and infection. Paraplegia is among the 
most common community based neurological disorders in Africa. The aim of this chapter is 
to review the causes and management of NTP. The student should aim to be able to localise 
the site and classify the main causes of paraplegia and to investigate and manage a patient 
presenting with it.
AETIOLOGY
Paraplegia can arise from a lesion either within or outside the spinal cord or cauda equina. 
These are classified as compressive and non compressive. Compression is caused either by 
bone or other masses. The main compressive causes are Pott’s disease (TB of spine) and tumours 
(usually metastases). The main non compressive causes are transverse myelitis secondary to 
viral infections, HIV, TB and very occasionally syphilis. Less common causes include Devic’s 
disease, B-12 deficiency and helminthic infections. There also exists in Africa a large group of 
nutrition related non compressive paraplegias, termed the tropical myeloneuropathies. These 
include konzo, lathyrism and tropical ataxic neuropathy (TAN). The main causes of paraplegia 
are presented in Table 10.1.
Table 10.1 Main causes of nontraumatic paraplegia in Africa
Classification Causes
Compressive
Extradural Pott’s disease, metastatic ca/myeloma, cervical spondylosis, epidural abscess, 
echinococcus cyst
Subdural
  extramedullary neurofibroma, meningioma
  intramedullary astrocytoma, ependymoma, tuberculoma, schistosome ova, syringomyelia
Non compressive
  transverse myelopathy viral infections, HIV, TB, syphilis, HTLV-1, Devic’s disease
  nutritional konzo, lathyrism, tropical ataxic neuropathy 
  vascular sickle cell disease, dural AV fistula
  hereditary familial spastic paraplegia
  deficiency B-12 
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Common causes of paraplegia in Africa
 · Pott’s disease (TB)
 · inflammation (transverse myelitis) 
 · malignancy (metastases)
 · infection (HIV)
 · nutritional (konzo)
Localization/anatomy
The spinal cord extends from C1 in the neck to the lower border of L1 (Fig. 10.1). The cauda 
equina extends from the end of the cord down to S5 within the sacral canal. Paraplegia arises 
from disorders affecting the thoracic spinal cord and the cauda equina, whereas quadriplegia or 
quadriparesis arises from disorders affecting the cervical cord. The most important information 
to elicit at the bedside is whether paraplegia is spastic or flaccid in type and whether there is a 
sensory level on the trunk above which sensation is normal (Chapter 2). This helps to localise 
the site of the lesion causing the paraplegia.
Figure 10.1 Spinal cord Spinal nerves and vertebral column
Key points
 · paraplegia is a common neurological disorder
 · clinically classified as compressive & non compressive 
 · main causes are Pott’s disease, transverse myelitis & malignancy
 · the most common community based cause is nutritional myelopathy 
 · disorders of the spinal cord result in a spastic PP 
 · disorders of the cauda equina result in a flaccid PP
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COMPRESSIVE CAUSES
The causes of compressive paraplegia can be classified on neuroimaging (CT/MRI) as being 
either extradural or subdural in site. Subdural includes those arising from either within the 
spinal cord (intramedullary) or those arising outside the cord (extramedullary) (Table 10.1). 
The two main compressive causes in Africa are Pott’s disease and metastatic malignancy, 
both of which are extradural. Acute cord compression is a medical emergency and needs 
rapid evaluation and intervention in order to prevent permanent disability. The history and 
neurological examination localise the level of weakness, and help to determine the likely cause 
of the paraplegia. However on their own without further laboratory and imaging investigations 
they may not reliably distinguish the cause. 
Spinal TB
Spinal TB accounts for <10% of extrapulmonary TB. Extrapulmonary TB accounts for about 
15% of all TB. Spinal TB can result in paraplegia in two main ways, either by infection of the 
spine (Pott’s disease) accounting for the majority of cases of paraplegia or less commonly by 
direct infection of the spinal cord and cauda equina (spinal cord tuberculosis).
POTT’S DISEASE
Pott’s disease is a leading cause of paraplegia in Africa and is the most common cause in 
childhood, adolescence and in young adults.  It arises from haematogenous spread of the 
tubercle bacillus from pulmonary infection. The paraplegia occurs either at the time of the 
primary infection or more commonly 3-5 years later by reactivation. This results in infection of 
the spine affecting the intervertebral disc space and adjacent vertebrae which if not treated may 
result in characteristic extradural compression of the spinal cord causing paraplegia. 
Clinical features
The main clinical features of Pott’s disease are a history of localised back pain, over weeks 
or months, which is made worse by weight bearing and followed by a slowly progressive 
paraplegia. The paraplegia may be accompanied by low grade features of active systemic TB 
including fever, sweating and weight loss but this is not common. Neurological examination 
confirms paraplegia, the clinical signs depending on the level and the extent of the lesion. The 
lower thoracic and the lumbar spine are the most common sites affected. The spine should be 
carefully inspected for signs of local tenderness and the presence of any deformity, in particular 
a gibbus formation. A gibbus is a visible angular deformity of the thoracic or lumbar spine 
caused by collapse and anterior wedging of adjacent vertebrae. Local tenderness is best elicited 
by gently tapping the spines of the vertebrae with a finger tip or a patellar hammer.
Investigations
The ESR is typically elevated early on and throughout the course of Pott’s disease and may 
be the only laboratory clue as to the likely underlying cause. Radiological evidence shows a 
characteristic loss of the disc space at the site of infection with destruction and wedging of 
adjacent vertebrae but the latter is a late finding. There may also be a paravertebral soft tissue 
swelling (Fig. 10.2) or uncommonly a psoas muscle abscess. A CT scan of the spine may also be 
helpful, particularly in early disease when plain X-rays may be normal. The diagnosis of Pott’s 
disease is usually made by clinical suspicion, in combination with an elevated ESR and typical 
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spinal X-rays. All suspected cases of Pott’s disease should have a chest X-ray to exclude active 
pulmonary tuberculosis. 
Treatment
Treatment is mostly carried out on clinical and X-ray grounds alone. Where possible a needle 
biopsy confirming the presence of acid fast bacilli should be performed and this is diagnostic. 
The standard anti tuberculous treatment for spinal TB is for a total of 18 months, however 
a shorter 12 month course has been recently recommended. Surgical treatment involving 
decompression of the cord and stabilization of the spine is helpful in a few mainly early cases 
of spinal cord compression. 
Prognosis
The treated mortality rate is between 10-20% and full recovery rates of from 25 to 40%. 
SPINAL CORD TUBERCULOSIS
Direct infection of the spinal cord with TB presents clinically either as an acute myelitis 
developing over days or as a chronic radiculo-myelitis (Fig. 10.3) occurring over weeks to 
months. The resulting paraplegia is mostly lower motor neurone or flaccid in type with absent 
or depressed reflexes with urinary and faecal incontinence. Tuberculoma of the cord may also 
result in paraplegia but this is uncommon. TB meningitis may also arise from a source of 
infection within the spinal cord and the combination of TB meningitis and paraplegia is not 
uncommon in Africa. All patients presenting with paraplegia should be screened for HIV 
infection. The diagnosis and management of spinal cord tuberculosis is similar to that of TBM 
which is presented in chapter 6.
TB spine & paravertebral abscess Vertebral collapse & wedging & gibbus
Figure 10.2 Pott’s disease
X-ray chest & spine
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Key points
 · Pott’s disease is one of the most common causes of PP in Africa
 · PP can also arise from direct TB infection of spinal cord or meninges
 · clinical features of Pott’s disease are back pain, spinal tenderness & progressive PP 
 · laboratory findings are a high ESR with typical spinal x-ray changes 
 · treatment is with anti TB Rx for at least 12 months 
 · CFR is 10-20% & morbidity rate is 25-40%
TUMOURS
Tumours affecting the spinal cord can be either primary arising from the cord, roots or meninges 
or secondary or metastatic arising from outside the cord. The most common overall cause of 
spinal cord tumours is secondary or metastatic. The main sources are prostate, breast, lung, 
kidney, lymphoma and multiple myeloma. They are mostly located extradurally and the most 
common sites affected are the thoracic followed by the lumbar spine. These are the main cause 
of paraplegia in older age groups (>50 years). Primary spinal cord tumours are very uncommon 
with an expected incidence of <1/100,000 per year and can occur in all age groups. These 
include meningioma arising from the meninges, neurofibroma arising from peripheral nerves 
and astrocytoma and ependymoma arising from the cord. 
Clinical features
Patients presenting with paraplegia resulting from metastatic tumours typically have a history 
of localised back pain in combination with a mainly flaccid type paraplegia developing over 
a short period, usually days or weeks. Pain arising from the spinal site of metastasis is usually 
L5/S1 arachnoiditis
Figure 10.3 TB cauda equina
MRI T2 lumbar sacral spine
tumours
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a distinctive feature. The paraplegia may be the first presenting complaint or a complication 
of known systemic malignancy. In contrast benign tumours tend to present with paraplegia 
evolving more slowly over months or years, and pain is less pronounced. 
Investigation
Investigations help to confirm the suspicion of a malignancy with plain spinal x-rays showing 
lytic or blastic lesions or vertebral collapse depending on the primary (Fig. 10.4). CSF may 
sometimes show a high protein level and yellow discolouration particularly if there is a block 
to flow resulting in a concentration of CSF constituents. This is called the Froin syndrome. 
Neuroimaging (CT/MRI) of the spinal cord is necessary in all patients with suspected primary 
cord tumours and in some with suspected metastatic tumour.  
Treatment
The treatment depends on the type of underlying tumour. Metastatic tumours causing cord 
compression initially require urgent steroids and analgesia if needed. More definitive treatments 
include local radiotherapy and occasionally surgical decompression. Chemotherapy may be 
helpful in patients with lymphoma and myeloma, whereas hormonal therapy can be very 
beneficial in those with metastatic breast and prostate cancer. Some benign tumours can be 
removed depending on their histology, size and local invasiveness. The prognosis for metastatic 
spinal cord tumour is generally poor.
Key points
 · metastatic malignancy is the most common cause of PP in the elderly 
 · prostate and breast are the most common primary sources
 · paralysis is usually painful & flaccid with a sensory level on the trunk
 · treatment includes steroids, analgesia, radiotherapy & chemotherapy
ACUTE EPIDURAL ABSCESS
Acute spinal epidural abscess is a relatively uncommon cause of paraplegia but is a medical 
emergency when it happens. It tends to occur in debilitated patients with diabetes, alcoholism 
or renal failure but may occur in an otherwise healthy person. Staphylococcus aureus is the most 
Metastatic carcinoma loss of height & pedicle Multiple myeloma involving spine and skull
Figure 10.4 Malignancies
X-rays spine & skull
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common organism accounting for 90% of cases, skin abscesses and boils are the most common 
sources of infection. It can affect all age groups. 
Clinical features
The clinical features are those of a painful sub acute paraplegia developing over hours or days. 
The distinguishing features are very severe pain, sometimes radicular, and local tenderness 
at the site of the epidural abscess which is usually situated in the cervical or lumbar spine. 
These are frequently but not always coupled with fever and signs of infection with or without 
meningism. 
Investigations
Investigations suggest a bacterial cause when the peripheral WBC (neutrophil count) and ESR 
are both elevated but these can be normal. CSF examination may reveal the presence of a few 
white blood cells and elevated protein level or be normal. Lumbar puncture should not be 
performed near the suspected abscess site as this may spread the infection to the CSF causing 
meningitis. A CT scan of the spinal cord with contrast may show epidural enhancement but 
can also be normal. MRI of the spinal cord with contrast is the investigation of choice.
Treatment
Emergency treatment is recommended on the grounds of clinical suspicion without waiting 
for the results of any investigations. Appropriate high dose intravenous antibiotics including 
cloxacillin are started and continued for a period of up to 6 weeks. High dose intravenous 
steroids may be of value if given early on during the first week or two of treatment. Urgent 
decompressive laminectomy may sometimes be indicated. 
Key points
 · epidural abscess is a medical emergency which requires urgent treatment
 · sub acute painful PP occurring over hours or days 
 · occurs in DM, alcoholism, renal failure & skin infection & in healthy persons 
 · diagnosis is confirmed by contrast enhanced CT/MRI spinal cord 
 · treatment is iv antibiotics & steroids & sometimes surgery
CERVICAL SPONDYLOSIS
This is one of the most common causes of paraplegia in high income countries but appears to 
be a relatively uncommon cause in Africa. 
Clinical features
Affected patients are usually older, >60 yrs and typically present with a slow insidious onset 
of weakness or stiffness in the legs, sometimes coupled with numbness and tingling in the 
upper limbs. There may be a history of previous neck injury or accident. Pain and bladder 
symptoms are uncommon. The main clinical findings are those of a spastic paraplegia coupled 
with wasting of the small hand muscles. 
CerviCal spondylosis
William Howlett Neurology in Africa 237
Investigations
Plain X-ray or CT of the cervical spine confirms the diagnosis, showing narrowing of one or 
two disc spaces with prominent osteophytes, narrowing of the cervical canal and evidence of 
cord compression (Fig. 10.5). 
Management
Management is mostly conservative and includes analgesics, cervical collar and very rarely 
traction. Indications for consideration for decompressive surgery include progressive 
paraplegia, severe weakness and intractable pain. Surgery is aimed at the prevention of any 
further deterioration rather than making the patient better, although neurologic improvement 
is occasionally seen. 
Key points
 · cervical spondylosis is an uncommon cause of PP in Africa
 · presents with slow onset spastic PP with numbness & wasting in hands 
 · occurs in older persons, often with a history of previous neck injury
 · X-ray/CT neck: narrow disc spaces & canal with osteophytes & cord compression 
 · treatment usually conservative with analgesics & cervical collar
FLUOROSIS
Fluorosis is a disorder characterized by the deposition of excess fluoride in bones (osteofluorosis) 
and teeth (dental fluorosis). It results from chronic ingestion of fluoride rich waters over many 
years. Water contamination with fluoride occurs naturally in volcanic areas of the world. This 
is particularly the case in volcanic areas in the rift valley region of East Africa where there can 
be exposure to high levels of fluoride in drinking water. The degree of water contamination 
and exposure can vary enormously within adjacent areas in affected regions. Neurological 
disorders are uncommon and arise in fluorosis as consequence of the chronic deposition of 
fluoride in bone occurring over many years. This can result in narrowing of the diameter 
Narrowing & osteophytes Compression Compression
Figure 10.5 Cervical spondylosis
X- ray cervical spine MRI T2 cord (lateral) MRI T2 cord (axial)
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of the spinal canal and the intervertebral foramina which can cause compression. It mainly 
affects the cervical canal but may also affect the lumbar sacral canal. The resulting neurological 
disorders are mostly forms of spastic paralysis with or without associated radiculopathies. These 
lead to quadriplegia and paraplegia characterized by immobility, flexion deformities, severe 
spasms, and urinary incontinence. The diagnosis is usually suggested by the typical clinical 
and X-ray findings occurring in a person from a known volcanic area (Fig.10.6). Treatment is 
symptomatic. Primary prevention is the intervention of choice either by filtering all water at 
the point of access or drinking water at the point of usage.
Key points
 · skeletal fluorosis results from chronic high fluoride intake in drinking water
 · cervical & lumbosacral spine are most commonly affected sites
 · result in a quadri/paraparesis  & radiculopathy
 · PP is an uncommon complication of skeletal fluorosis 
 · skeletal X-rays confirm the diagnosis 
 · prevention is by filtering drinking water
SYRINGOMYELIA
This is an uncommon disorder in which a CSF filled cavity called a syrinx forms in the centre 
of the spinal cord. The time course of symptoms and signs is one of slow progression over 
many years. It typically starts slowly in the lower cervical cord and over many years, the cavity 
can involve the whole spinal cord down to T12 & L1. The cause is considered to be related to 
abnormalities in the dynamics of local CSF pressure and flow. Predisposing causes include a 
developmental abnormality of the skull base with flattening or platybasia coupled with variable 
protrusion of the lower brain stem and cerebellar tonsils through the foramen magnum. This 
is called the Arnold-Chiari malformation. Neck and cervical cord injury is another risk factor 
which is an important cause in Africa, particularly in women because of falls whilst carrying 
Whitening of bones Severe skeletal fluorosis
Figure 10.6 Fluorosis
syringomyelia
William Howlett Neurology in Africa 239
heavy loads on the head. There is usually a gap of 20-30 years from the time of the accident to 
the onset of first symptoms.
Clinical features
Syringomyelia results in a characteristic pattern of motor and sensory deficits with signs of 
a spastic paraplegia in the legs, and lower motor neurone signs in the upper limbs. Pain is a 
feature; this is often severe, burning or neuropathic in type and often in a radicular distribution 
in the limbs. The sensory findings are diagnostic, with involvement of the spinothalamic tracts 
producing loss of pain and temperature in a characteristic cape distribution over the shoulders. 
Sensory involvement occurs in the arms and legs depending on the site and extent of the syrinx. 
Because the cavity is situated in the centre of the cord there is sparing of the posterior columns 
with preservation of joint position, vibration and light touch. Characteristic clinical findings 
include neuropathic scars because of the loss of pain sensation, wasting of small hand muscles 
and claw hand deformities (Fig. 10.7). The clinical course in severe cases is a slowly progressive 
quadriplegia or paraplegia occurring over many years with the patient gradually becoming 
wheelchair and bedbound. 
Treatment
Treatment is usually conservative. Neurosurgery, if indicated is aimed at stabilizing the 
condition with decompression of the foramen magnum and drainage of the syrinx. 
Key points
 · syringomyelia is uncommon cause of PP caused by a cavity within the spinal cord
 · previous spinal injury & platybasia are the main risk factors
 · history of  injury is often >20 years earlier 
 · CFs are burning pains  & wasting & neuropathic scars on the hands/arms 
 · & a slowly progressive SPP with loss of pain & temp but joint position/vibration are intact
NON COMPRESSIVE
The main non compressive causes of paraplegia in Africa are transverse myelitis, HIV, TB, 
schistosomiasis, syphilis, B-12 deficiency and HTLV-1. 
Neuropathic scars Clawing
Figure 10.7 Hands in syringomyelia
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TRANSVERSE MYELITIS (TM)
Transverse myelitis is a term used to describe an episode of inflammation affecting the spinal 
cord which results in an acute paraplegia. It is one of the major causes of paraplegia in young and 
middle aged persons in Africa. Mechanisms are considered to be infectious and autoimmune in 
origin, but in most cases the exact cause is not known. Viruses known to be involved are herpes 
zoster, herpes simplex, HIV and HTLV-1. Devic’s disease (neuromyelitis optica) and systemic 
lupus erythematosis (vasculitis) are uncommon causes. 
Clinical features
Transverse myelitis typically results in an acute devastating flaccid paraplegia, developing over 
hours or days with a sensory level on the trunk and loss of control of bladder and bowel. Pain 
though frequently present at onset is mild and usually clears. Spasticity usually develops later, 
but may not in very severely affected cases who remain flaccid because of involvement of the 
anterior horns in the spinal cord. At onset the CSF may show elevation in leucocytes and 
protein and MRI imaging may show high signal in the cord (Fig.10.9). CT examination of the 
spine is useful to exclude other causes.
Treatment
Treatment initially is with high dose intravenous steroids in combination with a course of 
antiviral medication e.g. acyclovir 10 mg/kg (800 mg) iv/po/3-4 times daily for 10 days if 
clinically appropriate. High dose steroids include methylprednisolone 1000 mg iv daily 
for 5 days followed by oral prednisolone 60 mg daily, tapering over 2-3 weeks. High dose 
dexamethasone, 24-32 mg daily can also be used if methylprednisolone is unavailable. 
Prognosis
Recovery is variable, it may be rapid but in some cases can be slow and incomplete, occurring 
over months or years. However, most patients are permanently disabled and confined to a 
wheelchair.
Key points
 · transverse myelitis is one of the common forms of PP in Africa 
 · affects mainly young & middle aged persons 
 · viruses are a known cause but in most cases the cause is not identified 
 · paraplegia occurs over hours or days with initial flaccidity, sensory level & incontinence  
 · treatment: antiviral medication & iv steroids but most persons are left permanently disabled
HIV
Paraplegia is a major neurological disorder in HIV disease (Chapter 8).  It can occur during the 
asymptomatic stage of HIV infection when CD4 counts are >200/cm3 and more commonly 
during the symptomatic stage when CD4 counts are very low <100/cm3. The main causes are 
opportunistic processes and direct HIV infection of the spinal cord. Opportunistic infections 
(OIs) include tuberculosis, herpes zoster, herpes simplex, CMV, syphilis and co-infection with 
HTLV-1 in endemic areas. The main opportunistic tumour is lymphoma. 
Direct infection of the spinal cord causes a vacuolar myelopathy (VM) in advanced HIV 
infection. (Chapter 8). This results in a progressive spastic paraplegia associated with urinary 
transverse myelitis (tm)
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incontinence and sensory ataxia in <1% of patients. More common findings in vacuolar 
myelopathy are isolated hyperreflexia in the legs, usually the knees and extensor plantar reflexes. 
These isolated neurological signs are present in >20% of patients with advanced disease. 
Infection with cytomegalovirus can uncommonly cause a paraplegia during the later stages 
of HIV infection. This is due to lumbosacral radiculopathy and results in a flaccid paraplegia. 
Management of paraplegia in HIV is directed at finding and treating the underlying cause and 
starting ART depending on the degree of immunosuppression.
Key points
 · PP is a major but a relatively uncommon neurological complication in HIV disease 
 · main mechanisms are OIs & direct HIV infection of the cord
 · main OIs are TB, viral infections & syphilis
 · vacuolar myelopathy arises from HIV infection of cord & causes PP in <1% of pts 
 · management is by treating the underlying cause & by starting ART
SCHISTOSOMIASIS
Involvement of the spinal cord is considered to be uncommon, although 1-5% of all cases of 
non traumatic paraplegia in schistosome endemic parts of Africa are reported to be caused 
by schistosomiasis (Chapter 7). Reports from schistosome affected areas of Malawi suggest 
that it may be even more common there. Paraplegia occurs mostly with S. mansoni (SM) and 
occasionally with S. haematobium. It happens particularly in early infection in the non immune 
host and when there is a heavy worm and egg load. 
Pathogenesis
The paraplegia arises because of marked acute inflammatory response of the host to schistosome 
eggs being deposited in and around the spinal cord (Fig. 10.8). The likely source of the eggs 
are ectopic adult worms either living in veins around the cord or by retrograde flow of eggs 
through valveless spinal veins in connection with the iliac veins. The time between exposure 
and onset of the paraplegia is usually weeks to months and rarely years. The conus medullaris 
and the cauda equina are the most common sites affected (Chapter 7). 
Clinical features
The clinical features include lumbar pain followed by difficulty passing urine, which may 
precede the other symptoms by days or weeks. The main presentation is that of a progressive 
flaccid paraplegia, occurring over days or weeks, usually with sensory and bladder involvement. 
Other neurological presentations include myeloradiculopathy and spastic paraplegia. 
Diagnosis
The diagnosis should be considered in any patient with an acute onset paraplegia who is 
living in or has come from an endemic area. The diagnosis is difficult because the paraplegia 
mainly occurs during the early invasive phase of the adult worms, when there is little clinical 
or laboratory evidence of underlying schistosome infection. Stool examination for eggs may 
be negative and rectal snips are positive in only about 50% of cases. A positive serological test 
is useful in non endemic patients as an indicator of previous exposure. CSF examination may 
show lymphocytes and occasionally eosinophils as well as an elevation in protein. CT of the 
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spinal cord is usually not helpful but MRI imaging with contrast may show hyper intense areas 
in the cord or irregular enhancement and dilation of the conus. 
Treatment
Treatment is with praziquantel 40 mg/kg/day orally for up to 14 days in combination with 
oral prednisolone 60-90 mg daily for 3 weeks. Surgery has been tried for acute cases of failed 
medical treatment. The prognosis is guarded, with about 10% mortality, 30% remaining 
permanently paraplegic and 60% showing moderate to good recovery. 
Key points
 · schistosomiasis is a known cause of acute PP in endemic areas
 · lower end of spinal cord & the cauda equina are the main sites affected 
 · flaccid PP is the main clinical presentation
 · diagnosis is difficult because there is little laboratory evidence of infection
 · treatment is with praziquantel & steroids for 2-3 weeks 
 · CFR is 10% & 30% left paralysed
Other causes of non compressive paraplegia include syphilis, human T cell lymphotropic 
virus type 1 (HTLV-1), Devic’s disease, vitamin B-12 deficiency, ischaemia, sickle cell 
disease, vasculitis, arteriovenous malformation (AVM) and hereditary spastic paraplegia. 
SYPHILIS
Syphilis is a sexually transmitted disease caused by the spirochete Treponema pallidum (Chapter 
6). It is estimated that neurological involvement will occur in about 7% of patients 10-25 
years after primary infection, if primary syphilis is untreated. However despite the frequency 
of primary syphilis in Africa, neurosyphilis remains uncommon in many countries there. The 
reason for this has been ascribed to the continued widespread use of antibiotics inadvertently 
treating early infection or altering the natural history of clinical disease. The incidence of 
neurosyphilis is increased when syphilis is associated with HIV infection. 
Granuloma around SM eggs SM egg shells
Figure 10.8 Schistosome mansoni eggs in the spinal cord, histopathology
syphilis
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Clinical features
Spinal syphilis typically presents either as a progressive spastic paraplegia or as tabes dorsalis 
with posterior column loss, lightning pains and Charcot’s joints. However tabes dorsalis 
remains a distinctly uncommon clinical presentation in Africa.
Diagnosis
The diagnosis of neurosyphilis depends on the serological detection of antibodies in both 
blood and CSF. The Venereal Disease Research Laboratory (VDRL) is the screening test most 
commonly used in Africa although it may be negative in HIV infection. Limitations to VDRL 
include false positives in serum but not in the CSF which can however be negative in 20-30% 
cases. More sensitive and specific diagnostic antibody tests include the fluorescent treponemal 
antibody absorption (FTA) and the treponemal antibody immobilization test (TPI). The CSF 
may also show elevated leucocytes and protein. 
Treatment
Treatment is with penicillin 2-4 million units i.v. 4 hourly for 14-21 days. 
HUMAN T CELL LYMPHOTROPIC VIRUS TYPE 1 (HTLV-1)
HTLV-1 is a retrovirus which is endemic in some areas of western, southern and central Africa 
with just a few clusters reported in eastern Africa. It is endemic in areas of Japan, the Caribbean 
and South America. The serological prevalence rates are 3-6% in some of the worst affected 
communities. It is transmitted perinatally, sexually and by blood transfusion. Chronic infection 
for up to 20-30 years can result in a slow progressive form of tropical spastic paraplegia known 
as HTLV-1 associated myelopathy (HAM). However this occurs in only 1-5% of persons 
infected with the virus with the majority being asymptomatic carriers. The distinctive clinical 
feature of HTLV-1 is that of a progressive spastic paraplegia characterized by slow onset over 
years of stiffness and weakness affecting the legs with paraesthesiae, back pain and urinary 
symptoms. The diagnosis is confirmed by finding HTLV-1 antibodies in the blood and CSF. 
There is no effective treatment although steroids have been tried.  
DEVIC’S DISEASE (NEUROMYELITIS OPTICA)
This is an uncommon but severe disease in Africa characterized by recurring attacks of acute 
severe demyelinating transverse myelitis and optic neuritis. This results in paraplegia and 
blindness. Occasionally, the disease is monophasic but this appears to be unusual in Africa. It 
occurs predominantly in females in their late teens or early 20s in Africa but may affect older 
women in their 30s and 40s in high income countries. The optic neuritis typically precedes the 
transverse myelitis but can also occur concurrently with it. The relapses are severe, occurring 
usually within 6 months of the first and subsequent episodes. 
Diagnosis
The diagnosis in Africa is mainly clinical. Examination of CSF may show increased protein and 
the presence of lymphocytes. A highly specific immunoglobulin antibody to aquaporin (NMO 
–IgG) can now be detected in blood and CSF of infected persons but the test is only available 
in some specialised neurological centres in Africa. MRI imaging if available shows increased 
signal in the spinal cord often spanning several vertebral levels and almost complete withering 
of the cord in cases of long standing disease (Fig. 10.9).
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Treatment
Treatment for the acute attacks is with high dose steroids for periods of 4-6 weeks and if 
available, repeated plasma exchange or intravenous immunoglobulin for the non responders. 
Long term prophylaxis with a combination of steroids and azathioprine or other forms of 
immunosuppression has been tried but the response is variable. Residual disability after an 
attack is usual with many patients becoming wheelchair or bed bound within 1 to 2 years of 
onset.
VITAMIN B-12 DEFICIENCY
Vitamin B-12 deficiency causes a peripheral neuropathy, sub acute combined degeneration of 
the cord (SACD), optic atrophy, dementia and pernicious anaemia. The main spinal findings 
are those of a myelopathy with brisk knee reflexes and up going plantars. These typically occur 
in combination with signs of neuropathy, including absent ankle jerks and loss of peripheral 
sensation including joint position sense. All or some of the above may be present in any 
one patient. The main causes of SACD are nutritional deficiency, seen most commonly in 
vegetarians, and malabsorption. Malabsorption may be caused either by a lack of intrinsic 
factor which seems to be quite uncommon in Africa and also by diseases of the terminal ileum. 
Diagnosis
Diagnosis is by finding the typical neurological findings in combination with evidence of 
megaloblastic anaemia i.e. elevated mean corpuscular volume (MCV) and low serum B-12.
Treatment
Treatment is with intramuscular injections of B-12. The dose is 1 mg on alternate days for a 
total of five injections followed by 1 mg injections every 3 months for life. If intramuscular 
injections are not available then B-12 can sometimes be given orally, in a dose of 1 mg po daily. 
Inflammation within the cord 
Figure 10.9 Transverse myelitis in Devic’s disease
MRI T2 cervical & upper thoracic cord
vitamin b-12 defiCienCy
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This may provide adequate replacement particularly in cases secondary to nutritional or dietary 
deficiency. 
Key points
 · neurosyphilis is uncommon in many countries in Africa
 · HTLV-1 is endemic in selected areas of South, West & Central Africa
 · Devic’s disease is uncommon but severe demyelinating disorder of CNS 
 · B-12 deficiency is a treatable but uncommon cause of neuropathy & paraplegia
TROPICAL MYELONEUROPATHIES
These are a group of paraplegias and peripheral neuropathies that are considered to be nutritional 
in origin. They include the tropical spastic paraplegia (TSP) group, konzo and lathyrism, 
and the peripheral neuropathy group, tropical ataxic neuropathies (TAN). These disorders 
represent a distinct group of community based myeloneuropathies which result in paraplegia. 
They occur largely as epidemics and are the commonest cause of neurological disability in the 
rural communities in which they occur in Africa. These are non curable when they happen and 
their management lies mainly in prevention. 
KONZO
Konzo is a distinct form of tropical myeloneuropathy characterized by abrupt onset of a 
non progressive but permanent spastic paraplegia related to cassava consumption. It occurs 
mainly as epidemics in exclusively cassava growing areas of the east, central and western Africa. 
Epidemics have been known to occur in cassava growing of the former Belgian Congo as far 
back as 1928 and possibly earlier. In epidemics as many as 1-30/1000 persons are affected, 
mainly growing children and fertile women. It also occurs in an endemic form but at much 
lower rates. 
Aetiology
The cause of konzo has been attributed to the combined effect of months of high cyanide 
and low protein (methionine and cysteine, sulphur based amino acids) intake from exclusive 
consumption of insufficiently processed bitter cassava (Fig. 10.11). The bitter cassava grow 
well in poor soils but contain increasing amounts of cyanogenic glycosides mainly linamarin. 
Processing disrupts the root tissue and releases volatile hydrogen cyanide and this makes 
the food safe for human consumption. The main processing methods used in Africa involve 
hydrolysis or soaking in water, crushing and fermentation or sun drying. Safe processing takes 
days in the case of hydrolysis and fermentation, to weeks for sun drying. Shortening of these 
methods is a risk factor for the disease. 
Clinical features
The clinical features are characterized by an abrupt (usually <24 hours) onset of a permanent 
but non progressive spastic paraplegia (Figs. 10.10). The upper limbs and optic nerves may 
also be involved in some cases. The bladder, bowel and sensation are all spared. The range of 
disability varies from very mild upper motor neurone findings in the legs to spastic paralysis of 
all four limbs in very severe cases. The majority of persons with konzo can walk with the aid 
of crutches. 
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Diagnosis
The clinical criteria for diagnosis are an abrupt (<1/52) onset of spastic paraparesis in the 
absence of any other cause in a patient coming from a cassava growing area. Supportive 
investigations include elevated blood or urine thiocyanate levels and low levels of the essential 
amino acids methionine and cysteine. These investigations are only available in specialist or 
research laboratories.  
Clinical criteria for diagnosing konzo
 · spastic paraplegia
 · abrupt onset in <one week
 · occurring in a cassava growing area
 · no other cause is found
Treatment and prevention
There is no medical treatment for the condition. Prevention is mainly directed at growing 
cassava with lower cyanide content and public education concerning safer methods of 
cassava processing. A newer and safer “wetting method” of cassava processing has recently 
Konzo patients (all from same family) Typical spastic gait in konzo Spastic feet in konzo
Figure 10.10 Konzo patients
Cassava shrubs & harvested tubers
Figure 10.11 Cassava
konzo
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been promoted in some affected communities in East Africa. Additional measures include 
establishing early warning systems of potentially high cyanide levels in cassava tubers and 
of pending epidemics and the provision of supplementary protein before or early on during 
epidemics. Surgical treatment involving Achilles tendon lengthening operations have proved 
successful in increasing mobility in some patients.
LATHYRISM
Lathyrism is an epidemic form of spastic paraplegia found almost exclusively in parts of India, 
Bangladesh and South East Asia where large quantities of the grass pea (Lathyrus sativus) a 
drought resistant crop are grown and consumed. In Africa it is found only in parts of North 
Western Ethiopia where the grass pea is widely grown and consumed. The association of 
paraplegia with grass pea consumption was already recognized in ancient Greece. 
Aetiology
The disease is caused by a neurotoxic amino acid found in the grass pea called beta-N-
oxalylamino-L-alanine (BOAA). Lathyrism occurs after weeks or months of almost exclusive 
consumption of the grass pea. 
Clinical features
It occurs mostly as epidemics and occurring with about the same frequency and age distribution 
as Konzo. It is clinically almost identical to konzo, apart from the mild sphincter involvement 
occasionally found in lathyrism (Fig. 10.12). However, they are distinguishable from each 
other because they both occur in geographically distinct areas which do not overlap. 
Treatment and prevention
The management and prevention are along the same principles as that for konzo.
India (1922) Ethiopia India
Figure 10.12 Lathyrism
Illustration & photos
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Key points
 · konzo and lathyrism are distinct forms of tropical spastic paraplegia
 · occur mainly as epidemics in different areas in Africa
 · konzo occurs only in cassava growing & lathyrism occurs only in grass pea growing areas 
 · each is caused by weeks/months of almost exclusive consumption of a staple food
 · both result in permanent spastic paraparesis & are prevented by similar measures  
TROPICAL ATAXIC NEUROPATHY (TAN)
This is another distinct form of tropical myeloneuropathy. It has originally been described 
in cassava eating populations in Nigeria and Tanzania in the 1960s and more recently again 
in Nigeria and in southern India. The disease is characterized by a combination of gradual 
onset in older adults of peripheral neuropathy, sensory ataxia, optic neuritis, deafness and 
sometimes spastic paraplegia. The presence of any two or more of these findings is sufficient 
to make the diagnosis. The cause is not known but is linked to chronic cyanide exposure from 
chronic cassava consumption in combination with possible vitamin B nutritional deficiency. 
Management includes vitamin B supplementation.
MANAGEMENT OF PARAPLEGIA
There are four major principles governing the management of patients presenting with 
paraplegia.
Do not delay
The early establishment of correct diagnosis, treatment and the prevention of complications 
are critical to the outcome for the patient. It is important to preserve whatever neurological 
function is still remaining. 
Establish the cause
The cause is established by history, physical examination, laboratory and radiological 
investigations. The main investigations are outlined below in Table 10.2. 
Table 10.2 Main investigations in paraplegia
Type of investigation Investigation Disease
Bloods
Haematology
Biochemistry
 
Serology
FBC, ESR, B-12, sickle cell test 
glucose, creatinine, electrolytes, 
calcium, total protein and 
electrophoresis
HIV, VDRL, schistosome, cysticercosis 
and echinococcosis serology
TB, malignancy, SACD, sickle cell disease, 
abscess
myeloma, malignancy
 
HIV disease, syphilis, helminthic infections
continues
tropiCal ataxiC neuropathy (tan)
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Imaging
X-rays: plain
CT/MRI
spine, chest
skeletal survey 
myelography
spinal cord
TB/abscess 
malignancy
cord compression:  
TB, malignancy transverse myelitis
Procedures
Lumbar puncture opening pressure, colour,
cells, protein, glucose, culture, VDRL 
malignancy, TB, transverse myelitis,  
other infections
Treat the cause
The treatments for the main causes of paraplegia are outlined below in Table 10.3. There is a 
low threshold for starting TB treatment in Africa, particularly in younger patients presenting 
with paraplegia. 
Table 10.3 Summary: Treatment for some reversible causes of PP
Disease Treatment
Potts disease TB Rx
TB spinal cord TB Rx & steroids
metastatic malignancy steroids & analgesia
transverse myelitis steroids & acyclovir 
HIV treat the cause & ART
cervical spondylosis/disc surgical decompression if indicated
schistosomiasis praziquantel & steroids for 2 weeks
syphilis penicillin for 21 days
Devic’s disease steroids
SACD B-12 
acute epidural abscess iv antibiotics
Prevent complications
The patient needs assistance to care for skin, limbs, bladder and bowels. This is best achieved by 
the early involvement of the patient’s family in cooperation with the nurses and physiotherapists.
Skin
The prevention of pressure sores is critical to the patient’s survival. In immobile patients 
pressure sores develop quickly over bony prominences particularly the sacrum, hips and heels. 
This is more likely to occur during the first days of the illness. Specially designed air mattresses 
that minimize this risk are unavailable in most hospitals in Africa. Prevention of bed sores can 
best be achieved by a rigorous approach which involves 2 hourly turning of the patient day and 
night and starting immediately on admission. This task should be entrusted to a family carer 
or carried out by the nursing staff. 
The skin should be inspected frequently and always be kept dry and clean. Attention early to 
adequate nutrition and measures to prevent infection are also very important. These measures 
include the use of mosquito bed nets to prevent malaria and a bed cage to keep weight of 
blankets off the paralysed legs. If bed sores do become established they require vigorous 
cleaning, surgical debridement and possible skin grafting. 
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Bladder and bowels
Urinary catheterization is necessary when there is a non functioning bladder. This typically 
occurs during the first days of an acute paraplegia and persists particularly in patients with 
flaccid paraplegia. The bladder is innervated by both the autonomic and the somatic or 
voluntary nervous system. Loss of control of bladder function or neurogenic bladder arises 
because of lesions situated in either the spinal cord or cauda equina. Patients with spinal cord 
lesions and usually a spastic paraplegia may eventually after months develop satisfactory reflex 
bladder emptying or require intermittent self catheterization and treatment with antispasmodic 
or anticholinergic drugs. Patients with a cauda equina lesion and flaccid paraplegia usually 
require permanent catheters. It may be necessary to use antibiotics for urinary tract infections. 
Constipation is a feature of both flaccid and spastic paraplegia with the bowels opening every 
week or less often. Measures to prevent it include satisfactory fluid intake, adequate fibre/bulk 
in the diet, and the early use of laxatives usually the combination of a lubricant and an irritant. 
Manual evacuation may be necessary when there is faecal impaction.
Limbs
Care of paralysed limbs involves frequent passive movements. This helps to prevent thrombosis, 
joint stiffness, spasticity and contractures, and to exercise the non affected muscles. The 
management of spasticity and avoidance of contractures is best done by a physiotherapist and 
trained family members, and also through the use of antispasmodics. 
The main antispasmodics available are baclofen and diazepam. The starting dose of baclofen is 
5 mg twice daily increasing slowly over weeks to 20-40 mg twice daily as required. The limiting 
adverse effects are drowsiness, fatigue, and the fact that it can sometimes take away the spasticity 
that the patient needs and uses to be able to stand and mobilise. The starting dose of diazepam 
is 2-5 mg three times daily, increasing to a maximum of 20 mg three times daily. The limiting 
adverse effects are drowsiness and fatigue, and anxiety may occur on sudden withdrawal. Other 
drugs used for spasticity include dantrolene and tizanidine. Further measures include the use of 
support stockings and low dose heparin which help to prevent deep vein thrombosis.
Key points
 · treat the cause without delay & aim to prevent complications
 · main complications are bedsores, urinary retention, infection & spasticity
 · 2 hourly turning should start immediately on admission
 · entrust care to a relative or carer
LONG TERM MANAGEMENT
Paraplegia is a devastating illness which results in disappointment, depression, shame, 
resentment, anger and an altered role in family. Patients with chronic paraplegia have to come 
to terms with the loss of function of the lower half of their bodies. They need support in 
the activities of daily living (ADL), mobility, work and family life. They benefit particularly 
from specialized knowledge, support and encouragement. In a medical setting, this is usually 
provided by medical staff including nurses, doctors, physiotherapists, occupational therapists 
and carers. In order to cope at home, the person and their family need the wider support of 
carers, friends and the community. Longer term measures should include plans for social and 
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recreational activities and employment in order for the patient to be more able to participate as 
fully as possible in everyday life. Some specific measures are outlined below. 
Motor
The provision of a wheelchair is often both necessary and essential for mobility. The patient 
needs to be educated about the use of a wheelchair and learn the skills needed for independent 
transfers. This will involve the patient learning some knowledge about the level of cord 
involvement and injury and the extent and severity of any resulting paralysis and disability. 
The patient needs to train to strengthen the non paralysed muscles and family members need 
to be instructed and trained to regularly passively move paralysed limbs in order to prevent 
contractures and bed sores. House adaptation is usually necessary for use of a wheelchair.  
Skin
Great care needs to be taken to prevent the development of pressure sores. A routine of avoiding 
prolonged periods of weight bearing will need to be established and maintained. This is helped 
by the person regularly taking the weight of the body off the seat of chair or wheelchair a couple 
of times every hour and by using protective cushions to guard against pressure points. Regular 
inspection of skin is essential and may of necessity have to be carried out by the carer. 
Bladder and bowels
The patient needs training in reflex bladder emptying, condom drainage, intermittent self 
catheterization, indwelling catheter management, anticholinergic drugs and early recognition 
and treatment of urinary tract infections. The patient needs a healthy wholesome and regular 
diet with laxatives and suppositories to avoid constipation. 
Sex and fertility
This needs to be discussed and explained with the patient and partner. Erectile potency may 
be retained in upper motor neurone spinal cord disorders and respond to oral medications 
phosphodiesterase inhibitors e.g. sildenafil. In contrast erectile potency is lost in cauda equina 
or lower motor neurone disorders. In female patients local spasticity in the thigh adductors 
may be helped by local antispasmodic injections or medications.
Weight and calories
Paraplegic patients need on average 40-50% less calories. This needs to be explained clearly to 
the patient in order to avoid excessive weight gain.
Key points
 · assist & support the person to recover functional independence
 · involves prevention of bed sores, urinary tract infection & weight gain
 · includes  provision, use and maintenance of a wheelchair 
 · long term aim is to participate as fully as possible in everyday life
 · needs support of carers, family, friends & community
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CHAPTER 11
DISORDERS OF PERIPHERAL NERVES
Peripheral neuropathies are a major cause of neurological disability in Africa. They occur as a 
result of disease or injury and can affect nerve roots, individual nerves and peripheral branches 
of nerves (Fig.11.1). The main causes are HIV, leprosy, diabetes mellitus, drugs, nutrition and 
alcohol (Table 11.1 & 2). This chapter reviews the main clinical presentations, investigations 
and management of peripheral nerve disorders. The student should aim to be able to recognize 
the different types of neuropathies and know their main causes and management. 
Pathophysiology
Peripheral nerves are made up of multiple axons surrounded by myelin, Schwann cells and their 
covering sheaths. Individual axons are either myelinated or nonmyelinated. In neuropathies 
the nerves may be damaged at three main sites: the axon, the myelin and the cell body. If the 
axon is damaged, it is called an axonal neuropathy. This is the most common form of peripheral 
neuropathy and usually affects sensation greater than power and has a mainly distal distribution. 
If the myelin is damaged this is called a demyelinating neuropathy. This affects power more 
than sensation and the weakness is usually proximal as well as distal. If the cell body is damaged 
then either sensory or motor nerve fibres or both may be damaged permanently depending on 
which cell body is involved. Recovery occurs if the basement membrane survives but is faster 
in demyelinating than in axonal neuropathies. 
Figure 11.1 The peripheral reflex pathway
posterior
spinal cord
anterior
muscle
The peripheral reex pathway
sensory afferent
motor efferent
anterior horn cell
neuromuscular junction
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TYPES OF PERIPHERAL NERVE DISORDER (PND)
Peripheral neuropathies are divided into two main groups: mononeuropathies which involve 
single nerves and polyneuropathies which involve many nerves. 
MONONEUROPATHY
This describes a group of focal peripheral nerve disorders (FPNDs) where individual nerves 
or their branches are affected. The main mechanisms are compression, entrapment, vasculitis, 
infiltration and infection. In the upper limbs, this happens mostly at the wrist, elbow and 
occasionally the upper arm. In the lower limbs, the most common sites are at the level of the 
inguinal ligament, the knee and the buttocks. A misplaced injection in the buttocks in young 
children is the main cause of sciatic nerve injury in Africa. If more than one nerve is involved, 
this is called multiple mononeuropathy or mononeuritis multiplex. Leprosy is a common cause 
of both mononeuropathy and mononeuritis multiplex in Africa. Other causes include HIV, 
diabetes and vasculitis. The main clinical features of the most common focal nerve lesions are 
outlined in Table 11.1 and illustrated in Figs 11.2-5. 
Table 11.1 Common focal peripheral nerve disorders
Nerve Main site Mechanism Main Cause Clinical Features
Median wrist entrapment carpal tunnel 
syndrome, leprosy
pain, tingling hand/wrist, arm, 
numbness radial 3 & 1/2 fingers, 
wasting thenar muscles, weakness of 
thumb abduction 
Ulnar elbow compression trauma/injury, 
leprosy
pain, tingling hand wrist, numbness 
ulnar 1 & 1/2 fingers, wasting 
hypothenar muscles, weakness little 
finger flexion, claw hand deformity
Radial arm compression sleep wrist drop, weakness wrist, dorsiflexion 
Sciatic buttock infiltration injection pain buttock, leg, foot, numbness leg 
and foot, weakness knee flexion & 
muscles below knee, absent ankle jerk
Femoral thigh vascular diabetes pain thigh (severe), numbness 
anteromedial thigh & medial leg, 
weakness hip flexion & knee extension, 
absent knee jerk
Lateral 
cutaneous 
nerve thigh
inguinal 
ligament
compression occupational, 
carrying baby on hip
numbness, tingling and pain 
over anterolateral thigh (meralgia 
paraesthetica)
Common 
peroneal 
knee compression 
infiltration
illness, leprosy,  
leg crossing
numbness dorsum foot, foot drop, 
weakness foot eversion 
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Figure 11.2 Sensory and motor loss in main mononeuropathies
Median nerve compression occurs mostly at the wrist as the median nerve passes through the 
carpal tunnel resulting in carpal tunnel syndrome (CTS). CTS is characterized by tingling pain 
in the hand or arm particularly at night. The pain and paraesthesiae are in the distribution 
of the median nerve and involve the thumb, index, middle and half the ring finger but may 
extend up the forearm and arm. It often wakes the patient from sleep at night and is relieved 
by hanging the arm down and shaking the hand. CTS is frequently provoked by manual tasks. 
Sensory loss in CTS usually affects the lateral (radial) three and a half fingers and spares the 
palm. Sensation to the lateral fingers and palm are lost in median nerve lesions located in 
the forearm (Fig. 11.2). In long standing cases there is wasting of the thenar eminence and 
weakness of thumb abduction and opposition (opponens pollicis) (Figs 11.2 & 3). Tinel’s 
sign may be positive i.e. tapping the carpal tunnel at the distal crease of the wrist reproduces 
pain and tingling. Alternatively there may be tingling on extreme wrist flexion for one minute 
(Phalen’s sign). However, in clinical practice these signs, although useful when present are 
unreliable when absent. Treatment is by local injection of steroids, wearing a night time wrist 
splint or by surgical decompression if necessary
Sensory and motor loss in peripheral nerves
ulnar nerve
small muscles of
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abductor pollicis
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ulnar half of exor
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exor carpi ulnaris
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motor motor
sensory
common peroneal nerve
motor
sensory motor sensory
Typical wasting of thenar muscles
Figure 11.3 Median neuropathy (bilateral)
mononeuropathy
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Ulnar nerve is prone to compression along its path. The main site of pressure or stretching is at 
the elbow within the cubital tunnel or the ulnar groove. This results in dyasthesia/paraesthesia 
and sensory impairment/loss in the distribution of the little finger and adjacent half of the 
ring finger and ulnar aspect of the hand front and back. There is wasting and weakness of the 
intrinsic muscles of the hand and the deep flexors of the 4th and 5th finger with sparing of the 
thenar muscles (Figs. 11.2 & 4). This gives rise to the characteristic claw hand deformity seen 
in chronic ulnar lesions. 
Radial nerve compression arises mostly from prolonged abnormal posture with resulting 
compression of the radial nerve in the radial groove above the elbow e.g. drunkard’s palsy. 
It can also arise from compression in the axilla, e.g. using crutches, and from fracture of the 
shaft of the humerus. Compression results in wrist drop with weakness of the finger and wrist 
extension and sometimes a small patch of sensory loss on the dorsum of the hand and web of 
the thumb (Fig. 11.2). 
Lateral cutaneous nerve of thigh travels under the lateral part of the inguinal ligament. 
Compression results in a patch of sensory loss over the anterolateral aspect of the thigh of 
variable size ranging from a palm sized patch to an area extending from the hip to the knee but 
never crossing the midline of the axis of the thigh (meralgia paraesthetica). This is one of the 
most common mononeuropathies and its onset is associated with weight gain e.g. pregnancy 
and also occupational e.g. chronic abnormal posture, bending (e.g. plumber). It is usually self-
limiting. 
Sciatic nerve injury most commonly occurs as a result of a misplaced injection in the buttocks 
in early childhood. The sciatic nerve (tibial & common peroneal nerves, L4,5,S1,2) is 
responsible for sensation below the knee involving the entire anterolateral aspect of leg and the 
sole and dorsum of the foot. It is responsible for the following movements, hip extension, knee 
flexion and ankle plantar and dorsiflexion. Injury results in loss of sensation and power in these 
distributions along with a decreased or absent ankle jerk. 
Common peroneal nerve compression at the fibular head results in foot drop and sensory loss 
on the dorsum of foot and lateral leg (Figs 11.2 & 5). The main causes are trauma and pressure. 
It occurs more commonly in immobile patients who are prone to compression. 
Clawing & wasting of hypothenar muscles Wasting ulnar border
Figure 11.4 Ulnar neuropathy
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Figure 11.5 Common peroneal nerve neuropathy Bilateral foot drop (left > right)
Femoral neuropathy most commonly occurs in association with diabetes mellitus. The main 
symptoms are thigh pain, weakness of hip flexion and decreased or absent knee jerk. Treatment 
is pain relief and treating the underlying cause.
Key points
 · mononeuropathies are recognised by their clinical setting & pattern of sensory & motor loss
 · include CTS: ulnar injury, peroneal palsy, meralgia paraesthetica, sciatic injury & femoral ischaemia
 · main mechanisms: trauma, entrapment, compression, infection & inflammation
 · leprosy is a major cause of mononeuropathies
 · a misplaced injection is main cause of sciatic nerve injury
POLYNEUROPATHIES
Polyneuropathies are diffuse, symmetrical disorders usually affecting the limbs distally to a 
greater extent than proximally. Clinically, they are classified as acute or chronic, motor or sensory 
or mixed and also autonomic. Patients presenting with polyneuropathies typically present with 
impairment or loss of sensation in a distal or peripheral glove and stocking distribution. Distal 
weakness may occur later in the feet and legs followed by the hands and arms. Neurological 
examination usually reveals wasting, fasciculation, distal weakness with absent reflexes and 
loss of light touch. Vibration and joint position sense may also be involved. The sphincters 
involving bowel and bladder are typically spared. The main causes of polyneuropathy are 
outlined in Table 11.2. 
polyneuropathies
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Table 11.2 Main causes of polyneuropathies in Africa
Classification Cause Crude frequency
Infection HIV, leprosy very common
Metabolic diabetes, (renal failure) common
Drugs ARTs (stavudine, didanosine),  isoniazid, dapsone, vincristine common
Toxic alcohol, (chronic cassava consumption) common 
Deficiency vitamin B-1 (alcoholics), B-6 (isoniazid), B-12 (pernicious anaemia) uncommon
Inflammatory Guillain-Barre Syndrome (GBS), chronic inflammatory 
demyelinating polyradiculoneuropathy (CIDP)
very uncommon
Vasculitis rheumatoid arthritis, systemic lupus erythematosus (SLE), 
polyarteritis nodosa (PAN)
uncommon
Hereditary Charcot-Marie-Tooth disease, others uncommon
Neoplastic
paraproteinaemia 
paraneoplastic
monoclonal gammopathy, carcinoma lung, breast, ovary very uncommon
Idiopathic 
(>50% of all peripheral 
neuropathies)
unknown most common
Main causes of polyneuropathy in Africa
 · HIV
 · diabetes
 · leprosy
 · drugs
 · alcohol
 · nutrition
Clinical features
The history may provide the first clue as to the aetiology of a neuropathy. There may be a 
history of a known risk factor for neuropathy, e.g. HIV, use of antiretroviral drugs (ART) in 
particular stavudine, diabetes, alcohol abuse, renal failure or very rarely a family history. The 
history provides essential information concerning the mode of onset, time course, distribution, 
character and pattern of symptoms. 
The clinical distribution will indicate whether it is confined to just one nerve or is more 
generalised affecting all peripheral nerves. An acute onset over days with both proximal and 
distal weakness suggests a demyelinating disorder like GBS, whereas a more chronic onset over 
months suggests a distal sensory motor axonal neuropathy as occurs in DM or HIV. Burning 
or pain in the feet is very characteristic of the neuropathy in HIV, diabetes, vitamin deficiencies 
and alcoholism. Additional clinical findings may also indicate the cause; the peripheral 
nerves may be thickened in leprosy, or clawing of the feet or pes cavus is seen in hereditary 
neuropathies or the low blood pressure on standing characteristic of autonomic neuropathies. 
The predominance of either sensory or motor findings is also helpful.
Motor
Muscle weakness suggests motor neuropathy. Motor symptoms include mild to severe weakness 
in the limbs, problems with walking or running, and difficulties manipulating or using fingers 
and hands. The main causes of motor neuropathy are GBS, polio and very rarely lead poisoning. 
Main findings on neurological examination include wasting, weakness and loss of reflexes in 
the limbs (Fig.11.6). 
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Sensory
Numbness, tingling or pain in a glove and stocking distribution suggest a mainly sensory 
neuropathy. Terms used to describe the superficial sensory symptoms include: paraesthesia, 
meaning abnormal tingling sensation; hyperaesthesia, meaning increased sensitivity to a 
stimulus and dysaesthesia, meaning unpleasant tingling. The term allodynia means painful 
sensation from light non painful stimulus e.g. stroking. Sensory symptoms tend to occur before 
motor symptoms and typically involve the feet earlier than hands. Findings on neurological 
examination include loss of light touch, pain and joint position sense distally in the limbs 
mostly the feet. A sensory polyneuropathy may also cause poor balance and unsteady gait 
due to a loss of position sense in the feet. This is called sensory ataxic neuropathy. When the 
neuropathy involves loss of pain then trophic changes and digital loss can occur (Fig. 11.7)
Differential Diagnosis
The differential diagnosis of neuropathies includes diseases affecting muscle, neuromuscular 
junction and occasionally myelopathy and rarely motor neurone disease. Polymyositis and 
myopathy may sometimes mimic a neuropathy but skin involvement and the mainly proximal 
pattern of weakness should suggest underlying muscle disease. Fatigability after exercise, a 
mainly truncal-axial pattern of weakness, ptosis and intact reflexes all point to myasthenia 
gravis. While myelopathy symptoms may sometimes mimic neuropathy, the predominantly 
upper motor neurone signs, the sphincteric involvement and pattern of sensory loss or alteration 
should all suggest spinal cord involvement. Exclusive motor involvement with weakness and 
Wasting forearms & small hand muscles Distal wasting & foot drop
Figure 11.6 Motor and sensory neuropathy
Loss of terminal digits, ulcers & trophic changes
Figure 11.7 Sensory neuropathy
polyneuropathies
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fasciculation are pointers towards progressive muscular atrophy (PMA), a form of motor 
neurone disease, although this is uncommon.
Diagnosis
The diagnosis of peripheral neuropathy relies mainly on the clinical findings and in as many as 
half the cases no underlying cause is found. Investigations should include laboratory screening 
tests for the common causes as outlined in Table 11.3. Simple blood tests exclude causes such 
as HIV, diabetes and B-12 deficiency. CSF examination may show an elevated protein in GBS 
and CIDP. Nerve conduction studies and electromyography are very helpful if available.
Nerve conduction studies (NCS) and Electromyography (EMG)
These are used mainly to determine whether there is a disease of the peripheral nerves, 
neuromuscular junction or muscle and to distinguish between them. NCS can also determine 
whether the neuropathy is purely sensory or also affects the motor fibres and whether the 
primary disease is axonal (causing death of axons) or demyelinating (affecting Schwann cells 
and myelin sheaths) or a mixture of both. 
NCS involve stimulating a nerve with an electrical impulse and measuring the speed of 
conduction at two points along the nerve. This is called the conduction velocity. NCS also 
involves recording and measuring the amplitude of muscle action potential (MAP). NCS can 
distinguish demyelinating from axonal neuropathies. In general, a reduction in conduction 
velocity and normal MAP favours demyelination whereas normal conduction velocity and 
reduced MAP favours axonal neuropathies. Most neuropathies are axonal in type and largely 
untreatable. The most common type is termed distal symmetrical polyneuropathy (DM and 
HIV). In contrast demyelinating neuropathies (GBS) are uncommon but are largely treatable. 
EMG involves insertion of a needle electrode into muscle and measures electrical activity in 
muscles. The patterns of electrical recordings at rest and during activity can determine the 
likely origin of the disorder.
Table 11.3 Laboratory investigations in peripheral neuropathy
Type Investigation Disorder
Haematology FBC, B-12, folate, HIV, VDRL, ESR vit deficiency, HIV, syphilis infection, 
vasculitis
Biochemistry glucose, renal, liver, thyroid function tests, 
protein electrophoresis
diabetes, renal failure, myxoedema, 
paraproteinaemia
Urine cells, protein casts
Immunology auto antibodies: ANCA, rheumatoid factor, 
antinuclear antibody
RA, SLE, PAN
X-ray chest, bones malignancy, myeloma
Lumbar puncture protein GBS, CIDP
Electrical NCS axonal versus demyelinating
Skin slit smears/biopsy acid fast bacilli leprosy
Management of neuropathy
The first principle of management is to diagnose and treat the underlying cause of neuropathy. 
High dose corticosteroids are used in neuropathies complicating vasculitis and chronic 
inflammation. Other forms of immunosuppression include intravenous immunoglobulin 
(IVIG) and plasma exchange (PE). These are used in GBS but these are unavailable to all 
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but the largest medical centres in Africa. Pain is controlled by local and general measures. 
Local measures include application of heat, and topical anaesthetics. General measures include 
analgesics, anti inflammatories, tricyclics, the antiepileptic drugs carbamazepine, pregabalin 
and gabapentin and also opiates (Chapter 20). Weak or paralysed limbs may be assisted with 
orthoses. General advice is given to prevent ulcers by wearing protective foot wear and avoiding 
injury. The most common or important individual neuropathies are presented below.
Key points
 · main causes of neuropathy are HIV, diabetes, leprosy & ART
 · history and examination provide clues to diagnosis & aetiology
 · neuropathies are either sensory or motor or a mixture of both
 · investigations involves bloods, csf examination and X-rays
 · main aim is treat the underlying cause & to control symptoms
INDIVIDUAL NEUROPATHIES
HIV
HIV frequently affects peripheral nerves. The main mechanisms are direct HIV infection 
and autoimmunity (Chapter 8). The most common neuropathy in HIV is a distal sensory 
neuropathy (DSN) secondary to HIV infection itself and to ART. Less common neuropathies 
include Bell’s palsy and inflammatory neuropathies including Guillain-Barre syndrome. 
Distal sensory neuropathy (DSN)
DSN is the main HIV related neuropathy and occurs as a result of direct HIV infection 
triggered immune activation affecting peripheral nerves (Fig.11.8). It affects about one quarter 
of AIDS patients, occurring mostly but not exclusively in more advanced HIV disease with 
CD4 counts <200/cm3. 
The main symptoms of DSN are a painful, hot, burning, numbness or paraesthesia like sensation 
occurring symmetrically in a foot and stocking distribution, developing slowly over weeks and 
months. Power is usually maintained but may very occasionally be decreased around the ankle 
joint. The ankle and infrequently the knee reflexes are absent or decreased and this may be 
the only sign to indicate the presence of DSN. Sensation involving touch is mostly intact 
but touch is characteristically perceived by the patient as painful or dysaesthetic, particularly 
when touched crudely on the soles of the feet and the palms of the hands. Vibration and 
pinprick may be impaired distally in the feet in advanced disease. The upper limbs are typically 
unaffected apart from the dyaesthesia in the palms. 
The mainstay of management is to start ART as soon as possible. Symptomatic relief of 
pain may be obtained using simple analgesics and/or amitriptyline; however opiates may be 
necessary in severe cases. 
individual neuropathies
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Figure 11.8 DSN in HIV, histopathology Perineural inflammation
ART associated neuropathy
Peripheral neuropathy may also occur as an adverse effect of antiretroviral therapy. The 
symptoms and signs are very similar to HIV related neuropathy, although the sensory signs 
may be more marked in ART neuropathy. Both HIV and ART related neuropathy are termed 
DSN. In Sub-Saharan Africa, DSN is one of the main limiting side effects of first line ART. In 
particular this occurs with the use of the nucleoside reverse transcriptase inhibitor, stavudine 
(d4T). The incidence of DSN in HIV has been shown to increase with the use of d4T, in 
particular with 40 mg dosage and its duration of use. DSN may affect up to 20% of patients 
who have been on dT4 for 6 months or more and this increases the overall rate of DSN in 
HIV to >40%. 
Management involves either reducing the standard dose of d4T from 40 to 30 mg (as 
recommended by WHO) or stopping and replacing d4T or the likely causal ART drug. Two 
thirds of patients may improve if switched to a non d4T regime. Other ART drugs associated 
with peripheral neuropathy include didanosine (ddl), lamivudine (3TC) and zalcitibine (ddC). 
Known risk factors for DSN include a history of previous or active antituberculous therapy, 
older age, alcohol use and malnutrition. Care should be taken to ensure that pyridoxine 20 
mg/po/daily has been prescribed in all patients taking isoniazid, and that thiamine 100 mg/
po/daily should be given in suspected cases of B-1 vitamin deficiency. Otherwise symptomatic 
management is the same as in HIV disease.
Bell’s palsy
Bell’s palsy or facial nerve palsy is the most frequent presentation of mononeuritis in HIV 
infection (Chapter 8). On screening during the acute phase of the HIV epidemic in some 
areas in Africa as many as 50% of patients presenting with Bell’s palsy tested positive for HIV. 
Bell’s palsy occurs typically during the asymptomatic phase of HIV infection when the patient 
feels otherwise well and is still relatively immunocompetent. The facial weakness develops 
over 24 hours and the clinical course is similar to that in non HIV associated Bell’s palsy, 
however it may occasionally be bilateral. Facial nerve palsy onsets during the later stages of 
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HIV infection occur mostly in association with opportunistic infections involving the CNS, 
mainly meningitis.
Inflammatory neuropathies
Guillain Barre Syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy may 
also occur in association with HIV infection. These occur during the otherwise asymptomatic 
phase of HIV infection when immunity is relatively intact. They are both relatively uncommon 
forms of neuropathy but may be the first clinical indication of underlying HIV infection. Their 
mechanism is considered to be autoimmune based. Clinically GBS in HIV is indistinguishable 
from non HIV associated GBS apart from the presence of a number of lymphocytes in the CSF 
possibly due to the concurrent HIV infection. The management and the prognosis is the same 
as in non HIV associated demyelinating neuropathies. 
Key Points
 · neuropathy in very common in HIV disease
 · most common is DSN in 40% of patients
 · mechanisms are direct HIV infection, ART toxicity & autoimmunity
 · management includes starting ART & reducing/stopping offending drug
 · frequency of GBS & Bell’s palsy are increased in HIV infection
LEPROSY
Leprosy is a chronic progressive potentially disabling granulomatous disease of the skin, and 
or peripheral nerves caused by Mycobacterium leprae. It causes damage to nerves which results 
in characteristic deformity and disability. It used to be the commonest cause of neuropathy 
worldwide but since the introduction of multi drug therapy (MDT) in the late 1980s over 15 
million cases of leprosy worldwide have been treated successfully. Despite a reported decline in 
the incidence of leprosy, there are still a quarter to half a million new cases reported worldwide 
each year with most occurring in India. Africa accounts for over 40,000 newly reported cases 
annually. The countries with the highest incidence in Africa are the DRC and Mozambique.
Transmission
Leprosy is transmitted  by inhalation of aerosolized nasal secretions from an infected person. 
Effective transmission requires regular prolonged close household or community contact with 
an infected person. The incubation period from infection to clinical disease varies from months 
to up to 30 years. The average incubation of contracting the disease from contact household 
cases is estimated to be about 5 years. Touching does not spread the disease.
Clinical features
The clinical features are determined by the host immune response. The main clinical 
presentations are anaesthetic skin lesions and peripheral neuropathy. 
Host response
The majority of persons infected with M. leprae never develop clinical disease and this represents 
an effective host response. When disease does develop the clinical spectrum corresponds with 
the degree of T cell mediated immunity of the patient. Leprosy has a wide range of clinical 
presentations ranging from polar tuberculoid (TT) through borderline to polar lepromatous 
leprosy
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(LL) (Figs. 11.9-10). While TT leprosy represents a good but still ineffective cell mediated 
immunity, LL represents little or no cell mediated immunity. 
In TT at histology there are high levels of cell mediated immunity with granuloma formation 
and very few if any bacilli seen on histology, which limits the disease to a single or few well 
defined anaesthetic skin patches or palpable nerve trunks. This is in contrast to LL where there 
are no granuloma and many bacilli which result in multiple, bilateral, symmetrical skin and 
nerve lesions which are consequently more extensive and slowly progressive (Fig. 11.10). 
In between, there are borderline states ranging from paucibacillary disease in borderline 
tuberculoid (BT) with 3-5 skin lesions with local palpable enlarged nerves to multibacillary 
disease in borderline lepromatous (BL) with multiple skin lesions with variable sensory loss and 
symmetrical nerve enlargement.  
Figure 11.9 Immunological spectrum of leprosy
Tuberculoid Borderline Lepromatous
Granuloma & no AFB No granuloma & AFB++ AFB+++
Figure 11.10 Histopathology leprosy
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Skin
The skin lesions in leprosy vary with type, stage and immunity. The most common are plaques 
and macules but papules and nodules also occur. In tuberculoid leprosy there are single or 
few well circumscribed hypopigmented lesions with sharp borders. These are macular or 
plaque-like hypoanaesthetic patches often with loss of sweating and occurring usually on 
the trunk (Fig. 11.11). In lepromatous leprosy there are multiple, widespread, symmetrical, 
hypopigmented lesions with mostly intact sensation and/or infiltrated patches, papules and 
nodules. Widespread skin infiltration of the face results in the classical “leonine facies” of 
lepromatous leprosy (Fig. 11.11). All suspected skin lesions should be tested carefully for light 
touch, pain, temperature and for sweating. 
Nerves
The main sequela of untreated leprosy is chronic disability secondary to nerve damage. Patients 
with leprosy present with skin lesions, muscle wasting, weakness or numbness in a peripheral 
nerve distribution or a burn or an ulcer in an anaesthetic hand or foot (Fig. 11.19). Nerve 
damage in leprosy occurs at two main levels; at the level of peripheral nerves and their main 
branches in TT and at the level of the small nerve twigs in skin and subcutaneous tissues in LL. 
In TT, there is localized and asymmetrical involvement of the peripheral nerves. This occurs 
near the surface of the skin, where they present with palpable, thickened sometimes tender 
nerves and loss of neurological function in the distribution 
of the nerve. The common sites are the greater auricular 
in the neck, the ulnar at the elbow, median at the wrist, 
radial cutaneous at the wrist, common peroneal at the 
knee and posterior tibial behind the medial malleolus 
(Figs. 11.12-13).  
In LL the dermal nerves are destroyed and there is a 
symmetrical peripheral neuropathy with a peripheral 
glove and stocking sensory loss. 
Borderline leprosy produces most nerve damage as 
multiple nerves are involved earlier and more rapidly than 
in LL. Patients typically present with new skin lesions, 
nerve pain and sudden nerve palsies. 
Figure 11.12 Sites to examine for enlarged nerves in leprosy
TT BT Indeterminate LL
Figure 11.11 Skin in leprosy
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William Howlett Neurology in Africa 271
Neurological findings
There is a wide spectrum of sensory and motor neurological findings in leprosy. The sensory 
findings range from a subtle loss or decrease of temperature, pain, touch and sweating in a 
single skin patch in TT to a widespread peripheral neuropathy with evidence of sensory loss 
in the cooler extremities in LL. The sensory loss in LL may involve the extensor surface of the 
legs, feet, forearms and hands, nose, cheeks, breasts, abdomen and buttocks with sparing of 
the palms soles and scalp. An abrupt transition to normal sensation on the scalp is called the 
“hairline sign”. Marked single or multiple peripheral nerve damage can occur in TT leprosy 
resulting in wrist drop, claw hand, dropped foot or failure to close an eye (lagophthalmos) 
(Figs.11.14-15). Motor findings in LL present as distal weakness of the intrinsic muscles of 
hands and feet. Loss of peripheral reflexes, joint position and vibration sense are typically late 
findings in leprosy being preserved early on in the disease. 
Great auricular Common peroneal
Median Ulnar
Figure 11.13 Nerve enlargement in leprosy
Early clawing (ulnar) Clawing & loss of sensation (ulnar) Lagophthalmos
Figure 11.14 Nerve damage in leprosy
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Eyes
Damage to the eye results from involvement of both trigeminal and facial nerves. This results in 
a loss of sensation on the cornea and inability to close and protect the eye (Fig. 11.14). A minor 
injury may result in corneal scarring and blindness. Direct massive invasion of the cornea can 
occur mainly in LL causing conjunctivitis, iritis and eventually blindness (Fig. 11.15).
Diagnosis
The diagnosis of leprosy is above all a clinical one and early diagnosis is crucial to management. 
The diagnostic features are hypopigmented patches with definite loss of sensation (Fig. 11.11) 
(however skin lesions in BL/LL may not have sensory loss), palpably thickened peripheral 
nerves (Figs. 11.12-13) and the presence of acid fast bacilli in slit skin smears or biopsy. 
Samples are taken from the ear lobes (Fig. 11.16), eye brows and the edges of active lesions. The 
density of bacilli on slit skin smears is called the bacterial index (BI). WHO classifies leprosy as 
paucibacillary (PC) when no bacilli are seen and multibacillary (MB) when bacilli are seen. If 
more than five skin lesions are seen, this is also classified as MB disease regardless of the absence 
of bacilli on skin smear. This method is used when slit skin smears are not available. 
Diagnostic features of leprosy
 · skin lesions with sensory loss 
 · thickened peripheral nerves
 · acid-fast bacilli on slit skin smears or biopsy
Ectropion & blindness Iritis & blindness
Figure 11.15 Eye damage in leprosy
Slit ear lobe Scrape & smear evenly on glass slide AFB+++
Figure 11.16 Slit skin smear
leprosy
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Differential diagnosis
The differential diagnosis for neuropathy in leprosy includes mononeuropathies, sensorimotor 
polyneuropathies, hereditary neuropathies and syringomyelia. Amyloid and neurofibromatosis 
also can cause nerve thickening mimicking leprosy. While the typical pattern of skin and 
neurological involvement help to establish the diagnosis in leprosy particularly in endemic 
areas, a keen index of suspicion is always necessary especially in non endemic areas. 
Key points
 · leprosy is chronic infection of skin and nerves caused by M leprae
 · a major cause of disabling peripheral neuropathy in Africa
 · findings explained by variation in degree of cell mediated immunity
 · neurological features: numbness or weakness in individual nerves & polyneuropathy
 · diagnosis: anaesthetic skin lesions, thickened peripheral nerves & AFBs in skin snips
Treatment
Education of the patient about their disease has been identified as the most important strategy 
in successful management of leprosy. The key areas are an understanding of its low infectivity, 
importance of drug compliance, an awareness of reversal reactions, the critical need for care of 
anaesthetic feet and hands and social issues. 
The main aim of treatment is to cure the patient without residual permanent disability. The 
treatment of leprosy depends on whether it is lepromatous or tuberculoid in type. All patients 
should receive multiple drug treatment (MDT); for 6 months in TL or paucibacillary disease 
and for 12-24 months in LL or multibacillary disease. The treatments include dapsone, 
clofazamine and rifampicin and are outlined in Table 11.4. Patients are no longer infectious 
after 72 hours of treatment. Relapse rates range from 0 to 2.5% in paucibacillary disease to 
0-8% in multibacillary disease. The main side effects of MDT include red urine discolouration 
with rifampicin, red-brown discolouration of the skin with clofazamine and haemolysis with 
dapsone, particularly in patients with G6PD deficiency. Nerve damage in leprosy can occur 
before, during and after MDT. The main mechanism of nerve damage after starting MDT is 
by reactions (Table 11.5). 
Table 11.4 MDT regimes (WHO)
Type of Leprosy Drug Treatment
Daily  
(self administered)
Monthly  
(supervised)
Length, 
months
Side effects
Paucibacillary dapsone 100 mg and rifampicin 600 mg 6 haemolysis (G6PD), allergy, 
hepatitis, red urine
Multibacillary clofazimine 50 mg
dapsone 100 mg
and rifampicin 600 mg
clofazimine 300 mg
12-24 red skin, ichthyosis
Reactions
The clinical course of leprosy can be made acutely worse by reversal reactions. These can be 
precipitated by drug therapy (MDT), pregnancy and other illnesses. These are two main types 
of reactions, type 1 reversal reactions and type 2 erythema nodosum leprosum (ENL) reactions 
(Table 11.5). Type 1 reactions tend to occur in immunologically unstable borderline patients, 
(BT, BB and BL) upgrading towards tuberculoid leprosy during the first or second year of 
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MDT or after treatment. It occurs in about 30% of BL patients. The peak time is within 
the first 2 months of treatment. They present with acute inflammation, erythema, oedema 
and tender nerves, sometimes with dramatic loss of nerve function (Fig.11.17). Short course 
steroids are used for 3-4 months in BT and 6 months in BL patients. Erythema nodosum 
leprosum (ENL) type 2 reaction occurs in about 20% of LL and in 10% of BL patients 
(Fig.11.18). Patients with a high bacterial load are more at risk. It presents with fever and crops 
of small pink nodules mainly over the extensor surfaces. Systemic and nerve involvement are 
also common. To suppress the inflammation repeated short courses of steroids may be necessary 
and clofazamine is also used. Thalidomide has been successfully used in young men. However, 
it is relatively contraindicated in young females because of the high risk of teratogenesis mainly 
phocomelia and has not therefore been licensed in the majority of centres.
Table 11.5 Reversal reactions on treatment
Classification Leprosy risk 
group
Frequency Clinical features Occurrence Management
Type 1 
(reversal)
borderline 
leprosy
30% skin: erythema, 
oedema hands and 
face mainly
nerves: tender & loss 
of function in nerve 
distribution
1) within the 
first 2 months of 
treatment 
2) within 12/12 
or after Rx
3) puerperium
prednisolone 
40-60 mgs daily 
decreasing by 
5 mg every 2-4 
weeks for 3-6 
months
Type 2 
(ENL)
lepromatous
 
borderline 
lepromatous
20%
 
10%
skin: crops of painful 
pink nodules
others: fever
uveitis/iritis,
arthritis
neuritis
orchitis
1) within 
the first or 
second year of 
treatment
2) may occur 
years after 
treatment 
 
3) pregnancy, 
lactation
prednisolone 
1mg/kg/day/2-
3/52 weeks only
 
clofazimine 300 
mg daily for 2/12, 
followed by 200 
mg daily for 2/12
thalidomide 400 
mg daily (use in 
men) for months
Complications
The complications of leprosy arise as a result of nerve damage leading to deformity and 
disability. This occurs through loss of pain sensation leading to trauma, burns, tissue damage, 
injury and secondary infection. The main complications are ulceration, osteomyelitis, foot 
and wrist drop, contractures, loss of digits and blindness (Fig. 11.19). Prevention is by patient 
education about the early recognition of the disease, reactions, complications and the initiation 
of appropriate treatment. Teaching patients about their disease is most important. The patient 
needs to be particularly aware of risk and guard an anaesthetic limb by protective measures 
including special footwear and routine daily inspection for signs of trauma. Ulcers should be 
treated with rest, surgical debridement and antibiotics if infected. Reconstructive surgery is 
helpful in contractures and in eye complications. 
leprosy
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Prevention
The mainstay of the prevention of leprosy in endemic areas is by passive case finding and 
then directly observed treatment (DOTS) rendering the patient non-infectious to others. 
Chemoprophylaxis of close contacts may also be an effective strategy in the future and studies 
are underway to assess its role. BCG gives variable (>50%) protection against clinical leprosy. 
Lepra reactions Granuloma like & no AFB
Figure 11.17 Type 1 reversal reactions
Nodules Ulcers No granuloma & AFB ++
Figure 11.18 Type 2 reversal reactions, ENL
Histology
Swelling & acroderma of face and feet
Histology
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Key points
 · educating the patient about their disease is best way to manage leprosy
 · Rx includes MDT & compliance, awareness of reactions & prevention of disability
 · complications occur as a result of nerve damage causing anaesthesia and weakness
 · they include ulcers, osteomyelitis, foot/wrist drop, contractures, loss of digits & blindness
 · prevention of leprosy is by passive case finding, DOTS &  BCG vaccination
DIABETES
Diabetic neuropathy is the most common type of neuropathy worldwide. It is present in about 
one in ten diabetic patients at diagnosis and in the majority of patients 25 years later on. The 
main finding is a slowly progressive distal sensory neuropathy (DSN) starting in toes and 
gradually spreading up to knees and later to fingers and hands. It is characterized by numbness, 
tingling, pain, decreased sensation in the feet and legs and areflexia. Autonomic neuropathy 
may occur and its main clinical features include orthostatic hypotension, gastroparesis and 
impotence. Infrequently diabetes may cause isolated mono and multiple neuropathies. The 
most common ones are 6th and 3rd cranial neuropathies, femoral neuropathy and radiculopathies 
affecting the lumbar and sacral nerve roots. Management is by strict control of blood glucose 
levels, treatment of neuropathic pain and the prevention of foot and leg ulcers much in the 
same way as in leprosy.
Ulceration & osteomyelitis
Figure 11.19 Complications of leprosy
Ulceration & loss of digits
diabetes
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Key points
 · neuropathies are very common in diabetes
 · DSN is the most common neuropathy
 · isolated mononeuropathies may also occur
 · treatment involves control of glucose, pain and prevention of complications
 · blood sugar should be checked in all patients with unexplained neuropathies
VITAMIN DEFICIENCY
The main causes of neuropathy due to vitamin deficiency are B-1 (thiamine), B-6 (pyridoxine) 
and B-12 (cobalamin). 
Vitamin B-1 deficiency
Thiamine (B-1) deficiency causes beriberi and Wernicke-Korsakoff-Syndrome (WKS). 
Beriberi can be dry or wet. Dry beriberi results in a sensory motor polyneuropathy while wet 
beriberi results in cardiac failure and generalised oedema. Beriberi in Africa is mainly caused 
by malnutrition arising from food shortages and also occasionally from alcoholism. WKS is 
an encephalopathy which can be acute or chronic. The usual cause is thiamine deficiency in 
alcoholism. Acute WKS is characterized by confusion, amnesia, ataxia and nystagmus and ocular 
paralysis. When WKS becomes chronic, it is characterized by an irreversible confabulatory type 
dementia with a devastating loss of short term memory. Treatment for both conditions is by 
thiamine replacement either intravenously or orally. The response is variable in acute or mostly 
none at all in chronic WKS. The dose of thiamine is 100 mg/daily. It is essential to first replace 
the missing thiamine before giving intravenous dextrose or treating infections or replacing 
other vitamins, as failure to do this can precipitate an irreversible WKS.
Vitamin B-6 deficiency
Pyridoxine (Vit B-6) deficiency causes a mainly sensory neuropathy. The main cause in Africa 
is isoniazid in TB treatment. It can be prevented by giving pyridoxine 20-50 mg orally daily, 
whenever isoniazid is used. Overdoses of vitamin B-6 may actually cause neuropathy so it is 
important to avoid doses greater than 100 mg daily.
Vitamin B-12 deficiency
Cobalamin (Vit B-12) deficiency causes a polyneuropathy, sub acute combined degeneration 
of the cord (SACD), optic atrophy, dementia and pernicious anaemia. Vitamin B-12 deficiency 
may be less common in Africa than in high income countries. The main clinical findings of 
the neuropathy are absent ankle jerks, loss of peripheral sensation (especially joint position and 
vibration) in combination with brisk knee reflexes and up going plantar responses. The main 
causes are nutritional deficiency and malabsorption of B-12. Malabsorption may be due to lack 
of intrinsic factor and diseases of the terminal ileum. Treatment is with hydroxycobalamin (Vit 
B-12) 1 mg (1000 micrograms) intramuscular injections on alternate days for a total of five 
injections or 5 mg. This is followed by 1 mg injections every 3 months for life. In the absence 
of severe malabsorption, replacement can be given orally at a dose of 1 mg daily.
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ALCOHOL
Alcohol misuse is an increasingly common cause of neuropathy worldwide. Apart from 
malnutrition related thiamine deficiency, alcohol causes a direct effect on nerves by the toxic 
effect of its metabolites. It presents with a history of a slowly progressing burning dysasthesia 
mainly in the feet and legs over months or years in a person misusing alcohol. On examination, 
there are signs of a distal sensory motor neuropathy usually without significant loss of power. 
Treatment is to stop the alcohol and replace thiamine (Vit B-1) although painful symptoms 
frequently persist. Tricyclics and/or the antiepileptics may be helpful for treatment. 
Key points
 · Vitamin B deficiencies occur mainly because of food shortages & disease 
 · B-1 (thiamine) deficiency causes beriberi and WKS
 · B-6 (pyridoxine) deficiency occurs with isoniazid in TB treatment
 · B-12 (cobalamin) deficiency causes neuropathy treatable with B-12 injections
 · chronic excessive alcohol may result in a painful persistent sensory neuropathy
GUILLAIN-BARRE SYNDROME (GBS)
GBS is an immune mediated demyelinating polyneuropathy. It is an uncommon disease 
affecting about 2/100,000 each year. It presents as an acute progressive usually ascending 
flaccid paralysis that reaches its peak usually around 10-14 days but always by definition in 
less than 4 weeks. This is followed by a plateau phase and eventual recovery for most patients 
after 3-6 months. Two thirds of cases are associated with a history of preceding febrile illness, 
diarrhoea, immunization or surgery during the previous 2-3 weeks. Preceding causes of fever 
associated with GBS include campylobacter jejuni, cytomegalovirus, and other respiratory 
and gastrointestinal infections. HIV infection is associated with an increased risk of GBS and 
patients with suspected GBS should be screened for HIV.
Clinical features
The presenting complaint is that of a rapidly developing motor weakness occurring over 
days and sometimes hours. Sensory symptoms, mainly paraesthesiae, often painful may 
accompany the weakness but these are usually mild. Motor weakness is usually marked early 
on both proximally and distally. Reflexes are diminished or absent. Sensation is mostly intact 
but may be impaired. There is no sensory loss on the trunk. Sphincters are spared. Lower 
motor neurone type facial weakness occurs in about half the patients but may be mild and is 
frequently bilateral. Other cranial nerves may be involved. Respiratory failure and autonomic 
symptoms occur in over a fifth of patients. The main complications and cause of death in 
GBS are respiratory failure, pneumonia, cardiac arrhythmias and pulmonary embolism. The 
differential diagnosis includes other causes of acute flaccid paralysis. These include transverse 
myelitis, organophosphorous poisoning, diphtheria, polio, botulinum and lead poisoning. 
Chronic inflammatory demyelinating polyneuropathy is a more chronic form of GBS with a 
slower onset, over 2-3 months and responds well to steroids. 
Investigations
These include a full blood count, HIV test, blood glucose, creatinine and electrolytes. A lumbar 
puncture should be carried out to check for the characteristic elevation in CSF protein in 
alCohol
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the absence of white blood cells (WBC <5/mm3). The CSF protein may be normal during 
the first week of the illness and this may need repeating during the second or third week. If 
available, nerve conduction studies will show marked slowing of motor conduction velocities 
characteristic of a demyelinating polyneuropathy.
Key points
 · GBS typically presents with acute rapidly progressing limb weakness over 1-2 weeks
 · lower back and proximal limb pain may be an initial presenting complaint
 · facial nerve palsies may be present
 · approximately two thirds have a recent (2/52) history of either diarrhoea or a febrile illness
 · diagnosis is supported by elevated csf protein without WBCs
General management
The outcome of GBS depends on the quality of nursing care. The patient should be initially 
placed in an intensive care unit. Nursing care is directed at checking for signs of increasing 
weakness, respiratory failure and the prevention of bedsores and contractures. The vital signs 
and in particular the vital capacity should be measured 4 hourly for the first few days of the 
illness. If the vital capacity falls to the range of 1.5-1 litre, then assisted ventilation must be 
considered. The heart should be monitored for arrhythmias and any surges in blood pressure 
treated with beta blockers. Compression stockings and low dose heparin are used to prevent 
deep vein thrombosis and pulmonary emboli. A nasogastric tube may need to be passed if 
swallowing is a concern. The patient may need analgesia for pain and psychological support. 
Physiotherapy should be started on admission.
Specific treatments
Steroids have no role in the treatment of GBS. Specific treatments include intravenous 
immunoglobulin (IVIG) or plasma exchange (PE). IVIG is the treatment of choice but both 
are equally beneficial. Disease progression, respiratory failure and significant disability are all 
indications for their use and they should be administered within the first 2 weeks of onset of 
the illness, as they are not of value after that time. Their main role is to halve the average period 
of hospital stay from about 12 to 6 weeks. However, these treatments are mostly unavailable 
because of their high cost and limited resources.
Prognosis
The mortality in GBS in Africa is around 10%. Recovery in the remaining 90% is good but 
some (10-20%) remain partially disabled at 12 months. 
Key points
 · acute care involves regular monitoring for respiratory failure ie FVC <15 litres
 · main complications are respiratory failure, pneumonia, arrhythmia & pulmonary emboli 
 · specific treatments include IVIG & PE 
 · CFR in Africa is about 10%, with most patients recovering fully after 3-6/12
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CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)
CIDP is similar to GBS but follows a chronic progressive course over months rather than 
weeks. It is very uncommon but represents a treatable neuropathy. The cause is not known. 
The clinical features are characterized by a mixed motor sensory peripheral neuropathy usually 
with proximal as well as distal weakness. Cranial nerves and autonomic system are not usually 
involved. The results of investigations are similar to GBS with elevated protein in CSF and 
evidence of demyelination on NCS. 
Treatment is with high dose steroids prednisolone initially 60 mg/od for 4-6 weeks, reducing 
slowly over months until on a minimum maintenance dose of 5-20 mg on alternate days. IVIG 
or plasma exchange can also be used as in GBS. Azathioprine or methotrexate can be added as 
steroid sparing agents. Response to immunosuppression is good but may have to be continued 
in the longer term.
Selected references
Agrawal A, Pandit L, Dalal M, Shetty JP. Neurological manifestations of Hansen’s disease and their 
management. Clin Neurol Neurosurg. 2005 Oct;107(6):445-54.
Bademosi O, Osuntokun BO. Diseases of peripheral nerves as seen in the Nigerian African. Afr J Med Med 
Sci. 1981 Mar-Jun;10(1-2):33-8.
Britton WJ, Lockwood DN. Leprosy. Lancet. 2004 Apr 10;363(9416):1209-19.
de Freitas MR. Infectious neuropathy. Curr Opin Neurol. 2007 Oct;20(5):548-52.
Evans D, Takuva S, Rassool M, Firnhaber C, Maskew M. Prevalence of peripheral neuropathy in 
antiretroviral therapy naïve HIV-positive patients and the impact on treatment outcomes-a retrospective 
study from a large urban cohort in Johannesburg, South Africa. J Neurovirol. 2012 Jun;18(3):162-71
Haimanot RT, Abdulkadir J. Neuropathy in Ethiopian diabetics: a correlation of clinical and nerve 
conduction studies. Trop Geogr Med. 1985 Mar;37(1):62-8.
Haimanot RT, Melaku Z. Leprosy. Curr Opin Neurol. 2000 Jun;13(3):317-22.
Howlett WP, Vedeler CA, Nyland H, Aarli JA. Guillain-Barre syndrome in northern Tanzania: a 
comparison of epidemiological and clinical findings with western Norway. Acta Neurol Scand. 1996 
Jan;93(1):44-9.
Koike H, Sobue G. Alcoholic neuropathy. Curr Opin Neurol. 2006 Oct;19(5):481-6.
Lockwood DN. Leprosy–a changing picture but a continuing challenge. Trop Doct. 2005 Apr;35(2):65-7.
Lockwood DN, Suneetha S. Leprosy: too complex a disease for a simple elimination paradigm. Bull World 
Health Organ. 2005 Mar;83(3):230-5.
Maritz J, Benatar M, Dave JA, Harrison TB, Badri M, Levitt NS, Heckmann JM. HIV neuropathy in 
South Africans: frequency, characteristics, and risk factors. Muscle Nerve. 2010 May;41(5):599-606.
McGrath CJ, Njoroge J, John-Stewart GC, Kohler PK, Benki-Nugent SF, Thiga JW, et al. Increased 
incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-
based antiretroviral regimens in Kenya. J Neurovirol. 2012 Jun;18(3):200-4.
Melaku Z, Zenebe G, Bekele A. Guillain-Barre syndrome in Ethiopian patients. Ethiop Med J. 2005 
Jan;43(1):21-6.
Ooi WW, Srinivasan J. Leprosy and the peripheral nervous system: basic and clinical aspects. Muscle Nerve. 
2004 Oct;30(4):393-409.
Radhakrishnan K, Thacker AK, Maloo JC. A clinical, epidemiological and genetic study of hereditary motor 
neuropathies in Benghazi, Libya. J Neurol. 1988 Sep;235(7):422-4.
Sitati FC, Naddumba E, Beyeza T. Injection-induced sciatic nerve injury in Ugandan children.Trop Doct. 
2010 Oct;40(4):223-4.
ChroniC inflammatory demyelinating polyneuropathy (Cidp)
William Howlett Neurology in Africa 281
Van Veen NH, Lockwood DN, Van Brakel WH, Ramirez J, Jr., Richardus JH. Interventions for erythema 
nodosum leprosum. A Cochrane review. Lepr Rev. 2009 Dec;80(4):355-72.
Wadley AL, Cherry CL, Price P, Kamerman PR. HIV neuropathy risk factors and symptom characterization 
in stavudine-exposed South Africans. J Pain Symptom Manage. 2011 Apr;41(4):700-6.
Walker SL, Lockwood DN. Leprosy. Clin Dermatol. 2007 Mar-Apr;25(2):165-72.
Walker SL, Lockwood DN. Leprosy type 1 (reversal) reactions and their management. Lepr Rev. 2008 
Dec;79(4):372-86.
Chapter 11  disorders of peripheral nerves
Part ii – Neurological Disorders 282
Part ii – Neurological Disorders
Dr William P. Howlett
2012
CHAPTER 12  
CRANIAL NERVE DISORDERS
Kilimanjaro Christian Medical Centre,  
Moshi,  
Kilimanjaro, 
Tanzania
BRIC 2012
 
University of Bergen 
PO Box 7800 
NO-5020 Bergen 
Norway
NEUROLOGY IN AFRICA
William Howlett
Illustrations: Ellinor Moldeklev Hoff, Department of Photos and Drawings, UiB
Cover: Tor Vegard Tobiassen
Layout: Christian Bakke, Division of Communication, University of Bergen
Printed by Bodoni, Bergen, Norway
Copyright © 2012 William Howlett
NEUROLOGY IN AFRICA is freely available to download at  
www.uib.no/cih/en/resources/neurology-in-africa
ISBN 978-82-7453-085-0
Notice/Disclaimer
This publication is intended to give accurate information with regard to the subject matter covered. 
However medical knowledge is constantly changing and information may alter. It is the responsibility of the 
practitioner to determine the best treatment for the patient and readers are therefore obliged to check and 
verify information contained within the book. This recommendation is most important with regard to drugs 
used, their dose, route and duration of administration, indications and contraindications and side effects. 
The author and the publisher waive any and all liability for damages, injury or death to persons or property 
incurred, directly or indirectly by this publication.
MIL
JØMERKET
241    Trykksak    
699
CONTENTS
CRANIAL NERVE DISORDERS 287
OLFACTORY NERVE                                                                                             287
PUPILLARY RESPONSES                                                                                       287
THE LIGHT REFLEX                                                                                              288
THE ACCOMMODATION REFLEX                                                                             289
PUPILLARY DISORDERS                                                                                        289
VISUAL ACUITY (VA)                                                                                            291
VISUAL FIELDS                                                                                                   292
FUNDOSCOPY                                                                                                    293
OCULOMOTOR, TROCHLEAR AND ABDUCENS: EYE MOVEMENTS                                 295
SQUINT                                                                                                            298
NYSTAGMUS                                                                                                      299
TRIGEMINAL NERVE                                                                                             300
FACIAL NERVE                                                                                                    301
BELL’S PALSY                                                                                                      301
ACOUSTIC NERVE                                                                                               303
HEARING                                                                                                          303
VERTIGO/DIZZINESS                                                                                            304
BENIGN PAROXYSMAL POSITIONAL VERTIGO (BPPV)                                                 304
ACCESSORY NERVE                                                                                             305
GLOSSOPHARYNGEAL, VAGUS AND HYPOGLOSSAL NERVES                                       305
CHAPTER 12
CRANIAL NERVE DISORDERS
Cranial nerve disorders are common neurological disorders. The clinical skills needed to 
examine the individual cranial nerves are presented in chapter 1.The overall aim of this chapter 
is to present the main cranial nerve disorders and to integrate examination and localization in 
their diagnosis. After reading the chapter the student should be able to localize and diagnose 
main disorders affecting pupils, vision, eye movements, facial sensation and movements, 
hearing, speech and swallowing.
OLFACTORY NERVE
Smell
Neurological disorders involving the olfactory nerve are uncommon and the olfactory nerve 
is rarely tested in day to day clinical practice. During a routine neurological examination it 
is sufficient to ask the patient if there is a loss or decrease in the sense of smell (anosmia). 
Frequently patients are unaware of a loss of smell or may only complain of losing their sense of 
taste. This is because both smell and taste are used together to appreciate the flavors of food and 
drink. If there is a loss or deterioration in smell, then each nostril should be tested separately as 
outlined in chapter 1. The most common cause of transient loss of smell is mucosal swelling in 
the nose or sinuses as a result of local infection e.g. head cold, allergy or smoking. Anosmia may 
occur after a head injury when there is a shearing injury to the olfactory bulb and its central 
connections through the cribriform plate. A rare cause of unilateral anosmia is a meningioma 
in the olfactory groove. Olfactory hallucinations are a feature of temporal lobe epilepsy. 
Optic nerve
Disorders affecting the optic nerve are common and clinical assessment involves a history and 
examination. The history involves asking about a loss or decrease in vision, double vision, pain 
and headache and their mode of onset, progression and time course. The examination of the 
optic nerve includes testing the pupillary responses, visual acuity, visual fields and fundoscopy. 
Details concerning the technique of examination have already been set out in chapter 1. 
PUPILLARY RESPONSES
Pupillary size and reactions
Both pupils should be normal in size (2-6 mm), equal, central and circular (ECC). The iris 
controls the size of the pupil. It does this by means of two groups of muscle fibres supplied by 
William Howlett Neurology in Africa 287
the autonomic nervous system. The sphincter pupillae is a circular constrictor smooth muscle 
supplied by the parasympathetic and the dilator pupillae is a radial smooth muscle supplied 
by the sympathetic nervous system. The balance between these accounts for normal pupil size.
The important aspects in their examination are summarized below.
Key points
 · look at the pupils and note their size & whether they are equal or not
 · shine a bright light into one eye and look at pupil reaction in that eye (direct light reflex)
 · repeat and look at the pupillary reaction in the other eye (consensual reflex)
 · do the same for the other eye
THE LIGHT REFLEX
Pathway for pupillary constriction (parasympathetic)
A light (torch) is shone in each eye separately whilst asking the patient to fix on an object 
at least 3m away. The light in one eye sends an afferent impulse along the optic nerve to the 
midbrain. The afferent anatomical pathway to the midbrain involves the retina, optic nerve, 
chiasm and optic tract. From the midbrain, a second order neurone travels to the Edinger-
Westphal nucleus on both the same and opposite side of the midbrain. From there, efferent 
parasympathetic fibres travel back to the eyes, via the outside of the oculomotor nerve to the 
ciliary ganglion and to the constrictor sphincter pupillae. If all pathways are working normally, 
then the pupils in both eyes constrict equally and at the same time in response to light shone 
in one eye (Fig 12.1A). This represents the normal light reflex in the light stimulated eye and 
the consensual reflex (response) in the other eye. A lesion anywhere along that pathway results 
in a dilated pupil (mydriasis) on the affected side. The resulting defect is called an afferent 
pupil defect if it affects the optic pathway (Fig 12.1C) and an efferent pupil defect if it affects the 
parasympathetic pathway (Fig 12.1 B). 
Figure 12.1 Testing for afferent and efferent pupillary disorders
Pathway for pupillary dilatation (sympathetic)
The sympathetic fibres descend on the same side from the hypothalamus via the lateral brain 
stem to the cervical spinal cord leaving the cord anteriorly at C8, T1. The fibres then ascend on 
A
B
C
Pupillary disorders
A normal
B eerent defect
C aerent defect
A normal: both pupils constricted
B efferent defect: shine torch in affected eye (dilated pupil): light is perceived but 
affected pupil is unable to react because of a defect in the efferent pathway Because 
the afferent pathway is unaffected, there is a normal consensual response in the 
other eye
C afferent defect: shine torch in affected eye (dilated pupil); light is not perceived and 
affected pupil in unable to react because of a defect in the afferent pathway Because 
the afferent pathway is affected, there is no consensual response in the other eye
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the same side in the sympathetic chain to the superior cervical ganglion and from there on the 
outside of the wall of the internal carotid artery to the ciliary ganglion and the dilator pupillae 
in the iris. A lesion anywhere along its path results in a constricted, small pupil (miosis). Because 
sympathetic nerves also supply fibres to the ipsilateral eyelid (levator palpebrae superioris), the 
orbit and adjacent skin, a lesion in the sympathetic chain also results in ptosis, enopthalmos and 
anhydrosis. The presence of all four signs together is called Horner’s syndrome, (Table 12.1). 
Swinging torch test
A relative afferent pupil defect is a sign of optic neuritis in the eye being examined. It can be 
demonstrated by the swinging torch test, during which light is repeatedly shone alternatively 
into the good eye and the affected eye. When light is shone on the non affected good eye, both 
pupils constrict normally, however, when the light is transferred briskly to the affected or bad 
eye both pupils dilate (Fig. 12.2). The explanation for this is that the weak direct effect on the 
bad eye is counterbalanced by the withdrawal of the stimulus from the good eye and the loss of 
the consensual response. This is a sign of incomplete optic neuropathy and is most commonly 
seen in optic neuritis.
Figure 12.2 Testing for a relative afferent pupillary defect
THE ACCOMMODATION REFLEX
When using near vision the eyes converge and pupils constrict, this is the accommodation 
reflex. The afferent component of the accommodation reflex is conveyed in the optic nerve 
and the efferent pathway is less certain but does involve the visual cortex and some of the 
same pathways as the efferent light reflex. Testing for the presence of the accommodation 
reflex has become less useful in clinical practice especially with the decrease in the frequency of 
neurosyphilis worldwide (Chapter 6). 
PUPILLARY DISORDERS
Disorders affecting pupils occur at four main sites; the eye, the afferent or optic pathway, the 
efferent or parasympathetic pathway and the sympathetic pathway (Table 12.1). The main 
disorders affecting the eye include infection, inflammation and trauma.
Neurological disorders affecting the afferent pathway are relatively common in Africa. These are 
termed optic neuropathies and result in loss of vision and afferent pupil defects (Fig 12.1C). The 
main causes are inflammatory (optic neuritis), nutritional and toxic. However, in many cases 
their cause is unknown. 
Disorders affecting the efferent pathway (Fig 12.1 B) also occur. If the oculomotor (3rd nerve) 
is compressed on its path from the brain stem to the eye, then damage to the parasympathetic 
Both pupils dilate on shining light in 
aected right eye 
(relative aerent pupillary defect)
A Both pupils constrict on shining light in unaffected left eye
B Both pupils dilate on shining light in affected right eye (relative afferent pupillary defect)
the aCCommodation reflex
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fibres which travel on the outside will result in a fixed, dilated pupil on that side. There may 
also be features of 3rd nerve palsy depending on the extent of the compression. Important 
neurological causes include raised intracranial pressure above the tentorium and an aneurysm 
compressing the nerve. 
Disorders affecting the sympathetic pathway can occur anywhere along its pathway from the 
lateral brainstem to the eye, resulting in Horner’s syndrome. A small constricted pupil and slight 
ptosis are characteristic. Neurological causes are uncommon and mainly involve lesions in its 
central pathway. Primary lung cancer involving the apex of the lung is an important cause, 
although this disorder is still relatively uncommon in Africa. 
Other disorders affecting pupils include the Holmes Adie pupil which is a benign condition 
usually affecting one side which is found in women in their 20-40s. The affected pupil is 
dilated with an impaired response to light but also accommodates slowly. It may be or becomes 
bilateral and is also associated with absent ankle reflexes (Table 12.1). The Argyll-Robertson pupil 
is a small and irregular pupil that accommodates to near vision but has a reduced or absent 
light reflex (Table 12.1). It was a well known sign of neurosyphilis but is very uncommon in 
clinical practice nowadays. 
Table 12.1 Characteristics of main pupillary disorders
Disorder/site Neurological findings Main Causes
Optic neuritis
(optic nerve, afferent)
pupils dilated,
(afferent pupil defect)
inflammatory, infections,
nutritional (vit B def ), konzo, TAN* 
toxic (alcohol, drugs)
Third nerve palsy
(parasympathetic, efferent)
compression
non compression
pupil dilated, (efferent pupil defect) 
ptosis (partial or full), eye in down and 
out position, paralysis of adduction & 
up/down movements
pupil not dilated, otherwise the same 
as in compressive lesions
ICP, SOL, aneurysm, cavernous sinus 
thrombosis 
diabetes, meningitis
Horner’s syndrome
(sympathetic fibres)
ptosis (mild), 
miosis (pupil < other pupil), 
enopthalmos (eye less protruding), 
loss of sweating (may be absent)
cluster headache, apical lung 
tumours, cervical cord/brain stem 
lesions, dissecting aneurysms of 
carotid arteries
Holmes-Adie pupil
(iris)
pupil(s) dilated, impaired to light 
(reacts slowly to near light)
variant of normal, autoimmune
Argyll-Robertson pupil
(frontal lobe)
both pupils small & irregular,
accommodate but no reaction to light 
syphilis & diabetes
* tropical ataxic neuropathy
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Key points
 · pupillary disorders can arise from disorders of the eye, optic, parasympathetic & sympathetic 
nerves
 · commonly found in association with disorders of eyelid (Horner’s) and eye movements  
(3rd N palsy)
 · afferent disorders (optic nerve) are mainly caused by inflammation & toxicity
 · efferent disorder (parasympathic) is mainly caused by pressure from the outside on the 3rd nerve
 · Horner’s syndrome is caused by local compression along the sympathetic nerve pathway
VISUAL ACUITY (VA)
VA is tested using a Snellen chart and the result is expressed as a fraction; the numerator being 
the distance between the chart and the patient (usually 6 metres depending on the size of the 
chart) divided by the denominator which is the smallest full line of letters identified correctly 
by the patient (Chapter 1). 6/6 is normal vision whereas 6/60 represents poor VA, meaning the 
patient can only read the largest letter on the chart. If the largest letter cannot be read from a 
distance of 6 metres, then the chart should be brought closer to the patient and VA rechecked. 
If this still fails, then the patient’s ability to correctly count fingers, identify hand movements 
or perceive light should be checked in each eye respectively. Remember to check patients VA 
wearing glasses (if the patient uses them) and recheck decreased VA with a pin hole to exclude 
cataracts and refractive errors as a likely cause. Illustrative charts are available for illiterate 
patients and hand held reading charts can be used to formally test near vision. Identifying the 
various sizes of letters from a local newspaper can suffice for a general impression of VA. The 
main causes of decreased VA are ocular. These include refractive errors in the lens, cataracts and 
retinal diseases, particularly of the macula. The main neurological causes are disorders affecting 
the optic nerve. 
Key points
 · first ask if the patient can see, using both eyes or with glasses
 · test VA in each eye separately using a Snellen chart or a hand held chart or a newspaper
 · if pt is still unable to read large letters check VA by counting fingers, hand movements & light 
perception
 · commonest causes of decreased VA are refractive lens errors & cataracts
 · most frequent neurological cause of decreased VA is optic neuropathy
Colour vision
Colour vision is not routinely tested but can be tested using a set of Ishihara colour plates. These 
consist of a series of plates of coloured dots arranged so that persons with normal colour vision 
can see and identify correctly, a hidden set of numbers or trails arranged in different colours on 
each plate of dots. The patient must be able to read the first (control) plate before proceeding 
and each eye should be tested separately. Defective colour vision may be inherited and is a 
feature of diseases involving the optic nerve in particular optic neuritis. 
visual aCuity (va)
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VISUAL FIELDS
Patient’s visual fields are tested by confrontation. The confrontation method is useful for 
detecting large visual field defects in the visual pathway. In order to interpret and localize the 
main findings correctly it is important to remember the following three points. The nasal side 
of each eye picks up the opposite or temporal half of the visual field whilst the temporal side of 
the eye picks up the opposite or nasal half of the visual field (Fig. 12.3). The optic nerve fibres 
serving the nasal sides of the retina decussate to the opposite side at the level of the optic chiasm 
(Fig. 12.3). Finally by convention the patient’s visual fields are always described and illustrated 
from the patient’s own perspective i.e. as if the patient were looking outwards (Fig. 12.4). The main 
visual defects, their sites of origin and causes are outlined below (Table 12.2).
Table 12.2 Visual field defects, sites & causes
Field defect Site Main causes
1. monocular optic nerve neuritis, vasculitis,  
compressive: aneurysm, meningioma
2. bitemporal hemianopia optic chiasm pituitary adenoma, craniopharyngioma
3. homonymous hemianopia optic tract/occipital lobe stroke, SOL, tumour
Figure 12.3 & 4 The three most common sites of visual field defects
Visual eld defects caused by lesions at
1: Optic nerve
2: Optic chiasm
3: Optic radiation
1
2
3
object
retina
optic nerve
optic chiasm
optic tract
lateral
geniculate
body
occiptial
cortex
image
The visual pathway and the three common sites of lesions
1. Optic nerve lesion:  monocular loss of vision
2. Optic chiasm lesion:  bitemporal hemianopia
3. Optic radiation lesion:  homonymous hemianopia
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Key points
 · check for visual field defects in both eyes by confrontation
 · if defect is suspected, then test each eye individually
 · define the limits or extent of any field defect found
 · main sites of origin of visual field defects are optic nerve, chiasm & optic tract/radiation 
 · most common defect is homonymous hemianopia secondary to a stroke/SOL 
FUNDOSCOPY
The technique and details of fundoscopy are described in chapter 1. In summary, it is important 
to look at and inspect the optic disc, blood vessels and retinal background. An example of a 
normal fundus is shown in fig 12.5. Disorders affecting the optic nerves may result in swelling 
of the optic disc, called papilloedema or wasting of the optic nerve called optic atrophy. Both of 
these disorders can be easily seen and identified by fundoscopy and are illustrated below (Figs 
12.5 & 6). Examples of retinopathy in hypertension and diabetes are included for comparison 
(Fig 12.7).
Papilloedema
Papilloedema is swelling of the optic disc sometimes with surrounding retinal haemorrhages 
and exudates. It is nearly always caused by raised intracranial pressure but it may also be due 
to inflammation of the optic nerves when it is termed optic neuritis or papillitis. Papilloedema 
is nearly always bilateral and occurs mostly without visual symptoms. On examination VA is 
typically normal but the blind spot may be enlarged and the peripheral visual fields constricted. 
Fundoscopy confirms features of papilloedema, a swollen and sometimes haemorrhagic disc 
(Fig. 12.5). If the papilloedema is long standing, then VA is lost due to increased pressure around 
the optic nerve and the optic disc becomes atrophied and pale. The main cause of papilloedema 
in Africa is raised intracranial pressure secondary to either infections, (cryptococcal and TB 
meningitis), space occupying lesions (SOL) or malignant hypertension (Table 12.3). 
Optic neuritis
Optic neuritis is inflammation of the optic nerve or nerve head. It is usually bilateral but may 
occasionally be unilateral. It presents with loss of vision and occasionally a dull ache behind 
the eyes. On examination, VA is decreased or lost and there may be afferent pupil defects, if 
both eyes are involved. Fundoscopy may show papilloedema in the acute stage; however the 
accompanying loss of VA suggests optic neuritis rather than papilloedema as the true cause. In 
long standing cases there is optic atrophy (Fig. 12.6). The main disorders causing optic neuritis 
are inflammatory, toxic, nutritional and infections (Table 12.4). 
fundosCopy
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Table 12.3 Main causes of papilloedema
Disorder Disease
raised intracranial pressure cryptococcus/TB, malignant hypertension, SOL
optic nerve lesions tumours, leukaemia, Drusen
inflammatory Devic’s disease
Optic atrophy
Optic atrophy can be caused by any chronic optic nerve disease process (Table 12.4). The 
nerve which was swollen acutely in inflammatory optic neuritis and in cases of long standing 
papilloedema later when chronic becomes pale and atrophic. Optic atrophy is characterized 
clinically by a loss of visual acuity coupled with a clearly visible pale/white optic disc with clear 
margins on fundoscopy (Fig 12.6). The treatment is directed at the underlying disorder. It is 
important to exclude chronic glaucoma which may present with optic atrophy and painless loss 
of vision, however it is usually monocular.
Table 12.4 Main causes of optic atrophy
Disorder Disease
chronic raised intracranial pressure any cause
post infectious TB, syphilis, viral
post inflammatory Devic’s disease, autoimmune disorders
toxic alcohol, methanol, isoniazid, ethambutol, quinine
nutritional Konzo, TAN*, Vitamin B deficiency
vascular ischaemia
hereditary Leber’s optic neuropathy
* tropical ataxic neuropathy
Pallor, loss of optic cup & disc swelling
Figure 12.5 Fundoscopy findings in papilloedema
Normal fundus Loss of optic cup, disc swelling, indistinct & elevated disc margins, haemorrhages  
& exudates around the disc
Fundoscopy findings in chronic papilloedema
Fundoscopy findings in papilloedema
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Key points
 · is essential to be able to use the ophthalmoscope
 · main disorders are papilloedema & optic atrophy
 · in papilloedema the patient sees well but the doctor can’t see the disc well
 · in optic neuritis the patient can’t see well but the doctor can see the disc well
 · it is important to be able to distinguish the other main causes of retinopathy
OCULOMOTOR, TROCHLEAR AND ABDUCENS: EYE MOVEMENTS
Disorders affecting eye movements are common. The third, fourth and sixth nerves working 
together are responsible for normal eye movements. A lesion in any one of these nerves results 
in a loss of movement in the direction of action of the paralyzed muscles and double vision 
(diplopia), which is most marked when looking in the direction of action of the paralysed 
muscles. Eye movements are controlled by two mechanisms: tracking and by voluntary saccades 
(jumps). Tracking or pursuit occurs when we look at and follow a moving object without 
thinking. This smooth action is controlled automatically in the occipital lobe and brain stem 
where all eye movements are joined up together into what are termed conjugate eye movements. 
Tracking is tested by asking the patient to follow your finger moving in both vertical and 
horizontal planes just as you would do when testing for normal eye movements (Chapter 1). 
Pale white & atrophic optic disc
Figure 12.6 Fundoscopy findings in optic atrophy
Haemorrhages & cotton wool exudates Haemorrhages, perimacular exudates  
& new vessel formation
Figure 12.7 Fundoscopy findings in hypertension and diabetes
Hypertension Diabetes
oCulomotor, troChlear and abduCens: eye movements
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Observe carefully for any impairment, jerkiness (nystagmus) or loss of eye movement (paralysis) 
in one or more directions and enquire if there is any double vision. Voluntary saccadic eye 
movements originate in the frontal lobe and are tested by asking the patient to look at or fixate 
between two alternating targets e.g. right fist to left index finger and vice versa. This is an 
uncommon source of disordered eye movements.
Diplopia
Diplopia or double vision can be either binocular or monocular in origin. Monocular diplopia 
is distinctly uncommon and is nearly always optical in origin. The majority of diplopia occurs 
when the eyes fail to look together in the same direction and the resulting images no longer 
correspond with each other. This imbalance between the eyes may occur as a result of disorders 
at different sites. These sites are at the level of the brain stem, the individual 3rd 4th or 6th cranial 
nerves, the neuromuscular junction, and the eye muscles. Disorders affecting the individual 
cranial nerves account for most cases and are the most common cause of diplopia (Table 12.5).
Table 12.5 Main sites & causes of diplopia
Sites Causes 
3rd, 4th & 6th nerves ICP, vascular, trauma, infections, diabetes
brain stem stroke, inflammation, SOL
neuromuscular junction myasthenia gravis 
muscle myopathy (thyroid disorders, hereditary)
With disorders affecting individual cranial nerves the double vision is nearly always described 
by the patient as sudden in onset. The separation of images is described as lying either side 
by side in the horizontal plane or on top of each other in the vertical plane. In most patients 
presenting with double vision, the muscle site of origin becomes apparent whilst observing 
the patient’s eyes either at rest or during normal eye movements. If the origin is not readily 
apparent, then it is necessary to find out the direction in which the diplopia is greatest and 
in which plane the images are maximally separated. In general the double vision is always 
maximal in the direction of action of the paralyzed muscle. The false image is always the 
outermost image, and arises from the affected eye. In order to test for this, each of the patient’s 
eyes is covered in turn and the eye from which the outer image disappears is noted and this is 
the affected eye. Horizontal diplopia (i.e. images side by side) is due to weakness of the medial 
rectus (3rd CN) or the lateral rectus (6th CN) and vertical or oblique diplopia (i.e. the images 
on top/side) is due to weakness of other muscles (3rd or 4th CNs).
Third nerve palsy
In a complete 3rd nerve palsy, there is full ptosis and the eye (when it is uncovered), is seen to lie 
in the down and out position as a result of the unopposed action of the 4th and 6th CNs (Fig. 
12.8). On attempting to test for normal eye movements, there is paralysis of adduction and up 
and down movements on the affected side (Figs. 12.8-9). If the parasympathetic fibres which 
lie on the outside of the 3rd CN (the efferent limb of the light reflex) are compressed, then 
the pupil on that side is dilated and fixed (non responsive to light). This is frequently termed 
surgical 3rd nerve palsy because it indicates mechanical compression from outside the nerve 
which may require urgent surgical attention. A common cause of painful unilateral 3rd nerve 
palsy is an aneurysm arising on the posterior communicating artery on the Circle of Willis. 
If the pupil is spared or is not dilated then this is often termed a medical 3rd nerve palsy and 
these may resolve spontaneously over the next 3-4 months. The most common causes of third 
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nerve palsy are tentorial herniation secondary to raised intracranial pressure, aneurysms, DM 
and infections. Less common causes include granuloma (Tolosa Hunt syndrome) and lesions 
in the cavernous sinus. 
Figure 12.8 Oculomotor palsy (left)
Left occulomotor palsy (compressive type)
A  Ptosis
B  Pupillary dilatation (with the eyelid held open)
C  Failure of adduction of the left eye on looking 
     towards the right
Failure of down gaze left eye 
(looking down)
Failure of up gaze left eye 
(looking up)
Figure 12.9 Oculomotor palsy (left)
Ptosis & left eye down & out 
(looking ahead)
Failure of adduction left eye 
(looking right)
oCulomotor, troChlear and abduCens: eye movements
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Fourth nerve palsy
In 4th nerve palsy, there is failure to depress the adducted eye. The diplopia is most noticeable by 
the patient on walking down steps or stairs and he tries to compensate by tilting the head away 
from the paralysed eye. Isolated 4th nerve palsies are uncommon but do occur in association 
with DM, head trauma and cavernous sinus lesions. Uncomplicated 4th nerve palsies usually 
resolve with time. 
Sixth nerve palsy
In 6th nerve palsy, the patient is unable to abduct the affected eye and has diplopia. The diplopia 
is most noticeable by looking horizontally in the direction of action of the paralysed muscle 
(Fig. 12.10). The eye at rest is held in the adducted position because of unopposed action of 
the medial rectus (Fig. 12.10). It is a common cranial nerve palsy occurring in diabetes and 
hypertension and usually resolves spontaneously. However it may also be a false localizing sign 
in raised intracranial pressure, because during its long intracranial course it is vulnerable to 
increased pressure as it passes over the sphenoid ridge. 
Figure 12.10 Sixth nerve palsy (left sided)
Key points
 · diplopia arises from either CN disorders or diseases of neuromuscular junction or muscle
 · most common cause are CN disorders, 3rd 4th & 6th 
 · double vision is maximal in the direction of gaze of the paralysed muscle
 · false image is always the outer one
 · false image arises in the affected eye
SQUINT
A squint occurs when the visual axes of both eyes are no longer together. It is a common 
disorder in children when it is usually termed a non paralytic squint (NPS). This is in contrast 
to paralytic squint (PS) which mostly affects adults. The main causes of squint in children are 
refractive lens problems. Diplopia does not occur in non paralytic squint whereas it does occur 
in paralytic squint. This is because in children the brain gets accustomed over years to false 
image and suppresses it. If the non paralytic squint continues beyond the age of 6 years, then 
a permanent lazy eye develops with poor or no vision in that eye. 
Left sixth nerve palsy
A Normal conjugate eye movement to the left
B Failure of abduction of left eye on looking to the left
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The diagnostic feature of a non paralytic squint is that movements are full in each eye when 
tested separately. This is in contrast to paralytic squint where movement in the affected eye is 
usually not full. This can be easily demonstrated by testing movements in each eye individually 
in turn, whilst at the same time covering the other eye. This is termed the cover test. In non 
paralytic squint when conjugate eye movements are tested together, a weakness in one or both 
eyes may become apparent. To test for non paralytic squint first ask the patient to look with both 
eyes at your right eye and cover his left eye. Then uncover his left eye and cover his right eye and 
look to see if his left eye has to correct in order to look back at your right eye. Repeat the same 
sequence covering the right eye. The test is positive when the squinting eye immediately moves 
to fixate when attempting to look at an object, in this case your right eye. This is the basis for 
correction of a non paralytic squint in childhood. This is achieved by the wearing of a patch 
over the good eye thereby forcing the bad eye to work fully. If wearing a patch over the good 
eye fails then corrective surgery may be necessary. Squints are usually classified as non paralytic 
or paralytic. They may also be classified as congenital or acquired, as affecting one eye or both 
eyes and as convergent or divergent.
Key points
 · NPS is common in children whereas PS is common in adults 
 · in NPS full movement is preserved in each eye when examined individually 
 · in NPS the cover test reveals weakness in one or both eyes
 · correction of NPS should take place before 6 yrs of age
 · treatment includes wearing a patch over the good eye +/- corrective surgery 
NYSTAGMUS
Nystagmus is an abnormal rhythmic oscillatory or to and fro movement of the eyes. 
Characteristically it has a slow drift in one direction with a fast corrective phase in the other 
direction. By convention, nystagmus is described in the direction of the fast phase. Disorders 
causing nystagmus are classified as peripheral (arising from the vestibular system/nerve), central 
(arising from the brain stem/cerebellum) and ocular (arising from the eye, retina/lens). In order 
to check for the presence of nystagmus, you must first inspect the patient’s eyes in the at rest 
or primary position with the eyes looking ahead and then ask the patient to follow your finger 
with both eyes, moving vertically and horizontally as if testing for normal eye movements. 
Be careful not to move the eyes too far laterally (<30 degrees from midline), otherwise a few 
beats of non sustained physiological nystagmus can occur normally. Note if any nystagmus 
occurs and whether it is symmetrical or jerky and the direction of the fast phase e.g. horizontal, 
vertical or rotary and the position of the eyes when the nystagmus occurs and is most marked.
The characteristics of the nystagmus help to localize its site of origin. If it is symmetrical with 
movements of the same speed in both directions this is called pendular nystagmus. Pendular 
nystagmus is nearly always ocular in origin and is seen in persons with longstanding blindness 
or impaired vision; a major cause is congenital cataracts. If the nystagmus is characterized 
by a slow phase in one direction followed by a fast corrective phase in the opposite direction 
this is called jerk nystagmus. This is the most common type and is seen in both peripheral and 
central disorders. Jerk nystagmus occurs only on attempted gaze holding in any direction (up, 
down, left or right) and is not present in the primary position looking straight ahead. The 
nystagmus
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fast phase determines the direction of the nystagmus i.e. upbeat or downbeat nystagmus. Jerk 
nystagmus is commonly seen in cerebellar disease. The direction of the fast phase is towards 
the lesion in central disorders of the brain stem and cerebellum, and away from the lesion 
in peripheral disorders in the vestibular system. The commonest causes of jerk symmetrical 
horizontal nystagmus with the quick phase in the direction of gaze are drugs or medications 
e.g. phenytoin and alcohol. Rotary nystagmus can occur in both peripheral and central disorders, 
though mainly in disorders of the peripheral vestibular system. The main distinguishing clinical 
features between peripheral and central nystagmus are presented below in Table 12.6. 
Table 12.6 Key clinical features distinguishing peripheral and central nystagmus
Clinical features Peripheral  
(vestibular nerve & labyrinth)
Central  
(brain stem and cerebellum)
main causes neuronitis, BPPV*
Ménière’s disease 
vascular, drugs, alcohol, structural 
duration of illness short (3-6 weeks) long (often years)
duration of nystagmus <60 secs continuous
direction away from lesion, horizontal, 
unilateral 
towards lesion, multidirectional 
latency/vertigo/vomiting/worsened by 
position and fatigues
yes no
associated neurological signs no yes
* benign paroxysmal positional vertigo 
Key points
 · decide whether nystagmus is present
 · describe the type, direction & position it occurs maximally 
 · determine whether it is peripheral or central
 · persistent nystagmus suggests a central origin 
 · vertigo, vomiting & worsening with change in position suggests a peripheral origin
TRIGEMINAL NERVE
The fifth nerve has three branches, ophthalmic V1, maxillary V2 and mandibular V3. It is a mixed 
motor and sensory nerve (Chapter 1). Power is tested by measuring resistance to jaw opening, 
closure and side to side movement. Motor involvement is rare but occurs clinically in myasthenia 
gravis and muscular dystrophy (myotonic and fascioscapular). To test sensation touch the face 
lightly with cotton wool separately in all three divisions (V1-V3) comparing sides. Only very 
occasionally is it necessary to test for pain and temperature on the face. Disorders affecting 
the fifth nerve can arise either centrally in the brainstem or peripherally involving the whole 
nerve or more commonly in one of its main branches. Causes of central brain stem disorders 
include stroke and mass lesions. In healthy persons the jaw jerk is either minimally present or 
absent. The jaw jerk may be increased in upper motor neurone disorders affecting the upper 
brain stem and above e.g. motor neurone disease (MND) and stroke. Disorders affecting 
the peripheral nerve are mostly caused by herpes zoster (Fig. 12.11), trigeminal neuralgia and 
rarely compression by tumours compressing the nerve e.g. acoustic neuroma. The frequency of 
herpes zoster is increased in HIV disease (Chapter 8). An absent corneal reflex in the presence 
of normal facial movements (7th CN) is a sign of sensory 5th CN (V1) neuropathy. Patients with 
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trigeminal neuropathies present mostly with pain or impairment or loss of facial sensation, 
typically without any loss of power of mastication. Trigeminal neuralgia is the most common 
clinical disorder affecting the 5th CN or its branches (Chapter 15). 
Key points
 · sensory involvement is more common than motor in 5th CN neuropathy 
 · jaw jerk is increased in some UMN lesions 
 · absent corneal reflex indicates a lesion in either the 5th or the 7th CN 
 · herpes zoster is the commonest cause of trigeminal neuropathy
Figure 12.11 Herpes zoster in HIV Vesicular eruption in V3 division of trigeminal nerve (left)
FACIAL NERVE
Facial nerve paralysis is one of the most common cranial nerve disorders. The examination 
has already been outlined in chapter 1. In brief first inspect the face for asymmetry, loss of 
normal wrinkling, eye closure, nasolabial fold and decreased facial movement. To demonstrate 
the facial nerve ask patient to smile (show teeth), close eyes tightly and look up. Facial nerve 
paralysis may either be central (upper motor neurone) in origin as occurs in stroke or peripheral 
(lower motor neurone) in origin as occurs in Bell’s palsy. Peripheral facial nerve disorders arise 
mainly from inflammation, infiltration or compression of the nerve along its course. The 
main inflammatory causes are Bell’s palsy and infections including herpes zoster i.e. Ramsay-
Hunt syndrome. The main infiltrative and compression causes include acoustic neuroma, 
meningioma and diseases affecting the skull base or parotid gland. 
BELL’S PALSY
Bell’s palsy is the most common disorder of the facial nerve. It is an acute lower motor neurone 
disorder (LMNL) which is associated with viral infection and facial nerve swelling within the 
facial canal although its precise cause is not known. It is associated with asymptomatic HIV 
infection (Chapter 8). It presents as a painless loss of power on one side of the face over 24 
hours; there may be an associated ache around the ear at the start which typically clears. The 
patient becomes very aware of his facial appearance and may have difficulties smiling, speaking 
or initiating swallowing and closing the eye on the affected side (Fig. 12.12). It affects all the 
muscles on one side of the face (Fig. 12.13) which distinguishes it from central causes which 
affect only the lower half of the face. It may occasionally occur bilaterally when the correct 
faCial nerve
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diagnosis can be easily missed (Fig. 12.14) unless it is tested. The main differences between a 
lower and upper motor neurone lesion are presented in Table 12.7. The weakness usually clears 
fully without any treatment in the majority >90% of patients within 6 to 12 weeks. However if 
at onset the paralysis is complete and there is involvement of taste and hearing (increased) then 
the outlook for a full recovery is worse.
Figure 12.12 Lower motor neurone facial nerve palsy (right sided)
Figure 12.13 Lower motor neurone facial nerve palsy (left sided)
Loss of wrinkling Loss of eye closure Loss of nasolabial fold & drooping mouth
Figure 12.14 Lower motor neurone facial nerve palsies (bilateral)
Loss of wrinkling Loss of eye closure Loss of smiling
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Table 12.7 Differences between lower and upper motor neurone facial nerve palsy
Main clinical features Lower motor neurone lesion Upper motor neurone lesion
Main Cause Bell’s palsy stroke
Clinical findings*
forehead wrinkling
eye closure
movement lower face
absent
absent 
absent 
spared
partially spared
absent/decreased
Outcome 90% recover fully variable
* may only be partially present in incomplete lesions 
Management
If the patient is seen within 48 to 72 hours of onset then a short course of steroids and 
antiviral drugs may help to improve outcome. This includes prednisolone 60 mg/po/daily and 
aciclovir 400 mg/po/tds for a total of 7 days. Prevention of corneal damage during recovery 
is important. The use of artificial tears and application of a cover patch particularly overnight 
may be sufficient to prevent the cornea from being damaged before recovery. Glasses with 
side protection and eye covers may help during the day. Severe cases may need a temporary 
tarsorrhaphy. Physiotherapy with facial exercises may be helpful to the patient. 
Key points
 · Bell’s palsy is the most common cause of LMN facial nerve paralysis
 · signs are drooping of the corner of the mouth, loss of eye closure & absence of wrinkling 
 · loss of eye closure and wrinkling distinguish it from an UMN facial nerve lesion 
 · frequency of Bell’s palsy is increased in HIV infection & patients should have a screening HIV test
 · recovery occurs in most patients without treatment 
ACOUSTIC NERVE
The eight nerve or acoustic has two divisions: cochlear and vestibular. Disorders affecting the 
cochlear division result in difficulties with hearing whereas disorders affecting the vestibular 
division result in difficulties with balance. The main symptoms of the cochlear division are 
deafness and tinnitus and the vestibular division are vertigo and loss of balance. 
HEARING
Details concerning the examination of the cochlear division of the acoustic nerve are presented 
in chapter 1. Bedside tests include asking and checking the patient’s ability to hear by whispering 
about 1 metre way when the other ear is blocked. If hearing is found to be reduced then do 
the Rinne and Weber tests. In the Rinne test the beating tuning fork is held first on the mastoid 
(bone conduction, BC) and then placed just outside the ear (air conduction, AC). In the 
Weber test the beating tuning fork is placed on the vertex of the head. The possible results of 
the tuning fork tests are summarized in Table 12.8. The main causes of deafness alone are wax 
in the outer ear, otitis media in the middle ear, presbycusis in the cochlea and diseases affecting 
the cochlear nerve in the inner ear. Neurological causes of hearing loss include nerve deafness 
after meningitis, ototoxic drugs e.g. quinine and streptomycin and rare causes such an acoustic 
aCoustiC nerve
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neuroma. Ménière’s disease is the most common cause of combined deafness and vestibular 
dysfunction.
Table 12.8 Possible results of tuning fork tests in deafness
Rinne (deaf ear) Weber
Conductive deafness BC > AC best in the deaf ear
Sensorineural deafness AC > BC best in the non deaf ear
VERTIGO/DIZZINESS
Vertigo is an illusion of a sensation of giddiness or spinning during which the patient or more 
commonly the world outside the patient appears to move. Dizziness is commonly used to 
describe the unsteady feeling or sensation of vertigo and care must be taken to distinguish 
it from true vertigo. Vertigo can be caused by either peripheral or central disorders. Diseases 
affecting the peripheral vestibular nerve causing vertigo include viral infections causing acute 
labyrinthitis, benign paroxysmal positional vertigo (BPPV) and drugs e.g. quinine and 
streptomycin. Centrally, the main cause of vestibular dysfunction is ischaemic or vascular. 
Vertigo of vestibular origin is characteristically paroxysmal and brought on or aggravated by 
a change in position. This in contrast to vertigo of central origin which is more continuous 
and is not usually provoked by change in position. The Hallpike’s test (see below) can help 
to differentiate and distinguish between these two sites. The duration of symptoms depends 
on the cause and may last from weeks in labyrinthitis to less than a minute in BPPV. Drugs 
commonly used in the treatment of acute vertigo include betahistine 16 mg/po/tds or 
prochlorperazine 5 mg/po/tds.
Ménière’s disease
This is a disease characterized by intermittent attacks of severe vertigo, tinnitus and deafness. 
The deafness eventually becomes permanent and the vertigo eventually ceases after years. 
Management is by decreasing salt intake, thiazide diuretic, and using an antihistamine e.g. 
betahistine, cinnarizine, cyclizine or prochloperazine.
BENIGN PAROXYSMAL POSITIONAL VERTIGO (BPPV)
BPPV is a benign condition characterized by transient vertigo brought on by head movements. 
The acute vertigo lasts less than a minute but symptoms may persist for weeks or months 
and may recur. There may be associated nausea and vomiting in severe persistent attacks. It 
arises mainly from dislocation of otoliths or debris blocking the posterior semicircular canals. 
Characteristically, a change of head position particularly rolling over in bed or rising suddenly 
from the lying or seated position provokes an attack. The diagnosis may be confirmed by 
bedside techniques including Hallpike’s test. Epley’s manoeuvre can help to disperse the debris. 
Hallpike’s test
This is a bedside test of vestibular function which is used in patients suspected as having 
positional vertigo. The test begins with the patient seated upright on the examining couch and 
is positioned so that when he lies flat his head and neck will extend beyond the examining 
couch unsupported. Whilst seated the patient is first instructed to turn the head to one side 
with the eyes looking in the same direction as the head. Whilst maintaining that head position 
the patient is reassured and instructed to lie flat. The head should now lie about 30 degrees 
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below the horizontal and now be supported by the examiner’s hands. In normal persons there 
is no nystagmus or vertigo. In vestibular disorders nystagmus and vertigo starts after a delay 
of a few seconds, and then fatigues and resolves after a number of seconds. This is a positive 
Hallpike’s test. After sitting upright the test may be repeated on the other side. In central or 
brain stem disorders there is usually no delay in the onset of symptoms and signs which are not 
worsened by change in position and any nystagmus which is present persists. 
Epley’s manoeuvre
This involves lying down sideways in the position in which the Hallpike test brings on the 
vertigo and then rolling over changing sides and remaining sideways there until symptoms 
subside followed by sitting upright for 30 seconds and then back to the first position. This 
manoeuvre should be repeated at least 3-4 times daily until symptoms persistently resolve. 
Key points
 · disorders of the vestibular division of the 8th CN result in difficulties in balance
 · symptoms include dizziness, vertigo, tinnitus, nausea, vomiting & ataxia
 · main causes are BPPV, vestibular neuronitis & Ménière’s disease
 · nystagmus provoked by change in position is characteristic of vestibular origin
 · relief with antiemetics, antihistamines & positional manoeuvres
ACCESSORY NERVE
This nerve supplies the sternomastoid and the trapezius muscles and is responsible for turning 
and flexing the head and shrugging the shoulders. The clinical examination is done by 
inspection of the main neck and shoulder muscles for any obvious wasting, fasciculations or 
hypertrophy and then by opposing each of the main movements, in turn resisting elevation 
of the shoulders and turning the head (Chapter 1). The main neurological disorders affecting 
these movements are diseases of muscle and neuromuscular junction including myopathies, 
polymyositis, dystrophies and myasthenia gravis (Chapter 13). Management is by treatment of 
the underlying disorder. 
GLOSSOPHARYNGEAL, VAGUS AND HYPOGLOSSAL NERVES
These cranial nerves supply the mouth, throat and tongue for the main functions of speech 
and swallowing. The glossopharyngeal is sensory to the posterior one third of tongue and the 
pharynx and middle ear whereas the vagus is motor to the muscles of the palate, pharynx and 
larynx. Their joint function is tested by inspecting the uvula at rest, getting the patient to say 
“Aah” and testing the gag reflex. The hypoglossal nerve is motor to the muscles of the tongue 
and is examined by inspecting the tongue at rest, and on repeated protrusion in and out. If an 
abnormality is still suspected the movements and strength of the tongue can be further assessed 
by asking the patient to push his tongue into his inside cheek against your thumb outside 
opposing the movement. The pharynx and larynx can be assessed functionally by checking the 
patient’s ability to generate a normal cough and swallow a cup of water normally. The larynx 
can be visualized by laryngoscope but this requires an ENT specialist. 
The lower cranial nerves are commonly involved together in diseases and their joint impairment 
results in a significant loss of function in the mouth and bulbar area. If the site of the lesion is 
aCCessory nerve
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a lower motor neurone, then the disorder is termed a bulbar palsy and if the site of the lesion 
is an upper motor neurone, it is termed a pseudobulbar palsy. The main symptoms common to 
both types of disorders are difficulty speaking (dysarthria) and swallowing (dysphagia) which 
is frequently progressive depending on the aetiology. A lower motor neurone lesion results in 
wasting and fasciculation of the tongue and a reduced or absent gag reflex. There is deviation of 
the tongue to affected side if it’s unilateral. An upper motor neurone lesion results in spasticity 
with a contracted immobile tongue and an increased gag reflex. The main neurological causes 
of a bulbar palsy are motor neurone disease (MND) and myasthenia gravis and of pseudobulbar 
palsy are stroke and MND. The main non neurological cause is local malignancy. Emotional 
lability is a feature in patients with a pseudobulbar palsy. Management is the treatment of the 
underlying disorder. 
Key points
 · disorders of the lower cranial nerves present with difficulties with speaking & swallowing
 · they are classified as bulbar (LMNL) or a pseudo bulbar (UMNL)
 · main neurological disorders causing these are stroke, MND & myasthenia gravis 
 · the differential diagnosis includes local malignancy
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CHAPTER 13
MYOPATHIES AND MYASTHENIA GRAVIS
Myopathies are classified as either inherited or acquired. The main inherited myopathies are 
muscular dystrophies and acquired myopathies are inflammatory and non inflammatory. 
The main disorder which affects the neuromuscular junction is myasthenia gravis (MG). The 
aim of this chapter is to review the clinical features and management of muscular dystrophy, 
polymyositis and MG. The student should aim to be able to recognize these main muscle 
disorders and manage a patient presenting with muscle weakness.
Clinical history
The defining symptom of disorders of muscle and neuromuscular junction is weakness. Muscle 
weakness in myopathy is usually proximal. Patients typically present with weakness or difficulty 
elevating their arms above the shoulders, getting out of chairs or rising from the lying position. 
Other symptoms may include muscle pain and tenderness, muscle cramps on exercise and 
dysphagia. The history should include age of onset, time course, pattern and distribution of 
weakness, fatigability and any relevant past, family and drug history. Muscular dystrophies tend 
to have their onset in childhood or teens and are usually recognizable clinically. Inflammatory 
myopathies present with proximal muscle weakness, frequently with muscle pain, tenderness 
and sometimes dysphagia. The diagnostic characteristic of myasthenia gravis is fatigable muscle 
weakness, worse after exercise and commonly affecting the extra ocular and bulbar muscles. 
Physical Examination
The characteristic clinical finding in myopathies and MG is muscle weakness. The weakness 
affects mainly the trunk and proximal limb muscles, and may also affect the neck muscles and 
facial expression. Power distally may be maintained in early disease but is lost or decreased 
later on. Muscle wasting occurs in most myopathies, tone is typically decreased and reflexes 
are preserved but may be reduced or absent in advanced disease. There are no sensory signs. 
Patients with muscle disease often have a very characteristic myopathic or “waddling” gait due 
to hip girdle weakness. The pattern of muscle weakness may indicate the underlying disorder. 
Muscle hypertrophy confined to the calves in boys is diagnostic of dystrophy and contractures 
may occur in long standing disease. Weakness of the eye muscles suggests myasthenia gravis 
whereas weakness of the face muscles is more of a feature of facioscapulohumeral dystrophy 
and myotonic dystrophy. Weakness of the neck muscles is typical of myasthenia gravis 
and polymyositis. Proximal weakness in combination with a skin rash is characteristic of 
dermatomyositis. 
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Key features of myopathy/MG
 · proximal weakness 
 · fatigability
 · hypertrophy 
 · contractures
 · myopathic gait
Investigations
Routine bloods tests should include FBC, ESR, HIV, glucose, creatinine, electrolytes, thyroid 
function tests and serum creatine kinase (CK). CK is the best indicator of muscle disease with 
very high levels in inflammatory muscle disease and in most dystrophies but can be normal 
in myotonic dystrophy (MD) and facioscapulohumeral dystrophy (FSHD). It is important 
to remember that CK may be modestly elevated after strenuous exercise, injections, and viral 
infections and occasionally in healthy African populations which may sometimes lead to 
unnecessary investigation. Molecular genetic testing is increasingly important in the diagnosis 
of inherited muscle disease. An ECG and echocardiogram are indicated in the dystrophies to 
screen for cardiomyopathy
Electromyography (EMG)
This measures the electrical activity in a motor unit. In myopathies there is a decrease in the 
duration and amplitude of motor unit potentials with spontaneous fibrillations. There are also 
characteristic EMG findings in MG and in myotonic dystrophy.
Muscle biopsy
The biopsy site should be from moderately affected muscle and away from injection sites. This 
may show evidence of inflammation and dystrophic changes. Immunostaining is also helpful 
depending on the diagnosis. 
Key points
 · muscle disorders may be inherited (dystrophies) or acquired (polymyositis)
 · proximal weakness is the key clinical finding in muscle disorders
 · pattern of weakness points to the underlying disease
 · marked elevation in CK is the best lab indicator of muscle disease
INHERITED MYOPATHIES
The main inherited myopathies are the dystrophies, myotonic dystrophy (MD), Duchenne 
(DMD), Becker (BMD), limb girdle (LGMD) and facioscapulohumeral (FSHD). The main 
clinical features and genetics are presented below (Table 13.1). DMD and BMD are both 
X-linked inherited and occur almost exclusively in males. Disease is caused by mutations of the 
X-linked dystrophin gene which leads to the complete absence of the muscle protein dystrophin 
in DMD or abnormal dystrophin in BMD. This affects both skeletal and cardiac muscle. The 
diagnosis of muscular dystrophy is usually based on clinical findings and a markedly elevated 
CK. A muscle biopsy can confirm the clinical diagnosis and genetic studies identify the 
causative mutation. Management includes genetic counselling.
inherited neurological disorders
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Table 13.1 Characteristics of Muscular Dystrophies
Type Genetics Sex/age of onset Clinical features
Myotonic autosomal dominant m = f,/birth to adult proximal & distal limb 
weakness, facial weakness, 
myotonia, frontal balding, 
cataracts
DM, cardiomyopathy
Duchenne X-linked recessive males/early childhood proximal limb weakness, 
Gower’s sign,
calf pseudohypertrophy,
cardiomyopathy
Becker X-linked recessive males/in teens or as adult proximal limb weakness, 
slow progression, 
calf pseudohypertrophy,
cramps,
cardiomyopathy
Facioscapulo-humeral autosomal dominant m = f/in teens facial weakness,
winging of scapulae,
proximal upper limb weakness, 
waddling gait,
lumbar lordosis
Limb girdle autosomal recessive 
autosomal dominant
m = f/in teens/young adult proximal limb girdle weakness, 
cardiomyopathy (variable)
MYOTONIC DYSTROPHY
Myotonic dystrophy is an autosomal dominant multisystem disorder characterized by 
progressive proximal and distal muscle weakness, especially affecting the upper limbs. It 
gets its name from its characteristic of sustained muscle contraction or myotonia. It is the 
most common dystrophy with a prevalence of around 1/10,000 in high income countries. 
The frequency in Africa is not known and although isolated cases have been reported it is 
considered to be very uncommon in black populations there. It presents most commonly in 
adults of either sex but can present at any age. 
Genetics
It is caused by an unstable expanded trinucleotide repeat (>50 CTG repeats) in the myotonin 
gene on chromosome 19q. There is a strong correlation between the number of repeats and the 
age of onset and thus severity of the disorder. 
Clinical features
The clinical presentation varies from lethal disease at birth (congenital DM with CTG repeats 
above 1000) to very mild disease with late onset cataracts (CTG repeats 50-80). The classical 
or adult form (20-50 yrs; CTG repeats 200-500) presents with myotonia, frontal balding 
(even in women), bilateral ptosis, facial weakness, wasting and weakness of sternomastoids, 
proximal and distal weakness of mainly the upper limbs, cataracts, testicular atrophy, diabetes 
and sometimes cognitive impairment. Myotonia is persistence of muscle contraction, lasting 
several seconds if the muscle is actively used. It typically occurs during gripping or hand shaking 
when the affected person is unable to let go for the first few seconds. It is more pronounced 
during cold weather. Tapping affected muscles repeatedly with a tendon hammer demonstrates 
myotoniC dystrophy
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a sustained dimple and a typical muscle contraction. Classic myotonic discharges on EMG 
testing sounding like a dive bomber are diagnostic. The diagnosis can be confirmed by DNA 
testing. 
Management
Management includes genetic counselling especially as the severe congenital form occurs in 
children of affected females with >100 repeats. Myotonia if disabling may be treated with 
phenytoin and also mexilitine if ECG QT interval is normal. There is an increased risk of 
sudden death and anaesthetic complications.
Key points
 · MD is an autosomal dominant disorder confirmed by DNA testing
 · uncommon in the black population in Africa
 · C/Fs: ptosis, facial, sternomastoid &, limb weakness, cataracts, balding and DM 
 · characterised by sustained muscle contraction & inability to release grip
 · increased risk of sudden death & anaesthetic complications
 · management includes  genetic counselling
DUCHENNE’S MUSCULAR DYSTROPHY
The incidence of DMD in high income countries is about 1 per 3,500 live births. There are 
few reports of DMD from Africa for comparison but a much lower prevalence of 1/250,000 
was reported in one study in South Africa, suggesting that it is much more uncommon there. 
Clinical features
DMD almost always presents in early childhood (1-5 yrs) usually presenting early with 
difficulty or a delay in walking and a characteristic toe walking gait. Other diagnostic features 
are calf hypertrophy and contractures. Patients may also demonstrate “Gower’s sign” which 
is using the hands to climb up the legs whilst getting up from the squatting or lying position 
(Fig 13.2). The main complications are scoliosis, cardiomyopathy and immobility with nearly 
all patients becoming wheelchair bound by the end of the first decade. There is no long term 
effective drug treatment although the use of steroids is now established practice in some high 
income countries. 
Prognosis
In high income countries most deaths used to occur before or in the early teenage years but 
now occur in late teens or early twenties. This improved survival is mainly due to intervention 
with assisted nocturnal ventilation and early management of complications.
BECKER’S MUSCULAR DYSTROPHY
The incidence of BMD in high income countries is around 1/35-40,000. There are few reports 
from Africa but a very much lower prevalence of <1/750,000 has been reported from South 
Africa. The range of symptoms is similar to DMD but it is much milder. It frequently has its 
onset during the first decades at around 10-11 years of age but many are mild and usually go 
unnoticed in childhood. They present mostly in teens or early adult life with mild limb girdle 
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weakness, cramps and calf hypertrophy. Many are wheelchair bound by their late 20s. Cardiac 
involvement occurs in around 10% and shortens life expectancy.
Key points
 · Duchenne presents with walking difficulties in boys in very early childhood 
 · most progress to wheelchair dependence by the start of second decade
 · death usually occurs before or by early teens in Duchenne in Africa
 · Becker is a much milder form affecting males in their early teens 
 · C/Fs: calf  hypertrophy, contractures and Gower manoeuvre 
 · elevation of CK is a characteristic finding in all dystrophies 
OTHER DYSTROPHIES
The other main muscular dystrophies include facioscapulohumeral dystrophy (FSHD)(Fig. 
13.1), an autosomal dominant dystrophy caused by a complex genetic defect on chromosome 
4q and limb girdle muscular dystrophy (LGMD)(Fig. 13.2). LGMD is genetically very 
heterogeneous: mostly autosomal recessive with at least 15 genes involved and less frequently 
autosomal dominant with at least 8 genes involved. These dystrophies are uncommon with a 
reported incidence rate for FSHD in high income countries of 1-2/100,000. Their frequency 
in Africa is not known. The pattern of muscle weakness follows the description in their names. 
Severity is variable from the uncommon rapidly fatal mainly childhood forms, to the more 
common mild and slowly progressive mainly adult forms.
Wasting of proximal (humeral) limb muscles, triceps & biceps
Figure 13. 1 Facioscapulohumeral dystrophy
Incomplete eye closure Failure of smiling Winging of scapulae
other dystrophies
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Key points
 · muscular dystrophies are uncommon in adults 
 · two main types, limb girdle and facioscapulohumeral
 · the pattern of muscle weakness follows their name
 · survival into early and mid adulthood is a feature of both types
INFLAMMATORY MYOPATHIES
DERMATOMYOSITIS AND POLYMYOSITIS
Dermatomyositis and polymyositis are the main inflammatory myopathies. They are defined 
by inflammation in muscles and their general characteristics are presented below (Table 13.2). 
Their approximate frequency in high income countries is 5/100,000. In Africa they mostly 
affect the age group 20-40 yrs but occur in other age groups. Females are more commonly 
affected than males. 
Clinical features
Patients present with sub acute mainly proximal muscle weakness and pain over months but 
occasionally over weeks. Dysphagia may occur because of involvement of pharyngeal muscles. 
Wasting of proximal lower limb girdle muscles Gower’s manoeuvre
Figure 13. 2 Limb girdle muscular dystrophy
Wasting of upper limb girdle muscles
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In dermatomyositis both skin and muscle are involved. On examination, there is marked 
symmetrical proximal weakness and signs of muscle atrophy in long standing disease. There 
is a characteristic blue-purple rash, plus oedema of upper eye lids (heliotrope), erythema over 
cheeks, knuckles and chest (Fig. 13.3) and dilated capillaries at the base of finger nails. 
Table 13.2 Characteristics of inflammatory myopathies
Characteristics Polymyositis Dermatomyositis
age group  20-40 yrs 10-50 yrs
female:male ratio 2:1 2:1
onset months weeks to months
proximal muscle weakness yes yes
skin involvement no yes
malignancy no slight risk
elevation in ESR & CK marked marked
response to steroids yes yes
Investigations
The ESR and serum CK are markedly elevated in polymyositis. The diagnosis is confirmed by 
muscle biopsy. Malignancy should be screened for in patients with dermatomyositis. 
Management
The management of polymyositis is based on corticosteroids and immunosuppressant drugs. 
Treatment is with prednisolone 1mg/kg or 60 mg/po/daily. After months, when CK returns 
to normal and there is clinical improvement, the steroids can be reduced gradually by 5 mg 
decrements per dose on the alternate day, until the steroids are being administered only on 
alternate days. If the improvement is maintained, the prednisolone can be further decreased by 
10 mg decrements every 4 weeks, until a maintenance dose is found. The usual maintenance 
dose is 5-10 mg prednisolone on alternate days. This may need to be continued for a further 
period of 3-6 months. Consider using an immunosuppressant drug from the start with steroids. 
The drug of choice is azathioprine 2.5 mg/kg/day. Start with 50 mg per day and increase by 
weekly intervals to 125-150 mg daily in divided doses. The main side effects are bone marrow 
suppression and hepatic toxicity. A FBC and liver function should be checked at the start and 
at least every four months during treatment with azathioprine. Alternatives are methotrexate 
or cyclophosphamide.
Rash/oedema/heliotrope sign Rash on neck & chest Rash/oedema over hands/knuckles
Figure 13. 3 Dermatomyositis
dermatomyositis and polymyositis
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Key points
 · C/Fs include progressive proximal muscle weakness & pain over weeks/months
 · proximal weakness & characteristic skin rash are diagnostic of dermatomyositis
 · ESR and CK are both elevated 
 · diagnosis is confirmed by muscle biopsy
 · treatment is with steroids & another immunosuppressant for >6-12 months
INCLUSION BODY MYOSITIS
Inclusion body myositis (IBM) is another form of progressive inflammatory muscle disease 
which occurs in people >50 yrs. It is relatively common in high income countries but its 
frequency in Africa is not known. It occurs more frequently in older males and presents with 
painless proximal weakness with selective involvement of finger flexors and quadriceps muscles 
and frequently involves swallowing. Diagnosis is established by muscle biopsy and long term 
treatment is unsatisfactory. The differential diagnosis of inflammatory myopathies includes 
myasthenia gravis, non inflammatory myopathies and neuropathies. 
OTHER MYOPATHIES
There is a large group of acquired non inflammatory myopathies. The main causes are outlined 
in table 13.3. Patients may range from being relatively asymptomatic with just muscle wasting 
to having severe weakness of limbs and trunk muscles. Most cases remit once the underlying 
disorder is treated or the offending drug is withdrawn. 
Table 13.3 Causes of acquired non inflammatory myopathies
Classification Causes
infections HIV, TB
endocrine thyroid disorders
Cushing’s disease
neoplastic any malignancy
metabolic hyper/hypokalaemia
organ failure chronic cardiac, respiratory, liver disease
drugs alcohol, steroids, statins, ARTs (zidovudine)
MYASTHENIA GRAVIS
Myasthenia gravis (MG) is an uncommon autoimmune disease that is caused by acetylcholine 
receptor antibodies (AChRA) at the neuromuscular junction. The antibody binds to the post 
synaptic acetylcholine receptor sites which makes them unavailable for the transmission of 
nerve impulses. It is a worldwide disorder with an incidence in high income countries of 
around 3-30/1,000,000 per year and with most cases expected to survive, the approximate 
prevalence rate is much higher at around 10/100,000 with a reported increase over time in 
age related MG. The incidence rates across Africa are not known, but a detailed study from 
Cape Town in SA using AChRAs as in indicator of MG reported an incidence rate there of 
12.6/1,000,000 which is similar to that in high income countries. MG affects all age groups 
but mainly females in the age group 20-40 yrs and males in an older age group. It is associated 
with hyperplasia of the thymus (70%) and less commonly with thymoma (10%). 
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Clinical features
Symptoms
The most important diagnostic feature of MG is fatigable muscle weakness. In the early stages, 
weakness may be transient and variable. The busiest muscles at rest are the ones most commonly 
affected and patients frequently present for the first time with involvement of the extra ocular 
muscles (diplopia), eyelid (ptosis) and bulbar muscles (dysphagia) (Fig. 13.4). These may be 
accompanied by proximal weakness of the limbs and involvement of the face, neck, and trunk; 
typically the weakness worsens after exercise or at the end of the day.
Signs
On examination, fatigable ptosis, diplopia and limitation of eye movement are the main 
demonstrable eye signs. Bulbar involvement is evident by nasal type speech, difficulty in 
swallowing and nasal regurgitation of liquids. Facial weakness is demonstrated by bilateral 
weakness of eye closure and inability to smile normally giving the characteristic “myasthenic 
snarl” (Fig. 13.4). Fatigability may be demonstrated by asking the patient to look upwards 
holding the gaze in that position for 1-2 mins or to repeatedly elevate the arms above the head 
(>20 times) in quick succession without resting. In patients with MG, ptosis or upper limb 
weakness may appear for the first time or becomes more obvious during these manoeuvres. 
Reflexes and sensory exam are normal. In about one fifth of cases, the weakness is confined to 
the eyes only. When this persists without systemic involvement, it is called ocular myasthenia 
gravis. 
Differential diagnosis
The differential diagnosis includes other causes of neuromuscular weakness in Africa, including 
inflammatory myopathies, motor neurone disease, and other myopathies. 
Complications
Involvement of bulbar and respiratory muscles in MG is a neurological emergency (Fig 13.4). 
The major complication is respiratory failure. It is essential to monitor patients closely who are 
weak or bedbound and to measure vital capacity regularly. A forced vital capacity level <1.5 
litres requires ITU care and urgent assessment for emergency ventilation. 
Table 13.4 Symptoms of weakness in myasthenia gravis
eyes double vision & drooping eye lids
face, mouth weakness smiling, chewing & swallowing 
speech voice weak & easily tires  
limbs weakness combing hair
weak hand grip
difficulty arising from chairs or climbing stairs
central muscles head drop
weakness sitting up
respiratory shortness of breath 
myasthenia gravis
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Figure 13.4 Myasthenia gravis
Key points
 · key feature of MG is fatigable muscle weakness
 · CFs are double vision, ptosis, dysphagia & weakness 
 · bulbar & respiratory involvement is an emergency 
 · may require ITU care & possible ventilation
Diagnosis
The diagnosis can be confirmed by a Tensilon (Edrophonium) test (Table 13.5). Edrophonium 
is a quick acting cholinesterase inhibitor which prevents available acetylcholine being 
broken down at the neuromuscular junction; this allows the excess acetylcholine to increase 
neuromuscular transmission and temporarily improve symptoms and signs. In order to carry 
out the test, two observers should ideally be present and cardiac resuscitation measures should 
be available. Other investigations are acetylcholine receptor antibodies (AChRA) which are 
present in 85% of patients with systemic MG. EMG shows a characteristic diagnostic pattern 
of decreasing amplitude of the compound muscle action potential with repeated stimulation. 
A CT of chest may show an enlarged thymus or a thymoma.
Ptosis & ocular paresis (note overactive frontalis) Ptosis & snarl
Complications
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Table 13.5 Tensilon (edrophonium) test
1 tensilon 10 mg is drawn up into a syringe 
2 a test dose of 3 mg is given intravenously as a bolus 
3 observe the patient for any improvement in the weakness 
4 in MG the weakness improves within a minute and lasts only 5 minutes or less 
5 if there is no response then 7 mg is given intravenously
6 the outcome may be difficult to interpret hence the need for a second observer
7 atropine 05 to 10 mg should always be available for emergency iv use because of potential bradycardia 
8 atropine may also be given prophylactically just before the tensilon is given
Key points
 · confirmatory tests are positive tensilon test, AChRA & EMG
 · clinical diagnosis is confirmed by response to anticholinesterase drug treatment
 · chest X-ray/CT may show thymic enlargement or infrequently a tumour
Management
The management of myasthenia involves the use of cholinesterase inhibitors and 
immunosuppression (Table 13.6). Treatment is very effective at reducing or abolishing weakness 
but requires scrupulous attention to detail.
Cholinesterase inhibitors
Pyridostigmine (60 mg tablets) is a long acting anticholinesterase which acts within 1 hour 
and lasts for 4 hours. The starting dose is 15 mg/po/qds and this is doubled every 2 days until 
the patient is taking 60 mg/po/qds. The patient’s response will determine the dosage needed 
and the maximum total daily dose is 360 mg. Overdose causes a cholinergic crisis with severe 
bulbar and respiratory weakness, and patients need to be strictly warned about this possibility. 
The main side effects are abdominal pain and diarrhoea. Probanthaline 15-30 mg given 15 to 
30 minutes before each dose of pyridostigmine is helpful to stop these in particular during the 
first few weeks of treatment. While anticholinesterases may suppress the symptoms they do not 
alter the disease and hence the need for immunosuppression. 
Immunosuppression
Alternate day steroids are the treatment of choice. These are indicated in most cases. The 
patient should be admitted to hospital and started on prednisolone 10 mg/po/alternate days 
increasing slowly by 10 mg increments per dose (every second day) until 1.5 mg/kg or 100 
mg is reached whichever is the lower dose. This should be maintained until the patient is 
stable in remission. Improvement begins after 2-4 weeks and maximises at 6-12 months. Then 
prednisolone is reduced by 10 mg every 4 weeks until the patient is on 40 mg alternate days, 
and by 5 mg every 4 weeks until on 20 mg and then by 1 mg every month thereafter. If during 
this steroid reduction stage there is a relapse, then begin again as at the start of treatment. If 
there is steroid intolerance or lack of response, azathioprine is started in addition to steroids at 
a dose of 25 mg/po/bd and increased by 25 mg/daily until the patient is on 2.5 mg/kg/po or 
150 mg/po/daily. The main side effect is bone marrow depression. The patient needs a FBC 
and liver function tests every week for 2 months and then every 3 months. 
myasthenia gravis
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Intravenous immunoglobulin (IVIG) or plasma exchange and ventilation 
These may be needed in myasthenic crisis. The main indications for their use are increasing 
respiratory and bulbar weakness. However, these treatment options are unavailable at most 
centres in Africa. Respiratory failure (FVC <1.5 litres) is an urgent indication for consideration 
for mechanical ventilation. 
Thymectomy
This is considered in patients on treatment who are under 45 years or who have the disease for 
less than 10 years or for suspected thymoma. As many as half the patients will go into complete 
remission after a thymectomy.
Table 13.6 Summary of management of myasthenia gravis
Treatment Drugs Indication
cholinesterase 
inhibitors
pyridostigmine any muscle weakness
immunosuppression prednisolone
azathioprine
inadequate control on pyridostigmine alone
inadequate control on prednisolone & pyridostigmine
IVIG/plasma exchange myasthenic crisis, bulbar & respiratory weakness
ventilation bulbar/respiratory failure
thymectomy all patients <45 years and suspected thymoma at any age
Key points
 · mainstay of management is with pyridostigmine and steroids
 · steroids should be introduced slowly under close supervision  
 · IVIG and plasma exchange are indicated in myasthenic crisis
 · ventilation is necessary in respiratory failure 
 · treatment of MG is very effective but requires scrupulous attention to detail
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CHAPTER 14
MOVEMENT DISORDERS AND MOTOR NEURONE 
DISEASE
Movement disorders occur mainly because of disease of the basal ganglia and its central 
connections. Drugs may also cause them. They are characterized as those with too little 
movement or hypokinetic disorders as occurs in Parkinson’s disease or with too much movement 
or hyperkinetic disorders as occur in tremor, dystonia and chorea. The most common overall 
movement disorder is tremor and the most common major movement disorder is Parkinson’s 
disease (PD). This chapter outlines the main movement disorders and also motor neurone 
disease. The student should aim to be familiar with their main clinical features and management.
PARKINSON’S DISEASE (PD)
Parkinson’s disease is a progressive neurodegenerative disorder characterized by four key clinical 
features: tremor, rigidity, poverty of movement also known as bradykinesia or akinesia, and 
loss of normal posture with a tendency for falls (Figs. 14.1 & 2). PD occurs all over the 
world affecting >1% of the population >65 years in high income countries. PD also occurs in 
Africa but may be less frequent there with lower reported age adjusted prevalence rates of 40-
67/100,000. Males and females are both equally affected. PD typically begins in the age group 
50-60 years and then occurs with increasing frequency in older age groups. PD may also affect 
a younger age group <40 yrs (5-10%). Juvenile onset PD (<20 yrs) is usually hereditary and 
may have more dystonic features than the adult onset disorder.
Causes
The underlying cause of most cases of PD is not known and the term idiopathic PD is used 
to describe the disease. Many of the clinical features of PD can result from a variety of other 
conditions including vascular disease, drugs, neurodegeneration and rarely encephalitis. When 
this happens the condition is called parkinsonism rather than PD. 
Pathophysiology
The classic features of PD are a result of degeneration of dopamine secreting substantia nigra 
neurones which project from the brainstem via the striatal neurones to the basal ganglia. This 
leads to a loss of the characteristic black pigment and the remaining dopamine secreting cells 
may show Lewy inclusion bodies. Clinical disease starts when the substantia nigra cell loss is 
>50% and striatal dopamine levels are reduced by >80%. Recent studies have shown however 
that the pathology in PD is more widespread and occurring much earlier than originally 
believed. 
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Clinical Diagnosis
The initial presentation of PD is often mild with up to two thirds of patients presenting at 
onset with an asymmetrical rest tremor, affecting one limb or difficulty with fine repetitive 
motor movements e.g. doing buttons or tying shoelaces. If the dominant hand is involved 
then writing as it crosses the page becomes noticeably smaller. The tremor is characteristically 
coarse, regular, occurs at rest and disappears initially on intent such as holding a cup. The 
tremor becomes more noticeable when the person is distracted or whilst walking. It mostly 
affects the limbs but can affect any part of the body including the head, chin and tongue. The 
typical resting tremor is a rhythmical movement of the thumb on the hand called pill rolling. 
This is usually accompanied by increasing bradykinesia or slowing down of movements e.g. 
carrying out the activities of daily living (ADL) or walking. There may be a lack of spontaneous 
movement and facial animation (expressionless face), (Fig. 14.1 & 2) and the blink rate is 
decreased. 
On neurological examination, there is rigidity or stiffness of the limbs which results in 
increased tone throughout the full range of passive movement. This is called lead pipe rigidity 
or cog wheel rigidity if a tremor intrudes. Gait disturbances are usually mild in the first few 
years. Then posture becomes stooped and the gait is semi-flexed and shuffling with reduced 
arm swing and difficulty starting or stopping walking and turning (Fig. 14.1). There is a loss 
of postural righting reflexes which may lead to falls. The patient’s voice may become quiet and 
muffled or hypophonic. Smell has recently been shown to be decreased or absent, sometimes 
for years before the onset of the other main symptoms.
Table 14.1 Main parkinsonian disorders
Extrapyramidal disorder Clinical characteristics Main Causes
Parkinson’s disease rest tremor
rigidity
akinesia
loss of posture
idiopathic 
neurodegeneration
genetic
Parkinsonism akinesia & rigidity neuroleptics antiemetics
vascular
head injury
Diagnosis
The diagnosis of PD is made clinically and laboratory investigations and standard CT/MRI 
neuroimaging are usually not helpful. The diagnosis is made if there are at least two of the four 
major clinical features present (Table 14.1) and is supported if there is a rapid clinical response 
to treatment with dopaminergic drugs. 
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Key points
 · PD is caused by a progressive loss of dopamine secreting cells in substantia nigra
 · key features are rest tremor, rigidity, poverty of movement & postural instability
 · tremor at rest in one hand /arm is often the earliest clinical sign
 · diagnosis is supported by a good response to dopamine treatment
Treatment
Levodopa
Early Parkinson’s disease does not require any drug treatment. The main aim of treatment of 
PD (Table 14.2) is to reduce motor disability. Levodopa (L-dopa) does this by replacing the 
missing dopamine which helps to relieve the symptoms but does not prevent disease progression. 
L-dopa is given orally and this is later converted into dopamine in the brain by the enzyme 
dopa decarboxylase which comes from the remaining substantia nigra neurones. In order to 
prevent conversion of the inactive L-dopa to dopamine in the peripheral circulation L-dopa 
is given in combination with a dopa decarboxylase inhibitor, either carbidopa or benserazide. 
Because the dopa decarboxylase inhibitors do not cross the blood brain barrier, this will result 
in increased dopamine levels in the brain without similar increases in the peripheral blood. This 
also reduces the nausea that results from peripheral dopamine. The overall aim is to keep the 
daily maintenance dose of L-dopa as low as possible in order to maintain good motor function 
and yet reduce any long term motor complications. 
Generic preparations of these are available as carbidopa/levodopa and benserazide/levodopa. 
Treatment is started slowly with gradual increases in dosages. The usual starting dose is in 
25/100 mg tabs, either ½ or 1 tab taken three times daily taken initially with meals. The main 
acute side effects are nausea, vomiting, hypotension, confusion and hallucinations. These often 
resolve spontaneously or with concurrent administration of an antiemetic e.g. domperidone 
bradykinesia
rigidity
tremor at rest
postural
instability
Patient with Parkinson’s disease
Patient with Parkinson’s disease Akinesia & semi flexed posture
Figure 14.1 Parkinson’s disease Figure 14.2 Parkinson’s disease
parkinson’s disease (pd)
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10-20 mg tds for the first 4 weeks of treatment. If the initial response is inadequate, then the 
L-dopa dose can be increased slowly every 4-6 weeks by ½ tab tds to a usual maintenance 
dose of 25/250 mg tabs 1 tds. However, any necessary increases in dosage (½ tab tds) can be 
brought forward to weekly if it is clinically indicated and the patient tolerates it. Later, usually 
after years L-dopa may have to be given more frequently (changing from 8 to 6 to 4 to 3 hourly 
as necessary). A controlled release (CR) preparation may be helpful to be taken at night because 
of a longer duration of effect. Most patients respond very well initially but larger doses are 
required as the disease progresses. 
In the later stages, the duration of response to each dose may shorten (the wearing off effect) and 
motor fluctuations may occur (the on–off phenomenon) and involuntary motor movements 
or dyskinesia are likely. The response to treatment may then become unpredictable and any 
sudden reduction or withdrawal of L-dopa is associated with deterioration.
Table 14.2 Levodopa treatment of Parkinson’s disease
Medication Class Initial dose Maintenance dose When to use Main side effects
carbidopa/levodopa 
or 
benserazide/levodopa
levodopa (25/100 mg 
tab) 
½-1 tab tds 
(25/250 mg tab)  
1 tab tds
early and 
throughout 
illness (effect 
good) 
nausea, vomiting, 
hypotension, 
confusion, 
hallucinations, 
dyskinesia
Other drug treatments
The L-dopa/decarboxylase inhibitor combinations are the most effective symptomatic 
treatment for PD. Other treatments include dopamine agonists, catechol-O-methyltransferase 
inhibitors (COMT), NMDA antagonists, monoamine oxidase B inhibitors (MOB) and 
anticholinergics (Table 14.3). In general, these treatments are added on when the response 
to L-dopa preparations has decreased or failed. The dopamine agonists may be used early on 
either as first line treatment alone or in combination with L-dopa especially in younger onset 
PD patients. The use of dopamine agonists is associated with less dyskinesia after 3-5 years of 
therapy. They act postsynaptically and therefore mimic the effects of dopamine in the basal 
ganglia. The dopamine agonists fall into two main groups: the ergot derived group which 
includes bromocriptine and cabergoline and the non ergot derived group which includes 
ropinirole among others. 
The side effect profiles are similar to dopamine except that ergotism may occur in the first 
group. Ergotism is a serious limitation to their long-term use as up to 3% of treated patients 
develop pulmonary or less frequently retroperitoneal fibrosis. The newer non-ergot agonists have 
been associated with hypersomnolence and impulse control disorders, including, overeating, 
excessive shopping, gambling and hypersexuality. Their use is contraindicated in pre-existing 
vascular, heart and lung disease. Amantadine is considered a useful drug to start treatment 
for the first 6-12 months. It has relatively few side effects but only a modest effect on motor 
symptoms and a limited duration of action. It is effective however, for the dyskinesia seen as a 
side effect of levodopa. Other useful add on drugs include the COMT inhibitor entacapone 
and the MOB inhibitor selegiline. These inhibit the breakdown of dopamine and prolong its 
activity. Their use is mainly indicated in late disease for motor fluctuations and decreasing 
response to L-dopa. The side effects are largely similar to levodopa. The use of anticholinergics 
(benzhexol) may be helpful mainly in tremor dominant disease in younger patients. The drug 
treatment of PD is summarised in the table below.
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Table 14.3 Other drug treatments of Parkinson’s disease
Medication Class Initial dose Maintenance dose When to use Main side effects
amantadine NMDA 
antagonist
100 mg/day 100 mg/bid/tds early (effect 
modest), 
dyskinesia
restlessness, 
confusion
bromocriptine 
 
cabergoline
ropinerole
dopamine 
agonists 
(ergot) 
(ergot)
(non ergot)
25 mg/day 
 
05-1 mg/day
025 mg/tds
5-10 mg/tds 
 
2-6 mg/day
2-6 mg/tds
early delays 
need for 
L-dopa 
late motor 
symptoms, 
fluctuations
early or late
as in levodopa 
*ergotism
 
as in levodopa 
*ergotism 
as in levodopa 
somnolence, 
impulse control 
disorders
entacapone COMT inhibitor 200 mg 
tab with 
each dose 
levodopa
max 2000 mg/day late motor 
symptoms & 
fluctuations
as in levodopa, 
dyskinesia, 
diarrhoea
selegiline MOB inhibitor 5 mg/bd 5 mg/bd late motor 
symptoms & 
fluctuations
confusion, 
insomnia
benzhexol anticholinergic 1-2 mg/bd 2-5 mg/tds early for 
tremor (effect 
modest)
confusion, 
cognitive 
impairment, 
dry mouth, 
constipation 
urinary retention
* Ergotism: 3% of patients develop pulmonary or less commonly retroperitoneal fibrosis
Non drug treatments
Physiotherapy is helpful to many patients with PD and their quality of life can be helped by 
the provision of simple aids to the activities of daily living. Surgical treatment is helpful when 
drug treatment has failed or is intolerable usually in selected younger patients. Surgery usually 
involves either a thalamotomy or pallidotomy or deep brain stimulation of the globus pallidus 
or subthalamic nucleus and accounts of these are available in larger textbooks.
Course
PD progresses slowly over many years. There is no cure and progression is variable with many 
patients functioning well despite the presence of the disease for years. Drug treatment is 
necessary for patients with motor disability and can be effective and long-lasting. As the disease 
progresses immobility, pain, sleep disturbance, depression and dementia (40-50%) are all very 
common and these may require separate management and treatment. The deterioration is slow 
and variable with death occurring on average 10-15 years after onset. 
parkinson’s disease (pd)
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Key points
 · early PD does not usually require drug treatment
 · Levodopa is the most effective drug treatment for PD
 · side effects are  nausea, vomiting , hypotension, confusion, hallucinations & dyskinesia
 · drug treatments are started at a lower dosage & slowly increased over weeks
 · PD typically progresses slowly over years with death following after 10-15 yrs
OTHER EXTRAPYRAMIDAL SYNDROMES
Parkinson plus syndromes
There are other uncommon or rare neurological disorders with features of parkinsonism 
which are briefly mentioned here. These are all disorders characterized by clinical features of 
parkinsonism in addition to other neurological findings more typical of the specific underlying 
neurological disorder. These are multiple system atrophy (MSA), progressive supranuclear 
palsy (PSP), corticobasal degeneration (CBD), vascular parkinsonism and dementia with 
Lewy bodies. MSA is characterized by parkinsonism coupled with cerebellar and/or autonomic 
dysfunction (hypotension) and partial initial response to L-dopa. PSP is characterized 
by akinetic rigidity, late onset dementia and a slowing or failure of voluntary vertical and 
eventually all eye movements. CBD is characterized by asymmetric bradykinesia, rigidity 
and limb apraxia. Vascular parkinsonism involves mainly the lower half of the body with a 
prominent gait disorder. Dementia with Lewy bodies is characterized by dementia, rigidity and 
hallucinations. A characteristic of all these disorders is either a reduced, nonsustained or absent 
response to levodopa treatment. Management is mostly symptomatic and supportive.  
Key points
 · Parkinson plus syndromes are uncommon
 · characterized by akinesia & other distinguishing neurological features
 · they can be separated clinically from PD 
 · response to L-dopa treatment is generally poor
 · prognosis is determined by the underlying condition
PARKINSONISM
Drug induced parkinsonism
The neuroleptic drugs, phenothiazines (e.g. chlorpromazine) and the butyrophenones (e.g. 
haloperidol) are one of the main causes of drug induced parkinsonism in Africa where they 
are mostly used in the treatment of schizophrenia and chronic confusional states. This is 
particularly the case with the use of long acting depot or intramuscular preparations. The long 
term use of some antiemetics including metoclopramide and prochloperazine may also cause 
parkinsonism. These drugs cause parkinsonism by blocking the effect of dopamine centrally 
in the brain. Drug induced parkinsonism is characterized by generalized slowness and rigidity 
without any tremor. 
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Management is to lower the dose or stop the offending drug. The parkinsonism usually remits 
within days or weeks of stopping the drug. However if the preparations have been used long 
term it may take a year or two to recover or there may be no recovery at all. The anticholinergics 
benzhexol or benztropine prescribed in adequate doses are the drugs of choice in the treatment 
of drug induced parkinsonism (Table 14.3).
Key points
 · long-term use of antipsychotic & antiemetics can cause drug induced parkinsonism
 · management is to stop the offending drug and use anticholinergic drugs
Neuroleptic malignant syndrome
This is an important syndrome because of the widespread use of neuroleptics and in particular 
the use of depot preparations for sedation of confused or aggressive patients. The main causes 
are phenothiazines and haloperidol. The symptoms usually start within days or weeks or 
months of starting the offending drug and is commonly misdiagnosed as meningitis because of 
neck rigidity and fever. It is characterized by generalised rigidity, altered level of consciousness 
and autonomic instability and high fever. The disorder is life threatening and the patient needs 
intensive medical care. Management is to stop the neuroleptic and to add a dopaminergic drug 
e.g. bromocriptine. Anticholinergics and muscle relaxants may also be used. 
Key points
 · neuroleptic syndrome is characterized by  fever, rigidity & history of  recent drug exposure
 · Rx: withdraw offending drug, use dopamine agonist & anticholinergic & muscle relaxants 
Akinetic-rigid syndrome
Decreased or absent movement (akinesia) can be the outcome of all causes of parkinsonism. 
It is characterized by generalised rigidity and immobility with the patient eventually confined 
to bed. The main causes are summarized in Table 14.4. It is a life threatening condition which 
frequently requires urgent medical attention. Complications include dehydration, pneumonia 
and pressure sores. The differential diagnosis in Africa includes other causes of increasing 
immobility including stroke, subdural haematoma, SOL, dementia and chronic psychosis. 
Management includes the use of parenteral anticholinergics and muscle relaxants and treating 
the underlying cause and complications.
Table 14.4 Causes of akinetic-rigid syndrome
Parkinson’s disease
parkinsonism
parkinson plus syndromes
Drugs 
neuroleptics 
antiemetics
Vascular
strokes (multiple lacunar)
subdural haematoma (chronic)
continues
parkinsonism
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Trauma
traumatic brain injury
Chronic psychosis
schizophrenia
Other causes
dementia
post encephalitic/inflammatory
toxins, chronic carbon monoxide, manganese
Wilson’s disease
Key points
 · akinetic-rigid syndrome is characterized by immobility & rigidity
 · management includes anticholinergics & muscle relaxants 
 · treat the underlying cause & complications
INVOLUNTARY MOVEMENTS
The main involuntary movement disorders are tremor, dystonia, chorea, athetosis, 
hemiballismus, myoclonic jerks and tics (Table 14.5 & 6).
Tremor
Tremor is an involuntary repetitive, rhythmical shaking movement of a part of the body, 
most commonly seen in the fingers, hands and arms. Tremors are categorized as either fine 
or coarse and according to the position in which the tremor occurs maximally. In order to 
demonstrate this, the hands are examined in three main positions: at rest, with the arms and 
hands outstretched and on action. The common tremors in these positions are outlined in 
Table 14.5.
Rest
This is a coarse, regular tremor which mainly affects the limbs, occurs at rest and improves 
initially on action such as holding a cup or newspaper. It can affect any part of the body 
including the fingers, toes hands, feet, limbs, chin, tongue, head and trunk. The main causes 
are Parkinson’s disease and parkinsonism.
Postural
This is a fine regular tremor and is the most common type of tremor. This occurs on posture 
e.g. when holding the hands outstretched and affects the fingers and hands. It may also affect 
the lower limbs, head, and trunk. The two most common types are physiological and benign 
essential tremor. 
Action
This is a regular coarse tremor which occurs on action and mainly affects the limbs but may 
involve the trunk. It is most evident when testing for finger nose or heel shin co-ordination 
during neurological examination of the limbs. The main causes are cerebellar disease and 
benign essential tremor. 
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Table 14.5 Common Tremors
Position Cause Clinical features Treatment
Rest Parkinson’s disease regular, coarse, slow anticholinergics
levodopa
Postural physiological,
benign essential tremor, 
anxiety,
hyperthyroidism
beta agonists, 
alcohol, HIV
regular, fine, medium, fast treat the cause
beta-blockers
Action cerebellar,
essential 
regular, coarse, slow  no effective treatment
beta-blockers or primidone 
(essential tremor)
BENIGN ESSENTIAL TREMOR
Benign essential tremor (BET) or familial tremor is one of the more common neurological 
disorders and is a very recognizable tremor. There are few studies on its frequency in Africa 
but its reported frequency there ranges widely from 5-81/100,000. It is frequently inherited 
as autosomal dominant, so there is often a positive family history. It occurs in all age groups 
including teenagers and young adults but with increasing frequency in advancing age, hence is 
more common in older age groups. The tremor affects the hands and/or the head but usually 
spares the legs. It is most apparent during posture such as holding a cup or newspaper and may 
persist throughout the action as evident on finger nose testing. The tremor is usually helped 
by a small amount of alcohol, made worse by anxiety and worsens slowly but over many years.
Many patients require only reassurance and no further treatment. If treatment is required 
beta-blockers are the drugs of first choice. Propranolol is prescribed initially in a low dose of 
10 mg twice daily increasing slowly over months to a maximum dose of 80 mg twice or three 
times daily. The dose should be titrated against response or may be taken only on an as required 
basis at times when the tremor is likely to be very disabling. Adverse effects of beta blockers 
include fatigue, hypotension and bronchospasm. Primidone may also be used. The initial dose 
is 25-50 mg daily increasing slowly by 50 mg every 2 weeks to a maximum of 250 mg twice or 
three times daily. A dose of 100-150 mg three times daily may be effective.  Adverse effects are 
drowsiness, fatigue and occasionally idiosyncratic reaction. 
Key points
 · BET is a mainly postural tremor with a strong family history 
 · occurs in teenagers and young adults but is more common in old age 
 · worsens slowly over years but usually does not cause disability
 · patients may need reassurance because of anxiety & embarrassment
 · drug treatment is with propranolol or primidone
benign essential tremor
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DYSTONIA
Dystonia is a complex disorder of motor control characterized by prolonged muscular 
contraction that gives rise to abnormal postures and involuntary movements. These are most 
apparent during voluntary action but may also occur at rest. Dystonia may be focal affecting 
one part of the body (Fig. 14.3) or generalised affecting more than one part (Fig. 14.4). It 
may occur at any age and clinical pattern, age of onset, and systemic features may point to the 
underlying cause. The focal dystonias are fairly common and the main examples in clinical 
practice are torticollis, blepharospasm and writer’s cramp. The generalized dystonias are 
uncommon and these tend to occur in childhood or in young adults. 
The main causes of dystonia are idiopathic, genetic or secondary to a systemic disease such as 
stroke, drugs or Wilson’s disease. In a typical severe generalized dystonia the head may be tilted 
or retracted, the back rotated or twisted (Fig. 14. 4). and the limbs extended with inverted 
feet or cramping of the hand. This posture may be maintained or be triggered by movement 
or a specific action. The main causes of drug induced dystonias are levodopa, chlorpromazine, 
metoclopramide and haloperidol. A more complex involuntary chewing and grimacing 
movement, associated with the use of long term neuroleptics is called tardive dyskinesia. 
Management of drug related dystonia includes the withdrawal of suspected drugs and the 
use of benzodiazepines. Management of persisting dystonia is generally disappointing but 
all patients under 40 years should first have a trial of levodopa. Other treatments include 
high dose anticholinergics (Benzhexol 5-10 mg three to four times daily or tetrabenazine used 
either alone or  together in combination with a dopamine agonist e.g. bromocriptine). Focal 
dystonias e.g., torticollis, blepharospasm and laryngospasm respond well but temporarily to 
local botulinum toxin injections. Deep brain stem stimulation targeting the globus pallidus 
can be effective in some generalized dystonias.
Orofacial dyskinesia & blepharospasm Torticollis & hemifacial dystonia
Figure 14.3 Dystonia (Meige syndrome) Figure 14.4 Dystonia generalised
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Acute dystonic reactions
These occur typically within 24 hours after a single dose of neuroleptics or antiemetics, in 
particular metoclopramide. These may be focal or generalised and are usually self limiting. 
They are recognizable by the characteristic writhing movement of the tongue, mouth, face 
and neck and occasionally limbs and trunk. If the eyes roll up involuntarily, this is called 
an oculogyric crisis. The treatment of choice is parenteral benztropine 1-2 mgs iv/im and 
repeated within 30 mins, if the first dose is not effective. Oral anticholinergic therapy should 
be continued for the next 5-7 days. The patient should be advised to avoid the offending drug 
in the future. 
Chorea
Chorea is an irregular dance-like, semi-purposeful, non repetitive, movement involving flexion 
and extension of the limbs and trunk. The movement is unpredictable, jerky, chaotic and 
fidgeting in nature. The main causes are streptococcal infection in Sydenham’s chorea and 
genetic in the case of Huntington’s disease (Chapter 18). It occurs very occasionally in HIV 
disease secondary to an opportunistic process involving the basal ganglia and as a long-term 
side effect of dopaminergic drugs. Unilateral chorea can result from a stroke affecting the basal 
ganglia. Sydenham’s chorea is typically self limiting after a few days or weeks or occasionally 
months and does not require treatment. Huntington’s chorea may respond initially to low dose 
haloperidol, tetrabenazine and also benzodiazepine if there is a disability or anxiety. However 
over time it usually becomes resistant to symptomatic treatment. 
Athetosis
This is a characteristic slow writhing movement that mainly affects trunk muscles. The main 
causes are cerebral palsy and basal ganglia disease. It may occur in combination with chorea 
and dystonia and these can be difficult to distinguish from each other. Treatment is similar to 
that of chorea.
Hemiballismus
This is a sudden irregular explosive flinging movement of the limbs on one side. The main 
cause is vascular or a stroke affecting the contralateral subthalamic nucleus and it may occur 
after head injury in young persons. Opportunistic processes in HIV disease in particular 
toxoplasmosis affecting the area of the basal ganglia are also a known cause. Hemiballismus may 
remit spontaneously or with treatment of the underlying cause. Haloperidol or tetrabenazine 
may be helpful if it becomes disabling. 
Myoclonus
Myoclonus is a sudden shock movement or jerk that may occur normally in children and in 
adults on falling asleep. It is only pathological if it persists such as occurs in myoclonic epilepsy, 
organ failure, dementia and occasionally with the use of the SSRI drugs in the treatment of 
depression. It arises in the CNS from cortical, sub cortical and spinal cord levels and can be 
stimulus sensitive or elicited by noise or touch, disappearing in sleep. The management is 
the treatment of the underlying disease. Myoclonus may respond to benzodiazepines such as 
clonazepam or to the anticonvulsants sodium valproate or levetiracetam.
dystonia
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Tics
A tic is a brief stereotyped irresistible repetitive purposeful movement. It differs from chorea 
in that it can be voluntarily suppressed at will for a short while. Simple tics like blinking, 
grimacing or shoulder shrugging are common in children and are usually outgrown. A wider 
range of tics causing vocalizations, noises and sometimes expletives is very suggestive of Gilles 
de la Tourette syndrome. This responds to dopamine antagonists e.g. haloperidol but the drug 
needs to be continued long term. 
Asterixis
This is a characteristic sudden flapping of the outstretched dorsiflexed hands. It is an important 
clinical bedside sign suggestive of metabolic encephalopathy. It occurs in association with 
organ failure characteristically liver, renal and respiratory failure. Treatment is management of 
the underlying disorder.
Hiccups
Hiccups are caused by a sudden spontaneous contraction of the diaphragm. They are usually 
transient and are a normal phenomenon but may be a complication of renal failure. In rare 
cases hiccups can persist for days or even months. In this case a local source of irritation of the 
diaphragm, either from above or below, should be excluded. Management of persistent hiccups 
is not easy. The usual drug of choice is chlorpromazine initially 25 mg twice or three times daily 
increasing to 50 mg as needed. Baclofen and gabapentin have been used with variable success.
Table 14.6 Main characteristics of other involuntary movements
Type Clinical features Causes
Dystonia
  generalized
  focal
abnormal posture, involuntary movements 
localised abnormal posture  
(e.g. torticollis, blepharospasm, writer’s cramp)
neuroleptics: phenothiazines, 
haloperidol, levodopa, Wilson’s 
disease, idiopathic
Chorea irregular, dance-like, non repetitive,  
semi purposeful
Sydenham’s, Huntington’s, HIV, stroke 
Athetosis slow, writhing, purposeless cerebral palsy
Hemiballismus explosive, unilateral stroke, head injury, HIV
Myoclonus sudden jerk encephalopathy, epilepsy
Tics movement, brief, stereotyped,  suppressible  
(e.g. blinking, sniffing, shrugging)
psychological
Key points
 · tremor is a rhythmical alternating movement of part of the body
 · dystonia is an abnormal posturing & involuntary movement
 · chorea is a brief dance-like semi purposeful non repetitive movement
 · myoclonus is a sudden jerk like movement
 · a tic is a brief stereotyped irresistible repetitive purposeful movement
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MOTOR NEURONE DISEASE
Motor neurone disease (MND) is a progressive neurodegenerative disease that affects upper 
and lower motor neurones in the brain and spinal cord. The cause is not known. It is an 
uncommon worldwide disorder with an incidence rate of 2 per 100,000 reported in high 
income countries with most cases occurring in >60 year age groups. However MND can affect 
all age groups and around 5% of reported cases are familial; these occur mostly in a younger age 
group. The frequency of MND in Africa in not known but may be less frequent there because 
of the lower overall life expectancy. An association between MND and HIV has been reported 
in some high income countries.
The pathogenesis of MND is not known but may involve a form of neuroexcitatory cell death 
mediated by free radicals. MND is exclusively a motor disease without any clinical sensory, 
bladder or ocular involvement. It is made up of four clinical subtypes; amyotrophic lateral 
sclerosis, progressive bulbar palsy, progressive muscular atrophy and primary lateral sclerosis. 
CLINICAL SUBTYPES
Amyotrophic lateral sclerosis (ALS)
ALS is the most common clinical presentation of MND accounting for approximately three 
quarters of all cases. ALS is an alternative name which is frequently used to describe MND. 
Patients with ALS present typically with slow but progressive weakness and wasting involving 
the limbs occurring usually over months. The upper limbs are more commonly involved earlier 
on than the lower limbs and limb involvement can be asymmetrical early on (Fig. 14.5). 
On examination, there is a mixture of upper and lower motor neurone signs in the limbs. 
Typically there is marked wasting and hyperreflexia in the upper limbs combined with 
increased tone, hyperreflexia in the legs and extensor plantar reflexes. Fasciculation is frequently 
widespread involving limbs and trunk muscles and may involve the tongue. There are no 
sensory signs. Emotional lability is a feature in some patients. All four limbs and the brain 
stem become involved later on (Fig. 14.6). Clinical presentation in Africa is typically late with 
most patients at the time of clinical presentation having a mixture of quadriplegia and a bulbar/
pseudobulbar palsy. The average survival time from the onset of first symptoms is 2-3 years.  
Wasting of the hand muscles & clawing of the hands in advanced MND
Figure 14.5 Amyotrophic lateral sclerosis affecting the hands
motor neurone disease
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Progressive bulbar/pseudobulbarpalsy (PBP/PSP)
PBP/PSP is the main form of clinical presentation of MND in 10-20% of patients. It occurs 
more commonly in the elderly. Dysarthria and dysphagia progressing over months are the main 
presenting complaints. Signs of mixed bulbar and pseudobulbar palsy are always present. The 
main neurological findings are those of a spastic, immobile and fasciculating tongue (Fig 14.6) 
coupled with either an increased or absent gag reflex. The jaw jerk is usually brisk. Isolated signs 
of limb involvement including spasticity and hyperreflexia and occasionally fasciculation may 
already be apparent on neurological examination or more typically develop later on. Survival 
times are usually shorter than in ALS.
Progressive muscular atrophy (PMA) 
PMA accounts for about 5% of cases. PMA presents as progressive lower motor neurone 
weakness in the limbs (Fig. 14.7). The neurological findings are weakness, wasting, fasciculation 
and absent reflexes. Bulbar involvement may follow. Survival times are 4-5 years.
Figure 14.7 Progressive muscular atrophy Foot drop (bilateral) in MND
Spastic & ridged tongue in ALS
Spastic immobile tongue & wasted hands in ALS
Figure 14.6 Bulbar/pseudobulbar palsy
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Primary lateral sclerosis (PLS) 
PLS accounts for 1% of cases. PLS presents as a very slowly progressive upper motor neurone 
type weakness affecting the limbs. There are no lower motor neurone findings and survival 
times are 15-20 years. 
Other rarer clinical presentations of MND include flail arm, man in the barrel syndrome, head 
drop and dementia. Cognitive & behavioural changes may precede, accompany or follow the 
development of clinical MND/ALS. Cognitive changes in MND are much commoner than is 
generally appreciated and although in most patients these are subtle, a minority may develop a 
frank dementia or aphasia, usually of a frontotemporal dementia type (FTD). In some familial 
cases the same gene mutation can cause FTD, MND, or both. 
Differential diagnosis
The main differential diagnosis includes cervical spondylosis, syringomyelia, post polio 
syndrome and lead poisoning. Uncommonly or rarely some genetic or inherited muscle and 
nerve disorders need to be considered in the differential diagnosis. These include limb girdle 
muscular dystrophy (LGMD), spinal muscular atrophy (childhood or adolescent onset), 
affecting mainly the proximal limbs and slowly progressive and may mimic LGMD), and 
Kennedy’s syndrome (twitching movements of chin & tongue fasciculations, tremor hands, 
proximal weakness, gynecomastia, diabetes and neuropathy, slowly progressive). 
Investigations
Laboratory investigations in MND are usually normal apart from an occasional elevated 
creatinine phosphokinase and/or infrequently isolated elevation in CSF protein. X-ray of the 
neck excludes cervical spondylosis and neuroimaging of the brain may occasionally be necessary 
to exclude other possible causes. 
Diagnosis
The diagnosis in MND is mostly a clinical one and clinical diagnostic criteria for MND have 
been established by the World Federation of Neurology according to the degree of clinical 
certainty. The definite diagnosis of MND requires the presence of upper and lower motor signs 
in at least two spinal regions (cervical, thoracic and lumbosacral) and also involving the bulbar 
region. The diagnostic criteria are set out in Table 14.7
Table 14.7 El Escorial criteria for diagnosis of MND*
Diagnostic certainty Clinical features
Definite upper & lower motor neurone signs in the bulbar and two spinal regions or in three 
spinal regions
Probable upper & lower motor neurone signs in two or more regions; the regions may differ 
but some UMN signs must be proximal to LMN signs
Possible upper & lower motor neurone signs in only one region or UMN signs alone in two or 
more regions or LMN signs proximal to UMN signs
Suspected LMN (not UMN) signs in at least 2 regions
* criteria of the World Federation of Neurology
Management
The management of MND involves explaining to the patient and family the nature of the 
illness. It is important to emphasise the practical approach in caring for the patient. Most 
drug treatment is symptomatic. The anticholinergic drug benzhexol is used for reducing saliva 
CliniCal subtypes
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secretions and baclofen and diazepam for spasticity and anxiety. Other medications include 
paracetamol for pain, quinine sulphate for cramps and opiates as required for palliative care. 
The antiglutamate drug Riluzole 50 mg bd has been shown to increase life expectancy but only 
by about 3-6 months in some patients. 
Prognosis
Survival with MND from onset is on average 3-5 years with around 10% surviving 5 years or 
longer. The cause of death is most frequently respiratory infection. 
Key points
 · MND is an uncommon neurodegenerative disease 
 · characterized by a mixture of upper & lower motor neurone signs 
 · common presentations are limb weakness & bulbar palsy 
 · treatment is largely symptomatic & supportive 
 · survival on average ranges 3-5 years from onset
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CHAPTER 15
HEADACHE AND FACIAL PAIN
Headache is a very common problem which affects most persons at some point during their 
lives. The vast majority are due to tension headache, migraine and analgesic overuse. These 
are termed primary headaches and are mostly benign, but for some they are very debilitating 
disorders. The diagnosis of primary headache is made entirely from the history as there are no 
abnormal signs or investigations. A much smaller group consists of secondary or medically 
serious headaches. These headaches are caused by an underlying disease or disorder. This 
group includes infections, space occupying lesions, intracranial haemorrhage and usually have 
signs and abnormal investigations. It is important to separate these two groups clinically as they 
obviously have different implications for the patient. This chapter reviews the main headache 
disorders and facial pain and their investigation and treatment. After reading it the student 
should aim to be able to recognise and distinguish the medically serious headaches and the 
main primary headache disorders and also facial pain.
Pain
The brain itself is a painless organ. The source of the pain in headache arises from the structures 
overlying the brain; these include the scalp, skull, meninges and blood vessels. The dura and 
blood vessels are the most pain sensitive structures in the head. The site of the headache may 
sometimes be a guide to the origin of the headache. In general pain arising from the anterior 
and middle cranial fossa is referred to the forehead and front of the head whereas pain arising 
in the posterior fossa and upper cervical area is referred to the back of the head and neck. Pain 
arising from the surface of the brain tends to be diffuse, “all over” or occipital or nuchal as in 
meningitis or spread more focally over the overlying vertex or parietal and temporal areas as in 
tumours. Pain in the head may also be referred to the face, neck, ears, eyes, teeth and sinuses.
Classification
Headaches can be broadly classified into primary and secondary. The main causes are outlined 
below in Tables 15.1 & 15.4.
The history
A good history based on the temporal pattern of symptoms is essential in determining the 
cause of headache. This will include the time course, (onset, duration etc), site, severity, pattern 
and factors which alter or affect it. It is important to check specifically whether this is the 
first attack, the onset was sudden or gradual, continuous (daily) or intermittent (periodic), 
increasing or decreasing and whether the time course is acute (hours and days), sub acute 
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(days and weeks) or chronic (months years). Determine the main site of the pain, whether it is 
unilateral or bilateral, frontal, temporal or occipital and its radiation. The character of the pain 
is also important, whether it is sharp or dull or throbbing in nature. Severity can be scored by 
the patient and recorded on a scale of 1-10, with 10 being the worst pain ever experienced and 
1 the least. There may be some specific exacerbating factors e.g. movement, coughing, bending 
and relieving factors such as rest and analgesics. Check for any other associated symptoms and 
in particular whether there is any previous history of a similar headache or chronic analgesia 
intake. 
Examination
Carefully record the vital signs including BP and check particularly for signs of raised 
intracranial pressure, meningism, tenderness of the temporal arteries, and focal neurological 
signs. Fundoscopy is essential as papilloedema may indicate raised intracranial pressure. 
Examine for local causes in the head and neck.
Key points
 · headache is a common medical disorder
 · vast majority of headaches are primary 
 · only a small minority are medically serious
 · history is the most important part of evaluation of headache
 · fundoscopy should be performed in all patients with persistent headaches
PRIMARY HEADACHES
The main primary headaches are tension, migraine, analgesic overuse, and cluster (Table 15.1).
Table 15.1 Main primary headaches
Primary Frequency* Site Clinical Features Treatment
Tension 
(Chronic > 6/12)
2-3% bilateral, frontal, 
temporal, occipital, 
neck
dull, chronic, band 
like, scalp tenderness, 
episodic
reassurance, relaxation 
amitriptyline 10-25 
mg/nocte 6-12 weeks 
Migraine 5-10% unilateral, frontal, 
bifrontal holocephalic, 
vertex, occipital
throbbing, moderate/
severe, periodic, 
nausea or vomiting, 
photophobia, familial
avoid precipitants, 
regular sleep, aspirin, 
paracetamol, NSAIDs, 
ergotamine, triptans
Analgesic 
overuse
2% bilateral, generalised mild, bilateral, daily, 
migraine or tension like
stop all analgesics
Cluster 
headache
01% unilateral, retro-orbital very severe, redness 
& tearing, Horner’s 
syndrome, mostly in men
100% oxygen,  
steroids, verapamil
* based on studies in high income countries
TENSION HEADACHE
This is the most common form of headache experienced by most people during their lives. 
Tension headache is characterized by recurring daily attacks of mild to moderate bilateral 
headaches that may last from hours to weeks. The tension headache becomes chronic when it 
persists on >15 days per month and lasts for >6 consecutive months. Chronic tension headache 
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affects 2-3% of adults in high income countries at any one time. A lower prevalence (0.4%) was 
reported in one study in Tanzania. The pain in tension headache is bilateral mostly occipital, 
also frontal or temporal in site and often described as a tight band around the head, starting 
within an hour or so of waking and increasing in severity throughout the day. It frequently 
radiates to the back of the neck. The severity may fluctuate with the patient going for days or 
weeks without noticing it. It is distinguished from migraine by its bilaterality, a lack of nausea 
and lack of discrete episodic attacks. The source of the pain is considered to be secondary to 
chronic muscle contraction of the scalp, neck and face although this may in itself be a secondary 
phenomenon. The scalp may be painful and tender on palpation and this may provide a useful 
clue to the diagnosis. There may be a background of anxiety and worry and a lack of response 
to ordinary analgesics. 
Management
Management is by reassurance, regular exercise, relaxation and local measures. The dose of 
analgesics may need to be reduced and finally discontinued. Low dose amitriptyline 10-25 
mg/po/nocte for 3-6 months may help to break the cycle in chronic tension headache but can 
take at least 4-6 weeks to work. Benzodiazepines although effective in the short term should be 
avoided because of the danger of habituation.
Key points
 · tension, migraine & analgesic overuse are the main primary headaches 
 · tension headache is the most common & may persist for months or years
 · frequently described as dull “like a tight band around my head“
 · scalp may be tender to touch 
 · treatment includes stopping analgesics, increasing exercise & relaxation
 · specific measures include low dose amitriptyline at night for 3-6 months 
MIGRAINE
Migraine is a primary headache disorder characterized by periodic attacks that are variably 
associated with nausea, vomiting, and neurological symptoms. Pain is typically associated with 
increased sensitivity to light and noise. The attacks last 4-72 hours and their frequency is 
variable. The majority of patients have one attack or less per week which lasts <24 hours 
Migraine affects >10% of the world’s population and its frequency is reported to be >5% in 
Africa. A family history of migraine is present in most patients and people usually suffer their 
first attack in their teens or early twenties, or before the age of 40 yrs. Women are affected twice 
as often as men. There are a number of well known triggers for individual attacks of migraine; 
these include stress, relaxation, fatigue, hunger, exercise, menstruation and specific foods 
including cheese, chocolate, red wine, citrus fruits, food additives and caffeine. Spontaneous 
remission may occur during pregnancy and after the menopause. 
Clinical features
In over half of patients with migraine, the onset of headache is preceded in the first 24 hours 
by a prodrome of warning mood changes, cravings or hunger feelings. A typical migraine may 
begin with an aura in 10-20% of patients. It occurs characteristically during the hour before 
the onset of headache. The commonest aura is visual with bright zig zag lines and blurring or 
migraine
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loss of vision. Less commonly, there may be tingling in one limb spreading to ipsilateral tongue 
and face and dysphasia. Rarely there is a temporary hemiplegia or even complete aphasia. The 
aura typically lasts a few minutes but sometimes may last longer. These symptoms precede the 
headache and mostly resolve as the headache starts. When these are present, it is called classical 
migraine or migraine with aura and when absent is called common migraine. 
The next phase is the headache itself. The headache of migraine is characteristically dull at onset 
and later becomes throbbing, severe, usually unilateral, frontal, radiating to the neck. It may 
be bilateral in one third of patients. The headaches last between 4 hours and 3 days with most 
attacks lasting <24 hours. Normal physical activity usually makes the headache worse. The 
headache is often accompanied by pallor, nausea or vomiting and the need to lie in a quiet and 
darkened room. A period of sleep early on may abort the attack. The patient feels completely 
normal between the attacks but they can recur at variable intervals. Investigations are generally 
not necessary
Key points
 · migraine affects >5% adults in Africa, females >males and clusters in families
 · aura is characterized by bright zig zag lines and blurring or loss of vision 
 · headaches are periodic, mostly unilateral & throbbing lasting 4-72 hours 
 · associated with nausea/vomiting & visual/neurological disturbance
PATHOGENESIS
This involves abnormal nerve impulses originating mainly from the brain stem in the 
distribution of the trigeminal nerve and spreading to the cortex causing release of inflammatory 
substances and neuropeptides that stimulate pain fibres on meningeal arterioles. The symptoms 
of migraine have been attributed to an initial spreading occipital wave of vasoconstriction of 
cortical blood vessels with decreased blood flow (the aura phase) followed later by regional 
cortical vasodilatation (the headache phase). Serotonergic neurones occur extensively in the 
brain and brain stem and their involvement in migraine is suggested by the effectiveness of 
the 5–hydroxytryptamine (5-HT1) agonists e.g. the triptans in treating the headache phase of 
an acute attack. 
Treatment
Identification of trigger factor(s) and avoiding them should be the first line of treatment. Attacks 
are often infrequent and mild, and resolve with simple analgesics such as aspirin, paracetamol 
or ibuprofen taken either alone or in combination with an antiemetic, like metoclopramide. 
Failing that the triptans are of great benefit (Table 15.2).The triptans are the drugs of first 
choice but are contraindicated in pregnancy, coronary artery disease, vascular disease, and 
uncontrolled hypertension. They are not recommended in hemiplegic migraine or in migraine 
with complex auras (sensory, motor or speech disturbances). They are recommended to be taken 
at the onset of the headache but not before. The main route is oral but if vomiting is a problem 
then triptans can be given either by nasal spray or subcutaneous injection. A second dose is 
usually effective for relapse within the first 6-48 hours. The side effects of triptans include chest 
discomfort and nausea and are more common with parenteral administration. Information on 
sumatriptan is outlined below, but any of the other triptans are equally efficacious. 
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An alternative cheaper treatment regime is ergotamine, however it should never be used in 
pregnancy and regular repeated usage is not recommended because of the danger of ergotism, 
gangrene, and rarely pulmonary fibrosis. Ergotamine is also contraindicated in peripheral and 
cardiovascular disease. It is important to note that the combined use together of a triptan and 
ergotamine is also contraindicated. If the patient is not responding to the combination of 
analgesics and antiemetics then triptans may be helpful 
Table 15.2 Treatment of migraine
Acute treatment Dose/range/frequency Main side effects
Non specific treatment
aspirin
paracetamol
ibuprofen
metoclopramide/domperidone
300 mg tab, 2-3 tab/po/12 hourly
500 mg tab, 2 tab/po/6 hourly
2-400 mg tab, 1-2 tab/po/6-8 hourly
10 mg tab, 1 tab/po/6-8 hourly
bleeding
nausea
bleeding 
dyskinesia
Specific treatment
Ergot derivatives 
ergotamine tartrate 
 
 
dihydroergotamine*
1 mg tab, 2 tab/po or suppositories/at 
onset followed by 1 tab every 30 mins, 
(max 24 hours dose 6 mg, the total max 
weekly dose is 10 mg)
05-1mg/iv/8 hourly as required,  
(max total dose 10 mg, supervised)
nausea, vomiting, ergotism
Triptans
sumatriptan** 50 mg tabs, 1 or 2 tab/po/at onset, repeat 
in 2 hours, (max 24 hour dose 200 mg) 
or
6 mg/sc/at onset, repeat in 2 hours,  
(max 24 hour dose 12 mg) 
or
5-20 mg/nasal spray at onset, repeat in  
2 hours, (max 24 hour dose 40 mg)
chest tightness, 
paraesthesiae, fatigue
* used only in intractable migraine in specialist headache units
** other triptans are equally effective
PROPHYLAXIS
Dietary triggers for migraine should be avoided and oestrogen containing contraceptives used 
with caution. Preventative treatment reduces the frequency, severity and duration of the attacks 
(Table 15.3). If the frequency is weekly or greater or the attacks are disabling, then those 
patients may benefit from daily prophylaxis. Medications used in prophylaxis and their dosages 
and main side effects are outlined below, and the initial treatment duration is for 3-6 months. 
The most commonly used options include amitriptyline, beta-blockers and sodium valproate. 
The anticonvulsant topiramate can also be very effective in cases resistant to other medications, 
but it is more expensive.
prophylaxis
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Table 15.3 Prophylaxis of Migraine
Medication Dosage/range/frequency Main side effects
Beta blockers
propranolol
atenolol
10-80 (160) mg/po/bid
50-200 mg/po/daily 
postural hypotension, fatigue
Tricyclics
amitriptyline 10-100 mg nocte dry mouth, sedation, urinary retention 
Anticonvulsants
sodium valproate
topiramate
250-750 mg/po/bid
25–50 mg bid
nausea, weight gain, alopecia, tremor, liver 
dysfunction
renal stones, paraesthesia, weight loss
Calcium channel blockers
verapamil 40-160 mg/po/tid constipation, fatigue, oedema
5-HT2 antagonists
pizotifen 05-3 mg/po/daily weight gain
Key points
 · majority do not require treatment or respond to simple analgesics & antiemetics
 · triptans are the treatment of choice but are expensive and have contraindications
 · ergotamine preparations may also be used at onset but have contraindications 
 · if attacks are severe or >1 per week then daily prophylaxis is recommended 
 · main prophylaxis includes beta blockers or anticonvulsants in adequate doses
ANALGESIC OVERUSE HEADACHE
These are a group of headaches lasting longer than 4 hours a day which persist for at least 15 
days every month for at least 3 months. The term chronic daily headache (CDH) is also used 
to describe them. These are usually cases of transformed migraine or chronic tension headaches 
and may affect over 2% of the population in high income countries, most commonly females. 
These occur mostly as a result of prolonged use of analgesics including simple analgesics, non 
steroidal anti-inflammatory drugs (NSAIDs), opiates, ergotamine and triptans. Patients typically 
complain of daily throbbing bilateral headaches which are only transiently and incompletely 
relieved by increasing doses of medications. Neurological examination is entirely normal. 
Management
The management aim is to decrease the frequency, severity and duration of the headaches 
by complete withdrawal of medication. The patient will need to be encouraged to have a 
regular life style and avoid caffeine and be specifically educated about the overuse of analgesics. 
In particular they will need to understand that there will be persisting symptoms including 
headaches, nausea, agitation and insomnia, particularly during the first two weeks after 
stopping. Withdrawal for ordinary analgesics, ergotamine and triptans should be carried out 
abruptly over a period of 24-48 hours. Withdrawal of opioids may take a period of 2-4 weeks. 
Remission occurs 2-12 weeks after withdrawal. The patient may need interim symptomatic 
treatment with an antiemetic, NSAIDs and occasionally a brief course of steroids. Underlying 
anxiety and depression may also need to be treated. Preventive medications include amitriptyline 
10-50 mg/po/nocte. 
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Key points
 · analgesic overuse is a cause of chronic daily headache 
 · most common sources of CDH are chronic tension headaches & transformed migraine
 · management is abrupt withdrawal of all non opioid medication over 24-48 hours
 · opioids may take 2-4 weeks to withdraw
CLUSTER HEADACHE
This is an excruciatingly severe, unilateral, headache located around one eye and accompanied 
by local autonomic dysfunction, redness, swelling and watering of the eye. It occurs in high 
income countries with a frequency of approximately 1/1000. It has its onset mostly in the 3rd 
and 4th decade and the male female ratio is about 5:1. It receives its name from its tendency 
to cluster usually 1-3 times daily (can be up to 8 times) for periods of 3-6 weeks or longer at 
a time with long intervals, sometimes years completely free of attacks. The attacks are brief, 
lasting between 30-120 minutes, in contrast to migraine which persists for 4-72 hours. Cluster 
headaches typically occur at the same time in the 24 hour cycle often waking the patient from 
sleep. 
Management
Stopping the acute attacks of pain quickly is critical. These can be well controlled by inhalation 
via a mask of 100% oxygen @ 7-10 litres/min for 15-20 minutes. Triptans can be successful if 
used by injections (e.g. sumatriptan 6 mg/sc) or intranasally (sumatriptan 20 mg). Alternatives 
include zolmitriptan 5 mg orally. They can be repeated once in 24 hours but should be avoided 
in patients with multiple attacks because of the danger of overuse. Concomitant use of ergot 
drugs is absolutely contraindicated because of the danger of a stroke. Prophylaxis during a cluster 
can be helpful with high dose steroids, prednisolone 60 mg/po/daily for 5 days decreasing by 
10 mg every 3 days. Long term prevention is indicated for chronic cluster headaches. This 
includes verapamil 80 mg bd for 2 weeks increasing by 80 mg every 2 weeks to a maximum of 
320 mg bd or tds. Avoiding tobacco and alcohol is also important. 
Key points
 · cluster headache is severe, unilateral with redness and tearing of the eye
 · recognised by its distinctive pain, recurrence and male preponderance
 · acute attack can be treated with 100% oxygen inhalation or as for migraine
 · prophylaxis is with high dose steroids or verapamil for 1-2 months
SECONDARY HEADACHES
The main causes of secondary headaches are intracranial tumours, infections, intracranial 
haemorrhage, temporal arteritis and benign intracranial hypertension (Table 15.4). Other 
causes to be considered include hypertension, arterial dissection, head injury, brain abscess, 
subdural haematoma and medications. Secondary headaches may lead to serious consequences 
if the underlying cause is not identified and treated.
Cluster headaChe
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Table 15.4 Secondary headaches
Main Causes Onset Type Clinical features 
Tumour sub acute severe, generalised, worse on 
waking, aggravated by coughing & 
straining
ICP & FNDs*
Meningitis acute/sub acute severe, generalised & meningism fever, neck stiffness  
& Kernig’s sign 
Subarachnoid 
haemorrhage
acute explosive, thunderclap & meningism neck stiffness,  
Kernig’s sign, ± FNDs*
Temporal arteritis sub acute non specific/uni/bilateral tender temporal arteries, 
blindness, age >50-60 yrs, 
ESR>60
Benign intracranial 
hypertension
sub acute throbbing, visual obscurations & loss) female, young, overweight, 
visual loss, papilloedema, 
6th nerve palsy, gait ataxia
* focal neurological disorders/deficits
INTRACRANIAL TUMOUR
The majority of patients presenting with brain tumour do not have headaches. The headache 
of an expanding intracranial tumour is produced by raised intracranial pressure and is often 
described as bursting and severe in nature. The pain is typically continuous and increases in 
severity over weeks or months. Characteristically it is present on waking in the morning or 
may wake the patient at night and improves during the day. It is aggravated by measures that 
increase intracranial pressure; these include lifting, bending, lying down, coughing, sneezing 
and straining. The distribution of the pain is either generalized or referred to the fronto/
temporal area, or vertex/occipital area depending on the site of origin of the tumour. The 
presence of nausea, vomiting, visual disturbances, altered level of consciousness all suggest 
raised intracranial pressure. 
Neurological examination should check carefully for papilloedema (Chapter 12) and focal 
neurological findings. A CT scan of the head is indicated in patients when a SOL is suspected. 
Details on brain tumours, abscess, subdural haematoma and other space occupying lesions are 
presented elsewhere in this textbook (Chapters 6, 7, 16 & 19).
Key points
 · majority of patients with headache do not have an intracranial tumour
 · clinical features include bursting pain on waking, increasing over time, worse on coughing/
straining
 · tumours rarely present with headache alone & usually have FNDs or ICP 
 · head CT scan is indicated in patients with suspected SOL
MENINGISM
Meningism results from inflammation or irritation of the meninges. The two major causes 
are meningitis and subarachnoid haemorrhage (Chapters 5 & 6). The headache in meningitis 
is usually severe, generalised and associated with fever, photophobia and signs of meningism 
including neck stiffness and Kernig’s sign. In subarachnoid haemorrhage the headache is 
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typically sudden or explosive in onset with vomiting and meningism. Diagnosis is confirmed 
by lumbar puncture. Headaches frequently occur with other CNS infections including 
encephalitis.
Key points
 · headache in meningitis is severe & generalised 
 · headache in SAH is sudden and explosive
 · both result in symptoms and signs of meningism
TEMPORAL ARTERITIS (TA)
In persons >50 yrs old the extra cranial vessels may become inflamed with an arteritis. The 
arteritis causes a new onset, severe, throbbing, mostly bilateral headache and exquisite local 
scalp tenderness. The headache may be non specific at onset later localizing to the temples. 
Exacerbation of headache with chewing suggests the diagnosis. On palpation, the superficial 
temporal artery may be hot, tender, swollen and non pulsatile. Other arteries may be similarly 
affected and blockage of the ophthalmic artery may result in transient blindness which can 
become permanent in about 25% of cases. Strokes are not uncommon. Females are affected 
more frequently than males and temporal arteritis is associated with polymyalgia rheumatica. 
The ESR is characteristically elevated >60 mm/hr. The age of onset is usually >60 yrs. Diagnosis 
is confirmed by a temporal artery biopsy which ideally should be performed early on but this 
may not always be practical. 
Management is with immediate high dose steroids as soon as the diagnosis is suspected 
without waiting for investigation results. Prednisolone 60 mg/po/daily is prescribed for a 
total of 2-3 months and then tapering to a maintenance dose of 5-10 mg on alternate days. 
The response to steroids is usually dramatic, often within the first 24-48 hours. Steroids may 
be needed for a total of 18-24 months or until symptoms fully clear. Treatment is guided by 
monitoring the ESR.
Key points
 · headache in TA is intense, focal & localised to the temples
 · temporal arteries may be tender on palpation
 · blindness and strokes are major complications
 · both patient’s age and the ESR are generally >60
 · treatment: high dose daily steroids for 2-3/12 & maintenance dose for 18-24/12 
BENIGN INTRACRANIAL HYPERTENSION (BIH)
It is an uncommon disorder characterized by headaches with elevated intracranial pressure 
without any evident cause. It is more widely known in Africa as pseudotumour cerebri. This 
occurs mostly in young, overweight females in their 20s and 30s. The oral contraceptive pill is 
a risk factor. Patients typically present with a severe morning throbbing type headache often 
associated with nausea, vomiting and sometimes visual disturbances. Visual disturbances include 
transient often postural episodes of loss of vision lasting seconds, as well as more sustained 
temporal arteritis (ta)
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blurring and sometimes permanent loss of vision. The characteristic finding is bilateral 
papilloedema. Neurological examination is otherwise normal apart from occasional isolated 
6th nerve palsy and a mild gait ataxia. The differential diagnosis includes the other causes of 
medically serious headaches including cerebral venous sinus thrombosis. Brain imaging with a 
CT is always normal but should be carried out in order to exclude another organic cause. The 
diagnosis is confirmed by finding an elevated CSF opening pressure of >250 mm on lumbar 
puncture. 
Management
Acute treatment measures include repeated lumbar punctures in combination with high dose 
steroids used over 3-5 days. The main long term management includes weight loss, stopping 
the contraceptive pill and a diuretic, acetazolamide tablets 250 mg tid. Furosemide is an 
alternative diuretic. BIH remits spontaneously after these measures in many patients but the 
measures, in particular weight loss, have to be vigorously adhered to. If there is visual loss, 
(decreased visual acuity, and constricted visual fields) then a lumboperitoneal CSF shunt or 
optic nerve sheath fenestration should be considered to prevent permanent blindness. 
Key points
 · BIH presents as headaches, visual disturbances & papilloedema
 · typically occurs in young overweight females taking the contraceptive pill
 · neurological investigations are normal including neuroimaging 
 · acute measures include steroids over first 3-5 days and repeated lumbar punctures
 · long-term management includes weight loss, diuretics & stopping the pill
Other causes of headache
Other primary headaches include trigeminal neuralgia (see below under facial pain), exertional 
and coital headaches. These latter headache types are precipitated by exercise or sexual activity. 
These are benign but can mimic a SAH and this may need to be excluded. 
FACIAL PAIN
Facial pain has many local causes including diseases of the eyes, ears, nose, sinuses, throat, teeth 
and temporomandibular joints and referred pain. Neurologic causes of facial pain need to be 
distinguished from local causes. Many of the neurological disorders which cause headache 
may also cause facial pain; these include cluster headache, temporal arteritis and occasionally 
migraine. However there are some neurological disorders where the pain is restricted to the 
face, these include trigeminal neuralgia, post herpetic neuralgia and atypical facial pain. The 
local causes of facial pain are usually determined clinically by their site and associated clinical 
findings. 
TRIGEMINAL NEURALGIA (TN)
This is a very painful disorder affecting the trigeminal nerve. It affects persons of all age groups 
but mostly those over the age of 40 yrs. It is more common in females than males. Previously no 
cause was found in most patients with trigeminal neuralgia and these were termed idiopathic. 
However many of what were previously termed to be idiopathic causes have been shown by 
MRI to be due to compression of the trigeminal sensory nerve root near the brain stem by an 
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aberrant arterial branch. Secondary causes include herpetic infection and a cerebellopontine 
angle tumour compressing the trigeminal nerve during its intracranial course.
Clinical features
Patients with trigeminal neuralgia typically present with unilateral facial pain in the distribution 
of one or more divisions of the trigeminal nerve. The pains are characteristically sudden, severe, 
brief, shooting, electric shock like, lancinating or knife like stabs in the distribution of one or 
more branches of the trigeminal nerve. The attack lasts less than a second usually affecting only 
one side of the face, typically the corner of the mouth or nose. There are frequently trigger 
areas on the face where any stimulus however gentle may produce pain. The pain may be 
triggered by touching, talking, eating, drinking cold or hot liquids or cleaning teeth. The stabs 
of pains can recur continuously many times per day. Between the stabs there may be a lingering 
continuous background pain but it is usually much less severe. 
The natural history is one of remission but only after weeks or months of facial pain and the 
neuralgia typically recurs again after a few months. Spontaneous remission can occur. The 
differential diagnosis includes local causes of facial pain including dental infections, sinusitis, 
disease of the temporomandibular joint and other atypical forms of facial pain
Management
The pain does not respond to simple analgesics and requires adequate doses of anticonvulsants 
for control. Carbamazepine is the drug of first choice and a favourable response to treatment 
is diagnostic of TN. The standard starting dose is 100 mg/po/bd increased as needed over the 
next few days or weeks. A usual therapeutic and maintenance dose of carbamazepine is 200 to 
400 mg twice or three times daily. This may be continued for a period of one or two months 
depending on the duration of the episode of facial pain and the patient’s tolerance of the drug 
side effects. Drowsiness and ataxia are the main limiting side effects. Second line drugs include 
gabapentin, pregabalin, phenytoin and sodium valproate. If the pain becomes intractable or 
intolerable and an adequate trial of drug treatment fails then the nerve can be considered for 
interruption either temporarily with an injection of alcohol or more permanently with phenol, 
glycerol or a destructive procedure. 
Key points
 · trigeminal neuralgia is very painful & affects branches of trigeminal nerve
 · recurring shooting facial pains lasting less than a second are diagnostic 
 · pain is triggered by touching, eating, hot & cold, cleaning teeth & talking
 · natural history is remission but both attacks and remissions last months
 · carbamazepine taken in adequate doses daily is the treatment of choice
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CHAPTER 16
INTRACRANIAL TUMOURS
Intracranial tumours (ICT) include tumours arising from the brain or surrounding tissues. 
They are classified as either primary or secondary and as malignant or benign. Other 
classifications include tissue type, grade of malignancy and the main site affected. Primary 
intracranial tumours originate mostly from brain or meninges whereas secondary or metastatic 
tumours originate mostly elsewhere in the body. The most common primary tumours are 
gliomas accounting for between 30-50% of all adult intracranial tumours. Gliomas are 
malignant tumours which arise from glial support cells rather than neuronal cells and are 
termed astrocytoma, oligodendroglioma, ependymoma and pinealoma. 
The most common primary benign tumours are meningiomas. These arise from the meninges 
covering the brain and cranial nerves accounting for 20-30% of all adult intracranial tumours. 
Other benign intracranial tumours are pituitary adenoma, craniopharyngioma, colloid cyst and 
acoustic neuroma. The aim of this chapter is to present an overview of the main intracranial 
tumours. The student should aim to know the main types of tumour, their clinical presentation, 
diagnosis and management.
EPIDEMIOLOGY
The incidence of primary intracranial tumours in high income countries is 1-2/10,000 per 
year. The incidence in Africa is not known but some studies suggest they may be less frequent 
there. The cause of most brain tumours is not known but some are related to genetic factors, 
radiation exposure and possibly environment. Primary intracranial tumours account for the 
majority, 70-80% of all intracranial tumours, with metastatic tumours accounting for the 
remaining 20-30% (Table 16.1). The frequency of intracranial tumour increases with age and 
metastatic tumours are most common in older age groups. 
Table 16.1 Estimated intracranial tumour type (%) in Africa
Most common Uncommon
Glioma 30-50%
Metastases 20-30%
Meningioma 20-30%
Pituitary adenoma 10-15%
Craniopharyngioma 2-5%
Lymphoma 1%
Acoustic neuroma <1%
Pinealoma <1%
Colloid cyst <1%
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CLINICAL FEATURES
Intracranial tumours in Africa are characterised by late presentation with on average a 2 year 
delay before diagnosis and a high mortality of >80% at 1-2 years follow up. They can exist for 
long periods with no or few symptoms and when symptoms do occur the tumours may be 
advanced. Headache is the most common complaint though occurring only in <50% of cases. 
Pain is variable, ranging from being dull, low grade and intermittent to being severe, continuous, 
deep, nocturnal, present on waking and often associated with vomiting. Intracranial tumours 
have three recognizable main modes of clinical presentation (Table 16.2): (1) focal neurological 
deficits (FND), (2) seizures, and (3) raised intracranial pressure ( ICP). These can occur either 
alone or together depending on type, stage and site of tumour. The pathogenic mechanisms 
underlying these presentations include tumour mass effect, brain irritation and blocked CSF 
flow. Highly malignant or fast growing tumours tend to present with combinations of all 
three main modes of presentation occurring over weeks or months whereas low grade or slow 
growing tumours tend to present with isolated seizures and/or neurological deficits occurring 
over months or years. The age of the patient, speed of onset of symptoms and neurological 
findings all help to determine the site and the probable type of tumour. 
Table 16.2 Main presenting clinical features of intracranial tumours
Neurological finding Symptoms/Signs
focal neurological deficits hemiparesis, dysphasia, visual loss, field defect, ataxia, cranial nerve palsies
raised intracranial pressure headaches vomiting, papilloedema, LOC
seizures simple or complex partial, secondary GTC
Focal neurological deficits
FND are the most common neurological presentation of brain tumour. The type of FND is very 
variable and reflects the cell type, grade of malignancy and the site affected (Chapter 2). These 
include hemiparesis, dysphasia, visual loss, field defects, cognitive impairment, personality 
change, cranial nerve palsies and ataxia. The combination of ataxia and cranial nerve palsies 
occurs more frequently with tumours arising in the posterior fossa. 
Seizures
Seizures are the presenting complaint in approximately a quarter of patients and occur as 
a complication in about another quarter (Chapter 4). Seizures arise mostly from tumours 
affecting the temporal lobes and occur most commonly in association with malignant tumours. 
The seizures are mostly generalised tonic clonic-type seizures with a focal origin. 
Raised intracranial pressure ( ICP)
The symptoms and signs of ICP are headache, vomiting, papilloedema and altered level of 
consciousness; these occur because of either mass effect or hydrocephalus. Hydrocephalus arises 
because of mechanical blockage to CSF flow through the ventricles. Headache is the most 
common symptom being typically severe in advanced tumours, often waking the person from 
sleep during the night or early morning and frequently associated with vomiting (Chapter 15). 
The site of the headache is mostly frontal in supratentorial tumours and occipital in posterior 
fossa tumours, however the site may not necessarily be localising. Mass lesions arising from 
above the tentorium, and affecting both the hemispheres frequently give rise to combinations 
of features of FNDs and ICP. The most common neurological deficits include hemiparesis and 
3rd, 4th and 6th nerve palsies. These may be false localising signs, if they occur as a result of remote 
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compression at a site away from the tumour. Space occupying lesions (SOL) arising below the 
tentorium within the posterior fossa cause cranial nerve palsies, ataxia, and long track signs and 
raised ICP secondary to obstructive hydrocephalus. A history of visual disturbances and the 
presence of papilloedema are usually late clinical findings. Eventually, the expanding tumour 
results in herniation either through the tentorium or foramen magnum leading to death.
Key points
 · most common malignant ICTs are gliomas & metastases
 · most common benign ICTs are meningiomas & pituitary adenomas
 · main presentations include progressive FNDs, seizures & ICP 
 · other presentations are headaches, visual failure, cranial nerve signs & seizures 
 · most patients presenting with headaches do not have brain tumours
MAIN SITES
The site and types of intracranial tumour determine the presenting symptoms and signs and 
the main ones are outlined below (Chapter 2). 
Frontal lobe
Tumours involving the frontal lobe typically present late because the frontal lobe has a large 
silent area. Contralateral hemiparesis occurs if the motor strip is involved. Tumours involving 
the anterior frontal lobe may present with personality changes and a loss of initiative, inhibition 
and cognitive function. There may also be focal motor seizures, urinary incontinence and loss 
of smell. An expressive aphasia occurs if Broca’s area in the dominant hemisphere is involved.
Parietal lobe
Tumours of the parietal lobe result in difficulties or inability to recognise sensory and 
proprioceptive input from the opposite side of the body. This may show itself as tending to 
ignore the contralateral side visuospatially (hemineglect) or as difficulties recognizing familiar 
shapes, textures or numbers when placed in the opposite hand. If the dominant hemisphere is 
involved, there may be difficulties particularly with understanding speech, numbers, reading 
and writing and carrying out motor tasks (apraxia). Patients with non dominant hemisphere 
involvement may present with or develop hemineglect. Patients may also have a visual field 
defect involving the lower quadrant from the opposite side.
Temporal lobe
Tumours involving the dominant temporal lobe (usually left sided) may result in aphasia which 
is receptive in type and also memory impairment. Tumours on either side may result in recent 
onset temporal lobe seizures and visual field loss in the contralateral upper quadrant.
Occipital lobe
Tumours involving the occipital lobe present with visual disturbances, hallucinations, and a 
loss of vision from the opposite side of the body, a contralateral homonymous hemianopia.
Brain stem and cerebellum
Tumours of the brain stem present with a combination of ipsilateral cranial nerve palsies and 
cerebellar ataxia, and contralateral long tract signs. These may be associated with hydrocephalus 
main sites
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and ICP depending on the tumour type and site. Tumours involving this area of the brain are 
more common in children.
GLIOMA
Gliomas account for up to half of all brain tumours and occur most commonly in older age 
groups >50-60 years. Glioma is the generic name for brain tumours of neuroepithelial cell origin. 
These are the support cells in the brain and the main ones are astrocytes and oligodendrocytes. 
Astrocytic tumours are separated histologically into grades I & II which are low grade, well 
differentiated and relatively benign and into grades III & IV which are high grade, poorly 
differentiated and highly malignant. Glioblastoma multiforme represents the most malignant 
stage of glioma. Oligodendrogliomas on the whole tend to be lower grade tumours characterized 
by a capsule and the presence of cysts and calcium with a good prognosis, but after years about 
one third may evolve into more malignant tumours. 
Other forms of glioma include ependymomas which are derived from cells which line the 
ventricles and choroid plexus. Medulloblastomas are gliomas of the cerebellum and the roof of 
the 4th ventricle occurring mostly in young children aged 4-8 years (Fig. 16.1). 
Clinical features
Gliomas present clinically with increasing symptoms usually over weeks or months or years 
depending on the grade of malignancy. Presentations include headache and combinations of 
focal neurological deficit, seizures, and signs of ICP. Diagnosis is confirmed by neuroimaging, 
most commonly a CT of the head. It typically shows a unifocal enhancing mass with 
surrounding oedema and mass effect (Fig. 16.1). 
Management
Management where there are full resources includes a combination of surgery, chemotherapy 
and radiotherapy. Surgery is indicated for biopsy to establish a tissue diagnosis and for partial 
tumour resection to relieve symptoms. Chemotherapy is used in high grade malignant gliomas 
and usually involves the alkylating drug temozolomide in combination with other drugs. 
However temozolomide is expensive, used mostly but not exclusively in younger patients and 
only available in some specialized oncology units. Radiation is indicated for most high grade 
gliomas but this is only palliative at this stage. 
Prognosis
The prognosis in low grade gliomas is good with a median survival of 8-10 years. However in 
patients with higher grade malignancy the prognosis even with treatment is poor with survival 
of usually <12 months. 
Key points
 · gliomas account for almost half of all ICTs 
 · presentations include ICP, FNDs & seizures over weeks & months 
 · diagnosis is by neuroimaging, CT or MRI 
 · management is mainly with combination of surgery, chemotherapy & radiotherapy
 · prognosis for high grade gliomas is poor
Chapter 16  intraCranial tumours
Part ii – Neurological Disorders 370
MENINGIOMA
These account for about 20-30% of all intracranial tumours. They occur mostly in the middle 
and older age groups, >50 years and more commonly in females 2:1. They arise from either 
the dural or arachnoid meninges, overlying the surface of the brain, cranial nerves, falx and 
tentorium and are nearly always benign. Less than 1% of meningiomas are malignant. Small 
meningiomas <2 cm are usually asymptomatic and tumours only become symptomatic when 
they reach a size sufficient to affect function. Most tumours arise on the convexities of the 
brain, as these are the largest surface areas. 
Clinical features
Meningiomas tend to present clinically with focal neurological signs that reflect the site and 
size of the tumour in much the same way as malignant tumours but over a much longer 
time course usually months or years. Focal seizures are an early symptom of tumours that 
overlie the cortex. ICP may also be a late feature of large meningiomas. Meningiomas affecting 
certain areas have specific modes of presentation. Parasagittal meningiomas present with spastic 
paraparesis, olfactory groove meningiomas with anosmia and papilloedema and sphenoid 
wing and frontal meningiomas with Foster-Kennedy syndrome: unilateral optic atrophy with 
contralateral papilloedema. 
Diagnosis & management
Diagnosis is made by neuroimaging with CT or MRI scans. CT typically shows a meningioma 
as a uniformly homogenously enhancing extra axial mass which may be partially calcified or 
CT (with contrast)
Right frontal glioma Medulloblastoma & hydrocephalus in a child
MRI T1 & T2 (enhanced)
Right sided glioma with midline extension/shift
Figure 16.1 Gliomas
meningioma
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eroding adjacent bone (Fig.16.2). The majority of accessible meningiomas can be cured by 
resection and large symptomatic tumours are an indication for surgery. Convexity lesions 
are usually completely removed without any residual neurological deficit and the longer 
term prognosis for these is generally good. However recurrence is likely if surgical removal is 
incomplete as is frequently the case with very large or relatively inaccessible tumours. If the 
patient is clinically asymptomatic, then yearly follow up CT scans may be sufficient.
Key points
 · meningioma is the most common benign ICT & occurs mostly in older persons
 · symptoms can be similar to malignant tumours but occurring over a longer time period 
 · clinical presentations tend to reflect the site of the tumour 
 · diagnosis is confirmed by neuroimaging CT/MRI
 · management for large, symptomatic meningiomas is surgical removal
CT (with contrast)
Right sphenoid wing Left cerebellar tentorium (hydrocephalus) Left frontal
Left frontal Right frontal Midline
Figure 16.2 Meningiomas
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PITUITARY TUMOURS
Pituitary adenomas account for about a tenth of all intracranial tumours. 
Clinical features
These are benign intracranial tumours occurring outside the brain which present with 
headache, local pressure and also endocrine effects. Expansion of the adenoma upwards leads 
to compression of the optic chiasm which results in a visual field defect, most commonly 
bitemporal hemianopia, initially involving the upper quadrants. The endocrine effects may vary 
from being clinically asymptomatic in non functioning adenomas, to prolactinomas causing 
amenorrhoea/galactorrhoea and to micro or macro adenomas secreting growth hormone in 
acromegaly or microadenoma secreting ACTH in Cushing’s disease. Infrequently, pituitary 
tumours undergo infarction and patients then present with sudden headache, vomiting and 
features of acute hypopituitarism. The differential diagnosis of pituitary tumours includes other 
mass lesions that may compress the optic chiasm including craniopharyngioma, meningioma 
and internal carotid aneurysm. 
Diagnosis
Diagnosis is confirmed by endocrine and imaging studies. Endocrine studies should measure 
prolactin, TSH (thyroid stimulating hormone), free T4, morning cortisol and growth hormone 
levels if available. A plain skull X-ray may show an enlarged pituitary fossa and neuroimaging 
with a CT or preferably an MRI may show a pituitary tumour (Fig.16.3). 
Widened sella turcica
Skull X-ray (lateral view)
CT (with contrast) MRI T1
Pituitary tumour
Figure 16.3 Pituitary tumours
pituitary tumours
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Management
Management is either medical or surgical. Surgery via the transphenoidal route is usually the 
management of choice, if the tumour is intrasellar except in prolactin secreting adenomas 
which can often be managed medically with dopamine receptor agonists such as bromocriptine 
up to 20-40 mg daily. Growth hormone secreting tumours can also sometimes be managed 
medically as well with dopamine agonists or a somatostatin analogue (e.g. octreotide). Larger 
pituitary tumours extending above the sella may require a transfrontal craniotomy.
Key points
 · pituitary tumours are benign and account for about 10% of ICTs
 · symptoms are caused by local pressure effects, hormone secretion & pituitary failure
 · CFs include headache, visual failure, visual field defect & endocrine disease 
 · treatment involves hormone replacement, dopamine agonists & surgery
METASTASES
These account for about a quarter of all intracranial tumours and are usually the most common 
intracranial tumour in the older age groups >60 yrs. They arise mostly by haematogenous 
spread from cancers occurring outside the brain. The main sources are breast, lung, renal, 
gastrointestinal cancers and melanoma. Very rarely local metastases can arise within the brain; 
the usual source is a glioblastoma, the most malignant type of brain tumour. The history in 
metastatic brain tumour is usually short, involving day or weeks of progressive neurological 
symptoms of raised intracranial pressure, seizures and focal neurological deficits. Diagnosis is 
confirmed by neuroimaging usually a CT of the head. Metastases show as multiple ring or solid 
enhancing lesions anywhere in the brain with surrounding oedema and mass effect (Fig. 16.4). 
In about 10% of cases the metastases may be solitary. 
Differential diagnosis
The differential diagnosis of intracranial tumour includes other causes of mass or space 
occupying lesions (SOL). In Africa these are mostly infections. The most common infectious 
causes are HIV related and include toxoplasma encephalitis and tuberculoma. Other infectious 
causes include pyogenic and parasitic infections. The main parasitic infections are hydatid 
cysts, cysticercosis and very occasionally schistosomiasis. While there may be some difficulty 
separating a tumour from these causes clinically, the history and signs of systemic illness and 
CT (with contrast)
Multiple metastases
Figure 16.4 Metastases
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typical neuroimaging findings should suggest an infectious origin. The non infectious causes 
are mostly vascular and include large aneurysms and arteriovenous malformations. These can 
usually be differentiated from metastatic brain tumours by their typical history, vascular risk 
factors and appearances on CT scan. A chronic subdural haematoma particularly in the elderly 
without a history of head trauma may sometimes mimic a brain tumour in clinical presentation 
and require a CT scan of the head to confirm the correct diagnosis. Other neurological disorders 
to be considered include hydrocephalus and benign intracranial hypertension.
Investigations
Baseline haematological and biochemical investigations should be carried out in suspected 
cases. X-rays involving the chest and skull can be helpful. The chest X-ray may show evidence 
of metastases or a primary lung tumour. The skull X-ray may show enlargement of the pituitary 
fossa, erosion of bone or other signs of chronic raised intracranial pressure. A lumbar puncture 
is relatively contraindicated in patients with suspected intracranial tumours and possible ICP 
as any sudden decrease in intracranial pressure can result in death due to coning. Neuroimaging 
using computerized tomography (CT) or magnetic resonance imaging (MRI) is the method 
of choice in the detection of brain tumours. CT is now available in most specialised centres. 
In patients with a suspected brain tumour having neuroimaging, intravenous contrast is given 
unless there is a contraindication; a pattern of increased enhancement points to brain tumours.
Management
Management is mostly symptomatic and aimed mainly at palliation. Dexamethasone 4-6 mg 
3-4 times daily temporarily reduces cerebral oedema and symptoms. Chemotherapy is usually 
not indicated and excision surgery is reserved for isolated single accessible metastases. Prognosis 
is poor anywhere in the world with most untreated patients surviving less than a month after 
diagnosis.
Key points
 · metastases account for about 25% of all ICTs & occur mostly in older age groups
 · main sites of origin are breast, lung, kidney, GIT and melanoma
 · CFs are similar to gliomas but occurring over a faster time course
 · differential diagnosis includes brain abscess, parasitic cysts & vascular causes
 · diagnosis confirmed by (CT/MRI) & evidence of primary tumour elsewhere
OTHER TUMOURS
Craniopharyngioma
These are uncommon benign tumours that arise from primitive cells in Rathke’s pouch which 
lies just above the pituitary gland and below the floor of the third ventricle. They represent 2-5% 
of all intracranial tumours in high income countries and mainly affect children but are also 
seen in usually younger adults. They present clinically with pressure effects including headache, 
visual field defect, and occasionally diabetes insipidus and hydrocephalus. Neuroimaging using 
CT or MRI is diagnostic showing a non enhancing suprasellar cystic mass usually with irregular 
calcification (Fig. 16.5). The tumours can be quite large at the time of clinical presentation. 
Management is surgical and by irradiation; however the outcome is often unfavourable because 
of a high likelihood of recurrence.
other tumours
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Key points
 · craniopharyngioma are benign ICTs mainly in children and young adults
 · arise from primitive rest cells in Rathke’s pouch above pituitary gland
 · symptoms are caused by local pressure effects & occasionally diabetes insipidus
 · diagnosis is by CT/MRI showing a suprasellar cystic mass usually with calcification
 · treatment involves surgical resection & radiotherapy but recurrence is common
Primary CNS Lymphoma (PCNSL)
This is a primary B cell lymphoma that arises within the brain. It 
is a sporadic tumour affecting mostly older adults and accounts for 
around 1% of all primary intracranial tumours. PCNSL also occurs 
in HIV where it affects a mainly younger age group, occurring in 
<1% of AIDS patients in Africa. It presents in a similar manner 
to other brain tumours although seizures are less common and 
meningeal and spinal cord involvement may occur. The diagnosis is 
suspected when the CT of the head shows a deep seated enhancing 
periventricular mass lesion with surrounding oedema (Fig. 16.6). 
The tumour may also occur at more than one intracranial site in 
HIV disease. The main differential diagnosis in HIV disease in Africa 
is with a brain abscess secondary to toxoplasmosis or tuberculosis 
(Chapter 8). Appropriate management is with methotrexate and 
whole brain deep X-ray therapy (DXT) which can prolong survival 
rates to up to 3 years in non HIV patients. The prognosis is very 
poor in HIV disease and survival is usually <3 months. 
Colloid cyst
Colloid cyst is uncommon and accounts for <1% of primary intracranial tumours. It is a 
benign cystic tumour which arises from the roof of the 3rd ventricle and may block CSF flow 
initially intermittently. Patients with a colloid cyst present with intermittent headaches which 
may be sometimes severe, recurrent and related to posture. Affected patients are prone to drop 
attacks, leg weakness and hydrocephalus and also sudden death if the flow to CSF is completely 
CT (without contrast)
Large suprasellar tumour with cysts, calcification & severe hydrocephalus
Figure 16.5 Craniopharyngioma
CT (with contrast)
Tumour right temporal lobe 
with mass effect
Figure 16.6 Lymphoma
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blocked. CT may show a well demarcated rounded cyst arising within the 3rd ventricle with 
or without obstructive hydrocephalus (Fig. 16.7). The differential diagnosis includes other 
causes of intraventricular cysts including neurocysticercosis where cysts are usually multiple. 
Management is by surgical removal or destruction of the cyst. 
Acoustic neuroma (Schwannoma)
These are rare benign slow growing tumours that arise from 
Schwann cells of the vestibular nerve with an incidence rate of 1 per 
100,000 in high income countries. The corresponding incidence 
reported in a black population in SA is reported to be very low, 
(0.01/100,000). They arise sporadically on one side but may occur 
bilaterally in neurofibromatosis type 2 when they usually occur 
before the age of 21 years (Chapter 18). The principal sites are 
the internal auditory canal (IAC) and the cerebellopontine angle 
(CPA). The distinguishing clinical features are unilateral deafness 
coupled with tinnitus, vertigo, ipsilateral unsteadiness and facial 
weakness and numbness. Hydrocephalus and raised ICP are a late 
complication. Diagnosis is by showing high frequency hearing 
loss either clinically or by audiograph and by demonstrating 
an expanding lesion in the IAC or in the CPA by either CT or 
MRI (Fig. 16.8). The main differential diagnosis is between a 
meningioma and epidermoid cyst. Management is by deep X-ray 
therapy and by surgical resection, though resection is technically 
difficult with significant morbidity. 
Pinealoma
Tumours may arise from the pineal gland and are uncommon. These are classified as germinomas, 
pinealomas, teratomas and gliomas. They are uncommon slow growing tumours and occur 
mostly in children and young adults <30 years. Patients present clinically with disorders of eye 
MRI T1
Colloid cyst blocking foramen 
of Monro with dilatation of 
lateral ventricle
Figure 16.7 Colloid cyst
MRI T1 (with contrast) CT (with contrast)
Acoustic neuroma extending  
into right auditory canal
Acoustic neuroma (left sided)
Figure 16.8 Acoustic neuroma
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movement, mainly up gaze paralysis and symptoms of raised ICP. These symptoms are explained 
by the local effects of the tumour invading the upper midbrain and blocking the aqueduct of 
Sylvius causing hydrocephalus (Fig.16.9). The diagnosis is confirmed by neuroimaging, CT or 
MRI and management is neurosurgical.
MANAGEMENT OF TUMOURS
The management of intracranial tumours involves confirming the diagnosis histologically, 
grading the tumour when indicated and treating the patient medically and surgically.
Medical
General measures are aimed at controlling symptoms including pain and anxiety and reducing 
intracranial pressure. These measures include treating the symptoms and ensuring adequate 
cerebral perfusion by maintaining hydration, oxygen saturation and blood pressure. The use 
of osmotic therapy can be effective in reducing acute elevations of intracranial pressure but is 
only effective for a few days. The drug of choice in ICP is mannitol 20% solution in boluses 
of 0.25-0.75 g/kg every 4-6 hours. Corticosteroids are useful for patients with cerebral oedema 
secondary to mass lesions. Dexamethasone is the most commonly used steroid in a dose 4-8 
mg/po or iv/three to four times daily. This often provides significant symptomatic relief and 
can be maintained at the lowest dose that provides relief which is usually 4 mg twice daily. 
Opiates and anxiolytics may be necessary to control pain and anxiety.
Surgical
Meningiomas, pituitary tumours, acoustic neuromas are among the benign ICTs that can be 
successfully removed if not too advanced at presentation. Primary malignant brain tumours 
that are at or near the surface of the brain may be partially removed by debulking operations. 
The main aim is to palliate symptoms by removing as much tissue as is safely possible. Biopsy 
of the tumour is also important as the histological findings help to determine the type and 
grade of tumour and the subsequent management and prognosis. Patients presenting with 
resectable primary brain tumours should be referred to a national centre with neurosurgical 
facilities.
MRI T1 (with contrast) CT head
Pinealoma enhancing Pinealoma with calcification & hydrocephalus
Figure 16.9 Pinealoma
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Radiotherapy
Middle grade gliomas, acoustic neuromas, incompletely removed pituitary adenomas and 
some other tumours are often radiosensitive. Tumours of childhood in the posterior fossa of 
the brain, medulloblastoma and lymphoma are sensitive to radiotherapy.
Chemotherapy
Chemotherapy is sometimes given as adjunctive treatment for some high grade gliomas but the 
response is usually poor.
Anticonvulsants
Control of epilepsy is an important part of the management of brain tumour. Phenytoin 3-400 
mg daily is the drug of choice.
Prognosis
The majority of brain tumours are either malignant gliomas or metastases and carry a poor 
prognosis with few patients surviving longer than one year. However benign tumours such as 
meningiomas have a much better prognosis although they frequently present late in Africa.
Key points
 · resources in Africa are limited for investigation & management of ICTs 
 · if ICT suspected then refer to centre with scanning & neurosurgical facilities
 · symptomatic treatment of ICTs is very important
 · patient & family are helped by being informed of clinical diagnosis & prognosis
 · prognosis for most benign ICTs is good & for most malignant ICTs is poor
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CHAPTER 17
DEMENTIA
Dementia is a general term for any disorder in which there is progressive loss of higher cortical 
functions. These higher functions include memory, language production and understanding, 
visuospatial function, and “executive” or frontal lobe function e.g. planning and judgement. 
Dementia is not a diagnosis in itself, it is simply a consequence of a wide variety of underlying 
conditions, such as: degenerative brain disease e.g. Alzheimer’s disease (AD), cerebrovascular 
disease, cerebral infections e.g. HIV infection, deficiency states e.g. B-12, metabolic disorders 
e.g. hypothyroidism and substance misuse e.g. alcohol. The core features of dementia are 
impairment in at least two areas of higher cortical function, usually memory plus one other. 
There is a decline from a previous level of functioning severe enough to interfere with activities 
of daily living such as work, family or social activities and there is a progression over time. 
The aim of this chapter is to present a brief overview of dementia. The student should aim for 
an overall understanding of dementia including definition, aetiology, main clinical features, 
diagnosis and management. 
Key points
 · dementia is a loss of memory & at least one other cognitive function 
 · loss is sufficient to interfere with the activities of daily living
 · loss of higher cortical functions is progressive
 · need to exclude treatable causes of dementia
EPIDEMIOLOGY
Dementia affects >2% of the population in high income countries at the age of 65 years, with 
the prevalence doubling every five years thereafter. Thus by the age of 85 years approximately 
one third of the population there have a dementia of some type. However because of population 
distribution most persons with dementia now live in low or middle income countries and as 
life expectancy lengthens that burden is set to increase. There are few studies on dementia from 
Africa, but age adjusted studies from there in whole populations aged 65 years and over suggest 
a lower overall burden of 1-3%, this is in comparison to rates of 5-10% in similar age groups 
in other low and middle income parts of the world. However, the current HIV epidemic in 
Africa is increasing the overall burden of dementia there but in a mainly younger population. 
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AETIOLOGY
The main causes of dementia are Alzheimer’s disease, cerebrovascular disease and HIV disease. 
Less common degenerative causes include frontotemporal dementia (FTD) or Pick’s disease, 
dementia with Lewy bodies (DLB), Parkinson’s disease with dementia (PDD) and Huntington’s 
disease (Table 17.1). Treatable causes of dementia include HIV, B-12 deficiency, hypothyroidism, 
alcoholism and rarely syphilis. The differential diagnosis of dementia in Africa includes chronic 
confusional and psychiatric states, chronic brain disorders, tumours and subdural haematoma.
Main causes of dementia in Africa
 · Alzheimer’s disease
 · cerebrovascular disease
 · HIV
 · alcohol
Risk factors
The main known risk factors are old age, genetic predisposition (e.g. APO-E genotype) and 
vascular risk factors such as hypertension, hypercholesterolaemia and diabetes. Diet, lifestyle 
and lower level of education may also be risk factors. At present there are no known specific 
preventatives or curative measures for most forms of dementia. 
Table 17.1 Classification and main features of dementia
Dementia type Frequency* Overall % Main clinical features
Dementia  
(all causes)
2 % @ 65 yrs 
33% >85 yrs
100% progressive loss of two or more 
intellectual functions (eg memory, 
language), sufficient to disrupt daily life
Alzheimer’s 
disease
15% @ 65 yrs
commonest cause of 
dementia in later life
60% core feature is usually poor day-to-day 
memory, language and visuospatial 
function 
Vascular 
dementia
05% @ 65 yrs 20-30% usually a history of stroke with 
physical signs such as limb weakness & 
dysarthria: cognitive impairment may 
take many forms
Frontotemporal 
dementia
less common than AD but an 
important cause of young-
onset dementia: accounts for 
up to 20% of patients with 
dementia aged 45-65 years 
(HIV excluded)
<10% frontal: insidious changes in 
personality and behaviour, other 
domains often intact
temporal: progressive aphasia, fluent 
or non-fluent
HIV associated 
dementia
10-20% of patients with 
advanced HIV
not-known non-specific: generalised cognitive and 
motor slowing with poor day-to-day 
memory
Dementia with 
Lewy bodies
less common <1% parkinsonism, fluctuations, visual 
hallucinations
* based on high income countries
General course and prognosis in dementia
By definition, dementia is a progressive disorder. Consciousness is not altered, but with time 
impairments of higher function extend into all cognitive areas (see appendix 1). The level 
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of functioning declines until patients are entirely dependent on others for their care. Death 
follows either directly from the failure of core brain systems or more often as a secondary 
consequence of complications such as pneumonia, untreated pressure sores and venous 
thrombosis. The duration and course of dementia depends on the cause but typically lasts 
for years. Life expectancy in Alzheimer’s disease is about 6-7 years from onset in high income 
countries.
ALZHEIMER’S DISEASE
Alzheimer’s disease is the commonest cause of dementia worldwide (Table 17.1). It is reported 
to be less common in Africa as compared to similar aged populations in high income countries, 
including Afro-Americans. However studies from Africa suggest that it still accounts for >60% 
of all cases of dementia there. Its main cause is unknown. It is rare under 45 years of age but 
thereafter its prevalence rises exponentially with age and increasingly after 65 years of age. It 
is associated with a positive family history of dementia and affects females more than males. 
Genetics
Alzheimer’s is usually a sporadic disease, but can occasionally be familial when it is autosomal 
dominant, due to mutations in the genes for presenilin 1 & 2 (PS1 & 2) or amyloid precursor 
protein (APP) on chromosome 21.The majority of familial AD is caused by mutations in PS1, 
which usually results in very early onset disease (under 45 years) with rapid progression and 
additional physical signs. Apolipoprotein E (APOE e4), a lipid transport protein which has 
been identified as an independent risk factor for AD appears not to influence AD progression 
in SSA.
Pathophysiology
It is due to loss of neurones from the cerebral cortex and is associated with characteristic 
deposition of beta-amyloid plaques and neurofibrillary tangles in the neurones. This results in 
decreased acetylcholine synthesis in the brain. 
Clinical features
The clinical features range from mild cognitive impairment with an isolated difficulty in day-
to-day memory or forgetfulness, followed by slow progression over years to a severe loss of 
other cognitive functions, including recognition, language and visuospatial awareness. Loss of 
memory for recent events and recent personal experiences are typical. Behaviour and personality 
are often well preserved to begin with, and the diagnosis can be overlooked in the early stages. 
Physical signs appear later in the disease, when patients may develop parkinsonism, myoclonus 
and incontinence. 
Diagnosis
The diagnosis is made by a careful history from the patient and an informant, supported by 
objective evidence of cognitive impairment on bedside tests. A Mini Mental State Examination 
(MMSE) (see appendix 2) score of 24/30 or less is supportive of a diagnosis of dementia, having 
excluded other secondary causes of dementia with appropriate blood tests and brain imaging. 
Investigations
The main investigations in dementia are outlined in Table 17.2. The main aim is to exclude a 
treatable cause e.g. B-12 deficiency or HIV.
alzheimer’s disease
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Table 17.2 Main investigations in dementia
Investigation Aetiology
Haematology
FBC & ESR all causes
Chemistry 
blood sugar
renal & liver function tests
serum calcium
metabolic causes
Serology & others
HIV, VDRL, TPHA 
T4
B-12
CSF examination
infection: HIV, syphilis, hypothyroidism,
vitamin deficiencies,
neurodegenerative 
X-rays
chest
CT head
CVD, infection, TB, malignancy
brain atrophy, stroke, vascular changes, infection, tumours, subdural haematoma
Others
EEG, genetic testing CJD, APO-E genotype
Management
There is no cure at present for Alzheimer’s disease. Non drug interventions are the mainstay 
of management. This includes the provision of information and support for the carer’s family 
and the community. One aspect of the disease is a deficiency of acetylcholine synthesis in the 
brain, and centrally acting cholinesterase inhibitors that raise levels of acetylcholine in the brain 
may result in temporary symptomatic benefit. In high income countries, the cholinesterase 
inhibitors are recommended for patients with mild to moderate dementia (MMSE range 12-
24/30). Patients may derive some limited benefit in cognitive function for 1-2 years but there 
is no effect on the eventual progression of the disease. These are stopped if the MMSE score is 
<12/30.
Drug options include the cholinesterase inhibitors donepezil 5-10 mg daily or rivastigmine 1.5–
3 mg bid, or galantamine 4-6 mg bd. The main side effects are related to increased peripheral 
cholinergic activity and include nausea, abdominal colic and diarrhoea. However the high 
cost of the regular use of these drugs prohibits their widespread use in AD in Africa. For 
behavioural and psychiatric disorders, it may be necessary to use an antipsychotic medication. 
These include haloperidol 0.5-1.5 mg twice daily. Alternatives include risperidone 0.5 mg or 
olanzapine 2.5 mg/po daily initially. Valproic acid may decrease agitation and help as a mood 
stabilizer and be better tolerated than the antipsychotics. It is wise to start with low doses and 
adjust any increases in dosages slowly. 
Key points
 · Alzheimer’s is the most common form of dementia worldwide and in Africa
 · associated with increasing age >65 yrs & a positive family history
 · first symptom is often forgetfulness 
 · progresses to involve language, recognition, self-care & continence
 · there is no cure & death occurs after approximately 6-7 years
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VASCULAR DEMENTIA
Cerebrovascular disease is considered to be the second most common cause of dementia 
worldwide accounting for 20-30% of all cases. Patients are usually >40 years and have a 
known risk factor for vascular disease including hypertension, diabetes, atrial fibrillation, 
hyperlipidaemia and smoking. 
Clinical features
Vascular disease may cause cognitive impairment by different mechanisms. Firstly, a small 
(strategic) stroke in an eloquent area or secondly by the cumulative effects of repeated 
large-vessel strokes. This is associated with the classical “step-wise” deterioration of vascular 
dementia. Thirdly, due to hypertension affecting the small penetrating arteries supplying the 
sub cortical white matter, causing multiple lacunar infarcts. This leads to a more insidiously 
progressive sub cortical dementia with motor findings. Clinically there will usually be physical 
signs including pyramidal tract signs and often gait disturbance or pseudo-parkinsonism and 
frequently urinary incontinence. 
Diagnosis and management
Neuroimaging of the brain, in particular MRI shows widespread white matter changes 
particularly around the ventricles or areas of frank infarction. The management is unsatisfactory 
but involves the reduction and treatment of the usual vascular risk factors. 
FRONTOTEMPORAL DEMENTIA
Frontotemporal dementia (FTD), or Pick’s disease, is a neurodegenerative disorder characterised 
by progressive deterioration of behaviour, personality and language abilities together with 
prominent atrophy of the frontal and temporal lobes. It accounts for <10% of cases of dementia 
in high income countries and also occurs in Africa but its frequency there is not known. FTD 
is typically of younger onset, with age of onset between 45 and 65 years, although cases with 
older onset are well recognised. 
Genetics
Up to 40% of patients with FTD have a positive family history of early-onset dementia with 
an autosomal dominant inheritance pattern. A number of causative genes on chromosome 17 
have been identified, including tau & progranulin. 
Clinical features
In the frontal or behavioural variant of FTD, typical presenting problems include disinhibition, 
loss of empathy, changes in eating patterns, ritualized or stereotypical behaviours and apathy. In 
the language variants of FTD problems include loss of word meaning (semantic dementia) or 
nonfluent speech (progressive non-fluent aphasia). However, it must be emphasized that there 
is a good deal of overlap between these variants of FTD. Patients with a predominantly frontal 
presentation may also show language impairments, and equally patients with a predominantly 
language presentation may show behavioural disturbance. Physical signs are not usual but there 
is an overlap with motor neurone disease. A core feature is a lack of insight and patients with 
behavioural disturbance can be very challenging to manage. Eventually all patients progress to 
a global dementia.
vasCular dementia
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Diagnosis and management
Neuroimaging reveals a very characteristic selective atrophy of frontal and temporal lobes (Fig 
17.1). There is no specific treatment.
HIV-ASSOCIATED DEMENTIA (HAD)
Chronic HIV infection of the brain leads to a dementia in at least 10-20% of patients in Africa, 
affecting a younger population than is usual for dementia (Chapter 8). HAD occurs increasingly 
with advancing levels of immunosuppression and in particular with CD4 counts <100/cm3. 
HAD presents with abnormalities of cognition, memory and motor function. The dementia is 
characterized early on by apathy, disinterest and loss of attention with a characteristic slowing 
of both mental and motor function (HIV associated neurocognitive dysfunction or HAND). 
Later, it leads to a global loss of cognitive function, with immobility and incontinence in 
end stage disease. However, most patients in Africa never reach this advanced stage, dying 
beforehand mainly of opportunistic processes, mostly infections. Associated neurological 
findings include frontal lobe release signs (FLRSs), absent ankle reflexes (distal sensory 
neuropathy) and frequently isolated brisk knee reflexes and extensor plantar responses (vacuolar 
myelopathy). The FLRSs, the snout reflex and the palmomental reflex, (Chapter 8), are found 
in the majority (70-90%) of patients with HAD. CT of the head usually demonstrates cerebral 
atrophy and excludes other confounding causes. The frequency of HAD has been shown in 
Africa to decrease significantly six months after starting ART.
DEMENTIA WITH LEWY BODIES
This occurs most commonly in the elderly and without a positive family history. This is a 
degenerative disorder characterized by the presence of Lewy bodies in the neurones of the 
cerebral cortex, brain atrophy and loss of pigment in the substantia nigra. Clinically, patients 
present with a dementia, coupled with mild dopamine sensitive parkinsonism, visual 
hallucinations, delusions and fluctuating cognition. CT of head reveals mild generalised brain 
atrophy. Patients may benefit from the cholinesterase inhibitors, perhaps even more so than 
patients with AD. However, caution should be taken with antipsychotic drugs as they may 
CT (without contrast)
Selective atrophy of frontal & temporal lobes with ventricular dilatation
Figure 17.1 Frontotemporal Dementia
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cause a dramatic worsening of the parkinsonism and precipitate the neuroleptic malignant 
syndrome. Patients with Parkinson’s disease may develop a similar dementia later in the course 
of their illness and the situations are probably just two ends of a spectrum.
Key points
 · main causes of dementia are Alzheimer’s disease, cerebrovascular disease & HIV disease
 · there is no treatment that reverses the decline in Alzheimer’s & cerebrovascular disease dementia 
management involves care of patient in general & treatment of specific symptoms
 · care involves practical advice & support to patients, carers & families
 · drug treatment generally involves use of anticholinesterases & neuroleptics
APPENDIX 1 SUMMARY BEDSIDE COGNITIVE TESTING*
Higher cerebral function Clinical testing method Measurement 
Alertness level of wakefulness record level eg fully awake
Orientation time, person and place score out of 10
Attention and concentration count back from 20 or repeat string 
of increasing numbers (max 6)
record best result after two 
trials
Memory
Antegrade /short term fictitious name/address or four to 
seven numbers 
assess immediate recall and 
again after 5 min noting 
mistakes
Retrograde/long-term dates/places of schooling, work or 
marriage or country events
assess accuracy of recall 
(check with relatives)
Executive function (frontal lobe)
Word fluency name as many animals or fruits in 
one minute 
>20 normal
<10 abnormal 
Abstract thought proverb interpretation eg “a rolling 
stone catches no moss” 
interpretation
Cognitive estimates how many people in Tanzania accuracy
Alternating hand movements open and close right and left fists 
alternatively
ability to replicate examiner
Dominant hemisphere function
Aphasia speech content
understanding
expression 
reading/writing
assess spontaneous speech for 
fluency, content and errors
to simple commands 
to naming objects
to read/write a sentence
Calculation arithmetic simple addition/subtraction
Praxia “wave goodbye” or “hammer a nail” ability to follow instruction or 
replicate examiner
Non dominant hemispheric function
Neglect ignores all stimuli from one side 
hemispatial neglect
ignores stimulus on neglected 
side when bilateral stimuli 
presented (extinction)
when drawing clock face one 
side is left out
* done only on a patient who is awake and cooperative 
appendix 1 summary bedside Cognitive testing*
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APPENDIX 2 THE MINI MENTAL STATE EXAMINATION
The Mini-Mental state examination (MMSE) Maximum test score
Orientation
time, date, day, month, year
ward, hospital, district, town, country
(score one point for each correct answer)
5
5
Registration
examiner names three familiar objects (eg ball, pen, key)
patient asked to repeat the three names 
(score one point for each correct answer)
3
Attention and calculation
ask patient to subtract 7 from 100, stop after five subtractions, 93, 86, 79, 72, 65
or
spell a five letter word backwards eg world
(score one point for each correct answer)
5
Recall
ask patient to name the three objects that 
you previously named
(score one point for each correct answer)
3
Language
naming: point to two objects eg watch and pen
and ask the patient to name them
(score one point for each correct answer)
2
Repetition
ask patient to repeat sentence (“no ifs, ands or buts”)
no repeated attempt 
(score one point for correct answer)
1
3-Stage command
eg “take this piece of paper in your right hand, fold it in half, and place it on the table
(score one point for each stage done correctly)
3
Reading
ask patient to read and obey a written command on a piece of paper eg close your eyes
(score one point)
1
Writing
ask patient to write a sentence
sentence should be sensible and contain a noun and a verb 
(score one point)
1
Copying
ask patient to copy picture of two intersecting pentagons
(score one point if all ten angles are present and the two must intersect)
1
Total 30
Score: > 24/30 = normal, < 24/30 = cognitive impairment 
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CHAPTER 18
INHERITED NEUROLOGICAL DISORDERS
Inherited neurological disorders are generally relatively uncommon (Table 18.1).Their 
frequency in Africa is largely unknown. Inheritance follows the basic Mendelian laws for 
autosomal dominant, autosomal recessive and X-linked recessive inheritance. An example of 
an autosomal dominant disorder is neurofibromatosis and of an autosomal recessive disorder is 
Friedreich’s ataxia. Duchenne’s and Becker’s muscular dystrophy (Chapter 13) are both X-linked 
disorders. Huntington’s disease is an example of an autosomal dominant and a trinucleotide 
repeat disorder. A positive family history can usually be elicited in the autosomal dominant and 
X-linked disorders, underlining the importance of the family history. The aim of this chapter 
is to review the more commonly encountered hereditary neurological disorders. The student 
should aim to recognize and be familiar with the main ones. 
Table 18.1  Characteristics of the main inherited neurological disorders
Disorder Genetics Age of onset Frequency* Main clinical features
Neurofibromatosis type 1 autosomal 
dominant
children  
& adults 
1/4000 neurofibroma on nerves, café-au-
lait spots >5, axillary freckling
Neurofibromatosis type 2 autosomal 
dominant 
adults 1/50,000 deafness, bilateral acoustic 
neuromas
Tuberous Sclerosis autosomal 
dominant
children & 
young adults
1/15,000 epilepsy, adenoma sebaceum on 
face, hamartoma
Friedreich’s ataxia autosomal 
recessive
teens 1/50,000 cerebellar signs, progressive gait 
ataxia, upper motor neurone 
signs, absent ankle jerks
Charcot-Marie-Tooth 
disease 
autosomal 
dominant
young adults 1/3,000 peripheral neuropathy,
marked lower limb distal wasting, 
high arched feet (pes cavus)
Huntington’s disease autosomal 
dominant
middle aged 
adults
1/10,000 choreaform movements,
progressive dementia,
psychiatric symptoms
* frequencies based on studies in high income countries
NEUROFIBROMATOSIS TYPE 1
Neurofibromatosis type 1 is an autosomal dominant disorder with an age-dependent 
penetrance caused by a defect in the NF1 gene (neurofibromin) on chromosome 17q occurring 
with a frequency of about 1 in 4-5,000 (Table 18.1). Its frequency in Africa is likely to be 
similar. About 30-50% of cases are the result of new mutations. Clinically, it is characterised 
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by neurofibromata lying on peripheral nerves, multiple cutaneous fibromas, and more than 5 
hyperpigmented or café-au-lait (CAL) spots on the trunk (Fig. 18.1); see NIH clinical criteria 
and main clinical features NF1 (Table 18.2). The clinical picture can vary from very few 
to very many and distinctive skin lesions. Other clinical findings include axillary, neck and 
groin freckling, Lisch nodules on the iris and sometimes a scoliosis. Patients with type 1 may 
develop paraplegia secondary to an expanding intra axial neurofibroma arising from a nerve 
root pressing on the spinal cord (Fig. 18.1). They are also at risk for large deforming plexiform 
neuromas (Fig. 18.1), sarcomas, brain gliomas and pheochromocytoma. 
Table 18.2 Diagnostic criteria for NF1
Criteria: a diagnosis of NF type 1 is met if any two or more of the following is met.
6 or more CAL* spots
15 cm or larger in post pubertal patients
05 cm  or larger in prepubertal patients
2 or more neurofibromata of any type 
or
1 or more plexiform neurofibroma
freckling in axilla, neck or groin
optic glioma 
2 or more Lisch nodules
a distinctive bone lesion
dysplasia of the sphenoid bone
dysplasia or thinning of long bone cortex (tibia)
first degree relative, independently diagnosed with NF1
* Café-au-lait
Multiple neurofibromata & cafe au lait spots
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Involving the face Gigantic plexiform neurofibroma of lower back & leg
Giant plexiform neurofibroma involving upper mediastinum & right side of chest
Segmental neurofibromata localised to dermatomes of right arm
Neurofibroma in NF1 compressing cervical cord & nerve roots 
CT chest
NF type 1 variant
Plexiform neurofibroma
Clawing, wasting & weakness of hands
Figure 18.1 Clinical features NF type 1
neurofibromatosis type 2
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NEUROFIBROMATOSIS TYPE 2
Neurofibromatosis type 2 is a much rarer autosomal dominant disorder affecting about 1 in 
50,000 due to a defect in the NF2 gene (merlin) on chromosome 22. It is characterised by few 
skin manifestations and the development of intracranial tumours, acoustic neuromas (vestibular 
Schwannoma) (Fig. 18.2) and meningiomas; see diagnostic criteria (Table 18.3). Deafness due 
to an acoustic neuroma involving the eighth cranial nerve is the main clinical presentation of 
type 2. This is usually accompanied by tinnitus, vertigo, ataxia, facial numbness and weakness. 
The clinical features at presentation are usually unilateral although the acoustic neuromas are 
commonly bilateral on neuroimaging. The diagnosis is confirmed by neuroimaging of the 
brain, usually MRI (Fig. 18.2). Management is either conservative by observation only or with 
deep X-ray therapy (DXT), or surgery for the tumours where possible. Genetic counselling is 
a very important part of management. 
Table 18.3 Diagnostic criteria for NF2
Criteria: a diagnosis of NF2 is made if one of the following is met.
bilateral vestibular Schwannoma,
(either histologically or by MRI with contrast)
a parent, sibling or child with NF2 and either
a unilateral vestibular Schwannoma 
or
2 or more of meningioma, glioma, Schwannoma, 
posterior sub capsular lenticular opacities, 
cerebral calcifications
multiple meningiomas (2 or more) and one or more of glioma, Schwannoma, 
posterior sub capsular lenticular opacities, cerebral calcifications
MRI brain
Unilateral Schwannoma (right sided)
Figure 18.2 NF type 2
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TUBEROUS SCLEROSIS
This is an autosomal dominant condition, due to mutations in either TSC1 on chromosome 
9q (hamartin) or TSC2 on chromosome 16p (tuberin) with a prevalence of 1/15,000. Its 
frequency is not known in Africa but is most probably the same. About 60% of cases are due 
to new mutations. The main clinical features are the characteristic facial angiofibromata or 
adenoma sebaceum lesions on the cheeks and nose (Fig. 18.3), in combination with a history 
of epilepsy. There may be associated cognitive impairment. Additional skin manifestations 
include ash leaf hypopigmented macular type patches and the shagreen patch, a 1-10cm 
patch of orange peel like sub epidermal fibrosis found most often over the lumbar sacral area 
and subungual fibromas. CT shows a characteristic pattern of paraventricular subependymal 
calcified nodules or tuberi. Complications include tumours in the brain, hamartoma (Fig. 
18.3) and astrocytoma. There are frequently other affected family members, most commonly 
siblings. Epilepsy may be difficult to control. 
STURGE WEBER SYNDROME
This is an uncommon sporadic disorder affecting 1/50,000 in high income countries. It is 
a neurocutaneous syndrome characterized by a port wine staining affecting one half of the 
face (Fig. 18.4) usually in a V1 distribution and associated neurological abnormalities. The 
defining characteristic of the syndrome is an underlying intracranial vascular abnormality in 
the leptomeninges affecting the cortical regions of the hemispheres. The syndrome includes 
Adenoma sebaceum lesions on the cheeks and nose
Tuberous sclerosis & hamartoma CT scan (with contrast)
Adenoma sebaceum & left sided 3rd nerve palsy Calcified tuberi & hamartoma in the same patient
Figure 18.3 Tuberous sclerosis
tuberous sClerosis
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seizures, glaucoma, headaches, behavioural problems and stroke like episodes. It has its onset 
usually in early childhood and is usually progressive. However the clinical course is highly 
variable and it is important to note that not all children or adults with the characteristic port 
wine facial staining have the syndrome. Neuroimaging, usually CT confirms the presence of 
intracerebral calcifications affecting the parietal or occipital lobes on the affected side but they 
can be generalised. Management is largely symptomatic and supportive.
SPINOCEREBELLAR DISORDERS
These represent a wide but rare group of disorders with progressive cerebellar degeneration in 
combination with other neurological findings. Friedreich’s ataxia is one of the main early onset 
ataxias.
FRIEDREICH’S ATAXIA
Friedreich’s ataxia is an autosomal recessive condition caused by mutations in the FDRA gene 
(frataxin) on chromosome 9, mostly trinucleotide (GAA) repeat expansions (67–1700). It 
affects 1/50,000 with its onset usually in young persons under the age of 20 years (average 
15.5 years with a range of 2-51 years). The severity of the disease depends on the number of 
abnormal trinucleotide repeats. The disease is characterized by progressive degeneration of 
the main cerebellar tracts with involvement of the corticospinal and posterior columns. The 
main clinical feature is gait ataxia which progressively worsens and may be accompanied by 
pyramidal findings and peripheral neuropathy (absent ankle jerks). Other less frequent findings 
include optic atrophy and deafness. There may be a scoliosis, pes cavus, diabetes mellitus and 
an associated cardiomyopathy as evidenced by widespread T inversion on ECG. 
There is no treatment for the underlying genetic condition and management is mainly 
supportive and treatment of complications. The differential diagnosis includes the other 
hereditary cerebellar ataxias which are mainly the later onset type (>20 yrs) and are mostly 
Port wine staining V1 & 2 distribution
Figure 18. 4 Sturge Weber syndrome
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autosomal dominant, mostly due to CAG repeat expansions and often characterized by 
anticipation. These may have associated spasticity, parkinsonism, neuropathy and retinopathy. 
A rare form of familial autosomal recessive isolated vitamin E deficiency is clinically very similar 
to Friedreich’s ataxia and responds to high doses of vitamin E orally.
INHERITED NEUROPATHIES
These are also called the hereditary motor sensory neuropathies (HMSN). Charcot-Marie-
Tooth disease (CMT1 = HMSN1) or peroneal muscular atrophy is the most common 
example in clinical practice. It is an autosomal dominant disorder, mostly due to 1, 5 Mb 
duplication, involving the PMP22 gene on chromosome 17p. It affects about 1/3000 and the 
age of awareness of the disorder ranges from childhood to middle age, although it is already 
established in childhood but is subclinical. Patients present with a chronic distal wasting of 
the lower limbs (Fig. 18.5) which progresses very slowly over many years. Typically there is 
marked wasting of the calf and distal thigh muscles with bilateral pes cavus (high arched feet 
with clawed toes), reflexes are lost as may be distal sensation. When wasting is severe the leg is 
said to resemble an inverted champagne bottle with a long neck. This may be accompanied by 
wasting of forearms and clawing of the hands in about a third of patients (Fig. 18.5). The level 
of disability is less than expected for the degree of wasting. 
There is no specific treatment for inherited neuropathies. Nerve conduction studies show 
severe slowing of motor conduction velocities consistent with neuropathy. The differential 
diagnosis includes other long standing neuropathies including leprosy and less common forms 
of hereditary neuropathies. These rarer forms of hereditary neuropathies may be accompanied 
by signs of spastic paraparesis, deafness, optic atrophy and retinitis pigmentosa. 
HUNTINGTON’S DISEASE (HD)
This is an autosomal dominant inherited neurodegenerative disorder, affecting particularly 
the caudate nucleus and presenting in middle age with choreaform movements, progressive 
dementia and psychiatric symptoms. There is usually a positive family history. It affects 
about 1 in 10,000 persons and the causative gene lies on chromosome 4. It is an example of 
Characteristic wasting of  the legs Clawing of hands
Figure 18. 5 Charcot-Marie-Tooth disease
inherited neuropathies
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a trinucleotide repeat disorder with affected patients always having more than 36 cytosine-
adenosine-guanosine (CAG) repeats. The normal number of repeats is <30, intermediate 
is 30-35, HD with reduced penetrance 36-39, and >39 in HD. The length of the repeats 
predicts the onset of the disease, the greater the number of repeats the earlier the onset and 
vice versa. Juvenile HD, characterized by rigidity rather than the chorea, is almost invariably 
paternally inherited with repeat sizes of 60 or more. Early features of HD include psychiatric 
and behavioural problems, characteristic fidgetiness, chorea and loss of intellectual function. 
The symptoms typically start insidiously in middle age at around the 4th and 5th decade and 
progress relentlessly to death within 15-20 years. 
The diagnosis can be confirmed by diagnostic genetic testing, if available. Concerned relatives 
at risk need to be counselled carefully before presymptomatic or predictive DNA testing is 
performed. There is no effective treatment but the chorea and the anxiety may respond to 
treatment early on in the disease. If the patient’s chorea is symptomatic tetrabenazine can be 
effective but parkinsonism and depression are adverse effects. Benzodiazepines can be used for 
anxiety and low dose haloperidol (0.5 mg bd) for aggression. 
OTHER HEREDITARY NEUROLOGICAL DISORDERS
Muscular disorders
The main inherited myopathies are the dystrophies, Duchenne’s (DMD), Becker’s (BMD), 
limb girdle (LGMD), facioscapulohumeral (FSHD) and myotonic dystrophy. These are 
presented in chapter 13.
HEREDITARY SPASTIC PARAPARESIS (HSP)
This is an uncommon form of hereditary spastic paraparesis that usually follows an inheritance 
pattern of autosomal dominance and less frequently recessive and X-linked. Several genetic 
mutations occur involving over 20 different loci on different chromosomes with the spasmin 
gene on chromosome 2p22 accounting for 40-50% of cases.  Two main age groups are affected, 
the more common one <35 yrs and the other with later onset (40-60 yrs) although the onset 
can be at any age. The time course is usually one of slow progression over many years.  
The most common clinical phenotype is usually that of a slowly progressive spastic paraparesis 
beginning in childhood or teens characterized by hyperreflexia and up going toes with increasing 
difficulty in walking. If it occurs in childhood there may be pes cavus or arched feet coupled 
with tightening of the calf muscles which may result in heel-toe walking. Bladder and bowel 
function are not usually directly affected. The upper limbs are variably affected. HSP can occur 
in conjunction with other neurological abnormalities. These include cerebellar, optic atrophy, 
peripheral neuropathy, ocular palsies, macular degeneration and retardation and dementia. 
The differential diagnosis includes the main causes of chronic spastic paraparesis in Africa 
including cord compression, primary lateral sclerosis, Konzo and HTLV-1. Management is by 
genetic counselling and the paraplegia measures already outlined in chapter 10. 
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WILSON’S DISEASE
This is a rare autosomal recessive disorder of copper metabolism which affects mainly teenagers 
and young adults. It occurs with a frequency of between 1/50-100,000. It is characterized by 
the accumulation of copper in various organs of the body including the liver and brain. This 
is caused by a deficiency of caeruloplasmin a copper transporting protein in the blood. In the 
brain, it chiefly affects the basal ganglia resulting in a range of movement disorders including 
tremor, chorea, dystonia and parkinsonism. Diagnosis clinically is by finding evidence of 
cirrhosis in the liver or deposition of copper on the cornea called the Kayser-Fleisher ring. This 
may need a slit lamp examination. In the serum the caeruloplasmin level is low and copper 
level high. Treatment is with copper chelating drugs penicillamine and a low copper diet. 
Key points
 · hereditary neurological disorders are uncommon but cause serious long-term disability
 · follow genetic principles of  inheritance: autosomal dominance,  recessive & X-linked inheritance 
 · often start in childhood or during teenage years & other family members are affected
 · no effective treatment for most hereditary neurological disorders
 · genetic counselling is very important
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CHAPTER 19
HEAD AND SPINAL INJURY
Trauma including head injury (HI) resulting in traumatic brain injury (TBI) and spinal 
injury is the leading cause of death and disability in 15-45 yr olds in high income countries. 
It is also a significant and increasing cause of morbidity and mortality in low and middle 
income countries, particularly in Africa. Road traffic accidents (RTAs) involving occupants and 
pedestrians account for the majority of cases and are increasing year on year. They are now a 
significant cause of disease burden in Africa. Head and spinal injuries occur as a consequence 
of the increasing numbers of vehicles, motorcycles, speeding, poor quality of the roads, and 
lack of enforcement of statutory safety regulations for driving and the lack of safety belts 
and helmets (Table 19.1). Other causes include falls and violence. Interpersonal violence is 
increasingly a cause of HI in some countries in Africa. The aim of this chapter is to present an 
overview of head and spinal injuries. The student should aim to know the increasing burden, 
clinical features, management and prevention of head and spinal injuries.
EPIDEMIOLOGY
The annual incidence of traumatic brain injury ranges from 150-500/100,000 per year 
depending on the individual country. It is estimated that 1-2% of high income populations 
live with a TBI disability. The incidence is high in some countries in Africa. In South Africa 
the mortality rate in TBI was reported to be 81/100,000 per year, with a >10% all case fatality 
rate. High risk groups for TBI include children, adolescents, young adults and the elderly, with 
males being affected 2-3 times more often than females. 
Table 19.1 Main causes and risk factors for TBI in Africa
Cause Risk factor % Risk
Road Traffic Accidents speeding, driver sleepiness, lack of use of seat belts, poor 
roads, lack of law enforcement, alcohol, medications, drugs
>80 increasing
Falls climbing trees, poor work place safety, age & co-morbidity >10 static
Violence urban poverty, unemployment, alcohol <10 increasing
Pathology of head injury
The term HI includes injury to the brain, face, head and skull. Injury to the brain is called 
traumatic brain injury (TBI) and all grades can occur from mild to severe. Because the brain 
is a soft organ contained within a rigid box, any trauma to the skull will also cause movement 
of the brain inside the skull. This can result in TBI ranging from no visible signs in cases of 
mild head injury (concussion) to bruising, laceration, bleeding and oedema in severe head 
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injury. Bleeding from torn blood vessels may result in a haematoma, either intracerebrally 
(intracerebral haematoma, ICH), or in the extradural space (extradural haematoma, EDH) and 
in the subdural space (subdural haematoma, SDH). If the resulting volume is too large there 
may be herniation of the brain or brain stem through the tentorium or foramen magnum and 
coning and death will follow. In addition to the primary brain injury there may be secondary 
brain injury as a result of hypotension and hypoxia. The main causes of these are blood loss, 
lung injury and seizures. Secondary infection may arise as a result of penetrating injuries or a 
fractured skull. 
Clinical diagnosis
A history of the cause and the circumstances of the injury should if possible be obtained 
either from the patient or a witness. It is important to enquire if there was any period of loss 
of consciousness and the current state of consciousness of the patient. The main steps in the 
examination of head injury are outlined below in Table 19.2. The Glasgow Coma Scale (GCS) 
uses a point system out of a maximum of 15 to evaluate the best eye opening, verbal and motor 
response (Chapter 9). An underlying fracture of the skull is suspected if there is a CSF leak, 
bleeding from the ears, bruising around the eyes or ears, deafness or on the basis of a significant 
head wound. The severity of a head injury resulting in TBI is graded in terms of the following: 
current level of consciousness, any period of unconsciousness, memory loss, focal neurological deficit 
and skull fracture. The current level of consciousness of the patient is the most important 
indicator of the severity and progress of head injury.
Table 19.2 Summary of main steps in the examination of patient with head injury
Clinical finding
(examine  for the following)
Comments
STEP 1 level of consciousness most important of all assessments 
(repeat at regular intervals, usually every 15 mins)
STEP 2 signs of HI
lacerations, bruising or skull fractures
injury to cervical spine
may be absent in TBI 
check neck & limbs 
signs of basal skull fracture
csf leak from nose/ear, usually clear 
bleeding around eyes & subconjuctiva
bleeding from external ear
bruising over the mastoid (Battle’s sign)
confirm by testing fluid for glucose
no posterior limit indicates fractured skull
exclude laceration of external ear
may take 48 hours to develop
STEP 3 focal neurological signs
pupillary response to light pupil may dilate on same side in expanding lesion
limb weakness asymmetrical limb withdrawal to deep pain indicates focal 
brain lesion
eye movements observe for spontaneous eye movements 
cranial nerve lesions
other observations
may indicate a skull fracture 
BP may rise & pulse rate fall in ICP
Imaging
All head injuries should be considered for imaging. Imaging includes plain X-rays of skull 
and spine, CT of the head and occasionally MRI of the brain and spinal cord. Indications for 
urgent CT include depression/loss of consciousness, focal neurological signs, seizures, fractured 
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skull and CSF leak. CT may reveal evidence of fractures, intracranial haematomas and cerebral 
contusion (Fig. 19.1).
DIFFUSE AXONAL INJURY (DAI)
This occurs from the shearing of axons as a result of a high impact closed HI. It is usually 
associated with an immediate LOC which persists after the injury. Imaging initially by CT 
is normal in >50-70% of cases and this may need to be repeated after 24/48 hours before 
showing haemorrhages and cerebral oedema. MRI is more sensitive than CT in the early stages 
of DAI. Management includes sedation, ventilation and measures for intracerebral pressure 
monitoring and control. 
Classification
The classification or grading of HI is based on the initial history, clinical evaluation and GCS. 
This is made in order to identify and treat patients at risk. It is important to remember that the 
majority of cases of HI do not result in TBI. Of those that do, TBI is graded as mild if the GCS 
at assessment is >12, or the period of unconsciousness is <30 minutes. The majority, 85-90% 
of all TBIs are classified as mild. TBI is classified as moderate if the current GCS is 9-12 or 
there is persisting coma for >30 mins or there is a skull fracture but no evidence of brainstem 
malfunction (Table 19.3). TBI is categorised as severe if unconsciousness is greater than 24 
hours or current GCS ≤8 or there are focal neurological signs or intracranial haematoma or 
failing brain stem function. Patients with moderate and severe TBI represent about 10-15% 
of all cases. 
Table 19.3 Traumatic brain injury, summary of main clinical features
Grade GCS % CT signs present* Mortality % Morbidity % Disability 
mild 13-15 85-90 in one third 1 50 (minor) none/minor
moderate 9-12 5-10 in two thirds 2-5 60 disabled
severe 3-8 3-5 in all** 20-50 75 severely disabled
* includes fractured skull, contusion, bleeding, swelling
** except in diffuse axonal injury (DAI) when the initial CT of head may be normal
Skull fractures Skull fractures, EDH & TBI Swelling & midline shift
Figure 19.1 Traumatic brain injury
Plain X-ray skull CT scans (without contrast)
diffuse axonal injury (dai)
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Key points
 · main causes of HI are RTAs, falls & violence
 · obtain a history of the cause of the head injury
 · assess the level of consciousness 
 · examine for signs of head and neck injury& for neurological deficits 
 · TBIs are graded as mild, moderate and severe 
 · grade is the most important predictor of outcome
Management
The medical management of brain injured patients is complex. It involves 4 main sites/stages: 
pre hospital care, transport to hospital, in hospital care and rehabilitation. Any delay or failure at 
any of these stages results in increased mortality and morbidity. 
Trivial and mild
Trivial head injuries and mild TBIs account for the majority of TBIs and most patients may 
be discharged home after initial examination with a warning about possible complications. 
The risk of complications for mild TBIs is low <1%. However patients with mild TBI and 
other clinical features of head injury should be admitted for 24 hours for closer neurological 
observations, care, possible CT scanning and a re-evaluation later. This group has an increased 
risk (1-5%), of serious neurological deterioration. The main indications for a CT scan in mild 
TBI include alteration in level of consciousness, confusion, a history of transitory loss of consciousness, 
post traumatic amnesia, the presence of focal neurological signs and a possible skull fracture. A skull 
X-ray should be performed if a CT scan is unavailable. 
Moderate and severe injuries
This group represents 10-15% of all TBIs. Moderate and severe head injuries should all have 
a CT scan of the head, be admitted to an intensive care unit for observation and care and 
considered for any possible neurosurgical intervention. 
Evaluation of moderate and severe TBIs
The first priority is to check that the airway is clear and that breathing and circulation are 
adequate. This may involve inserting an airway and ensuring that oxygen saturation is >95%. 
Circulation is maintained by starting emergency intravenous fluids and ensuring that ≤2 litres 
is given in the first 24 hours unless the patient is hypovolaemic for other reasons (Chapter 9). 
The next step is the evaluation of the extent and seriousness of the injuries. Many patients, in 
particular RTA cases, have concomitant injuries of the chest, abdomen, spine and extremities. 
All patients with HI and altered consciousness should be assumed to have a neck injury 
and be immobilized until proven otherwise. This means a general evaluation in addition to 
measuring the level of consciousness, examining for neurological deficits and for evidence of 
head and spinal cord injury, and any skull or vertebral fractures. (Table 19.3) Check with 
family or friends for any history of any predisposing risk factors for head injury including loss 
of consciousness, stroke, seizures, alcohol and drugs. The GCS together with vital signs, pupil 
size and reaction to light should be checked every 15 minutes in unstable patients and then at 
1-4 hourly intervals appropriate to the patient’s condition. Special attention should be paid to 
avoiding the risk factors for secondary brain injury; this includes maintaining adequate blood 
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pressure and oxygen saturation. If the patient’s consciousness is deteriorating then mannitol 
1 gm/kg/iv is given stat followed by iv boluses of 1-200 ml of 20% mannitol depending on 
the clinical situation. This may be helpful as a short term measure to reduce intracranial 
pressure. Prophylactic antibiotics and antiepileptics are indicated for all severe head injuries. 
Indicators of a poor prognosis are: coma for >6 hours, fractured skull, non reacting pupils and 
focal neurological deficits. The main indications for neurosurgical intervention are extradural 
and subdural haematoma, depressed skull fracture and occasionally intracerebral haemorrhage. 
Key points
 · 4 main stages, prehospital, transport, in hospital and rehabilitation
 · aim is to prevent secondary complications of TBI
 · brain damage is prevented by adequate evaluation & care
 · this involves ABC & preventing seizures & infection
 · CT head scan indicated in all moderate & severe TBI
 · main indications for surgery are extradural & subdural haematomas and some ICH
OUTCOME
TBI accounts for up to half of all traumatic deaths with over half of these deaths occurring 
at the scene of the accident or on the way to hospital. The possible outcomes of TBIs are 
summarized in Table 19.3 and in the Glasgow Outcome Scale (Table 19.4). The initial grade 
of TBI after the primary injury is the most important predictor of outcome. 
Table 19.4 Glasgow Outcome Scale
Classification Description
dead
persistent vegetative state awake but unaware
severely disabled conscious but dependent
moderately disabled independent but disabled
good recovery may have minor sequelae
Mortality
The overall case fatality rate (CFR) for all TBI is over 10%; however this varies from less than 
1% in mild to 2-5% in moderate and 20-50% in severe TBI. The CFR for severe TBIs with 
coma lasting longer than 6 hours is >50%. 
Morbidity
Most patients with mild TBI make a good recovery but about half have minor sequelae e.g. 
headache, lack of concentration etc which usually clear after a variable period of months to 
years. There is also increasing evidence that repeated episodes of mild TBI can lead to dementia 
and/or depression with lesions deep in the brain identified at post-mortem. In contrast, the 
majority of surviving patients with moderate and severe TBI will be permanently disabled 
from the onset. This is the leading cause of neurological disability in young persons (<40 yrs) 
worldwide. Moderate disability is 3-4 times more common than severe. The range of moderate 
and severe disabilities includes personality changes, memory loss, dysphasia, paralysis and epilepsy. 
Persistent vegetative state is uncommon. Over 90% of patients reach their maximum recovery 
outCome
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by 6 months although some patients may continue to recover for years. Over 10% of patients 
with severe TBI develop epilepsy within 5 years of the injury. 
REHABILITATION
Most patients with mild head injury make a good recovery without requiring any special 
measures or rehabilitation. Patients with moderate or severe head injury benefit most from 
rehabilitation. This may involve a considerable period of hospitalization, usually >3 months 
together with extensive inpatient and later outpatient rehabilitation while waiting for recovery 
of neurological function and healing of injuries. Recovery of function reaches a peak in about 
90% of patients within the first six months after injury but may continue in some for years.  
Post concussion syndrome
Post concussion syndrome may follow after mild or moderate head injuries. Patients can be 
disabled by recurrent symptoms including headaches, dizziness, poor concentration, impaired 
memory, fatigue and depression. These usually subside after a few months but can continue 
for as long as 6 months to 3 years. There are no abnormal neurological findings and no 
abnormalities on neuroimaging of the brain. Management is conservative and supportive.
Key points
 · most patients with mild TBI eventually make a full recovery
 · patients with moderate and severe TBI have high mortality & morbidity rates
 · patients with moderate and severe TBI benefit most from rehabilitation
EXTRADURAL HAEMATOMA (EDH)
Extradural haematoma is a rapid collection of arterial blood occurring over minutes to hours 
in the extradural space as a result of a temporal/parietal skull fracture or a serious head injury. 
EDH results from a traumatic tear in the middle meningeal artery. The bleeding shells the dura 
mater from the inner table of the skull compressing the brain. The main cause is HI arising 
from RTA. 
Clinical features
In EDH, characteristically there is a lucid interval between the patient waking up from the 
acute head injury and then becoming unconscious again. This lucid period is variable ranging 
from minutes to over 24 hours. It should be suspected whenever there is a sudden decline in 
the level of consciousness of a patient with a very recent head injury. The site of the extradural 
haematoma is on the same side as the underlying skull fracture and the pupillary dilatation. 
Diagnosis
The diagnosis is suggested by the clinical presentation, neurological findings and a skull X-ray 
may show an underlying fracture. In EDH the CT scan of head shows on the affected side 
an area of increased density biconvex inwards with midline shift in severe cases (Figs. 19.2 & 
3). However obtaining the CT scan should not be a reason to delay surgery, as any delay will 
inevitably result in the death of the patient. 
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Management
This is a true surgical emergency and management is by emergency craniotomy in order to 
establish urgent ligation of the bleeding vessel and surgical drainage of the EDH. Emergency 
resuscitation and a burr hole may provide temporary relief before the craniotomy.
Prognosis
Prognosis depends on the preoperative state of the patient. The presence of fixed dilated pupils 
is not a contraindication for surgery. If GCS ≤ 8 the mortality is >30%.
Key points
 · EDH results from a meningeal artery tear outside the dura
 · main cause is a fractured skull secondary to a RTA
 · blood accumulates within minutes to hours in the extradural space 
 · lucid interval of minutes/hours followed by rapid onset of FND & LOC
 · management is urgent craniotomy to ligate the bleeding vessel & drain the EDH
CT (without contrast)
EDH (left) EDH (left) EDH (left) & small SDH
Figure 19.3 Extradural haematoma
A B
convex
inwards
concave
inwards
midline shift
   ventricle compression
A   Extradur l haematoma B   Subdural haematoma
A Extradural haematoma B Subdural haematoma
Figure 19.2 Illustrations of extradural and subdural haematoma
CT scans (without contrast)
extradural haematoma (edh)
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SUBDURAL HAEMATOMA (SDH)
Subdural haematoma (SDH) is a collection of blood which lies in the space between the dura 
and arachnoid layers of the meninges. It arises from an injury which causes rupture of bridging 
veins between the meningeal layers and can be acute or chronic. 
Acute SDH
An acute SDH immediately follows a high energy head injury with just a short delay of hours 
or at most days between the injury and the onset of symptoms. Clinically this can lead to 
a rapid clinical deterioration due to the accumulation of blood with an immediate loss of 
consciousness and progressive or fluctuating decline in GCS. The source of the haemorrhage 
in acute SDH is both arterial and venous from contused cerebral cortex and blood vessels. If 
left untreated this may eventually lead to transtentorial herniation, coning, hemiparesis, coma 
and death. Management is by emergency surgical drainage usually involving a craniotomy. 
Cerebral swelling is common and may require decompression surgery. The prognosis is poor 
with 50-70% mortality.
Chronic SDH
A chronic SDH is a late complication which can follow any head injury but may occur after a 
relatively minor low energy or non reported head injury particularly in the elderly, in those on 
anticoagulants and in persons prone to falling e.g. alcoholics. The injury may be so minor that 
it is not remembered. Very occasionally chronic SDH is spontaneous without previous history 
of trauma. In chronic SDH there is a slow accumulation over weeks or months of venous blood 
over one or occasionally both cerebral hemispheres. 
Clinical features
The clinical presentation is one of non specific gradual fluctuating drowsiness, confusion, and 
headache and only later followed by the onset of a focal neurological deficit, usually hemiparesis 
and progressing to alteration in level of consciousness, seizures and sometimes coma. The 
finding of a progressive hemiparesis or a recent onset confusional or dementia type illness is a 
feature in Africa because of late hospital presentation. 
Imaging
The diagnosis of SDH is either confirmed or else newly discovered by a CT of the head. The 
SDH shows as a crescent shaped concave inwards area of increased density spreading round the 
surface of the cerebral hemisphere with or without an accompanying mid line shift (Figs. 19.2 
& 4). Approximately 10-12 days after injury the appearance of SDH on CT becomes isodense 
and is then more difficult to notice. After about 3 weeks post HI the SDH becomes hypodense 
on non contrasted CT and is then more obvious. 
Management
The management of chronic subdural haematoma depends on the size and clinical state of 
the patient. Small subdurals without focal neurological signs can be managed conservatively 
and these may resorb spontaneously. Larger subdurals with changing levels of consciousness 
and focal neurological signs need surgical drainage and evacuation. CT indications for surgery 
include cortical compression, midline shift and hydrocephalus. Drainage is established via burr 
holes in the skull with or without a surgical drain. This procedure is carried out by most general 
surgeons in Africa. Steroids, dexamethasone 4 mg qds may be helpful in the early stages. 
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Prognosis
The outcome is generally good in all age groups but 10-15% of patients may require a second 
drainage procedure and a subdural empyema occurs in <1%. 
Key points
 · in SDH there is usually a history of HI 
 · acute SDH occurs within hours or days of HI
 · chronic SDH occurs within weeks/months of HI 
 · presentations include headache, confusion and coma, seizures & hemiparesis
 · SDH is usually confirmed or diagnosed by CT of head 
 · management is mostly by surgical drainage 
Intracerebral haematoma (ICH)
This arises from severe contusional HI or vascular injury. Common sites include the cerebral 
cortex, cerebellum and subarachnoid space (Fig. 19.5). Management depends on the severity, 
clinical condition and evidence of mass effect. Craniotomy and surgical evacuation is indicated 
in presence of focal neurological signs and decreasing GCS. 
CT scans (without contrast)
SDH (left) isodense SDH (left) hypodense SDH (bilateral, old)
Figure 19.4 Subdural haematoma (chronic)
CT scans (without contrast)
ICH & intraventricular extension
Figure 19.5 Intracerebral haematoma
subdural haematoma (sdh)
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SPINAL INJURY
Spinal injury arises mostly from road traffic accidents (RTAs) and falls and is a major cause 
of death and disability in Africa. It is often associated with HI and multiple trauma. Males 
in the age group 20-40 years are the main risk group affected. In Africa boys and adolescent 
males are frequently affected as a result of falls from trees and more recently RTAs. Females are 
also affected because of falls whilst carrying heavy loads on their heads. Early detection and 
immobilization are critical to avoid secondary damage. 
Clinical features
The cervical and the lumbar spine are the most common sites of injury with the cervical spine 
being more frequently affected. Paraplegia and quadriplegia are the main neurological disorders 
resulting from spinal injury. Spinal injuries anywhere from the cervical spine down to the level 
of the first lumbar vertebra inevitably involve the spinal cord whereas injuries below L1 involve 
the cauda equina. In spinal cord injury there may be an initial period of spinal shock which 
can persist for days to weeks (usually 1-2 weeks) before the characteristic spasticity and upper 
motor neurone signs develop. Spinal shock is characterized by flaccid paralysis with no reflexes 
or sensation below the level of spinal cord injury. In contrast paraplegia resulting from spinal 
injury affecting the cauda equina remains permanently flaccid with characteristic lower motor 
neurone signs. Bladder and bowel dysfunction occurs with both types. The completeness of 
the lesion is the most important factor in determining prognosis and management. Incomplete 
lesions may recover to a variable extent.
Spinal stability
The stability of the spine at the level of injury plays a crucial role in further management. 
Instability is defined as the loss of ability of the spine to maintain normal alignment under 
normal loads. Instability increases the risk of further spinal cord damage. The Denis three 
column model (Table 19.5) is used to classify spinal stability.
Table 19.5 Denis three column model of the spine
anterior column anterior one-half of the vertebral body and annulus fibrosus  
& the anterior longitudinal ligament (ALL)
middle column posterior one-half of the vertebral body & annulus fibrosus & posterior longitudinal 
ligament (PLL)
posterior column pedicles, laminae, spinous processes & ligaments
Spinal injuries are classified as stable when the interspinous ligaments are intact and as unstable 
when ligaments are disrupted. The spine is unstable if ≥2 columns on the Denis three column 
model are disrupted. The mechanism of injury helps to determine the degree of stability and 
type of cord injury. A shearing or hinge injury typically results in unstable spinal injury with 
cord involvement, whereas a compression injury results in stable fractures. Stable spinal injury 
occurs mostly without cord involvement. Typically the former arises from RTAs, whereas the 
latter arises from an object falling on to the head. However a severe or burst fracture from 
whatever cause results in an unstable spine and possible spinal cord injury. 
The initial examination should be targeted at checking for local injury in the spine, particularly 
in the neck and looking for paralysis of limbs, being careful to avoid aggravating existing 
injuries by any movement. It is critical to emphasise that the spine must be stabilized in any 
patient with evidence or suspicion of spinal injury before being moved. This is done by means of 
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using a hard cervical collar, putting the patient lying on a back board and using the logrolling 
method when turning the patient.
Key points
 · RTAs and falls are the main causes of spinal injury 
 · neck and lower back are the sites most frequently affected
 · spine should be stabilized in patients with spinal injury before being moved 
 · spinal shock lasting >24 hours is a bad prognostic sign 
 · death or paraplegia are the two main outcomes
X-rays spine
C2/C3 C4/5
T12/L1 Compression fracture T9
Figure 19.6 Fracture dislocation of spine
spinal injury
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Imaging
Management depends on the site and stability of the injury. Straight X-rays of the spine will 
confirm obvious fractures and dislocations (Fig. 19.6). X-rays, AP and lateral of the cervical 
spine should visualize C1 down to the upper border of T1. CT scan may reveal fractures not 
visible on plain X-rays. 
Management
In principle, an unstable cervical fracture risks further damage to the spinal cord and requires 
immobilization before being moved or mobilized. This can be done by operative fixation or 
skull traction with a Halo or plaster jacket immobilization for 12 weeks. If a cervical fracture is 
stable without cord injury, then a cervical collar is used. Thoracolumbar fractures are managed 
along the same general principles, although internal fixation is used less frequently.
General management includes support of arterial oxygenation and adequate spinal cord 
perfusion pressure. The use of high dose steroids in acute cord injury is still common practice 
although its value is controversial. Methylprednisilone in doses of 2 grams intravenously, if 
given within 8 hours of the spinal cord injury and continued over the first 24 hours may 
have a protective role but this it is not proven and may be actually deleterious. An up to 
date reference should be consulted before recommending their use. A urinary catheter should 
always be inserted. Very special attention from the onset should be paid to the prevention 
of respiratory complications, bedsores, urinary tract infections, DVT and limb contractures. 
Long term rehabilitation of paraplegia is already discussed in chapter 10.
Outcome
Patients with high cervical cord injuries seldom survive even with ventilatory support. Patients 
with a lesion above C7 remain dependent on others for continuous care. Patients with a lesion 
below C7 may be able to learn to transfer to wheelchair independently, while patients with 
lower spinal cord or cauda equina injuries gain complete wheelchair independence. Respiratory 
failure, infections and bedsores are the main complications of spinal cord injuries. Long initial 
periods of hospitalization of typically 3-6 months are usual, and mortality rates in Africa while 
recovering in hospital are frequently in the order of 20-30%. 
Key points
 · imaging is essential in the management of spinal  injuries
 · acute management includes stabilization of fractured spine & respiratory support
 · scrupulous attention is needed to prevent bedsores and infection
 · mortality rates are 20-30% and survivors need assistance with mobilization
PREVENTION
The main cause of head and neck injuries are RTAs. These are increasing at an alarming rate in 
Africa. They are mostly preventable by reducing both speed and dangerous driving. Measures 
to achieve these include adequate enforcing of traffic safety regulations, speed limits, road 
bumps, alcohol checks and ensuring that motor cyclists and cyclists wear helmets. Other causes 
of HI such as falls, work related accidents and violence are also partially preventable. General 
measures for prevention include better education and informed legislation. 
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Key points
 · head and neck injury is a leading cause of death in Africa
 · young adult males are a particularly high risk group 
 · main causes are RTAs and falls
 · measures for primary prevention are now urgently needed
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CHAPTER 20
CARE IN NEUROLOGY
The burden of neurological disease in Africa is already evident from earlier chapters where they 
account for >5% of all deaths and >14% of all disabilities. Neurological disorders account for 
10-20% of adult medical admissions to hospitals in Africa, 20-30% of whom die in hospital and 
>30% of whom are disabled at discharge. The leading neurological causes of death in hospitals 
are stroke, HIV disease, infections and head injury, and the leading causes of disability are 
stroke, paraplegia, trauma, and epilepsy. Most medical practice is concerned with the control of 
symptoms and this is particularly true when caring for patients with neurological disorders. The 
common symptoms and worries encountered in advanced neurological disorders are outlined 
below in Table 20.1. Neurological care invariably involves elements of palliative care. Palliative 
care is about caring for a patient when the disease no longer responds to curative treatment. 
This involves special attention to symptoms such as pain, and psychological, social and spiritual 
well-being. Palliative care regards dying as a normal process and offers practical support to help 
the patient and family. It is an integral part of patient care in hospital and is best delivered by a 
team approach. This includes family, nurses, doctors, physiotherapists, occupational therapists 
and spiritual advisors. The aim of this chapter is to present an overview of care and symptom 
control in patients with neurological disorders with an emphasis on palliative care. The student 
should aim to be familiar with this and in particular the relief of pain.
Table 20.1 Common symptoms and worries in patients with advanced neurological disorders
Physical Psychological Social Spiritual
pain
confusion/delirium
loss of communication
dysphagia
seizures
nausea/vomiting
spasticity
dyspnoea
immobility
constipation
depression
fear anxiety
stigma/guilt
loss of income
fear for children spouse & dependants
religious
non religious
why me?
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MAIN SYMPTOMS
Pain
Pain is defined as a subjective unpleasant sensory and emotional experience associated with actual 
or potential tissue damage. Pain is a common disorder and WHO estimates that 5-30% of 
the world’s population experience persistent pain depending on where they live. The most 
commonly affected sites worldwide are head, neck, knees and lower back. Pain is influenced by 
the patient’s mood, morale and the underlying reason for the pain. Chronic pain may persist 
long after the tissue damage has been done and is defined as pain lasting for >3/12. 
Total pain is an interaction of the physical, emotional, psychological and spiritual components. 
The consequences of pain include immobility, depression, poor sleep and nutrition and 
overdependence on family and carers. Longer term consequences affect employment, family, 
and social life. Chronic pain as a result of neurological disorders is a major and neglected cause 
of disability in Africa. The management of pain involves non pharmacological measures, drug 
treatments, psychological and spiritual support. The aim of drug treatment is to provide an 
effective and regular treatment which completely stops pain and prevents its recurrence. The 
commonly used drugs in pain control (Table 20.4) and the WHO steps in their use (Table 
20.5) are outlined below. 
Pathophysiology
Pain is broadly classified into two types: nociceptive and neuropathic (Table 20.2). The 
difference between nociceptive and neuropathic is not always clear-cut clinically and any one 
individual may suffer from one or both types of pain.
Nociceptive pain is caused by activation of primary pain receptors in tissues and is transmitted 
to the brain through slow non myelinated peripheral C fibres and faster conducting larger 
myelinated (A) fibres. It can be either somatic arising from skin, musculoskeletal (muscle 
spasticity, joint deformities) or visceral arising from internal organs (malignancy, stone) or 
bone (fracture). The type of pain depends on the site, origin and cause of pain. It ranges from 
the familiar pricking and burning pain in skin conditions to a dull, continuous, diffuse, aching 
as described in internal malignancy or the intermittent, sharp and colicky pain which occurs 
in gastrointestinal or ureteric colic. 
Neuropathic pain by contrast is mostly neurological in origin arising from damaged neural 
tissue either in the peripheral or the central nervous system. The main sites of origin are 
peripheral nerves (HIV, diabetes), nerve roots (herniated disc, herpes zoster), spinal cord 
(paraplegia) and the brain (post stroke). The sensations that characterize neuropathic pain 
are variable and often multiple and are described as burning, gnawing, aching or lancinating 
(knife-like) or shooting in character. There is frequently numbness or dysaesthesia (altered 
unpleasant sensation) or allodynia (when a non painful stimulus is perceived as pain) in a 
superficial sensory distribution coupled with local autonomic dysfunction. Neuropathic pain 
can be either intermittent, lasting seconds or continuous, lasting hours, and can persist even 
without the stimulus. It generally responds poorly to treatment. Pain without identifiable tissue 
or nerve damage is termed idiopathic. The N-methyl–D aspartate (NMDA) channel receptor 
complex, substance P, bradykinin and serotonin are all involved in the pathophysiology of 
pain. These are found predominantly in the spinal cord and peripheral nervous system. 
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Table 20.2 Neurological types of pain
Classification Main causes
Neuropathic
peripheral neuropathies: HIV, diabetes, neuralgia, injury, causalgia, complex regional pain 
syndromes (local limb injury)
central thalamic stroke, paraplegia, spinal cord injury, disc disease, HIV, syphilis
Nociceptive
spasticity & rigidity strokes, quadriplegia/paraplegia, dystonia, tetanus, stiff person syndrome
others headache, arthritis
Measurement
All types of pain should be described fully in terms of quality, severity, location, mode of onset, 
provoking and relieving factors, and time course. Pain is subjective but can be measured. The 
simplest measurement uses self reported severity in terms of mild, moderate, severe and very 
severe which can be recorded and graded on a corresponding scale of 1-4. In clinical practice 
however, there is widespread use of the verbal or written analogue scale. This is a scale of 1-10, 
where 1 is the least and 10 is the worst pain imaginable. The patient is asked ”where on this scale 
of 1-10 do you put your pain?” The value of the pain scale is that it is independent of language, 
easy to understand and use and can be recorded and repeated at each patient visit and response 
to therapy monitored. 
Major causes of neurological pain in Africa
 · spinal cord injuries
 · neuropathies 
 · myelopathies
 · malignancies
 · stroke 
 · chronic neurological disorders
MANAGEMENT OF PAIN
Relief of pain should be the responsibility of all health care workers. The main aim is to diagnose, 
treat and stop the pain. In chronic neurological disorders this frequently involves providing 
maximal pain relief, as complete alleviation is not always possible. The range of clinical treatments 
includes non pharmacological and pharmacological measures. The non pharmacological 
approach is summarised in Table 20.3. The drug treatment of pain of neurological origin 
is based on the distinction between the pain of nociceptive and neuropathic origin and is 
summarised in Table 20.4 In practice, although these may be difficult to distinguish, the pain 
of nociceptive origin responds better to non-opioid analgesics such as paracetamol, aspirin 
and non steroidal anti-inflammatory drugs whereas pain of neuropathic origin responds 
best to tricyclic antidepressants e.g. amitriptyline and the anticonvulsants e.g. gabapentin 
and carbamazepine. Opioids can be used in both types and their role in the management of 
pain is summarized below in Table 20.4. Pain due to local compression of peripheral nerves 
or nerve roots may be relieved by appropriate surgery. Nerve root blocks and epidural spinals 
provide temporary relief. Patients with chronic pain benefit from a multidisciplinary approach 
involving cognitive behaviour therapy, physiotherapy and occupational therapy.
management of pain
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Table 20.3 General and local measures used in pain management
Intervention Indication Comments
Non Pharmacological
Explanation, relaxation, positioning
Complementary therapies 
aromatherapy, massage
Transcutaneous electrical nerve 
stimulation (TENS) 
Acupuncture
 
Radiotherapy (palliative)
any pain
chronic pain
 
musculoskeletal, soft tissue 
 
chronic myofacial pain, migraine
 
bony metastases particularly spinal 
non invasive 
may improve pain relief 
(no evidence for use in severe 
pain)
patient is in control
 
pain relief (no evidence for 
use in severe pain)
excellent pain relief
Local 
Invasive anaesthesia
spinal, regional blocks spinal & localised root/plexus lesions very effective but needs 
skilled operator
Topical agents
heat/cold
capsaicin cream
lignocaine patch
any pain
burning, redness, cough 
(takes 2-6 weeks to work)
few side effects, expensive
DRUG TREATMENT OF PAIN
Non-opioids
These include non steroidal anti-inflammatory drugs (NSAIDs) and paracetamol. The 
most commonly used NSAIDs are aspirin, ibuprofen, and diclofenac. Their doses, routes 
of administration and side effects are outlined in Table 20.4. These are the main first line 
treatment for most pain regardless of whether it is of nociceptive or neuropathic origin and 
are used at all 3 steps in the WHO analgesic ladder (Table 20.5). NSAIDs should be used 
cautiously in patients with renal impairment as they may further impair function and may 
provoke renal failure. In patients with a history of dyspepsia the concurrent prescription of 
proton pump inhibitors or histamine-2 receptor blockers help to reduce the symptomatic 
upper GIT side effects. 
Opioids
Opioids include all drugs that act at opioid receptors. These receptors are scattered throughout 
the body though mainly in the central and peripheral nervous system. Opiates are either 
derived from the opium poppy (morphine and codeine) or synthesised in the laboratory 
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(pethidine). Opioids are indicated for pain at steps two and three of the WHO ladder (Table 
20.5). This includes pain in patients with advanced disease and their short-term use to relieve 
breakthrough or severe acute pain of any origin. 
The use of opioids for non-malignant chronic pain is controversial. In general, opioids on 
their own should be avoided for intractable chronic neurological pain (usually neuropathic) 
to reduce the risk of dependence. However their use in advanced or terminal disease should 
not be restricted as they are necessary and there is no risk of dependence in this setting. The 
biggest barriers to their use are availability and the stigma from both the doctor and the 
patient surrounding their use. Once these can be overcome they provide excellent pain relief. 
Whenever opioids are used, they should be given at regular intervals, e.g. morphine every 4 
hours (oxycodone can be given 6 hourly), preferably via the oral route or when necessary via 
the parenteral route. The dose and frequency should be according to the needs of the patient 
and be reduced in renal or hepatic failure and in the elderly. Constipation is usually not a major 
issue in clinical practice.
It is important to realise that opioids are controlled drugs with strict regulations concerning 
their availability, prescription and use anywhere in the world. A major limitation to their use in 
many low income countries are the stringent national control policies regarding the accessibility 
and use of opioids for pain. However some countries in Africa have recently prioritized their 
use in pain control and opioids are available for medical use. 
Adjuvants
These mainly include the antidepressants amitriptyline and the anticonvulsants carbamazepine 
and gabapentin or pregabalin. These are used in all three steps in the WHO analgesic ladder 
for the management of neuropathic pain. They are most commonly used as adjuvants in 
combination with opioids or non opioids depending on the severity of the pain. In some 
patients with chronic pain of neuropathic origin they are used on their own without analgesics. 
Examples of neurological disorders benefitting from their use include neuropathies (HIV & 
DM) and post herpetic and trigeminal neuralgias. 
Their dose, route, frequency and side effects are outlined in Table 20.4. The main limitations 
are their side effects and frequency of administration which may limit patient compliance. It is 
always wise to start at the lowest dose and increase it slowly. In general antidepressants are taken 
once daily, often at night whereas anticonvulsants are prescribed twice or three times daily. The 
main side effects of tricyclics are anticholinergic and include sedation, dry mouth, postural 
hypotension and constipation among others. Side effects of the anticonvulsants include 
drowsiness (which often clears with regular usage), confusion and ataxia. Both antidepressants 
and anticonvulsants may be used together as they have different mechanisms of action in the 
nervous system.
drug treatment of pain
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Table 20.4 Drugs used in pain management
Indication Drug/dose/route/frequency Side effects
Minor pain
(non opioids)
aspirin 300-500 mg tab, 1-2 po/6 hourly
ibuprofen 400 mg tab, 1-2 po/pr/8-12 hourly
diclofenac 50-75 mg, po/pr/im/12 hourly 
paracetamol 500 mg tab,1-2 po/pr/6 hourly 
gastric irritation, peptic
ulceration, GIT bleeding,
nausea, renal dysfunction
liver damage in over dosage
Intermediate pain
(opioids mild)
codeine/dihydrocodeine 30-60 mg, po/pr/im/6 hourly 
tramadol 50-100 mg/po/pr/im/6 hourly
constipation
Major pain
(opioids strong)
* pethidine 50-100 mg/po/im/4-6 hourly 
morphine 25, 5,10-20 mg/po/im/sc/4-6 hourly
constipation 
sedation, nausea, vomiting, 
respiratory depression (rare)
Chronic 
neurological pain 
(adjuvant)
amitriptyline 10-100 mg/po/nocte, starting dose is  
10-25 mg increasing as tolerated
 
carbamazepine 2-300 mg/po/8-12 hourly
(main use is in trigeminal neuralgia)
 
gabapentin 100 mg/po/8 hourly or 300 mg nocte 
increasing by 300 mg every 1-2 days to  
max of 24-36 gm daily as tolerated
or
pregabalin 75 mg/po/12 hourly increase to max of  
600 mg daily as tolerated
sedation, dry mouth, 
constipation, hypotension, 
blurred vision, confusion
sedation, dizziness, ataxia, 
blood dyscrasias 
sedation (transient) 
unsteadiness, oedema, 
headache
*duration of action of pethidine is too short for use in chronic pain relief
Table 20.5 WHO analgesic ladder
Step 1 non-opioid ± adjuvant
Step 2 mild opioid for mild-moderate pain ± non-opioid ± adjuvant
Step 3 strong opioid for severe pain ± non opioid ± adjuvant
Key points
 · adequate pain control is very important in patient care
 · controlling pain, if done properly does not shorten & may allow normal life
 · opioids are used for pain not responding to simple analgesics & NSAIDs
 · opioids are indicated for pain control in advanced neurological disease 
 · neuropathic pain frequently responds to combinations of antidepressants & analgesics
OTHER MAIN SYMPTOMS
Impaired communication
Impaired communication occurs in many neurological disorders. It ranges from aphasia in 
stroke to dysarthria in motor neurone disease and the inability to understand or comprehend 
in dementia. In virtually all situations, communication with the patient switches from speech 
to a non verbal form. This may take the form of “fixed expressions”, gestures, signs or written 
commands. The family should be encouraged to try anything they feel is acceptable as a way 
of communicating to the patient. A simple communication board with images or illustrations 
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indicating a person’s daily needs can be very helpful at this stage. It is also wise to advise 
health care workers, family members and carers to behave at the bedside as if the patient hears 
and understands what is being said. Impaired communication may be improved in certain 
circumstances. Measures include making certain the patient is comfortable and pain free, that 
the environment is conducive to communication, without outside noise or interference and 
with appropriate face to face seating. The help of a person trained in speech and language 
therapy should be sought where ever possible. 
Key points
 · make sure patient is pain free & comfortable 
 · encourage family to try to communicate 
 · communicate in a conducive environment without noise or interference
 · sit in front so the patient can clearly see your face
 · obtain help from a person experienced in speech and language therapy
Confusion/delirium
Neurological disorders have high rates of confusion and behavioural disturbances. The main 
causes include infections, stroke, anaemia/anoxia, metabolic disorders, neurodegenerative 
disorders e.g. dementia, extrapyramidal disorders, SOL, drugs and psychiatric disorders. The 
main causes of confusion/coma have already been outlined in chapter 9. Management depends 
on the clinical situation and the overall aim. In the early stages, it is important to retain a high 
index of suspicion for a reversible cause and the aim should be to screen for any underlying 
disorder. Simple bedside screening tests, include measuring oxygen saturation, glucose, malaria 
parasite and an HIV test. The patient should ideally be nursed in a quiet, dimly lit area or room 
away from other patients and surrounded by family. The health care worker should aim to be 
supportive and reassuring to the patient and family. If these measures do not succeed then drug 
treatment should be started with neuroleptics. 
Drug treatment
Haloperidol is the drug of first choice starting with low dose 0.5-1.0 mg/po/im/bd increasing 
as required. In patients with acute delirium, it may be necessary to use higher starting doses, 
1.5-3 mg stat po/im or sc and to repeat after the first 1-2 hours if necessary. The total 24 
hour dosage of haloperidol ranges from 5-30 mg. Chlorpromazine 25-50 mg (or 50-100 mg 
if necessary) po/im/8 hourly is an alternative. In the later stages of an advanced or terminal 
disease treatment should start directly with neuroleptics. 
If there is a major anxiety component, then an anxiolytic may be used in addition to neuroleptics. 
Diazepam 5-10 mg/po/im 8 hourly is usually the drug of first choice. If the cause is raised 
intracranial pressure, then steroids, usually dexamethasone 8 mg/po/iv is given twice or three 
times daily (steroids can be given once daily as a single dose) until symptoms are controlled 
and then it is reduced after 3-5 days to 4 mg twice or once daily or twice weekly as is necessary. 
The second dose should ideally not be later than early afternoon as steroids can sometimes 
cause insomnia. The drugs most commonly used to treat confusional states are outlined below 
in Table 20.6. 
other main symptoms
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Table 20.6 Drugs commonly used for confusion/delirium
Class Drug/dose/route/duration Indication Side effects
Neuroleptics
haloperidol 05-3 mg/po/sc/12 hourly 
increasing to 5-10 mg 12 hourly if necessary
delirium/
insomnia
drowsiness, dry mouth, 
parkinsonism
chlorpromazine 25-50 mg/po/im/ 
or 100 mg/po/8 hourly
psychosis dyskinesia, parkinsonism
thioridazine 10-75 mg/po/nocte confusion/
insomnia
arrhythmias, parkinsonism
Anxiolytics
diazepam 10-20 mg/po/rectally/8 hourly anxiety drowsiness
lorazepam 05-2 mg/po/im/iv/od anxiety drowsiness
midazolam 5-10 mg/sc/im/or rectally /8 hourly anxiety drowsiness
oxazepam/temazepam 10-15 mg/po/nocte insomnia drowsiness
Key points
 · neurological disorders have high rates of confusion & delirium
 · it is important to exclude a treatable cause
 · main antipsychotic drugs used are haloperidol & chlorpromazine
 · it is important to treat with an adequate dose
 · main anxiolytics are the benzodiazepines
Seizures
Epileptic seizures are a common complication in terminal neurological disorders and are 
usually self limiting. Acute management is directed at protecting the patient from immediate 
injury and aspiration and the emergency drug treatment and prevention of recurrences. 
Benzodiazepines followed by phenytoin or phenobarbitone are the drugs of first choice for 
active or prolonged tonic clonic seizures. The choice of drug, dosage and frequency may have 
to be adjusted according to the age of the patient and the underlying disorder and these have 
already been outlined in chapter 4.
Dysphagia
This is a frequent and very disabling symptom in patients with neurological disease. The main 
causes include all causes of coma, stroke, motor neurone disease, myasthenia gravis and acute 
neuropathies. The main presenting complaints are inability or difficulty eating, drinking 
or swallowing safely. Quite apart from the practical difficulties is the loss of enjoyment of 
eating and drinking. The main aim is to support safe oral feeding for as long as possible 
while avoiding aspiration, dehydration, malnutrition and patient exhaustion. Good nursing/
family care is needed as these patients are more difficult to feed and usually take longer. Some 
practical measures to deal with dysphagia include upright positioning whilst feeding, physical 
therapy with chewing and swallowing exercises, a high calorie diet with food/liquids thickened 
and regular oral hygiene every 2-4 hourly. Nasogastric tube feeding is a useful temporary or 
short term measure but should be avoided where death is inevitable as occurs in dementia. 
A percutaneous endoscopic gastrostomy (PEG) feeding tube may be used in patients with 
long term disorders presenting with intractable dysphagia. Measures used to treat dysphagia in 
neurological disorders are summarised in Table 20.7
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Table 20.7 Measures used to treat dysphagia in neurological disorders
Indication Intervention limitations
Partial dysphagia physical therapy with
chewing and swallowing exercises, 
head & neck position, increased 
frequency of swallowing
aspiration pneumonia
Dehydration fluids >2-3 litres/daily aspiration pneumonia
Malnutrition diet: food/liquids thickened, high 
calorie diet
dehydration/aspiration
Excess saliva/
drooling
oral hygiene 2-4 hourly
anticholinergics: 
amitriptyline 10-25 mg/day/po,
scopolamine 04 mg/sc/patches prn 
mouth too dry and saliva more difficult to 
swallow
Dysphagia nasogastric tube feeding (NGT)
percutaneous endoscopic 
gastrostomy (PEG)
aspiration pneumonia, (usually a short term 
intervention but can save lives)
perforation, infection, (used in long term 
dysphagia)
Nausea and vomiting
This is a common symptom complicating intracranial disorders. The main aim in treatment 
is to maintain adequate fluid and calorie intake and good oral hygiene. The antiemetics 
metoclopramide and domperidone are useful for nausea of gastrointestinal origin. 
Ondansetron is helpful for chemotherapy and drug induced nausea and cyclizine in 
combination with dexamethasone for vomiting in patients with raised intracranial pressure. 
The commonly used drugs to treat nausea and vomiting are presented in Table 20.8.
Table 20.8 Drugs commonly used for nausea and vomiting
Indication Drugs/dose/route/duration Side effects
Nausea vomiting metoclopramide10 mg/po/iv/8 hourly
prochloperazine 5 mg/po/im/8 hourly
domperidone10-20 mg/po/pr/8 hourly 
dystonic reactions, parkinsonism, 
drowsiness
cyclizine 25-50 mg/iv/im/6 hourly drowsiness, dystonic reactions, 
parkinsonism
ondansetron 8-16 mg/po/pr/iv 12 hourly constipation, headache
Raised intracranial pressure dexamethasone 4-16 mg/po/iv/bid indigestion, insomnia, mood 
disturbance, hyperglycaemia, 
(perforation increased with 
NSAIDs), bone necrosis
Spasticity
Spasticity is a common and complex problem in neurological care particularly in patients with 
stroke and paraplegia. The aim of treatment is to increase mobility and avoid pain, contractures 
and bedsores. The management of spasticity mainly involves physiotherapy, occupational 
therapy and drug treatment (Chapter 10). Physiotherapy involves passive stretching exercises 
and local measures including joint supporting and splinting. The antispasmodics most widely 
available in Africa are diazepam and baclofen. The starting dose of diazepam is 2-5 mg 
three times daily increasing gradually over weeks to a maximum of 20 mg three times daily. 
Clonazepam once daily is an alternative to diazepam. The starting dose of baclofen is 5 mg 
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twice daily orally increasing slowly over weeks to 20-30 mg twice daily as required. These can 
be used either as monotherapy or in combination if monotherapy fails. Both drugs are started 
at a low dose titrating slowly upwards against response. The limiting adverse effects of both are 
drowsiness and fatigue. 
Other oral drugs used for spasticity include dantrolene and tizanidine. These are mainly 
second line antispasmodics but are often used in conjunction with first line drugs. Baclofen can 
be administered intrathecally by injection or pump for intractable spasticity and botulinum 
toxin is used by local injections for intractable spasticity, but both of these measures are only 
available at specialised centres. Pain resulting from spasticity or spasms can be very severe and 
is sometimes opioid refractory and needs high doses of muscle relaxants. The main drugs used 
to treat spasticity are outlined in Table 20.9.
Table 20.9 Drugs used for spasticity
Indication Drugs/dose/route/duration Side effects
Spasticity diazepam 25-5 mg/po/8 hourly increasing to 
10-20 mg/8 hourly
baclofen 5-10 mg/po/12 hourly increasing to 
20-30 mg/12 hourly
dantrolene 25 mg/po/daily increasing slowly 
to 50-100 mg/6 hourly 
tizanadine 2 mg/po/6-8 hourly increasing 
slowly to 6 mg/6-8-hourly
drowsiness, fatigue
 
muscle weakness, drowsiness, headache, 
nausea, insomnia
drowsiness, fatigue, hepatocellular damage
 
drowsiness, GIT symptoms, allergy, 
hepatocellular damage 
Immobility
Immobility occurs in most patients with advanced or terminal neurological disorders. The main 
aim of management of the immobile patient is to prevent pain, bed sores and contractures and 
to make the patient comfortable. To help achieve this aim it is necessary to keep the skin dry 
and clean. This may involve urinary catheterization when there is a non-functioning bladder 
or the patient is unable to mobilise to the toilet. Care of paralysed or immobile limbs involves 
frequent passive movements and ensuring the patient’s position is regularly changed. This task 
is best done initially by a physiotherapist with the aid of antispasmodics and analgesics and the 
methods later taught to a family carer. 
Dyspnoea
Breathlessness and cough are common and distressing symptoms in patients with neurological 
disorders. The main causes include stroke, infections, neuromuscular disorders and 
neurodegenerative disorders such as motor neurone disease. It is important to exclude acute 
reversible causes of respiratory failure such as myasthenia gravis, Guillain-Barre syndrome, 
medications or infection. Non pharmacological management includes the use of oxygen and 
relaxation techniques. Ventilatory support is usually not a realistic option unless there is a 
reversible component. 
Management therefore in advanced neurological disorders involves the use of morphine 
initially 2.5-5 mg orally 6 hourly increasing the dose and frequency as required to relieve 
patient distress. The route of administration may be changed to parenteral depending on the 
Chapter 20  Care in neurology
Part ii – Neurological Disorders 440
patient’s overall condition. Increasing dyspnoea in neurological disorders is frequently a sign of 
underlying pneumonia. 
Constipation
Constipation is a frequent complication of neurological disorders, in particular those with 
spinal cord dysfunction, paralysis and immobility. Early intervention is important to prevent 
this. Measures include ensuring a satisfactory fluid intake, adequate high bulk and roughage 
diet and the careful use of laxatives. This includes the combined use of stool softeners (liquid 
paraffin), osmotic laxatives e.g. magnesium salts and lactulose and/or colonic stimulants 
including senna and bisacodyl. Rectal stimulants include glycerine and/or bisacodyl 
suppositories or enemas with phosphate or soap and water. Suppositories and enemas may be 
the best method of dealing with chronic neurological constipation and manual evacuation may 
be necessary in cases of faecal impaction.
PALLIATIVE CARE
Palliative care can be involved at any stage of a life-threatening condition, including at the 
time of diagnosis even if the survival prognosis is fairly long. A large part of palliative care is 
the provision of adequate relief of pain and other distressing symptoms. The most common 
problem identified in persons with advanced and terminal neurological disease in Africa 
is a lack of pain relief. Economic loss caused by lack of earnings, spiritual loss caused by a 
feeling of loss of God’s help, emotional loss caused by a loss of hope and the social stigma 
of the disease and of feeling isolated in the community have all been identified as problems. 
Difficulties identified for care givers in Africa are lack of finance, loss of time from work and 
other activities and the practical aspects of caring for an often bedbound patient. Their main 
activities include the provision of food, drugs, and consolation needed for the day to day care 
of the patient. Palliative care aims to provide practical measures to support both patient and 
family. These include provision of food, drugs, consolation and assisting with the day to day 
care for the patient. 
General care and support
Care in Africa is done mostly by the patient’s family and they should always be involved in all 
major decisions concerning the patient. Both patient and family need understanding of their 
difficult situation. The health care worker should aim to be informed, gentle, honest, and to be 
aware of the range of emotions that may be encountered including fear, denial, grief, sadness, 
worry and finally acceptance. Carers should also be sensitive to and respect the cultural and 
spiritual needs of the patient. These may involve traditional healers, alternative medicines and 
religious support depending on the patient’s wishes, needs and beliefs. It is important to ask the 
patient directly concerning the need for spiritual support. 
Needs of patients
Palliative care emphasises the importance of alleviation of symptoms particularly in the final 
stages of disease process. In the last days, weeks and months of life the patient’s main needs 
are symptom relief including pain, anxiety, secretions and nausea. Most people at this stage 
benefit from combinations of morphine/antiemetic/anxiolytic ± antimuscarinic. These can 
delivered either orally or parenterally by injection. A syringe pump driver is the preferred 
method of delivery in very ill people. A good death occurs when the patient is cared for where 
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he wishes to die which is usually at home and is free from pain, worry and other distressing 
symptoms. Palliative care aims to help patients and their carers achieve this (Table 20.10). 
Table 20.10 Aims & possible interventions with palliative care
Main Aim Intervention
Relieve pain & other symptoms provide analgesics and medications  that are accessible, 
affordable & available (AAA)
Provide resources necessary to care financial support 
Provide an infrastructure to deliver care teach, train health care workers & involve family members 
Include palliative care as part of the 
continuum of health care and living
make palliative care a right for everyone 
Selected references
Birbeck GL. Barriers to care for patients with neurologic disease in rural Zambia. Arch Neurol. 2000 
Mar;57(3):414-7.
Chetty S, Baalbergen E, Bhigjee AI, Kamerman P, Ouma J, Raath R, Raff M, et al. Clinical practice 
guidelines for management of neuropathic pain: Expert panel recommendations for South Africa. S Afr 
Med J. 2012 Mar 8;102(5):312-25.
Clark D, Wright M, Hunt J, Lynch T. Hospice and palliative care development in Africa: a multi-method 
review of services and experiences. J Pain Symptom Manage. 2007 Jun;33(6):698-710.
Collins K, Harding R. Improving HIV management in sub-Saharan Africa: how much palliative care is 
needed? AIDS Care. 2007 Nov;19(10):1304-6.
Frohlich E, Shipton EA. Can the development of pain management units be justified in an emerging 
democracy? S Afr Med J. 2007 Sep;97(9):826-8.
Hall EJ, Sykes NP. Analgesia for patients with advanced disease: I. Postgrad Med J. 2004 
Mar;80(941):148-54.
Hall EJ, Sykes NP. Analgesia for patients with advanced disease: 2. Postgrad Med J. 2004 Apr;80(942):190-5.
Harding R, Gwyther L, Mwangi-Powell F, Powell RA, Dinat N. How can we improve palliative care 
patient outcomes in low- and middle-income countries? Successful outcomes research in sub-Saharan 
Africa. J Pain Symptom Manage. 2010 Jul;40(1):23-6.
Harding R, Higginson IJ. Palliative care in sub-Saharan Africa. Lancet. 2005 Jun 4-10;365(9475):1971-7.
Kikule E. A good death in Uganda: survey of needs for palliative care for terminally ill people in urban areas. 
BMJ. 2003 Jul 26;327(7408):192-4.
Logie DE, Harding R. An evaluation of a morphine public health programme for cancer and AIDS pain 
relief in Sub-Saharan Africa. BMC Public Health. 2005;5:82.
Louw QA, Morris LD, Grimmer-Somers K. The prevalence of low back pain in Africa: a systematic review. 
BMC Musculoskelet Disord. 2007;8:105.
O’Brien T, Welsh J, Dunn FG. ABC of palliative care. Non-malignant conditions. BMJ. 1998 Jan 
24;316(7127):286-9.
Sepulveda C, Habiyambere V, Amandua J, Borok M, Kikule E, Mudanga B, et al. Quality care at the end 
of life in Africa. BMJ. 2003 Jul 26;327(7408):209-13.
Sepulveda C, Marlin A, Yoshida T, Ullrich A. Palliative Care: the World Health Organization’s global 
perspective. J Pain Symptom Manage. 2002 Aug;24(2):91-6.
Chapter 20  Care in neurology
Part ii – Neurological Disorders 442
Dr William P. Howlett
2012
INDEX
INDEX
A
abducens nerve  21, 295
absence seizures  79, 82
accessory nerve  27, 305
accommodation reflex  21, 289
acetylcholine receptor antibodies  320
aciclovir  141
acoustic nerve  25, 303
balance  26, 303
hearing  25, 303
acoustic neuroma  377, 402
activities of daily living (ADL)  251
acute bacterial meningitis (ABM)  123
aetiology  124
ceftriaxone  129
chloramphenicol  129
clinical diagnosis  126
CSF in ABM  129
diagnosis  128
epidemiology  124
Haemophilus influenzae type b (Hib)  125
management  129
Neisseria meningitidis  125
outcome  130
pathogenesis  126
penicillin  129
prevention  130
signs of meningitis  127
Streptococcus pneumoniae  125
acute demyelinating encephalomyelitis (ADEM)  
140
acute dystonic reactions  339
acute epidural abscess  236
adjuvants  435
agnosia  60
AIDS  191
akinesia  330
akinetic-rigid syndrome  335
alcohol  279
Alzheimer’s disease  387
amyotrophic lateral sclerosis (ALS)  341
analgesic overuse headache  356
management  356
aneurysms  109
anosmia  16, 287
anticholinergic drugs  335
antiepileptic drugs  89
carbamazepine  91
diazepam  94
ethosuxamide  92
phenobarbitone  91
phenytoin  91
sodium valproate  92
aphasia  51, 369
apraxia  51, 369
Argyll-Robertson pupil  290
Arnold-Chiari malformation  239
ART associated neuropathy  204, 268
astereognosis  59
asterixis  340
astrocytoma  367
ataxia  54, 278, 404
athetosis  339
aura  81
AVPU method  217
axons  259
B
Babinski sign  34, 48
bacterial meningitis. See acute bacterial meningi-
tis (ABM)
basal ganglia  47, 329
Becker’s muscular dystrophy  314
Bell’s palsy  204, 268, 301
benign essential tremor  337
benign intracranial hypertension (BIH)  359
benign paroxysmal positional vertigo (BPPV)  
304
beriberi  278
bladder  56
incontinence  56
parasympathetic  56
sympathetic  56
Blantyre coma scale  166
brain abscess  149, 166, 194
pyogenic  149
toxoplasmosis  166, 194
tuberculoma  132, 194
brain death  225
brain stem  47, 54
brain stem and cerebellum  369
brain tumours  367
chemotherapy  379
clinical features  368
index a – b
Index 444
focal neurological deficits  368
management of tumours  378
medical  378
radiotherapy  379
raised intracranial pressure  368
seizures  368
sites  369
surgical  378
Broca’s area  51
Brown-Sequard syndrome  56
Brudzinski’s sign  39, 127
bulbar palsy  342
C
café-au-lait spots  400
caloric testing  226
carbamazepine  91
care in neurology  431
carotid artery stenosis  107
carotid doppler  109
carpal tunnel syndrome  261
case fatality ratio  68
cauda equina  55
cerebellar ataxias  404
cerebellum  47, 54
cerebral hemispheres  47, 51
cerebral malaria  161
artemether  164
artemisinin compounds  164
artesunate  164
clinical features  162
coma  162
complications  164
definition  161
diagnosis  163
epidemiology  161
pathophysiology  161
Plasmodium falciparum  161
quinine  165
retinopathy  162
seizures  162
treatment  164
cerebral toxoplasmosis  123
cerebrovascular disease. See stroke
cervical spondylosis  237
Charcot-Marie-Tooth disease  405
Charcot’s joints  148
cholinesterase inhibitors  321
chorea  339, 406
chronic inflammatory demyelinating polyneu-
ropathy (CIDP)  281
clonus  29
cluster headache  357
cochlear division  25, 303
codeine/dihydrocodeine  436
cognitive function  38, 387
cognitive testing  391
colloid cyst  376
colour vision  291
coma  213
assessment  213
causes  215
emergency treatment  221
general examination  216
history  215
investigations  220
level of consciousness (LOC)  216
management  220
pathophysiology  213
common peroneal nerve  262
complex partial seizures  79
confusion/delirium  195, 225, 437
chlorpromazine  437
haloperidol  437
consciousness  37
consensual reflex  21, 288
constipation  441
coordination  32
corneal reflex  24, 300
corticobasal degeneration (CBD)  334
corticospinal tracts  55
cover test  299
cranial nerve disorders  287
cranial nerve examination  16
assessing the pupils  20
distinguishing the type of deafness  26
examining eye movements  21
examining the tongue  28
examining visual fields  18
fundoscopy  19
head turning  27
jaw opening, closure  24
pupillary reactions  20
shoulder elevation  27
testing facial movements  25
testing facial sensation  23
testing hearing  25
testing smell  17
C – C index
William Howlett Neurology in Africa 445
testing the gag reflex  27
testing visual acuity  17
the accommodation reflex  21
the consensual reflex  21
the light reflex  21
craniopharyngioma  375
cryptococcal meningitis  123, 136, 193
amphotericin B  138
clinical findings  136
CM and ART  138
cryptococcal antigen (CRAg)  137
Cryptococcus neoformans  136
diagnosis  136
fluconazole  137
flucytosine  138
prognosis  138
treatment  137
CSF findings in meningitis  129
cutaneous fibromas  400
cysticercosis  175
albendazole  176
clinical features  176
diagnosis  176
life cycle  175
pathology  176
praziquantel  176
prevention  178
seizures  176
steroids  177
Taenia solium  174
treatment  176
Cytomegalovirus (CMV)  198
D
deafness  25, 303
dementia  200, 385
aetiology  386
Alzheimer’s disease  386
cognitive testing  391
dementia with Lewy bodies  386
epidemiology  385
frontotemporal dementia  386
general course and prognosis  386
HIV-associated dementia (HAD)  200, 390
management  388
mini mental state examination  392
Parkinson’s disease  386
prognosis  386
risk factors  386
vascular dementia  389
dementia with Lewy bodies  334, 386
Denis three column model  422
dermatomes  58
dermatomyositis  316
Devic’s disease (neuromyelitis optica)  244
diabetes  277
diffuse axonal injury (DAI)  415
diplopia  21, 296
disability  70
disability-adjusted life years (DALYs)  69
disease burden  69
disease prevention  71
disorders of peripheral nerves  259
distal sensory neuropathy (DSN)  203, 267
dizziness  304
Doll’s eyes  225
dopamine  331
dorsal columns  49, 55
drug induced parkinsonism  334
Duchenne’s muscular dystrophy  314
dysarthria  52
dysdiadochokinesia  32
dysphagia  438
dysphasia  52
expressive  53
global  54
receptive  53
dysphonia  52
dyspnoea  440
dystonia  338
E
echinococcosis. See hydatid disease
electroencephalography (EEG)  86
electromyography (EMG)  266
encephalitis  139
encephalopathy  214
epilepsy  79
AEDs and women  93
aetiology  80
brain imaging  88
clinical diagnosis  84
common forms of seizures  81
discontinuing of AEDs  92
driving and epilepsy  95
drug treatment  90
epidemiology  80
epilepsy syndromes  79
index d – e
Index 446
investigations  86
management  89
prognosis  94
status epilepticus  93
treatment gap  95
Epley’s manoeuvre  305
ergotamine  355
examination of the gait  36
examination of the limbs  28
coordination  32
finger nose test  32
heel shin test  32
inspection  28
power  29
reflexes  33
sensation  34
tone  28
extradural haematoma  418
extrapyramidal disorder  330
Parkinsonism  334
Parkinson plus syndromes  334
Parkinson’s disease  329
eye movements  21, 295
tracking  295
voluntary saccades  295
F
facial nerve  24, 301
facial pain  360
facioscapulohumeral dystrophy  315
fasciculations  28
fatigability  319
febrile convulsions  84
femoral neuropathy  263
finger-nose test  32
flaccid paraplegia  55
fluorosis  238
foot drop  262
fourth nerve palsy  298
freckling  400
Friedreich’s ataxia  404
Froin syndrome  236
frontal lobe  51, 369
frontal lobe release signs (FLRSs)  40, 201
grasp reflex  40
palmomental reflex  40, 202
snout reflex  40, 201
frontotemporal dementia  389
fundoscopy  19, 293
G
gag reflex  27, 305
gait disorder  61
cerebellar  61
hemiparetic  61
myopathic  61
neuropathic  61
Parkinson’s  61
sensory ataxic  61
spastic  61
generalized tonic-clonic seizure  81
general paralysis insane (GPI)  148
Gilles de la Tourette syndrome  340
Glasgow Coma Scale (GCS)  38, 216
Glasgow Outcome Scale  417
glioma  370
clinical features  370
management  370
prognosis  370
global burden  67
glossopharyngeal  26
glossopharyngeal nerve  26, 305
Gower’s sign  314
grand mal  79
graphanaesthesia  60
grasp reflex  40
Guillain-Barre Syndrome (GBS)  205, 279
clinical features  279
general management  280
intravenous immunoglobulin  280
investigations  279
plasma exchange  280
prognosis  280
H
haemorrhage/haematoma  102, 108, 414
aneurysm  102
arteriovenous malformations  102
extradural  418
intracerebral  102, 421
subarachnoid  109
subdural  108, 420
Hallpike’s test  304
HAT. See human African trypanosomiasis
headache  351
primary  352
secondary  357
head injury  413
health delivery  72
f – h index
William Howlett Neurology in Africa 447
primary care  73
secondary care  73
tertiary care  73
health promotion  71
hearing  25, 303
Rinne’s test  26, 303
Weber’s test  26, 303
heel shin test  32
helminthic infections  161
hemiballismus  339
hemiparesis  59
hereditary spastic paraparesis (HSP)  406
herpes encephalitis  140
diagnosis  141
hiccups  340
history taking  13
HIV. See Human Immunodeficiency Virus
HIV-associated dementia (HAD)  200, 390
HIV infection  191
HIV related neurological illnesses  191
HIV related neuropathy  203, 267
ART associated neuropathy  204
Bell’s palsy  268
distal sensory neuropathy (DSN)  203, 267
inflammatory neuropathies  205, 269
Holmes Adie pupil  290
Horner’s syndrome  289
Human African Trypanosomiasis (HAT)  
161, 168
clinical features  169
CSF examination  172
diagnosis  171
eflornithine  173
encephalitic stage  170, 171
haemolymphatic stage  170
life cycle for trypanosomiasis  170
melarsoprol (Mel B)  173
nifurtimox  173
pentamidine  173
prevention  174
primary chancre  169
prognosis  174
suramin  173
treatment  173
Trypanosoma brucei gambiense (T.b.g.)  169
Trypanosoma brucei rhodesiense (T.b.r.)  168
Trypanosomiasis test (CATT)  172
Winterbottom’s sign  170
Human Immunodeficiency Virus  70, 123
Human T cell lymphotropic virus type 1 (HTLV-1)  
244
Huntington’s disease (HD)  339, 405
hydatid disease  182
albendazole  183
clinical features  182
diagnosis  183
Echinococcus granulosus  182
life cycle  182
praziquantel  183
prevention  184
treatment  183
hyperventilation syncope  223
hypoglossal nerve  28, 305
hypoglycaemia  224
I
immobility  440
immune reconstitution inflammatory syndrome 
(IRIS)  199
immunoglobulin  322
impaired communication  436
incidence rate  67
inclusion body myositis  318
India ink  137, 193
infections  123
bacterial  123
fungal  123
parasitic  123
protozoa  123
viral  123
inflammatory myopathies  316
inherited myopathies  312
inherited neurological disorders  312, 399
dystrophies  312
Friedreich’s ataxia  404
Huntington’s disease (HD)  405
neurofibromatosis type 1  399
neurofibromatosis type 2  402
neuropathies  405
spastic paraparesis  406
Sturge Weber syndrome  403
tuberous sclerosis  403
Wilson’s disease  407
inherited neuropathies  405
intention tremor  32
intracerebral haematoma  421
intracranial pressure  368
intracranial tumours (ICT)  367
index i – i
Index 448
benign  367
malignant  367
intravenous immunoglobulin  280, 322
involuntary movements  336
ischaemia  102
Ishihara plates  17
J
Jarish-Herxheimer reaction  149
jaw jerk  23, 300
JC virus  197
joint position sense  35
K
Kayser-Fleisher ring  407
Kernig’s sign  39, 127
konzo  246
aetiology  246
clinical features  246
cyanide  246
diagnosis  247
prevention  248
spastic paraplegia  246
treatment  248
L
lathyrism  248
beta-N-oxalylamino-L-alanine (BOAA)  248
grass pea (Lathyrus sativus)  248
paraplegia  248
Leber’s optic neuropathy  294
leprosy  269
anaesthetic skin lesions  269
biopsy  273
borderline  270
clinical features  269
clofazimine  274
complications  275
dapsone  274
diagnosis  273
eyes  273
host response  269
lepromatous (LL)  269
multiple drug treatment (MDT)  274
Mycobacterium leprae  269
nerve enlargement  272
neurological findings  272
peripheral neuropathy  269
prevention  276
rifampicin  274
skin  271
slit skin smears  273
thalidomide  275
transmission  269
treatment  274
tuberculoid (TT)  269
type 1 reversal reactions  274
type 2 erythema nodosum leprosum (ENL)  
274
levodopa (L-dopa)  331
light reflex  21, 288
afferent pupil defect  288
efferent pupil defect  288
limb girdle muscular dystrophy  315
Lisch nodules  400
localization  47
locked-in syndrome  219
loss of posture  330
lower motor neurone lesion (LMNL)  48
lumbar puncture  151
M
malaria. See cerebral malaria
mandibular V3  300
motor involvement  300
mannitol  417
maxillary V2  300
measurement of disease  67
median nerve  261
medical history  15
Meige syndrome  338
memory  52, 385
Ménière’s disease  304
meningioma  371
clinical features  371
diagnosis & management  371
meningitis  124, 193
mental state  38
meralgia paraesthetica  262
metastases  374
differential diagnosis  374
investigations  375
management  375
migraine  353
Mini Mental State Examination  392
miosis  290
mononeuritis multiplex  260
mononeuropathies  57, 260
common peroneal nerve  262
j – m index
William Howlett Neurology in Africa 449
lateral cutaneous nerve  262
median nerve  261
meralgia paraesthetica  262
pathophysiology  259
Phalen’s sign  261
radial nerve  262
sciatic nerve  262
Tinel’s sign  261
ulnar nerve  262
morphine  436
mortality rate  68
motor  23
motor neurone disease (MND)  341
clinical subtypes  341
diagnosis  343
investigations  343
management  343
motor seizures (Jacksonian epilepsy)  84
motor system  47
movement disorders  329
multiple system atrophy (MSA)  334
muscle disorders  311
acquired myopathies  311
dystrophies  312
other myopathies  318
muscular dystrophy  311
myasthenia gravis  318
cholinesterase inhibitors  321
complications  319
diagnosis  320
differential diagnosis  319
immunosuppression  321
management  321
pyridostigmine  321
signs  319
symptoms  319
myoclonus  339
myopathies  311
clinical history  311
electromyography  312
inflammatory myopathies  316
investigations  312
physical examination  311
myopathy  205, 311
myotonic dystrophy  313
N
nausea and vomiting  439
neck stiffness  127
Neisseria meningitidis  125
nerve conduction studies  266
neurocysticercosis  174
neurodegenerative disorder  329, 389
neurofibromatosis type 1  399
neurofibromatosis type 2  402
neuroleptic malignant syndrome  335
neurological disorders in HIV  136, 167, 191
acute bacterial meningitis (ABM)  193
Bell’s palsy  204
confusion and coma  195
Cryptococcal meningitis (CM)  136, 193
cytomegalovirus (CMV)  198
distal sensory neuropathy (DSN)  203
focal neurological disorder (FND)  191
Guillain-Barre Syndrome (GBS)  205
Herpes zoster  191
HIV-associated dementia (HAD)  200
HIV-associated neurocognitive dysfunction 
(HAND)  200
immune reconstitution inflammatory syn-
drome  199
lymphoma  194
meningitis  191
myopathy  191
palmomental reflex  201
paraparesis  202
polymyositis  204
progressive multifocal leucoencephalopathy 
(PML)  197
retinopathy  199
seizures  196
snout reflex  201
stroke  195
TB meningitis (TBM)  193
toxoplasma encephalitis (TE)  166, 194
tuberculoma  194
vacuolar myelopathy (VM)  191, 202
varicella-zoster  197
neurological examination  16
neurological infections  123
neuromuscular junction  60
neuromyelitis optica. See Devic’s disease
neuropathy. See peripheral neuropathies
neurosyphilis  147
non-opioids  434
non traumatic paraplegia. See paraplegia
nystagmus  299
index n – n
Index 450
O
occipital lobe  369
occupational therapists  251
ocular myasthenia gravis  319
oculocephalic reflex  225
oculomotor nerve  21, 295
oculovestibular reflex  226
olfactory nerve  16, 287
ophthalmic V1  300
opioids  434
opisthotonos  146
optic atrophy  294
optic nerve  17, 287
optic neuritis  293
Devic’s disease  294
orientation  37
P
pain  351, 432
adjuvants  435
causes  433
drug treatment  434
management  433
measurement  433
neuropathic  432
nociceptive  432
non-opioids  434
opioids  435
pathophysiology  432
WHO analgesic ladder  436
palliative care  441
aims  442
general care and support  441
needs  441
relieve pain & other symptoms  442
palmomental reflex  40, 202
papilloedema  20, 293
paraplegia  55, 231
paraplegia non traumatic  231
aetiology  231
compressive causes  233
management  249
non compressive causes  240
tropical myeloneuropathies  246
parietal lobe  49, 369
Parkinsonism  334
Parkinson plus syndromes  334
Parkinson’s disease  54, 329
bradykinesia  54, 330
causes  329
clinical diagnosis  330
course  333
gait  54, 330
levodopa (L-dopa)  331
other drug treatments  332
pathophysiology  329
rigidity  54, 330
treatment  331
tremor  54, 330
patterns of motor loss  59
patterns of sensory loss  59
peripheral nerve disorders  50
peripheral nervous system  57
peripheral neuropathies  203, 259
persistent vegetative state  219
pethidine  436
petit mal  79
phenytoin  91
Pick’s disease  389
pinealoma  377
pituitary tumours  373
clinical features  373
diagnosis  373
management  374
plasma exchange  322
plexiform neuromas  400
polymyositis  311, 316
polyneuropathies  263
causes  264
clinical features  264
diagnosis  266
electromyography  266
investigations  266
management  266
motor  264
sensory  265
Pott’s disease  233
clinical features  233
investigations  233
prognosis  234
treatment  234
power  30
presenting complaint  14
prevalence rate/ratio  68
primary CNS lymphoma  376
primary lateral sclerosis (PLS)  343
progressive bulbar/pseudobulbarpalsy (PBP/PSP)  
342
o – p index
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progressive multifocal leucoencephalopathy 
(PML)  197
progressive muscular atrophy (PMA)  342
progressive supranuclear palsy (PSP)  334
protozoal infections  161
pseudoseizures  85, 224
psychogenic coma  219
public health  67, 79
pupillary disorders  289
pupillary reactions  20
pupillary responses  287
Q
quadriplegia  56
R
Rabies  141
clinical features  142
laboratory diagnosis  143
pathogenesis  142
prevention  144
treatment  144
vaccination  144
radial nerve  262
Ramsay-Hunt syndrome  301
reflexes  33
rest tremor  330
retinopathy  198, 293
rigidity  330
Rinne’s test  26, 303
risus sardonicus  145
Romberg’s test  37
S
schistosomiasis  178, 242
clinical features  180
diagnosis  181
epidemiology  178
life cycle  178
paraparesis  180
paraplegia  242
pathogenesis  179
praziquantel  181
prevention  181
prognosis  181
Schistosoma haematobium  178
Schistosoma japonicum  178
Schistosoma mansoni  178
seizures  180
steroids  181
treatment  181
schwannoma  377, 402
sciatic nerve  262
secondary headaches  357
seizures  79
seizure types
absence  82
febrile convulsions  84
generalized tonic-clonic  81
motor seizures (Jacksonian)  84
myoclonic  83
partial onset  83
temporal lobe  83
sensory level  55
sensory testing  35
signs of meningism  39
Brudzinski’s sign  39
Kernig’s sign  39
neck stiffness  39
sixth nerve palsy  298
sleeping sickness. See HAT
smell  16, 287
Snellen chart  17, 291
snout reflex  40, 201
sodium valproate  92
spasticity  439
spastic paraplegia  55, 246
speech disorders  52
spinal cord  47
corticospinal tract  47
dorsal columns  49
spinothalamic tracts  49
spinal cord tuberculosis  233
spinal cord tumours  235
spinal injury  422
spinocerebellar disorders  404
squint  298
states of altered consciousness  225
status epilepticus  93
drug treatment  94
management  94
sternomastoid muscle  305
straight leg raising test  40
stroke  101, 195
aetiology  102
anticoagulation  112
antiplatelet drugs  112
blood pressure  112
clinical presentation  104
index Q – s
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complications  113
definition  101
differential diagnosis  108
epidemiology  101
investigations  108
localization  104
management  111
pathogenesis  102
prevention  115
prognosis  116
rehabilitation  114
thrombolysis  113
vascular risk factors  103
Sturge Weber syndrome  403
sub acute combined degeneration of the cord 
(SACD)  245, 278
subarachnoid haemorrhage (SAH)  109
clinical presentation  109
investigations  110
management  110
neurosurgical  110
prognosis  111
subdural haematoma  420
superficial reflexes  40
abdominal reflex  40
cremasteric reflex  40
swinging torch test  289
Sydenham’s chorea  339
syncope  222
syphilis  147, 243
general paralysis insane (GPI)  148
meningitis  148
meningovascular syphilis  148
tabes dorsalis (TD)  148
syringomyelia  239
T
tabes dorsalis  148
Taenia solium  174
temperature sensation  35
temporal arteritis  359
temporal lobe  52, 369
temporal lobe epilepsy  83
tendon reflexes  33
tensilon test  320
tension headache  352
management  353
tetanus  123, 145
clinical features  145
Clostridium tetani  145
diagnosis  146
management  146
pathogenesis  145
prevention  146
thalamus  49
third nerve palsy  296
thymectomy  322
tics  340
Tinel’s sign  261
tinnitus  305
Todd’s paralysis  84, 108
tone  28
touch sensation  34
toxoplasmosis  161, 166
clinical presentation  166
diagnosis  166
differential diagnosis  167
focal neurological signs  166
prognosis  168
Toxoplasma gondii  166
treatment  167
trimethoprim/sulphamethoxazole (TMP-
SMX)  167
tramadol  436
transient ischaemic attack (TIA)  105, 224
transient loss of consciousness  105, 213, 222
cardiac syncope  222
cerebrovascular syncope  223
hyperventilation syncope  223
hypoglycaemia  224
postural syncope  223
pseudoseizures  224
syncope and seizures  223
transient ischaemic attack (TIA)  105, 224
vasovagal syncope (faint)  222
transverse myelitis (TM)  241
clinical features  241
prognosis  241
treatment  241
traumatic brain injury  413
causes  413
classification  415
clinical diagnosis  414
epidemiology  413
evaluation  416
imaging  414
management  416
outcome  417
t – t index
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pathology  413
rehabilitation  418
tremor  336
trigeminal nerve  23, 300
motor  23
sensation  23
trigeminal neuralgia (TN)  360
triptans  354
trochlear nerve  21, 295
tropical ataxic neuropathy (TAN)  249
tropical myeloneuropathies  246
Trypanosoma brucei gambiense (T.b.g.)  169
Trypanosoma brucei rhodesiense (T.b.r.)  168
trypanosomiasis. See Human African Trypanoso-
miasis (HAT)
tuberculous meningitis (TBM)  123, 131, 193
clinical features  131
CSF  129
diagnosis  133
management  134
outcome  135
pathogenesis  131
prevention  135
TBM in HIV  135, 193
treatment  135
tuberous sclerosis  403
facial angiofibromata  403
hamartoma  403
tumour brain  367
tumour spinal cord  235
U
ulnar nerve  262
upper motor neurone lesion (UMNL)  47
V
vacuolar myelopathy  202
vagus nerve  26, 305
Varicella-zoster  197
vascular dementia  389
vascular parkinsonism  334
vasovagal syncope (faint)  222
ventilation  322
vertigo/dizziness  304
vestibular division  25, 303
vibration sense  35
viral encephalitis  139
clinical findings  140
Cytomegalovirus (CMV)  139
Epstein-Barr virus  139
Herpes simplex  139
HIV  139
management  141
rabies  139
viral meningitis  139
clinical features  139
visual acuity  17, 291
Snellen chart  291
visual fields  18, 292
bitemporal hemianopia  292
homonymous hemianopia  292
monocular  292
vitamin B-1 deficiency  278
vitamin B-6 deficiency  278
vitamin B-12 deficiency  245, 278
vomiting  439
W
wasting  28
Waterhouse-Frederickson syndrome  128
Weber’s test  26, 303
Wernicke-Korsakoff-syndrome  278
Wernicke’s area  53
WHO analgesic ladder  436
Wilson’s disease  407
winging of scapulae  315
wrist drop  262
writer’s cramp  338
X
xanthochromia  110, 153
X-linked dystrophin  312
Names of main infecting organisms in italics
Page number in bold face indicates major discussion
index u – x
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ABM acute bacterial meningitis
AC air conduction
ACA anterior cerebral artery
AChR acetylcholine receptor
AD Alzheimer’s disease
ADC AIDS dementia complex
ADEM acute disseminated encephalomyelitis
ADL activities of daily living
AED antiepileptic drug
AF atrial fibrillation
AIDP acute inflammatory demyelinating 
polyneuropathy
AIDS acquired immune deficiency syndrome
ALS amyotrophic lateral sclerosis
ART antiretroviral therapy
AVM arteriovenous malformation
AZT zidovudine
BB borderline leprosy
BC bone conduction
BET benign essential tremor
bd twice daily
BIH benign intracranial hypertension
BMD Becker muscular dystrophy
BP blood pressure
BPPV benign paroxysmal positional vertigo
BTL borderline tuberculoid leprosy
CATT card agglutination trypanosomiasis test
CBD corticobasal degeneration
CDH chronic daily headache
CFR case fatality ratio/rate
CIDP chronic inflammatory demyelinating 
polyneuropathy
CM cryptococcal meningitis
CMTD Charcot–Marie-Tooth disease
CMV cytomegalovirus
CNS central nervous system
COW circle of Willis
CPA cerebellopontine angle
CR controlled release
CRAg cryptococcal antigen
CSF cerebrospinal fluid
CT computerized tomography
CTS carpal tunnel syndrome
CV conduction velocity
CVS cardiovascular system
CXR chest X-ray
DA dopamine
DAI diffuse axonal injury
DALYs disability adjusted lost years
d4T stavudine
ddi didanosine
DHE dihydroergotamine
DLB dementia with Lewy bodies
DM diabetes mellitus
DMD Duchenne muscular dystrophy
DOT directly observed treatment
DSN distal sensory neuropathy
DVT deep vein thrombosis
EBV Epstein-Barr virus
ECG electrocardiogram
EDH extradural haematoma
EEG electroencephalogram
EMG electromyography
ENL erythema nodosum leprosum
ESR erythrocyte sedimentation rate
FBC full blood count
FC febrile convulsion
FH family history
FLRSs frontal lobe release signs
FND focal neurological disorder/deficit
FSH facioscapulohumeral dystrophy
FTP frontotemporal dementia
FTA fluorescent treponemal antibody 
absorption (FTA)
FVC forced vital capacity
GABA gamma-aminobutyric acid
GBS Guillain-Barre syndrome
GCS Glasgow Coma Scale
GTCS generalized tonic clonic seizure
HAART highly active antiretroviral therapy
HAD HIV associated dementia
HAM HTLV associated myelopathy
HAND HIV associated neurocognitive 
dysfunction
HAT human African trypanosomiasis
Hb haemoglobin
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HCW health care worker
HD Huntington’s disease
HI head injury
Hib haemophilus influenza
HIV human immunodeficiency virus
HMSN hereditary motor sensory neuropathy
HSE herpes simplex encephalitis
HSP hereditary spastic paraparesis
HSV herpes simplex virus
HTLV-1 human T-cell lymphotropic virus type 1
IBM inclusion body myositis
IAC internal auditory canal
ICA internal carotid artery
ICH intracerebral haemorrhage
ICP intracranial pressure
ICT intracranial tumour
ICU intensive care unit
IFA immunofluorescent antibody
IVIG intravenous immunoglobulin
im intramuscular
INO internuclear opthalmoplegia
INR international normalized ratio
IPD idiopathic Parkinson’s disease
IRIS immune reconstitution inflammatory 
syndrome
iv intravenous
JME juvenile myoclonic epilepsy
LCST lateral corticospinal tract
LFT liver function test
LGMD limb girdle muscular dystrophy
LMNL lower motor neurone lesion
LOC loss of consciousness
LL lepromatous leprosy
LP lumbar puncture
MAOI monoamine oxidase inhibitors
MAP muscle action potential
MCA middle cerebral artery
MD myotonic dystrophy
MDT multidrug therapy
MG myasthenia gravis
MMSE mini mental state examination
MND motor neurone disease
MR mortality rate
MRC Medical Research Council
MRI magnetic resonance imaging
MSA multiple system atrophy
MUP motor unit potential
NAP nerve action potential
NCD non communicable disease
NCS nerve conduction study
NF1 neurofibromatosis type 1
NF2 neurofibromatosis type 2
NGT nasogastric tube
NMJ neuromuscular junction
NMO neuromyelitis optica
NSAID non-steroidal anti-inflammatory drug
NTP non traumatic paraplegia
od once daily
OI opportunistic infection
ON optic neuritis
OP opening pressure
OT occupational therapist
PBP progressive bulbar palsy
PCL primary cerebral lymphoma
PC posterior column
PCA posterior cerebral artery
PCP pneumocystis pneumonia
PCR polymerase chain reaction
PD Parkinson’s disease
PE plasma exchange
PHB phenobarbitone
PHCW primary health care worker
PHT phenytoin
PLS primary lateral sclerosis
PM polymyositis
PMA progressive muscular atrophy
PMH past medical history
PML progressive multifocal 
leucoencephalopathy
PND peripheral nerve disorder
PNS peripheral nervous system
po per oral
PP paraplegia
PSP progressive supranuclear palsy
qds four times a day
RAPD relative afferent pupil defect
RDT rapid diagnostic test
RRT rapid reagent test
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RTA road traffic accident
Rx treatment
SACD subacute combined degeneration of 
spinal cord
SAH subarachnoid haemorrhage
sc subcutaneous
SDH subdural haematoma
SNAP sensory nerve action potential
SOL space occupying lesion
SSA sub Saharan Africa
STT spinothalamic tract
SUDEP sudden unexpected death in epilepsy
SVP sodium valproate
TA temporal arteritis
TAN tropical ataxic neuropathy
TB tuberculosis
Tbg Trypanasoma brucei gambiense
TBI traumatic brain injury
TBM tuberculous meningitis
Tbr Trypanasoma brucei rhodesiense
tds three times daily
TE toxoplasma encephalitis
TIA transient ischaemic attack
TLE temporal lobe epilepsy
TN trigeminal neuralgia
TPHA Treponema pallidum 
haemagglutination assay
TPI treponemal pallidum immobilization 
test
TT tuberculoid leprosy
U&E urea and electrolytes
UMNL upper motor neurone lesion
VA visual acuity
VDRL Venereal Disease Research Laboratory
VM vacuolar myelopathy
ZN Ziehl-Neelsen
VZ varicella zoster
WHO World Health Organization
WKS Wernicke-Korsakoff-syndrome
YLD years lived with disability
YLL years life lost
Abbreviations 458
Dr William P. Howlett
2012
USEFUL WEBSITES
USEFUL WEBSITES
General Medical Websites 
1. www.healthnet.org/essential-links
Highly systematic listing of health care websites aimed at professionals in the developing world.
2. www.pubmedcentral.nih.gov
“Large number of full-text biomedical journals available at publication date or after six months or 
one year.” John Eyers. 
3. extranet.who.int/hinari/en/journals.php
A highly useful resource for researchers; medical students may require initial formal instruction.
4. www.unaids.com
Useful resource covering both the socio-economic and medical aspects of HIV/AIDS.
5. www.cdc.gov
High yield resource for infectious disease; rapid response to on-line queries.
Neurology Websites
1. emedicine.medscape.com/neurology
Excellent link to neurology articles on a wide range of topics. Detailed yet concise information.
2. hardinmd.lib.uiowa.edu/neuro.html
Contains links to neurology websites chosen for quality; useful resource.
3. www.freebooks4doctors.com/fb/NEURO.HTM
Free downloads of various high quality neurology texts; excellent resource. 
4. www.freemedicaljournals.com/fmj/IP_NEURO.HTM
Free access to world-renowned neurology journals such as “Brain” and “Archives of Neurology”. 
5. www.neuroexam.com/neuroexam
Videos on neurologic exam from Yale New Haven Hospital; excellent website.
6. www.med.harvard.edu/AANLIB/home.html
Very useful resource; serves as an introduction to neuro-imaging for medical students. 
7. www.who.int/topics/meningitis/en
Simple but relevant information on bacterial meningitis; fact sheet is a must read for students.
8. www.refbooks.msf.org/MSF_Docs/En/Meningitis/Mening_en.pdf
Useful resource on case detection and management of epidemic meningococcal meningitis.
9. www.ilep.org.uk
Very useful for introducing leprosy diagnosis and treatment.
10. www.epilepsy.org.uk
Useful for introduction to epilepsy; med students may need additional information.
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About the book
Neurology in Africa is a practical guide to clinical neurology. It contains 20 
chapters in two main parts; part one covers clinical skills and part two covers 
the main neurological disorders. The book has many line drawings, photos, 
scans, tables and key points which help to illustrate the text. It is a single author 
book, written in an easy style with clear and comprehensive explanations. It is 
a core textbook for medical students and doctors in Africa.
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